
<html lang="en"     class="pb-page"  data-request-id="9aee5842-cc43-4d7c-8a63-d7fc8e15e4fd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01516;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions" /></meta><meta name="dc.Creator" content="Dean G.  Brown" /></meta><meta name="dc.Creator" content="Heike J.  Wobst" /></meta><meta name="dc.Description" content="A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, ..." /></meta><meta name="Description" content="A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 22, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01516" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01516" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01516" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01516" /></link>
        
    
    

<title>A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01516" /></meta><meta property="og:title" content="A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0026.jpeg" /></meta><meta property="og:description" content="A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, modalities, route of administration, first-in-class designation, approval times, and expedited review categories. From this review, oncology remains the top therapy area (25%), followed by infection (15%) and central nervous system disorders (11%). Regulatory incentives have been effective as evidenced by an increase in orphan drugs as well as antibacterial drugs approved under the GAIN act. Clinical development times may be increasing, perhaps as a result of the increase in orphan drug indications. Small molecules continue to mostly adhere to “Rule of 5” (Ro5) parameters, but innovation in new modalities is rapidly progressing with approvals for antisense oligonucleotides (ASO), small-interfering RNA (siRNAs), and antibody-directed conjugates (ADCs). Finally, novel targets and scientific breakthroughs that address areas of unmet clinical need are discussed in detail." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01516"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01516">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01516&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01516&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01516&amp;href=/doi/10.1021/acs.jmedchem.0c01516" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2312-2338</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00275" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01786" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Dean G. Brown</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dean G. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jnana Therapeutics, 6 Tide St., Boston, Massachusetts 02210, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 1-484-639-4153. Email: <a href="/cdn-cgi/l/email-protection#dabeb8a8b5adb49ab0b4bbb4bbaea2f4b9b5b7"><span class="__cf_email__" data-cfemail="325650405d455c72585c535c53464a1c515d5f">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dean+G.++Brown">Dean G. Brown</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7130-3928" title="Orcid link">http://orcid.org/0000-0002-7130-3928</a></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Heike J. Wobst</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Heike J. Wobst</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jnana Therapeutics, 6 Tide St., Boston, Massachusetts 02210, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 1-617-892-1824. Email: <a href="/cdn-cgi/l/email-protection#452d322a273631052f2b242b24313d6b262a28"><span class="__cf_email__" data-cfemail="fc948b939e8f88bc96929d929d8884d29f9391">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Heike+J.++Wobst">Heike J. Wobst</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01516&amp;href=/doi/10.1021%2Facs.jmedchem.0c01516" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2312–2338</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 22, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 August 2020</li><li><span class="item_label"><b>Published</b> online</span>22 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01516" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01516</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2312%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDean%2BG.%2BBrown%252C%2BHeike%2BJ.%2BWobst%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D5%26contentID%3Dacs.jmedchem.0c01516%26title%3DA%2BDecade%2Bof%2BFDA-Approved%2BDrugs%2B%25282010%25E2%2580%25932019%2529%253A%2BTrends%2Band%2BFuture%2BDirections%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2338%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01516"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">11452</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01516" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;G. Brown&quot;},{&quot;first_name&quot;:&quot;Heike&quot;,&quot;last_name&quot;:&quot;J. Wobst&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2312-2338&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01516&quot;},&quot;abstract&quot;:&quot;A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, modalities, route of administration, first-in-class designation, approval times, and expedited review categories. From this review, oncology remains the top therapy area (25%), followed by infection (15%) and central nervous system disorders (11%). Regulatory incentives have been effective as evidenced by an increase in orphan drugs as well as antibacterial drugs approved under the GAIN act. Clinical development times may be increasing, perhaps as a result of the increase in orphan drug indications. Small molecules continue to mostly adhere to “Rule of 5” (Ro5) parameters, but innovation in new modalities is rapidly progressing with approvals for antisense oligonucleotides (ASO), small-interfering RNA (siRNAs), and antibody-directed conjugates (ADCs). Finally, novel targets and scientific breakthroughs that address &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01516&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01516" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01516&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01516" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01516&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01516" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01516&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01516&amp;href=/doi/10.1021/acs.jmedchem.0c01516" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01516" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01516" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01516%26sid%3Dliteratum%253Aachs%26pmid%3D33617254%26genre%3Darticle%26aulast%3DBrown%26date%3D2021%26atitle%3DA%2BDecade%2Bof%2BFDA-Approved%2BDrugs%2B%25282010%25E2%2580%25932019%2529%253A%2BTrends%2Band%2BFuture%2BDirections%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2312%26epage%3D2338%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292016" title="Therapeutics">Therapeutics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, modalities, route of administration, first-in-class designation, approval times, and expedited review categories. From this review, oncology remains the top therapy area (25%), followed by infection (15%) and central nervous system disorders (11%). Regulatory incentives have been effective as evidenced by an increase in orphan drugs as well as antibacterial drugs approved under the GAIN act. Clinical development times may be increasing, perhaps as a result of the increase in orphan drug indications. Small molecules continue to mostly adhere to “Rule of 5” (Ro5) parameters, but innovation in new modalities is rapidly progressing with approvals for antisense oligonucleotides (ASO), small-interfering RNA (siRNAs), and antibody-directed conjugates (ADCs). Finally, novel targets and scientific breakthroughs that address areas of unmet clinical need are discussed in detail.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18158" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18158" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For the past decade, looming patent expirations, increasing research and development (R&D) costs, and forecasts of dwindling drug approvals have posed significant challenges for the pharmaceutical industry.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> A 2009 report estimated that more than $209B in annual sales would be at risk between 2010 and 2014 due to patent expirations.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These patent expirations included the blockbuster small molecule drugs atorvastatin (peak year sales of $13B in 2006), which lost exclusivity in 2011, as well as clopidogrel (peak year sales of $7.1B) and montelukast (peak year sales of $5.5B in 2012), both of which lost exclusivity in 2012.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The introduction of the Biologics Price Competition and Innovation Act (BPCIA) of 2009 similarly encouraged generic competition for biologics by creating a regulatory licensing path for biosimilars.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> A biosimilar is defined by the U.S. Food and Drug Administration (FDA) as “<i>highly similar reference product... [with] no clinically meaningful differences from a reference product</i>.”<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The first biosimilar approved by the FDA was filgrastim-sndz, a granulocyte colony-stimulating factor agent, in 2015.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Adalimumab, the number one selling prescription drug (peak year sales of $19.9B in 2018), faces no fewer than four biosimilar competitors, all approved in the past 4 years.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p last">In addition to the loss of the blockbuster drugs’ market share to generic competition, concerns arose at the turn of the decade that innovation in drug discovery, frequently measured by first in class (FIC) approvals,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> had stagnated and new approved drugs would not be able to replace the losses incurred by expiring patents.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> These concerns were fueled by the declining number of innovative new drugs coming to the market. For example, in 2007, only 19 new molecular entities (NMEs) were approved, the lowest number since 1983. Of these, only a small fraction (29%) were considered first-in-class, further dropping to 17% in 2009.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The “blockbuster” frenzy and the concept of “me-too” drugs which dominated the 1990s and early 2000s appeared to no longer be a viable model to sustain the industry. Taken together, these factors necessitated that the pharmaceutical industry reinvent itself to stop the predicted decline in productivity and bring innovative new drugs to the market. More importantly than the health of the industry, it was the patients with unmet medical needs that required the discovery of innovative new medicines. How did the industry respond and perform under this pressure? An assessment of pharmaceutical R&D productivity based on FDA approvals from 2010 to 2019 is thus presented and discussed.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Approved Drugs 2010–2019 by the Numbers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A total of 289 NMEs, 89 biological license applications (BLA), and 27 biosimilars were approved from 2010 to 2019 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> Over the decade, the median number of NME and BLA approvals per year was 40, with a low of 21 in 2010 and a high of 59 in 2018. This compares to a median of 25 drugs approved per year for the decade from 2000 to 2009, with a high of 36 in 2004 and a low of 18 in 2007.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The proportion of BLA approvals did not change over the past decade (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), with an average of 23% of all new drug approvals (excluding biosimilars). The lowest percentage of BLAs was approved in 2013, with 8% compared to a high of 32% in 2015. The number of biosimilar approvals has steadily increased since the first approval granted by the FDA in 2015.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. NME and BLA approvals from 2010 to 2019. Number of new molecular entities (NME), biological license applications (BLA), and biosimilars approved from 2010 to 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Approval Times</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The time from filing of the investigational new drug (IND) application to final new drug application (NDA) approval was compared for 268 new drugs from 2010 to 2019 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). This data was obtained either within FDA regulatory documents,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> or where the IND application date could not be found in FDA documents, the IND filing date was ascertained from the patent restoration (Drug Price Competition and Patent Restoration Act of 1984) documentation on the Federal Register.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Time from IND filing to drug approval. Approved drugs (<i>n</i> = 268) from 2010 to 2019. Drugs were included where IND filing times were accessible from FDA regulatory documents on <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e3a791968490a3a5a7a2">[email protected]</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> or from patent restoration documents on the federal register.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Mean and median times are included in the figure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The average time from IND filing to NDA approval was 8.7 years (±3.8), and the median was 8.1 years (range 2.2–23.2). The shortest time frame from IND filing to NDA approval was 2.2 years for osimertinib <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which was approved alongside a companion diagnostic for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive nonsmall cell lung cell cancer (NSCLC).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This was followed closely by deflazacort <b>2</b> (2.3 years), approved for Duchenne muscular dystrophy (DMD).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> On the other extreme, some examples with long IND to NDA approval times are ibalizumab and flibanserin <b>3</b>, which took ∼16 and ∼18 years from IND filing to NDA approval, respectively. Ibalizumab, a CD4 antibody that blocks entry of human immunodeficiency virus (HIV) into CD4+ T-cells, is the first novel treatment for HIV in >10 years as well as the first monoclonal antibody approved for HIV.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Flibanserin <b>3</b> was approved for the treatment of women with hypoactive sexual desire disorder.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of NMEs with examples of fastest (<b>1</b>, <b>2</b>) and slow (<b>3</b>) times from IND filing to NDA approval in the past decade. Osimertinib <b>1</b> (NSCLC with EGFR-T790 M mutation), 2.2 years; deflazacort <b>2</b> (DMD), 2.3 years; flibanserin <b>3</b> (hypoactive sexual desire disorder in females), 18 years. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previous studies of timelines from IND filing to NDA approval have been reported (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Between 1987 and 1989, the median total time for IND to NDA approval was 7.7 years, with a median time of 4.2 years in development and 2.5 years regulatory time.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This remained relatively constant between 1990 and 1992 (median of 7.8 years total time for IND to NDA approval, median of 4.9 years in clinical development and median of 2.0 years in regulatory review).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Between 1992 and 2002, the median time from IND filing to NDA approval decreased to 6.4 years, with median times of 5.1 years for clinical trials and 1.2 years for regulatory review (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The dramatic acceleration of regulatory approval was attributed to the Prescription Drug User Fee Act of 1992 (PDUFA) which utilized user fees as a mechanism to fund regulatory review and reduce review times.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Today, a number of expedited review designations can help to decrease regulatory review time, including Fast-track (instituted in 1988), Priority Review and Accelerated Approval (1992), and Breakthrough (2012) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> As a result, from 2012 to 2016, the median time from IND to NDA was 8.0 years for nonexpedited programs, while drugs with Breakthrough therapy designation received the fastest approvals, with a median of 4.8 years.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> According to current FDA data, approval times have remained consistent since the mid-1990s, with the median time for priority reviews in 2016 of ∼8 months versus ∼10 months for standard review applications.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Consistent with this data, our analysis of 268 drugs from 2010 to 2019 demonstrated a median regulatory approval time of 0.8 years (range 0.2–9.4 years) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entry 5).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Drug designation summary.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Comparison of IND to NDA Approval Times 1987–2019</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">data set</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th><th class="colsep0 rowsep0" align="center" char=".">median development time in years (range)</th><th class="colsep0 rowsep0" align="center" char=".">median regulatory approval time in years (range)</th><th class="colsep0 rowsep0" align="center" char=".">median time IND to NDA approval time in years (range)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1987–1989</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">7.7<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1990–1992</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">4.9 (1.3–25.0)</td><td class="colsep0 rowsep0" align="char" char=".">2.0 (0.4–10.2)</td><td class="colsep0 rowsep0" align="char" char=".">7.8 (3.0–27.6)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">1992–2002</td><td class="colsep0 rowsep0" align="char" char=".">168</td><td class="colsep0 rowsep0" align="char" char=".">5.1 (1.4–14.6)</td><td class="colsep0 rowsep0" align="char" char=".">1.2 (0.3–5)</td><td class="colsep0 rowsep0" align="char" char=".">6.4 (2.6–17.3)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2008</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">0.9 (0.3–3)</td><td class="colsep0 rowsep0" align="char" char=".">6.5 (1.6–19.4)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">2010–2019 (all cpds)</td><td class="colsep0 rowsep0" align="char" char=".">268</td><td class="colsep0 rowsep0" align="char" char=".">6.9 (1.7–22.6)</td><td class="colsep0 rowsep0" align="char" char=".">0.8 (0.2–9.4)</td><td class="colsep0 rowsep0" align="char" char=".">8.1 (2.2–23.2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">2010–2019 (BLA)</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">7.7 (1.8–18.6)</td><td class="colsep0 rowsep0" align="char" char=".">0.8 (0.2–3.5)</td><td class="colsep0 rowsep0" align="char" char=".">8.7 (2.7–19.9)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">2010–2019 (NME)</td><td class="colsep0 rowsep0" align="char" char=".">206</td><td class="colsep0 rowsep0" align="char" char=".">6.6 (1.6–22.6)</td><td class="colsep0 rowsep0" align="char" char=".">0.8 (0.2–9.4)</td><td class="colsep0 rowsep0" align="char" char=".">7.8 (2.2–23.2)</td></tr></tbody></table></div></div><div class="NLM_p last">Although approval times have improved in large part due to accelerated review designations, clinical trial cycle times (particularly Phase 2 and Phase 3 trials) have increased in recent years.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Martin et al. speculated that the increasing development time may be due to increasing complexity of trial design, increasing time for biologics versus small molecules, increase in the number of orphan disease trials, as well as increased time for running clinical trials in emerging markets.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We further analyzed the difference between NMEs and BLAs for this set of 268 drugs approved from 2019 to 2019, and did not see a statistical difference in development times or approval times between them (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entries 6 and 7).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Expedited Review Status</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To expedite the market entry of drugs for life-threatening or serious diseases, the FDA has instituted four expedited programs: Priority Review, Fast Track, Breakthrough, and Accelerated Approval (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). These categories are not mutually exclusive, meaning a drug can be granted expedited review status in more than one of these programs. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> illustrates the breakdown of expedited review designations for FDA-approved drugs from 2010 to 2019. For example, in 2019, of the 48 drugs approved, 17 were Fast Track (35%), 13 were Breakthrough (27%), 28 were Priority (58%), and 9 were Accelerated (19%). Priority Review designations make up the majority in the expedited review categories, with more than half of all drug approvals each year in this category since 2014 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The percentage of FDA-approved drugs with the Fast Track designation remained relatively constant over the decade (with the exception of 2010), with ∼35% of approved drugs on average. Since the introduction of the Breakthrough category in 2012, an increasing number of drugs has been awarded this designation and now makes up ∼25% of approved drugs. The most stringent category isAccelerated Approval, with an average of ∼13% of new drugs approved with this designation. The Accelerated Approval designation grants early approval of a drug, with the requirement that further clinical studies will be performed to confirm efficacy, and as such it is used sparingly. For example, only nine compounds in 2019 were given accelerated approval: erdafitinib <b>4</b>, zanubrutinib <b>5</b>, fam-trastuzumab deruxtecan-nxki, enfortumab vedotin-ejfv, polatuzumab vedotin-piiq, entrectinib <b>6</b>, and selinexor <b>7</b> were approved for oncology indications; voxelotor <b>8</b> was approved for sickle cell disease, and golodirsen was approved for DMD (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Three of these drugs are antibody-directed conjugates (ADCs) (fam-trastuzumab deruxtecan-nxk, enfortumab vedotin-ejfv, and polatuzumab vedotin-piiq) which we will discuss in more detail in the section on other modalities. Similar to 2019, the majority (3 out of 4) of accelerated approvals in 2018 were for oncology (larotrectinib <b>9</b>, duvelisib <b>10</b>, and lorlatinib <b>11</b>) while migalastat <b>12</b> was approved for the treatment of Fabry disease.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Drugs may have more than one designation; for example, of the 2018 accelerated approvals, larotrectinib <b>9</b> was given both Breakthrough and Priority review designation, duvelisib <b>10</b> was awarded Fast Track and Priority review, lorlatinib <b>11</b> was given Breakthrough and Priority review, and migalastat <b>12</b> was given Fast Track and Priority review.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Expedited review categories of FDA-approved drugs 2010–2019.<a onclick="showRef(event, 'ref14 ref32 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref14 ref32 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42">(14,32,34−42)</a> Each bar graph represents the percentage in each category against all drugs approved in a given year. A drug may be designated in multiple categories.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Accelerated NME small molecule drug approvals in 2018 and 2019. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Therapy Area Approvals</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An analysis of therapy areas was done for the 289 NMEs and the 89 BLAs approved from 2010 to 2019. The top five therapy areas for new drug approvals by the FDA (NME and BLA) were oncology (25% of all approvals), infection (14%), central nervous system (CNS) disorders (12%), metabolic disorders (7%), and cardiovascular diseases (6%) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a). Approximately 4% of new approvals were for the combined areas of hematology, respiratory, imaging/diagnostics, gastrointestinal, and immunology (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a). The analysis was also divided between therapy area approvals for 2010–2014 and 2015–2019 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>b) in order to see if any trends were emerging across the decade of approvals in particularly therapy areas. Of the therapy areas indicated above, hematology approvals increased over the decade, with only three drugs approved 2010–2014 (1.9%) compared to 14 drugs between 2015 and 2019 (6.3%). On the other hand, several diseases areas witnessed small to moderate decreases in [the fraction of] new drug approvals, including metabolic disorders (5.4% between 2015 and 2019 vs 10% between 2010 and 2014), respiratory diseases (3.1% between 2015 and 2019 vs 6.3% between 2010 and 2014), and imaging/contrast agents (3.1% between 2015 and 2019 vs 5.7% between 2010 and 2014). Notably, no cardiovascular or diabetes drugs were approved in 2018 and only one in 2019 (tafamidis for an orphan indication of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis). A slowdown in drug approvals for a given disease area may indicate that the current standard of care adequately covers the majority of patients. Furthermore, if many of the standard of care therapies are generic or will be generic soon, a new drug would need to have a clear patient benefit in order to justify the cost of the new therapy over the generic. Forecasts of patient need, competition, differentiation, and economic feasibility are all factors taken into consideration in a typical R&D strategy. However, these forecasts are frequently subject to significant change in early preclinical portfolios, evidenced by an AstraZeneca publication that reported “Strategy” being the leading cause of attrition in early preclinical development but a minor cause of attrition in later stage clinical development.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Finally, a slowdown or even lack of drug approvals for a disease area may indicate difficulties in identifying innovative therapies due to lack of a clear understanding of the underlying disease biology.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> However, as new drug approvals are a lagging indicator of investment, given the long average time from preclinical development to approval, any new drug on the market is likely a reflection of the previous decades’ research investments.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Approved drugs by therapy area 2010–2019. (a) Percentage of approvals by disease area based on 378 approved NMEs and BLAs 2010–2019. The category “other” was used to capture diseases which did not fit into any one of the other categories listed on the <i>X</i>-axis. A list of all the categories against each drug can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf" class="ext-link">Supporting Information</a>. (b) Therapy area approvals binned into 2010–2014 (orange) and 2015–2019 (green). The 2010–2014 percentage was based on an overall count of 158 drug approvals, and the 2015–2019 percentage based on 220 drug approvals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Oncology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A major breakthrough in cancer therapy over the past decade was the introduction of immuno-oncology (I-O) drugs, which harness the body’s immune system to attack cancer cells. A significant advance in this field came about with the discovery that T-cells could be turned on or off with so-called “immune checkpoints”.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A master regulator of this pathway was identified as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab, a CTLA-4 antibody, was approved in 2011 for metastatic breast cancer, marking the first approval of an immune-oncology drug. The novelty of the ipilimumab’s mechanism of action required the establishment of a new regulatory and clinical paradigm using immune-related clinical end point criteria.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> One reason was that the types of responses of I-O drugs in clinical trials were not captured by conventional response criteria such as Response Evaluation Criteria in Solid Tumours (RECIST). A further confounding factor was that the time to meet certain end-points (e.g., survival) was longer than that of traditional chemotherapy.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In 2014, pembrolizumab, a programmed death receptor-1 (PD-1)-blocking agent, was the first drug of the second generation of immune-oncology drugs to be approved.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> PD-1 has two known ligands, the cell surface proteins programmed cell death protein 1 ligand 1 (PD-L1) and PD-L2. A variety of tumor cells express PD-1, which interacts with PD-L1 on T-cells to inhibit T-cell function.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Thus, antibodies that block PD-1 on tumor cells prevent them from evading immunosurveillance by T-cells. Pembrolizumab was given initial Accelerated Approval for advanced, unresectable or metastatic melanoma but was later approved for a range of cancers including NSCLC, gastric cancer, and cervical cancer.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Nivolumab is another drug in the same class which was also approved in 2014, while two PD-L1 targeting antibodies, atezolizumab and durvalumab, were approved in 2016 and 2017, respectively.</div><div class="NLM_p">Another significant new class of cancer therapeutics approved in the past decade were inhibitors of poly(ADP-ribose) polymerases (PARP) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The first PARP inhibitor, olaparib <b>13</b>, was approved in 2014 for BRCA-mutated advanced ovarian cancer. Mutations in BRCA1 and 2 lead to defective homologous recombination (HR), a pathway by which DNA double-strand breaks are repaired.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Mutations in BRCA render tumor cells sensitive to PARP inhibitors, as PARP is recruited to damaged DNA and PARP inhibitors effectively trap PARP on DNA, leading to cell death.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Other PARP inhibitors approved following olaparib <b>13</b> were rucaparib <b>14</b> (2016), niraparib <b>15</b> (2017), and talazoparib <b>16</b> (2018) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Approved inhibitors of poly(ADP-ribose) polymerases (PARP). Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among the 103 oncology drugs approved during 2010–2019, the largest initial indications were leukemias (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, 17% of all approvals), followed by breast cancer (12%) and NSCLC (9%). Of the 18 approvals for leukemia, 50% were considered first-in-class (FIC) approvals. Among the small molecule approvals were the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosidenib (2018) <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), the IDH2 inhibitor enasidenib (2017) <b>18</b>, the tyrosine kinase KIT (KIT) and FMS-like tyrosine kinase-3 (FLT3) inhibitor midostaurin (2017) <b>19</b>, and the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax (2017) <b>20</b>. Other novel kinase inhibitors that were approved for leukemia were the phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (2014) <b>21</b>, Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (2013) <b>22</b>, and Bcr-Abl inhibitor ponatinib (2012) <b>23</b>. In addition, two BLA approvals were considered FIC: the CD22-directed antibody drug conjugate (ADC) inotuzumab (2017) and the bispecific CD19-directed CD3 T-cell engager blinatumomab (2014) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These targeted new medications are providing more options to leukemia patients.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. First-in-class (FIC) approvals in oncology for leukemia (2010–2019). Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. New Oncology Drugs Approved 2010–2019 for Leukemia</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">year</th><th class="colsep0 rowsep0" align="center">type</th><th class="colsep0 rowsep0" align="center">FIC (Y/N?)</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">indication</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">moxetumomab pasudotox</td><td class="colsep0 rowsep0" align="left">CD22-directed cytotoxin</td><td class="colsep0 rowsep0" align="left">hairy cell leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">calaspargase pegol-mknl</td><td class="colsep0 rowsep0" align="left">asparagine specific enzyme</td><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">ivosidenib (<b>17</b>)</td><td class="colsep0 rowsep0" align="left">IDH1 inhibitor</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">duvelisib</td><td class="colsep0 rowsep0" align="left">dual inhibitor of phosphatidylinositol 3-kinases PI3K-δ and PI3K-γ</td><td class="colsep0 rowsep0" align="left">chronic lymphocytic leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">glasdegib</td><td class="colsep0 rowsep0" align="left">hedgehog pathway inhibitor</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">gilteritinib</td><td class="colsep0 rowsep0" align="left">FLT3 inhibitor; other kinases</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">inotuzumab</td><td class="colsep0 rowsep0" align="left">CD22-directed antibody drug conjugate (ADC)</td><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">midostaurin (<b>19</b>)</td><td class="colsep0 rowsep0" align="left">FLT3 and KIT inhibitor</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">enasidenib (<b>18</b>)</td><td class="colsep0 rowsep0" align="left">IDH2 inhibitor</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">venetoclax (<b>20</b>)</td><td class="colsep0 rowsep0" align="left">BCL-2 inhibitor</td><td class="colsep0 rowsep0" align="left">chronic lymphocytic leukemia with 17p deletion</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">blinatumomab</td><td class="colsep0 rowsep0" align="left">bispecific CD19-directed CD3 T-cell engager</td><td class="colsep0 rowsep0" align="left">B-cell precursor acute lymphoblastic leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">idelalisib (<b>21</b>)</td><td class="colsep0 rowsep0" align="left">PI3Kδ inhibitor</td><td class="colsep0 rowsep0" align="left">chronic lymphocytic leukemia; follicular B-cell non-Hodgkin lymphoma; small lymphocytic lymphoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">obinutuzumab</td><td class="colsep0 rowsep0" align="left">CD20-directed cytolytic antibody</td><td class="colsep0 rowsep0" align="left">chronic lymphocytic leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">ibrutinib (<b>22</b>)</td><td class="colsep0 rowsep0" align="left">BTK inhibitor</td><td class="colsep0 rowsep0" align="left">Mantle cell lymphoma and chronic lymphocytic leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">bosutinib</td><td class="colsep0 rowsep0" align="left">Bcr-Abl; src-tyrosine kinase inhibitor</td><td class="colsep0 rowsep0" align="left">chronic myelogenous leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">Y</td><td class="colsep0 rowsep0" align="left">ponatinib (<b>23</b>)</td><td class="colsep0 rowsep0" align="left">Bcr-Abl inhibitor</td><td class="colsep0 rowsep0" align="left">chronic myelogenous leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">omacetaxine mepesuccinate</td><td class="colsep0 rowsep0" align="left">protein synthesis inhibitor; protein translation inhibitor</td><td class="colsep0 rowsep0" align="left">chronic myelogenous leukemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">asparaginase <i>Erwinia chrysanthemi</i></td><td class="colsep0 rowsep0" align="left">asparaginase</td><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td></tr></tbody></table></div></div><div class="NLM_p">A significant development in the past decade was the growing number of oncology drugs that were approved with a diagnostic FDA-approved companion test. The first companion diagnostic to come to the market was for trastuzumab in 1998.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Overall, the FDA has approved 44 companion diagnostics since 1998.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The vast majority of these approvals are for oncology indications (43/44). Notably, of the 38 FIC oncology approvals between 2010 and 2019, 12 have a diagnostic FDA-approved companion test. The NMEs approved with this designation include the previously mentioned erdafitinib <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, fibroblast growth factor receptor inhibitor), larotrectinib <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, TrkA, TkrB, and TrkC inhibitor<b>)</b>, olaparib <b>13</b>, (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), ivosidenib <b>17</b>, enasidenib <b>18</b>, midostaurin <b>19</b>, ventoclax <b>20</b>, (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), trametinib <b>24</b> (MEK1 and MEK2 inhibitor), vemurafenib <b>25</b> (BRAF serine-threonine kinase inhibitor), and crizotinib <b>26</b> (ALK and ROS1, cMET inhibitor) (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The additional oncology FIC approvals with a diagnostic FDA-approved companion test were two approved biologics, trastuzumab emtansine (2013) and ipilumab (2011). An illustration of this growing development of patient subpopulation-specific therapies in the industry was highlighted in a recent paper which showed a 9-fold increase in diagnostic approvals at AstraZeneca since 2005.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> In 2015, the FDA approved the first complementary diagnostic, a PD-L1 staining assay for nivolumab for the treatment of NSCLC. Unlike companion diagnostics, complementary diagnostics are not intended to exclude patients from receiving a particular treatment; rather they are intended to identify patients who may respond particularly well to a therapy.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Example FIC approvals in oncology with a diagnostic FDA-approved companion test. Year of approval in parentheses. Other NME approvals with a diagnostic FDA-approved companion test incude larotrectinib <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), olaparib <b>13</b>, (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), ivosidenib <b>17</b>, enasidenib <b>18</b>, midostaurin <b>19</b>, and ventoclax <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Infection—New Antiviral Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The decade of 2010–2019 witnessed the introduction of multiple new mechanisms to combat viral infections. The first monoclonal antibody and new therapeutic mechanism for HIV in more than a decade was approved in 2018 with the CD4 antibody ibalizumab-uiyk. In addition, a novel drug for cytomegalovirus (CMV), letermovir <b>27</b>, was approved in 2017 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). CMV is the leading cause of viral birth defects and opportunistic infections in stem cell or solid organ transplant patients.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The three drugs previously available for CMV (valganciclovir, foscarnet, and cidofovir) are associated with adverse drug reactions such as leukopenia and neutropenia (valganciclovir) and nephrotoxicity (foascarnet and cidofovir).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Letermovir <b>27</b> is a non-nucleoside CMV inhibitor that inhibits the deoxyribonucleic acid (DNA) terminase complex. Its distinct mechanism of action is associated with fewer adverse reactions.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Examples of recently FDA-approved antiviral drugs. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By far the largest impact in antiviral drug discovery in the past decade was in hepatitis C virus (HCV) therapy. In 2011, boceprevir <b>28</b> was approved as the first NS3/4A serine protease inhibitor to be used in combination with peginterferon alfa and ribavirin.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In 2013, the first NS5B polymerase inhibitor, sofosbuvir <b>29</b>, was approved,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> followed by NS5A inhibitors such as daclatasvir <b>30</b>.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The combination of ledipasvir <b>31</b> (also an NS5A inhibitor) and sofosbuvir <b>29</b> demonstrated remission of HCV with rates of 94% and 99% in patients who received ledipasvir/sofosbuvir for 12 and 24 weeks, respectively.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The therapeutic success of this combination treatment led to the withdrawal of boceprevir <b>28</b> in 2015 as well as another NS3/4A inhibitor, telaprevir, in 2014.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> In addition to daclatasvir <b>30</b> and ledipasvir <b>31</b>, another NS5A inhibitor velpatasvir <b>32</b> was approved in 2016. Further advances in the field led to many new HCV NS3/4A protease inhibitors such as simeprevir <b>33</b>, paritaprevir <b>34</b>, grazoprevir <b>35</b>, glecaprevir <b>36</b>, and voxilaprevir <b>37</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). These new protease inhibitors have provided pan-genotype coverage for HCV genotypes 2 and 3 and allow for broader treatment regimens and improved remission rates compared to early protease inhibitors that only covered genotype 1.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> These structures also highlight the synthetic complexity and significant innovation and achievements of drug discovery and development chemists in the industry. Overall, the success of HCV drugs that lead to complete remission is one of the spectacular examples of innovation and delivery over the past decade.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Examples of recently FDA-approved HCV NS3/4A protease inhibitors. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Infection—New Antibacterial and Antiparasitic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Approvals of antibacterial drugs also increased throughout the decade. Many articles have been written about the emerging crisis of superbugs and drug-resistant bacteria coupled with a large divestment of many major pharmaceutical companies.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> Because of this potential health crisis and paucity of new drugs coming to the market, the GAIN act (“Generating Antibacterial Incentives Now”) was passed in 2011 providing 5 years of market exclusivity and fast-track approval for new antibiotics.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Potential drugs that treat life-threatening infections can be given the qualified infectious disease products (QIDP) designation and allowed to take advantage of the GAIN act legislative incentives. However, it remains to be seen how well these products will do commercially and whether they can sustain future investments in this most critical area.</div><div class="NLM_p">A total of 15 new antibacterial drugs have been approved with the QIDP designation since 2014 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Despite the GAIN act’s incentive to develop novel antibiotics, new classes of antibacterial therapeutics still remain elusive, with the vast majority of approvals originating from legacy classes of therapeutics such as tetracyclines, aminoglycosides and fluoroquinolones. There have been some innovative developments in β-lactamase inhibitors such as vaborbactam <b>38</b> (2017), the first oxoborole β-lactamase inhibitor which was approved in combination with Meropenem (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Another new class of β-lactamase inhibitors, avibactam <b>40</b> (a non β-lactam), was approved in combination with ceftazidime <b>39</b> in 2015.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Finally in 2019, the first pleuromutilin (lefamulin <b>41</b>) was approved as both oral and intravenous formulations for use against community acquired bacterial pneumonia (CABP).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Pleuromutilins inhibit bacterial protein synthesis by binding to the peptidyltransferase center of the 50S subunit of the bacterial ribosome. Several drugs for neglected tropical diseases were also approved, such as pretomanid <b>42</b> for multidrug-resistant tuberculosis (TB) (2019),<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> moxidectin <b>43</b> for river blindness (2018),<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> tafenoquine <b>44</b> for the treatment of malaria (2018),<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and benznidazole <b>45</b> for Chagas disease (2017).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Charitable and philanthropic foundations have driven and enabled the development of a number of tropical disease drugs; for example, pretomanid <b>42</b> was developed by the Global Alliance for TB Drug Development (TB Alliance),<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> while tafenoquine <b>44</b> was developed in partnership by Medicines for Malaria Venture and GlaxoSmithKline (GSK).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> These types of foundations and collaborations are critical to addressing neglected tropical diseases that lack significant economic incentives to invest in the research, development, and commercialization of new drugs.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Examples of recently FDA-approved antibacterial drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. QIDP Approvals</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">year of approval</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">class</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">cefiderocol sulfate tosylate</td><td class="colsep0 rowsep0" align="left">cephalosporin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">cilastatin sodium; imipenem; relebactam</td><td class="colsep0 rowsep0" align="left">renal dehydropeptidase inhibitor, carbapenem, and beta lactamase inhibitor</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">lefamulin (<b>41</b>)</td><td class="colsep0 rowsep0" align="left">pleuromutilin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">plazomicin</td><td class="colsep0 rowsep0" align="left">aminoglycoside</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">eravacycline</td><td class="colsep0 rowsep0" align="left">tetracycline</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">omadacycline</td><td class="colsep0 rowsep0" align="left">tetracycline</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">rifamycin</td><td class="colsep0 rowsep0" align="left">ansamycin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">delafloxacin</td><td class="colsep0 rowsep0" align="left">fluoroquinolone</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">Meropenem-vaborbactam</td><td class="colsep0 rowsep0" align="left">carbapenem; oxoborole beta lactamase inhibitor</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">ceftazidime-avibactam (<b>39</b>–<b>40</b>)</td><td class="colsep0 rowsep0" align="left">cephalosporin; beta lactamase inhibitor</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">dalbavancin</td><td class="colsep0 rowsep0" align="left">lipoglycopeptide</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">tedizolid</td><td class="colsep0 rowsep0" align="left">oxazolidinone</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">oritavancin</td><td class="colsep0 rowsep0" align="left">lipoglycopeptide</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">finafloxacin</td><td class="colsep0 rowsep0" align="left">fluoroquinolone</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">ceftolozane/tazobactam</td><td class="colsep0 rowsep0" align="left">cephalosporin; beta lactamase inhibitor</td></tr></tbody></table></div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Central Nervous System Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The beginning of this decade ushered in significant changes in neuroscience drug development, with several major pharmaceutical companies closing research groups including AstraZeneca, GSK, and Novartis, along with Pfizer, Merck and Sanofi making major withdrawals in the area as well.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> This steep divestment was partly driven by increasingly risky paths to developing psychiatric drugs, once the mainstay of many large pharmaceutical pipelines and commercial sales, with costly late-stage failures due to poor target characterization and translational models.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Furthermore, in contrast to oncology and other disease areas, biomarkers were not readily available, especially for psychiatric diseases. Against this backdrop of substantial withdrawals in CNS research and drug development, it was surprising to observe that the number of CNS drug approvals remained steady through the decade at ∼10% of total approvals.</div><div class="NLM_p">Among notable recent approvals in CNS, edaravone <b>46</b> is the first new amyotrophic lateral sclerosis (ALS) treatment to be approved in 20 years (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The drug is derived from legacy stroke efforts and is presumed to work as a free-radical scavenger. Administered in i.v. formulation in 28-day cycles (14 daily infusions + 14 drug-free days for the first cycle, followed by 10 infusions within 14 days +14 drug-free days for subsequent cycles), edaravone was shown to slow down disease progression in a subset of ALS patients as measured by decline in the ALS functional rating scale-revised (ALSFRS-R).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. FIC approvals for CNS drugs 2010–2019. Ubrogepant <b>47</b> is not officially a FIC drug since erenumab-aooe was the first approved CGRP receptor blocker, but it is included since it is the first small molecule with such a mechanism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another notable approval was nusinersen, the first approved treatment for spinal muscular atrophy (SMA), a group of rare neuromuscular disorders characterized by the loss of motor neurons.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> SMA is an umbrella term for several disease subtypes, defined by age of onset and disease severity. SMA is caused by mutations in the survival of motor neuron gene 1 (SMN1) gene, one of two genes encoding the protein survival of motor neuron protein (SMN). Loss of SMN protein is the driver of the neurodegenerative phenotype. The second gene, SMN2, has a near-identical sequence to SMN1 but harbors a single nucleotide substitution that results in exclusion of exon 7, leading to the expression of a truncated protein.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Nusinersen is an antisense oligonucleotide (ASO) that modulates the splicing of SMN2 pre-mRNA, promoting inclusion of exon 7 in SMN2 and thus increasing the production of functional SMN. The drug is administered intrathecally with four loading doses, the first three at 14-day intervals and the fourth 30 days after the first dose. A maintenance dose is scheduled every four months.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">The past decade also saw approvals for migraine medications, with three new monoclonal antibody calcitonin-gene-related peptide (CGRP) antagonists approved in 2018 (fremanezumab, erenumab, and galcanezumab).<a onclick="showRef(event, 'ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82">(80−82)</a> These drugs marked the first new treatments for migraine in more than 20 years.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> They offer prophylactic control of migraines, an important distinction to the oral generic medications currently on the market. Injections are administered monthly (erenumab and galcanezumab) or quarterly (fremanezumab). In 2019, two oral migraine drugs were approved, the CGRP antagonist ubrogepant <b>47</b> and the serotonin (5-HT) 1F receptor agonist lasmitidan <b>48</b>.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a></div><div class="NLM_p last">Other FIC CNS drugs approved between 2010 and 2019 are highlighted in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>. Lofexidine <b>49</b> is an α2-adrenergic agonist for opioid withdrawal (2018), istradefylline <b>50</b> an adenosine receptor antagonist for use in Parkinson’s disease (2019), perampanel <b>51</b> a α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist acting as an antiseizure medication (2012), brexanolone <b>52</b> a γ-aminobutyric acid A receptor positive modulator (GABA<sub>A</sub>) for postpartum depression (2019), suvorexant <b>53</b> an orexin-1 antagonist for sleep disorders (2014), dimethyl fumarate <b>54</b> for multiple sclerosis (2013), fingolimod <b>55</b> a sphingosine receptor modulator for multiple sclerosis (2010), and pitolisant <b>56</b> an H3 antagonist for narcolepsy (2019).</div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Orphan Indications</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Orphan Drug Act of 1983 provided a 7 year period of market exclusivity as well as tax credits and grants to support clinical testing of drugs aimed at orphan diseases.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Based on the data set of 289 NME and 89 BLA from 2010 to 2019, the number of NME approved under the Orphan Drug Act has increased over the past decade, from a low of 20% of all approvals under this designation in 2010 to >40% for the past 4 years (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>), with a 10 year average of 37%. The average percentage of BLA approvals with orphan designation was 48% of all approvals. These numbers are consistent with a recent paper that indicated 41% of all approvals are under the Orphan Drug Act designation.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Orphan designations per year as a fraction of approved NME and BLA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recent examples of orphan disease approvals include migalastat <b>12</b> (F<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">igure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), which was approved in 2018 for the treatment of adults with Fabry disease, a life-threatening lysosomal storage disorder caused by α-galactosidase deficiency leading to the toxic accumulation of globotriaosylceramide (GL-3).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Some estimates place the prevalence of Fabry disease to be 1 in 40 000 to 1 in 60 000, although this number is disputed.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Migalastat <b>12</b> is proposed to act as a pharmacological chaperone correcting the conformation of mutant enzymes and thus enabling the breakdown of excessive glycolipids.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><div class="NLM_p">Another notable example of an orphan disease drug is burosumab, which was approved in 2018 for the treatment of adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), a vitamin D-resistant form of Rickets.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The prevalence of the disease is ∼1:20 000, and it is caused by mutations in the phosphate-regulating endopeptidase homologue X-linked (PHEX) gene.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Burosumab is a monoclonal antibody targeting circulating fibroblast growth factor 23 (FGF-23), a key protein involved in phosphate homeostasis.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The drug was shown to be effective at decreasing the severity and physical outcomes of XLH in a pediatric trial when administered by injection every 2 weeks.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><div class="NLM_p last">A final example is ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a very rare disease with a prevalence as low as 0.5–1.5 per million.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> PNH is caused by an immune response of the complement system against defective red blood cells, resulting in hemolysis, potentially life-threatening blood clots and bone marrow issues. Ravulizumab works as a complement C5 inhibitor and was shown to be noninferior to eculizumab (approved in 2007, and the current standard of care); it is administered every 8 weeks compared to every 2 weeks for eculizumab.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">First in Class Approvals</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Paul et al. demonstrated that only 17% of approved drugs in 2009 were considered FIC, down from 29% in 2008, suggesting a decline in innovation and productivity across the pharmaceutical and biotech industry.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Here we analyzed the 2010–2019 FDA-approved drugs and determined the percent FIC based on year of approval (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). We found that on average 37% of new drugs over the past decade are FIC, with a low of 32% in 2013 and high of 49% in 2012. This compares well to the previous numbers leading into the decade (17% of approved in 2009 and 29% in 2008), suggesting that innovation (as measured by FIC approvals) has not stagnated throughout the decade.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. First-in-class approvals by year.<a onclick="showRef(event, 'ref32 ref34 ref35 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref32 ref34 ref35 ref37 ref38 ref39 ref40 ref41 ref42">(32,34,35,37−42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Route of Administration and Combination Therapy for NMEs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25448" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25448" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The dominant route of administration for all NMEs from 2010 to 2019 remained oral administration (201 drugs approved for oral administration). Although the year-by-year percentage of oral drugs compared to other routes of administration is somewhat variable, there was no noticeable increasing or decreasing trend toward other routes of administration over the decade (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>a). On average, 66% of all new approvals in the past decade were for oral administration. Intravenous administration was the second most common route of administration of NMEs, with a 15% average of all approvals in this category. Other routes of administration included inhaled, intramuscular, otic, and topical. Only one intrathecal drug was given approval, the SMA drug nusinersen.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (a) FDA approvals from 2010 to 2019 based on route of administration and (b) FDA approvals from 2010 to 2019 categorized into single administration or fixed dose combination. Only the approval for the original route of administration was included in the analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We further classified approved NMEs into single agent or fixed-dose combination approvals. Only ∼10% of NMEs were approved as fixed dose combinations from 2010 to 2019 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>b). Infection drugs are the most dominant class in this category, with examples in HCV highlighted previously such as sofosbuvir <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) and ledipasvir <b>31</b> (2014, NS5B and NS5A inhibitors)<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and a fixed three drug combination of sofosbuvir <b>29</b>, (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), velpatasvir <b>32</b> (NS5A inhibitor), and voxilaprevir <b>37</b> (NS3/4A inhibitor) approved in 2017. In addition to HCV, a four-drug combination was approved in 2012 for HIV: elvitegravir <b>57</b> (integrase inhibitor), cobicistat <b>58</b> (CYP3A4 inhibitor), tenofovir <b>59</b> (reverse transcriptase inhibitor), and emtricitabine <b>60</b> (reverse transcriptase inhibitor) (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). A final example is the antibacterial combination of ceftazidime <b>39</b> and avibactam <b>40</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) approved in 2015. Of the 24 drugs in this category, 13 are for either viral or bacterial infections (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). This is largely driven by the need in infectious disease to have drugs working on multiple mechanisms in order to combat drug resistance.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Example of FDA-approved fixed dose combination drug for HIV (2012).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Approved Fixed-Dose Combinations</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">year of approval</th><th class="colsep0 rowsep0" align="center">combinations</th><th class="colsep0 rowsep0" align="center">indication</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">elexacaftor <b>61</b>, tezacaftor <b>62</b>, ivacaftor <b>63</b></td><td class="colsep0 rowsep0" align="left">cystic fibrosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">trastuzumab;hyaluronidase-oysk</td><td class="colsep0 rowsep0" align="left">breast cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">cilastatin sodium; imipenem; relebactam</td><td class="colsep0 rowsep0" align="left">antibacterial</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">bictegravir, embitcitabine, tenofovir and alafenamide</td><td class="colsep0 rowsep0" align="left">HIV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">tezacaftor <b>62</b> and ivacaftor <b>63</b></td><td class="colsep0 rowsep0" align="left">respiratory disorders</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">fosnetupitant and palonosetron</td><td class="colsep0 rowsep0" align="left">antiemetic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">segesterone acetate and ethinyl estradiol</td><td class="colsep0 rowsep0" align="left">sexual health</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">sofosbuvir <b>29</b>, velpatasvir <b>32</b>, and voxilaprevir <b>37</b></td><td class="colsep0 rowsep0" align="left">HCV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">glecaprevir and pibrentasvir</td><td class="colsep0 rowsep0" align="left">HCV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2017</td><td class="colsep0 rowsep0" align="left">Meropenem and vaborbactam</td><td class="colsep0 rowsep0" align="left">antibacterial</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">grazoprevir and elbasvir</td><td class="colsep0 rowsep0" align="left">HCV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">sofosbuvir <b>29</b> and velpatasvir <b>32</b></td><td class="colsep0 rowsep0" align="left">HCV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">ceftazidime <b>39</b> and avibactam <b>40</b></td><td class="colsep0 rowsep0" align="left">antibacterial</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">lumacaftor and ivacaftor <b>63</b></td><td class="colsep0 rowsep0" align="left">respiratory disorders</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">sacubitril and valsartan</td><td class="colsep0 rowsep0" align="left">cardiovascular</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">elvitegravir, cobicistat, emtricitabine, and tenofovir</td><td class="colsep0 rowsep0" align="left">HIV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">trifluridine <b>64</b> and tipiracil <b>65</b></td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">netupitant and palonosetron</td><td class="colsep0 rowsep0" align="left">antiemetic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">ledipasvir <b>31</b> and sofosbuvir <b>29</b></td><td class="colsep0 rowsep0" align="left">HCV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">ombitasvir, paritaprevir, ritonavir and dasabuvir</td><td class="colsep0 rowsep0" align="left">HCV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">ceftolozane and tazobactam</td><td class="colsep0 rowsep0" align="left">antibacterial</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">umeclidinium and vilanterol</td><td class="colsep0 rowsep0" align="left">respiratory disorders</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">elvitegravir <b>57</b>, cobicistat <b>58</b>, tenofovir <b>59</b>, and emtricitabine <b>60</b></td><td class="colsep0 rowsep0" align="left">HIV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2010</td><td class="colsep0 rowsep0" align="left">estradial valerate and dienogest</td><td class="colsep0 rowsep0" align="left">sexual health</td></tr></tbody></table></div></div><div class="NLM_p">Outside of infection, perhaps the most promising fixed-dose combinations are used for the treatment of cystic fibrosis (CF). The recent approval of the triple combination of elexacaftor <b>61</b>, tezacaftor <b>62</b>, and ivacaftor <b>63</b> in 2019 provided a new therapeutic option for CF patients who have at least one F508del mutation in the CFTR gene.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), a cell surface chloride channel regulating fluid transport in the lung and other organs. CF is characterized by respiratory distress and reduced life expectancy. The combination therapy includes two correctors that bind to different sites of the CFTR protein and are additive (elexacaftor <b>61</b> and tezacaftor <b>62</b>), leading to increased trafficking of CFTR to the cell surface, and a potentiator (ivacaftor <b>63</b>) that increases the transport of chloride (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> As ∼90% of CF patients harbor at least one mutant F508del allele, this triple-combination therapy is suitable for the vast majority of patients, marking a major advance compared to previous combination treatments that were specific for a narrow patient population.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Example of recently FDA-approved fixed dose combination drug for CF (2019).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Intriguingly, only two fixed-dose combinations for oncology were approved in the past decade. Most recently, the fixed dose combination of the HER2 receptor antibody trastuzumab and hyaluronidase-oysk, an enzyme that increases the tissue permeability in tumors that accumulate hyaluronan, was approved in 2019 for breast cancer.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> In 2015, the combination of trifluridine <b>64</b> and tipiracil <b>65</b> (2015) was approved for colorectal cancer (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Trifluridine is a nucleoside analogue that inhibits DNA synthesis, and tipiracil <b>65</b> increases the bioavailability of trifluridine by inhibiting thymidine phosphorylase, the enzyme responsible for breaking down the trifluridine complex.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Example of oncology drug approved as a fixed-dose combination (2015).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec13" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Black Box Warnings</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71751" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71751" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many FDA-approved drugs receive a black box warning, which is a statement made directly in the label to indicate serious or life-threatening side effects. Implemented in 1979, box warnings can be attached at the time of a drug’s approval or during the postmarket period.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> They can be specific for a drug or can be attached to a whole class of drugs, as in the case of fluoroquinolone antibiotics.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> We analyzed all 389 NMEs and BLAs from 2010 to 2019 to identify those that were initially approved with a black box warning (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Of NMEs, 21% were approved with a black box warning, while almost half (42%) of BLA approvals were issued black box warnings. The high number of BLA approvals with black box warnings may be due a number of factors. More BLAs are approved for orphan indications. Given the lack of treatment options for orphan diseases, the willingness to carry a monitored risk into the clinic is higher when compared to the alternative of no treatment. Furthermore, patients treated with biologics are at increased risk of opportunistic infections, either as a result of the disease indication itself, the mechanism of action of the biologic or the route of administration.<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101,102)</a> Biologic drugs can predispose toward various infectious agents including bacteria (e.g., <i>Listeria</i>, <i>Nocardia</i>, <i>Burkholderia</i>), viruses (e.g., CMV, herpes simplex), fungi (e.g., <i>Aspergillus</i>, <i>Cryptococcus</i>), and parasites (e.g., <i>Toxoplasma</i>, <i>Acanthamoeba</i>, <i>Leishmania</i>). Examination of the therapy areas of the approved drugs from 2010 to 2019 revealed that 31/103 (30%) of oncology drugs, 8/56 (14%) of infection drugs, 13/45 (28%) of CNS drugs, 7/28 (25%) of metabolic disease drugs, and 11/22 (50%) of cardiovascular drugs are approved with black box warnings. Based on this data set, cardiovascular drugs are most likely to carry black box warnings.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Percent of approved drugs with black box warning.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec14" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">What Do New Small Molecule Drugs Look Like?</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76080" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76080" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We next endeavored to understand the calculated physicochemical profile of small molecule drugs in the 2010–2019 approved drugs set, in particular oral drugs. The Ro5 analysis was based on 90th percentile predictions for each parameter and was formulated by examining the characteristics of oral drugs to estimate solubility and permeation, with certain caveats (e.g., transported mediated permeation).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The “Rule of 5” (Ro5) is a set of guidelines which characterizes a large majority of known oral drugs and is predictive of good permeability and absorption.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The rules are as follows (1) the molecule has no more than 5 H-bond donors (HBD); (2) the molecule has no more than 10 H-bond acceptors (HBA); (3) the molecular weight (MW) is <500; and (4) cLogP < 5.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> An oral drug is said to be within the guidelines if it violates no more than one of these four rules. We examined the drugs approved from 2010 to 2019 to see if they largely fell inside or outside those guidelines. In the original 2001 paper describing the Rule of 5 by Lipinksi et al, ∼90% of known oral drugs were within the guidelines. In this set (2010–2019), a total of 201 drugs were approved for oral administration (including four antibacterial drugs approved for both oral and intravenous route of administration). Oral drugs that did not need to have systemic exposure for their respective indications were removed. These included drugs for gastrointestinal disorders such as fidaxomicin (2011), linaclotide (2012), crofelmer (2012), plecanatide (2017), rifamycin (2018), and tenapanor (2019). Furthermore, the colonoscopy agents sodium picosulfate/citric acid/magnesium oxide (2012), sodium zirconium cyclosilicate (2018), and patiromer (2015) (a potassium binder in the gut) were also excluded from the analysis.</div><div class="NLM_p">This left a total of 192 approved drugs and oral drug combinations which are expected to be orally absorbed. Since several of these approved drugs were drug combinations with a previously approved drug, the combination partners were included in the analysis, giving a total of 204 small molecule oral drugs for evaluation. We found that only 17% (35/204) of the drugs included in the analysis violate more than one guideline, whereas 83% (169/204) violate one guideline or none (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>a). Furthermore, the number of approved oral drugs which have >1 violation did not change significantly over time in the decade from 2010 to 2019 (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>b). Of the violations, the majority (62/73) were due to MW, followed by clogP (18/73) and then hydrogen bond acceptor (13/73) violations. This data is consistent with a recent publication that indicates high MW is a more tolerable physical property than outlined the original Lipinski paper, as a number of higher MW oral drugs have been approved over the past decade.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Another recent analysis by Michael Shultz on two decades of Ro5 similarly found that MW and HBA cutoffs have increased, whereas clogP and HBD have remained constant and are least likely to be exceeded.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> It should also be noted that logP is a calculation and as such may have inherent errors, and this possibility should be considered as part of the Ro5 analyses.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. (a) Total analysis of Ro5 violations for 204 approved oral drugs and (b) Ro5 violations per year on 204 approved oral drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Properties that lend themselves to clinically successful hit-to-lead and lead optimization campaigns have been the topic of several recent review articles.<a onclick="showRef(event, 'ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref108 ref109">(108,109)</a> Of particular interest, Young and Leeson address the efficiency and lead-like trajectories in lead optimization across a broad range of therapy areas.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> For example, some of the marketed PARP inhibitors (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) originated from the same lead compound that possessed high ligand efficiency (LE) and excellent lead-like physicochemical properties. The authors also discuss the origins and trajectories of the HCV drug from both the NS3/4A NS5A inhibitor classes (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> and <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>). These examples fall into recently named “beyond the rule of 5” (bRo5) type compounds, a term applied to drugs that do not adhere to the Ro5 observations that characterize most oral drugs.<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110,111)</a> Young and Leeson conclude that although the characteristics that predict successful trajectories of bRo5 compounds are not fully known, many examples of successful drugs in this class possess high LE and high lipophilic ligand efficiency (LLE).</div></div><div id="sec15" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Other Modalities</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Both antisense oligonucleotides and small interfering RNA (siRNA) are RNA-targeted nucleotide therapeutics aimed at modulating gene expression. ASOs are single-stranded modified deoxyribonucleotides that bind to a complementary RNA sequence. This can lead to either steric hindrance of translation, degradation of the DNA-RNA complex by RNase H or modulation of splicing. In contrast, siRNA comprises double-stranded RNA molecules that are unwound inside the cell. The single-stranded RNA likewise binds a complementary RNA target sequence and causes degradation of the mRNA, thus leading to silencing of expression. A total of six ASOs and two siRNAs were approved from 2010 to 2019 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In comparison, only two ASOs and no siRNA therapeutics were approved prior to 2009.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Among these are eteplirsen (2016), an ASO for the treatment of DMDM amenable to exon 51 skipping, as well as the aforementioned ASO nusinersen for the treatment of SMA.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Nusinersen marked the only approval with an intrathecal route of administration in this cohort (2010–2019).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Another ASO, inotersen (2018), was approved for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> In 2018, patisiran, the first FDA-approved siRNA was granted for polyneuropathy in hATTR. This was shortly followed by givosiran (2019), an siRNA for the treatment of acute hepatic porphyria. This last example also highlights innovation in the delivery of new modalities, as the siRNA oligonucleotide is covalently attached to a tethered ligand with N-acetylgalactosamine that improves delivery to hepatocytes.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Aptamers are single-stranded oligonucleotides that specifically bind target molecules such as polypeptides or small molecules.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> The first approved aptamer pegaptanib was approved in 2004 for wet macular degeneration, but quickly lost market share to monoclonal antibodies bevacizumab and ranibizumab (2006) due to superior efficacy.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> No other aptamers have thus far been approved by the FDA; however, several aptamers have been advancing in clinical studies for macular degeneration, oncology and inflammation.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The lack of approved aptamers has been attributed to several factors such as lack of a well-defined development pathway, commercial infrastructure, as well as scientific and technical challenges in scale-up and formulation.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. FDA-Approved Oligonucleotide-Based Therapies</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">year of approval</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">mechanism</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1998</td><td class="colsep0 rowsep0" align="left">fomivirsen</td><td class="colsep0 rowsep0" align="left">ASO</td><td class="colsep0 rowsep0" align="left">cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS)</td><td class="colsep0 rowsep0" align="left">inhibits major intermediate early region (IE2) protein synthesis<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2004</td><td class="colsep0 rowsep0" align="left">pegaptanib</td><td class="colsep0 rowsep0" align="left">pegylated aptamer</td><td class="colsep0 rowsep0" align="left">neovascular (wet) and age-related macular degeneration;</td><td class="colsep0 rowsep0" align="left">targets VEGF receptor<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">mipomersen<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">ASO</td><td class="colsep0 rowsep0" align="left">homozygous familial hypercholesterolemia</td><td class="colsep0 rowsep0" align="left">inhibitor of apolipoprotein B-100 synthesis<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">eteplirsen</td><td class="colsep0 rowsep0" align="left">ASO</td><td class="colsep0 rowsep0" align="left">DMD</td><td class="colsep0 rowsep0" align="left">binds to exon 51 of dystrophin pre-mRNA<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">defibrotide</td><td class="colsep0 rowsep0" align="left">ASO</td><td class="colsep0 rowsep0" align="left">severe hepatic veno-occlusive disease</td><td class="colsep0 rowsep0" align="left">enhances the enzymatic activity of plasmin to hydrolyze clots<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">nusinersen</td><td class="colsep0 rowsep0" align="left">ASO</td><td class="colsep0 rowsep0" align="left">SMA</td><td class="colsep0 rowsep0" align="left">increases exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">patisiran</td><td class="colsep0 rowsep0" align="left">siRNA</td><td class="colsep0 rowsep0" align="left">hATTR</td><td class="colsep0 rowsep0" align="left">binds to a genetically conserved sequence in the 3′ untranslated region (3′UTR) of transthyretin TTR mRNA<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2018</td><td class="colsep0 rowsep0" align="left">inotersen</td><td class="colsep0 rowsep0" align="left">ASO</td><td class="colsep0 rowsep0" align="left">hATTR</td><td class="colsep0 rowsep0" align="left">degradation of TTR mRNA through binding to the TTR mRNA<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">golodirsen</td><td class="colsep0 rowsep0" align="left">ASO</td><td class="colsep0 rowsep0" align="left">DMD</td><td class="colsep0 rowsep0" align="left">induces exon 53 skipping<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2019</td><td class="colsep0 rowsep0" align="left">givosiran</td><td class="colsep0 rowsep0" align="left">siRNA</td><td class="colsep0 rowsep0" align="left">acute hepatic porphyria</td><td class="colsep0 rowsep0" align="left">targets hepatic aminolevulinate synthase 1 (ALAS1)<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Discontinued.</p></div></div></div></div><div id="sec16" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Antibody Drug Conjugates (ADC)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Three antibody drug conjugates were approved in 2019: trastuzumab deruxtecan, enfortumab vedotin, and polatuzumab vedotin. All three were approved for oncology indications. Deruxtecan is a topoisomerase inhibitor for the treatment of previously treated HER2-positive breast cancer.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Vedotin is a conjugate of microtubule-targeting monomethyl auristatin E and a Nectin 4-targeting antibody, approved for the treatment of metastatic urothelial cancer. By itself, monomethyl auristatin E <b>66</b> is highly toxic (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). Conjugation to an antibody mitigates this toxicity, as the toxic payload is directed to tumor cells. Once internalized, the payload is released from the targeting antibody by degradation of the antibody via the proteasome or by a cleavage of a peptide linker (<b>67</b> to <b>68</b>).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> These three new ADCs add to an additional list of four other antibody drug conjugates previously approved by the FDA: Inotuzumab (2017), trastuzumab emtansine (2013), brentuximab vedotin (2011), and gemtuzumab ozogamicin (2000).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Examples of recently FDA-approved ADCs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec17" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Drug Sales</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An analysis was done on the 548 top-selling drugs of 2017 and 2018 according to overall sales.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> Sales were rounded to the nearest million.  Both branded and generic sales were included for drugs with both types of sales.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> All drugs with sales >$0.01M in 2018 were included. <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>a shows the number of biologics versus NMEs in this analysis, whereas <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>b shows the overall sales for biologics and NMEs. Based on these numbers, biologics deliver proportional higher sales than NMEs. The average annual sales for a biologic were $1.84B compared to $0.85B for an NME. Biologic sales were largely driven by 10 products which generated a combined $77B in sales, almost half of the total of biologics sales shown in <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>a. Of these 10 products, only 3 are among the 2010–2019 cohort of approvals (aflibercept, nivolumab, ustekinumab). A recent forecast of 2019 sales predicts that two anti PD-1 monoclonal antibody drugs, pembrolizumab (approved 2014) and nivolimumab (approved in 2014) will be moving into the top 10 sales.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (a) Number of BLA vs NME (2010–2019). (b) Sales categorized by BLA and NME. Marketed sales for 2018 were taken from PharmaCompass and curated using the methods described in the text.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> For simplicity, all similar products were combined where sales were shared across multiple companies (e.g., apixaban is comarketed by Pfizer and BMS). Vaccines were not included in the analysis. Only drugs with FDA approval were included in the analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More than $170B in 2018 sales were generated from drugs approved between 2010 and 2019 (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> On average, ∼30% of all sales were derived from orphan drugs. The years of 2013 and 2014 were among the highest examples with >50% of 2018 sales from orphan drugs approved in those years (examples include 2013 approval for ibrutinib in oncology at $6.2B 2018 sales, 2014 approval of nivolumab in oncology at $7.5B 2018 sales, and 2014 approval for pembrolizumab in oncology at $7.1B 2018 sales). The top selling drugs in 2018 are listed in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. 2018 Sales (billions of USD) according to year of approval and orphan designation status. Sales figures taken from Pharmacompass.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Top 20 Prescription Drug Sales (2018)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">rank</th><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center" char=".">2018 sales (USD in billions)</th><th class="colsep0 rowsep0" align="center" char=".">2017 sales (USD in billions</th><th class="colsep0 rowsep0" align="center">approval year</th><th class="colsep0 rowsep0" align="center">type</th><th class="colsep0 rowsep0" align="center">disease area</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">adalimumab</td><td class="colsep0 rowsep0" align="char" char=".">20.4</td><td class="colsep0 rowsep0" align="char" char=".">18.4</td><td class="colsep0 rowsep0" align="left">2002</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">immunology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">apixaban</td><td class="colsep0 rowsep0" align="char" char=".">9.8</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">cardiovascular diseases</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">lenalidomide</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="left">2005</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">etanercept</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="left">1998</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">immunology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">nivolumab</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">infliximab</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="left">1998</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">autoimmune disorders</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">pembrolizumab</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">trastuzumab</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="left">1998</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">bevacizumab</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="left">2004</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">rituximab</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="left">1997</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">rivaroxaban</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">cardiovascular diseases</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">aflibercept</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">ophthalmology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">ibrutinib</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">insulin glargine</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">diabetes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">ustekinumab</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="left">2009</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">immunology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">pregabalin</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="left">2004</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">CNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">pegfilgrastim</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="left">2002</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">blood disorders</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">elvitegravir <b>58</b>, cobicistat <b>59</b>, emtricitabine <b>61</b>, tenofovir alafenamide</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">infection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">denosumab</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="left">2010</td><td class="colsep0 rowsep0" align="left">BLA</td><td class="colsep0 rowsep0" align="left">bone disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">dimethyl fumarate (<b>55</b>)</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">NME</td><td class="colsep0 rowsep0" align="left">CNS</td></tr></tbody></table></div></div></div><div id="sec18" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Future Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over the past decade the number of FIC approvals as well as the applications for new drug modalities have increased. Most importantly, new medicines have been brought to the market in areas where no other therapy option existed before. As the next decade of drug discovery begins, there are still key opportunities that remain, and with those opportunities, significant scientific challenges that must be overcome. These are discussed with some likely areas in need in both therapeutic class as well as new modalities in the next sections.</div><div id="sec18_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> CNS</h3><div class="NLM_p">Neurodegenerative diseases are one of the most significant challenges in the field. The World Health Organization (WHO) predicts that in 2040 neurodegenerative diseases will overtake cancer as the second leading cause of death after cardiovascular diseases.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Despite heavy investment, however, treatment options for neurodegenerative diseases including ALS, frontotemporal dementia and Alzheimer’s disease remain far and few in between. It took more than 20 years after the approval of riluzole for a second ALS therapy, edaravone, to get to the market, and both drugs have only modest effects on mortality and disease progression.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> To this day, a disease-modifying therapy for Alzheimer’s disease remains the white whale for CNS drug research, with over 190 investigational new drugs which have failed in clinical trials.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> A recent glimmer of hope came from the report of a statistically significant Phase 2 trial where the antiamyloid monoclonal antibody aducanumab was reported to show reduction in soluble and insoluble Aβ as well as a slowing of decline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and Mini Mental State Examination scores.<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> However, an interim futility analysis in early 2019 for two pivotal Phase 3 trials halted progression of the drug. Further analysis of the trial data in late 2019 led to a recommendation that one of the trials did meet the primary end point at the highest dose of 10 mg/kg. In addition, the compound demonstrated a dose-dependent reduction in brain amyloid and some CSF phospho-tau reduction. Biogen and Easai are planning to file for regulatory approval for the drug.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> However, the small effect size and absence of a confirmatory trial has not convinced all researchers and analysts.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> Among the most highly anticipated trials for neurodegenerative disorders are those investigating ASOs that target genes linked to neurodegenerative diseases through genetics or pathology.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Phase 1/2 trials have been completed or are underway for SOD1-ALS, Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease.<a onclick="showRef(event, 'ref134 ref135 ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref134 ref135 ref136 ref137">(134−137)</a> The recent approval of the SMA drug nusinersen has provided a blueprint for a pathway to regulatory approval for CNS-targeting ASOs. Nusinersen’s mechanisms of action also inspired the development of milasen, a patient-customized antisense oligonucleotide specifically created for a patient with Batten disease carrying a retrotransposon which interrupted the gene sequence for CLN7. Milasen was designed to correct the splicing defect introduced by the retrotransposon.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> It was fast-tracked via the FDA’s compassionate use pathway and was administered to the patient in a single patient trial.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></div><div class="NLM_p">While large pharmaceutical companies have made significant divestments from neuroscience,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> the percentage of CNS drug approvals remained constant throughout the past decade. This seeming paradox may in part be explained by a shifting investment from large pharmaceutical companies to CNS startups as described recently by in an intriguing blogpost.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> According to Booth, neuroscience venture funding was 40% higher in the past 5 years when compared to the previous 5 years. One of the reasons put forward for this resurgence is a steady improvement in the understanding of molecular mechanisms of neurological diseases, coupled with a high unmet medical need. Booth goes on to connect these advances to a significant investment in funding from the NIH (an order of magnitude increase in funding levels) for CNS research.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Still, development of CNS drugs remains challenging. A recent report by the Tufts Center for the Study of Drug Development demonstrated that CNS drugs take 20% longer to develop and 38% longer to approve than non-CNS drugs.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> A recent paper by O’Donnell et al. identified five key reasons that have hindered more substantive progress in neuroscience R&D.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> These included the lack of animal models that accurately recapitulate human disease, selection of targets not based on scientific evidence, clinical end points that are subjective and insufficiently robust, lack of adequate biomarkers and insufficient stratification of heterogeneous patient populations.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p last">Another significant unmet need is the rising incidence of opioid addiction, which has reached an epidemic status in the United States with over 450 000 fatalities from opioid overdose from 1999 to 2018.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Recently, the first nonopiod for opiod withdrawal symptoms was approved with the α2a antagonist lofexidine (2018), a drug which historically has been used to treat hypertension.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> While a significant advancement, lofexidine is a symptomatic treatment that does not prevent withdrawal. A statement made by the FDA announcing the approval also reinforced the willingness of the FDA to encourage and help foster innovation along with guidance to help accelerate approvals.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Similar to rare disease and antibacterial drugs, incentives and support from public agencies may provide the keys to helping new drugs to the market.</div></div><div id="sec18_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Infection</h3><div class="NLM_p">Over the past decade, 15 new antibacterial drugs have been approved with the QIDP designation, a designation intended to help introduce new antibacterial drugs to the market. This regulatory incentive appears to have improved the number of new antibacterial drugs coming to the market. In comparison to the 15 new drugs between 2010 and 2019, only 8 new drugs were approved in the previous decade (2000–2009).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><div class="NLM_p">While these results are promising, most of the approvals for bacterial infections are in known drug classes, highlighting the extreme difficulty to identify new and innovative therapies in the field. A recent article highlighted novel approaches taken by Genentech to find new therapies, such as an antibody-antibiotic conjugate in Phase 1b, as well as efforts in new potential classes such as arylomycins.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> The increasing threat of bacterial resistance makes the development of antibacterial drugs critical from a public health perspective. The WHO has assigned the highest priority to the development of drugs targeting carbapenem-resistant Gram-negative bacteria <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Enterobacteriaceae</i>.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> According to a recent review by Butler and Paterson, 53 antibacterial drugs were under clinical evaluation worldwide at the end of 2019.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> One antibody drug conjugate, DSTA4637S, has entered the clinical pipeline. DSTA4637S is a conjugate of an antibody targeting wall teichoic acid (β-WTA), a major cell wall component of <i>Staphylococcus aureus</i>, and the novel rifamycin-class antibiotic dmDNA31. It was shown to be safe in a Phase 1 trial in healthy volunteers.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Afabicin represents a novel pharmacophore for the treatment of staphylococcus infections.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> It is an inhibitor of the staphylococcal enoyl-acyl carrier protein reductase fab1, an enzyme required for cell wall synthesis. Zoliflodacin represents a new class of gyrase inhibitors which bind to a site distinct from fluoroquinolones.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> A recent Phase 2 trial demonstrated that a single dose of zoliflodacin was efficacious in the treatment of urogenital gonorrhea.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div><div class="NLM_p">Infectious tropical diseases affect more than 1 billion people worldwide and continue to place major burdens on developing countries. Significant progress in developing a pipeline for malaria medicines was made by the Medicines for Malaria Venture (MMV), which also supported the development of tafenoquine, approved in 2018. Other malaria therapeutics in clinical testing and supported by MMV include the PfPI4K inhibitor MMV048,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> the PfATP4 inhibitor cipargamin,<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> and artefenomel, a long half-life trioxolane peroxide.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><div class="NLM_p last">The twenty-first century has been witness to a number of viral epidemics and pandemics that have threatened developing and developed countries, including the 2002 severe acute respiratory syndrome (SARS) outbreak, the 2015–2016 Zika virus epidemic, the 2013–2016 Western African Ebola virus epidemic, and the 2016 Yellow fever outbreak.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> All have been eclipsed, however, by the inconceivable scale of the COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). First identified in 2019, COVID-19 has infected ∼46 million people worldwide and has claimed almost 1.2 million lives to date.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Through unprecedented collaboration, accelerated drug approval and regulatory times, as well as access to point-of-care diagnostics, governments, health and research institutions, and pharmaceutical and biotechnology companies are seeking to combat this pandemic. The FDA has created an emergency program to accelerate potential COVID-19 therapies, the Coronavirus Treatment Acceleration Program (CTAP).<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Therapeutic approaches include convalescent plasma, several classes of antiviral drugs including RNA polymerase inhibitors, protease inhibitors and viral entry inhibitors, neutralizing antibodies, and various anti-inflammatory agents.<a onclick="showRef(event, 'ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref159 ref160">(159,160)</a> There are currently five treatments authorized for emergency use (EUA).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> The corticosteroid dexamethasone, first developed in the 1950s, was found to reduce mortality in hospitalized COVID-19 patients requiring oxygen supplementation or mechanical ventilation.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The first treatment approved by the FDA was the RNA polymerase inhibitor remdesivir,<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> previously developed for the treatment of Ebola.</div></div><div id="sec18_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cardiovascular Diseases and Metabolic Syndrome</h3><div class="NLM_p">An area of intense activity with pivotal Phase 2 and Phase 3 trials is nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, with a variety of different mechanisms of therapeutic action.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> As there are no approved interventional therapies for the treatment of NAFLD, there is a significant unmet clinical need in this disease area. Drugs currently or recently under investigation include the farnesoid X receptor agonist obeticholic acid, the PPAR α/δ dual agonist elafibranor, the CCR type 2/5 dual antagonist cenicriviroc and the ASK1 inhibitor selonsertib.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Obeticholic acid improved fibrosis in a Phase 3 interim analysis,<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> but both elafibranor and selonsertib did not achieve their primary end points of NASH resolution and fibrosis.<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167,168)</a> Phase 3 data for cenicriviroc is not expected until late 2020.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p last">To date, cardiovascular diseases remain the number one cause of mortality worldwide, claiming almost 18 million lives annually.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> A major driver of CVD is metabolic syndrome, a group of conditions that co-occur frequently: obesity, hyperglycemia, dyslipidemia, and hypertension. Recently, two Phase 3 trials investigating inclisiran for patients with elevated low-density lipoprotein (LDL) cholesterol were completed. Inclisiran is a small interfering RNA (siRNA) targeted at proprotein convertase subtilisin-kexin type 9 (PCSK9). The trials showed that injections every 6 months reduced levels of LDL cholesterol by 50%.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div></div><div id="sec18_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Oncology</h3><div id="sec18_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Immuno-oncology</h4><div class="NLM_p last">Immune-based therapies in oncology have transformed the treatment options for cancer patients and have marked one of the most significant recent advances in oncology drug discovery and development. Since the launch of the first I-O drug pembrolizumab, the number of patients taking these medications has grown from ∼2500 in 2014 to over 200 000 in 2018. PD-1 and PD-1L-targeting I-O drugs in particular are becoming first line treatments in the United States for solid tumors such as metastatic NSCLC, metastatic melanoma, and metastatic renal cell carcinoma.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> In addition to the marketed therapies, a promising pipeline of new I-O therapies have recently been approved or are in late stage development. CD19 is expressed in a variety of B-cell malignancies, but conventional monospecific CD19 antibodies to CD19 have limited efficacy.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> The first CD19-targeted antibody, blinatumomab, was approved in 2014. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager, which brings a T-cell and a CD19-expressing target cell in close proximity, leading to killing of the target cell. Two new drugs have already been approved in 2020 that target CD19 (tafasitamab-cxix and brexucabtagene autoleucel). Tafasitamab was approved in combination with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> It contains a IgG1/2 hybrid Fc-domain to recruit natural killer cells and macrophages to enhance its cytotoxicity.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Brexucabtagene autoleucel is only the third chimeric antigen receptor (CAR) T-cell therapy to be approved, and works by re-engineering patient T-cells to target CD19-expressing tumor cells.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Following PD-1 and CTLA-4, a third inhibitory receptor, lymphocyte-activation gene-3 (LAG3), has garnered attention as a target for I-O therapeutic approaches. LAG3 likewise suppresses T-cell activation and cytokine release.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> LAG3 may provide synergy to PD-1 and as such is being studied in combination with anti-PD1 therapy.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Three LAG3-targeting antibodies intended to suppress inhibitory signaling are currently under evaluation in clinical trials (BMS-986016, LAG525, and MK-4280). The most advanced of these candidates is BMS-986016, which is in Phase 3 trials in combination with nivolumab for the treatment of patients with melanoma refractory to anti-PD-1/PD-L1 therapy.<a onclick="showRef(event, 'ref177 ref179'); return false;" href="javascript:void(0);" class="ref ref177 ref179">(177,179)</a></div></div><div id="sec18_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> A Need for New Biomarkers</h4><div class="NLM_p last">Anti-PD-1 and -PD-L1 therapies have proven efficacious in a variety of solid and hematologic tumors. However, objective response rates vary between different malignancies and clinical trials.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Furthermore, between 7 and 34% of patients experience high-grade immune-related adverse events.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Currently, there are no effective biomarkers available to select patients who are most responsive to treatment.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> In an encouraging development in the oncology therapy space, the use of biomarkers to select the right patient population has steadily increased throughout the decade, with ∼40% of all oncology clinical trials using a biomarker as of 2018.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Identification of biomarkers to predict responsiveness to PD-1/PD-L1 therapies and to decrease the risk of adverse events is an important area of active research. Biomarkers under consideration include, tumor mutational burden, tumor-infiltrating lymphocytes, mismatch-repair deficiencies and gut microbiome constituents.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div></div><div id="sec18_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Targeting of DNA Damage Repair Pathways</h4><div class="NLM_p last">The discovery that targeting DNA repair mechanisms is a safe and effective approach has provided transformational new therapies for cancer patients. Since the approval of the first PARP inhibitor olaparib <b>13</b> in 2014, three additional PARP inhibitors have entered the market. In addition, other DNA damage repair proteins are under investigation as therapeutic targets for a variety of tumors. In ataxia telangiectasia, Rad3-related protein (ATR) is recruited to replication protein A (RPA)-bound single strand DNA (ssDNA) in the homologous recombination pathway and in response to stalled replication forks. Activated ATR phosphorylates and in turn activates checkpoint kinase 1 (CHK1) which in turn regulates cyclin-dependent kinases.<a onclick="showRef(event, 'ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref184 ref185">(184,185)</a> The first-in-class ATR inhibitor M6620/berzosertib showed efficacy in combination with gemcitabine in an open-label Phase 2 trial in patients with platinum-resistant ovarian cancer.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> It is formulated as an intravenous infusion. In contrast, two other ATR inhibitors in clinical trials, BAY 1895344 and AZD6738, are orally bioavailable and are under investigation for solid and hematological malignancies.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> DNA-dependent serine/threonine protein kinase (DNA-PK) is recruited to the site of DNA double strand breaks (DSBs) and is a mediator of nonhomologous end-joining (NHEJ).<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Several DNA-PK inhibitors have entered the clinic as mono- or combination therapies.<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188,189)</a> Ataxia telangiectasia mutated (ATM) likewise mediates DSB repair. It is recruited to the site of DSBs and upon activation phosphorylates substrates including CHK2. ATM inhibitors have entered clinical trials to evaluate safety as a monotherapy or in combination with olaparib and chemotherapy.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a></div></div></div><div id="sec18_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Innovation in New Modalities</h3><div class="NLM_p">Novel therapeutic modalities have opened up a myriad of opportunities to affect targets and molecular pathways previously thought undruggable. The past decade has seen a sharp increase in approvals for RNA-targeted therapeutics, with many more in advanced phases of clinical trials.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> ADCs, which target cytotoxic agents to cancer cells using antibodies recognizing cancer cell antigens, make up a fast-growing number of anticancer drugs, with six FDA approvals in the past decade compared to only one approval prior to 2011. Since the approval of the first bispecific antibody blinatumomab (2014, targeting CD9 and CD13 for the treatment of acute lymphoblastic leukemia) and emicizumab (2017, targeting clotting factors IXa and X for the treatment of hemophilia A),<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> bispecifics have made up a growing share of all antibodies entering clinical trials, rising to 25% in 2018.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> The majority of bispecific antibodies are under evaluation for oncology indications, with 57 bispecifics in clinical trials in 2019.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><div class="NLM_p last">Other modalities are expected, or hoped, to provide further revolutions of the therapeutic landscape for previously intractable targets. Targeted protein degradation harnesses the ubiquitin-proteasome system (UPS) to lower levels of disease-associated proteins.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> More than $3.5B have been invested in protein degraders since 2014.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> Proteolysis-targeting chimeras (PROTAC) account for a large share of protein degraders in development. The first PROTAC that entered the clinic was ARV-110 in 2019. ARV-110 is an orally bioavailable PROTAC that targets the androgen receptor for degradation for the treatment of metastatic castration-resistant prostate cancer. Preliminary Phase 1 data has shown that the drug appears to have an acceptable safety profile and may show signs of efficacy.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Gene editing is another field experiencing explosive growth. The discovery in 2012 that the microbial immune tool CRISPR-Cas9 (clustered regularly interspersed short palindromic sequences) can be repurposed as a tool for efficient gene editing has accelerated this growth considerably. Several CRISPR therapies have been initiated, with most focusing on ex vivo editing of T-cells or hematopoietic stem cells.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> However, in 2019, the first human in vivo CRISPR study was initiated, targeting mutations in the gene CEP290, which cause a rare eye disorder called Leber congenital amaurosis 10 (LCA).<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></div></div></div><div id="sec19" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The banner year of approvals in 2018 and the steady introduction of FIC drugs indicate that the innovation and productivity crisis that was predicted to happen in this decade did not come to fruition.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Instead, the median number of NME and BLA approvals from 2010 to 2019 increased by 60% compared to the prior decade. The recent productivity of the pharmaceutical industry may be linked to regulatory incentives such as the breakthrough therapy, fast-track designation, and Orphan Drug and GAIN acts, through which a large proportion of new drugs were approved. Further, increased investments by the NIH in basic neuroscience research have recently been linked to an increase in CNS startup investments. The advent of new modalities has further allowed advances in therapeutic areas and disease pathways long impervious to classical drug targeting approaches. Innovation as measured by FIC approvals averaged 37% of all drug approvals from 2010 to 2019, up from 17% in 2009. Major breakthroughs in new mechanisms such as I-O have changed patient outcomes and have led to new and more effective clinical trial designs. However, new challenges will face the industry for the next decade of drug discovery and development. As the industry advances into novel mechanisms and new patient populations, clinical trial design may be more complicated, leading to longer and more costly development times. The use of companion diagnostics to predict the right patient population will become increasingly important to reduce the attrition of expensive or long clinical trials. Finally, new medicines and diagnostics must be affordable, be accessible, and provide differentiation of any current standard of care. The success of the past decade provides hope that the industry as a whole will address these challenges and continue to bring new medicines to the patients who need them.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01516" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01516?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01516</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Complete list of 2010–2019 FDA Approved NME, BLA and biosimilars categorized by year, class, FIC, target, indication, orphan designation, and route of administration (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf">jm0c01516_si_001.pdf (802.73 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01516" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15347" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15347" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean G. Brown</span> - <span class="hlFld-Affiliation affiliation">Jnana Therapeutics, 6 Tide St., Boston, Massachusetts 02210, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7130-3928" title="Orcid link">http://orcid.org/0000-0002-7130-3928</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c5a1a7b7aab2ab85afaba4aba4b1bdeba6aaa8"><span class="__cf_email__" data-cfemail="325650405d455c72585c535c53464a1c515d5f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heike J. Wobst</span> - <span class="hlFld-Affiliation affiliation">Jnana Therapeutics, 6 Tide St., Boston, Massachusetts 02210, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c1a9b6aea3b2b581abafa0afa0b5b9efa2aeac"><span class="__cf_email__" data-cfemail="660e1109041512260c08070807121e4805090b">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): H.J.W. is a shareholder of AZN stock.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51384" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51384" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Dean G. Brown</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=BIO-d7e3029-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dean Brown</b> is currently Vice President and Head of Chemistry at Jnana Therapeutics. Previously, he was Director of Chemistry at AstraZeneca. He obtained a B.S in chemistry at Abilene Christian University (Abilene, TX) and a Ph.D at the University of Minnesota (Minneapolis) in organic chemistry. He has over 23 years of experience in drug discovery. Dean has been responsible for building many new programs in both neuroscience and infection, several which have resulted in successful transition to clinical trials. His scientific interests are in lead generation, library design, synthetic chemistry, and applications of computational chemistry. Dean is listed as an author or coauthor on more than 50 publications and patent applications in medicinal chemistry and drug design, including granted patents on clinical candidates.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Heike J. Wobst</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=BIO-d7e3034-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Heike Wobst</b> is currently a Senior Scientist I at Jnana Therapeutics. She was previously at AstraZeneca within the Neuroscience Department, R&D BioPharmaceuticals Unit. She obtained a B.Sc. in Molecular Biotechnology from Heidelberg University, an M.Sc. in Molecular Medicine from Charité Universitätsmedizin Berlin and a D.Phil. in Physiology, Anatomy and Genetics from the University of Oxford. Her scientific interests are focused on molecular mechanisms of neurodegeneration and therapeutic intervention strategies targeting these mechanisms.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABSSI</td><td class="NLM_def"><p class="first last">acute bacterial and skin structure infections</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody directed conjugate</p></td></tr><tr><td class="NLM_term">AIDS</td><td class="NLM_def"><p class="first last">Acquired immunodeficiency syndrome</p></td></tr><tr><td class="NLM_term">AMPA</td><td class="NLM_def"><p class="first last">α-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid</p></td></tr><tr><td class="NLM_term">ASO</td><td class="NLM_def"><p class="first last">antisense oligonucleotide</p></td></tr><tr><td class="NLM_term">bcl-2</td><td class="NLM_def"><p class="first last">b-cell lymphoma-2</p></td></tr><tr><td class="NLM_term">BLA</td><td class="NLM_def"><p class="first last">biological license application</p></td></tr><tr><td class="NLM_term">bRo5</td><td class="NLM_def"><p class="first last">beyond the rule of 5</p></td></tr><tr><td class="NLM_term">CLTA-4</td><td class="NLM_def"><p class="first last">CD28-cytotoxic T lymphocyte-associated antigen 4</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton tyrosine kinase</p></td></tr><tr><td class="NLM_term">CF</td><td class="NLM_def"><p class="first last">cystic fibrosis</p></td></tr><tr><td class="NLM_term">CGRP</td><td class="NLM_def"><p class="first last">calcitonin gene-related peptide receptor</p></td></tr><tr><td class="NLM_term">DMD</td><td class="NLM_def"><p class="first last">Duchenne muscular dystrophy</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">FIC</td><td class="NLM_def"><p class="first last">first-in-class</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">GAIN Act</td><td class="NLM_def"><p class="first last">generating antibiotics incentives now</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">IDH1</td><td class="NLM_def"><p class="first last">isocitrate dehydrogenase inhibitor-1</p></td></tr><tr><td class="NLM_term">IDH2</td><td class="NLM_def"><p class="first last">isocitrate dehydrogenase inhibitor-2</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">I-O</td><td class="NLM_def"><p class="first last">immuno-oncology</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">MEK1</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase 1</p></td></tr><tr><td class="NLM_term">MEK2</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase 2</p></td></tr><tr><td class="NLM_term">NME</td><td class="NLM_def"><p class="first last">new molecular entity</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall-cell lung cell cancer</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerases</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed death receptor-1</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death protein 1 ligand 1</p></td></tr><tr><td class="NLM_term">PD-L2</td><td class="NLM_def"><p class="first last">programmed cell death protein 1 ligand 1</p></td></tr><tr><td class="NLM_term">PDUFA</td><td class="NLM_def"><p class="first last">Prescription Drug User Fee Act of 1992</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small-interfering RNA</p></td></tr><tr><td class="NLM_term">Trk</td><td class="NLM_def"><p class="first last">tropomyosin-receptor-kinase</p></td></tr><tr><td class="NLM_term">QIDP</td><td class="NLM_def"><p class="first last">qualified infectious disease product</p></td></tr><tr><td class="NLM_term">RECIST</td><td class="NLM_def"><p class="first last">Response Evaluation Criteria in Solid Tumours</p></td></tr><tr><td class="NLM_term">Ro5</td><td class="NLM_def"><p class="first last">rule of 5</p></td></tr><tr><td class="NLM_term">SMN1</td><td class="NLM_def"><p class="first last">survival motor neuron gene 1</p></td></tr><tr><td class="NLM_term">SMN2</td><td class="NLM_def"><p class="first last">survival motor neuron gene 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 200 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruffolo, R. R.</span></span> <span> </span><span class="NLM_article-title">Why Has R&D Productivity Declined in the Pharmaceutical Industry?</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1517/17460441.1.2.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1517%2F17460441.1.2.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=23495793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC3svntVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=99-102&issue=2&author=R.+R.+Ruffolo&title=Why+Has+R%26D+Productivity+Declined+in+the+Pharmaceutical+Industry%3F&doi=10.1517%2F17460441.1.2.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Why has R&D productivity declined in the pharmaceutical industry?</span></div><div class="casAuthors">Ruffolo Robert R</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-102</span>
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    </div><div class="casAbstract">Productivity in pharmaceutical R&D has been on the decline for the past several years, and much has been written on the subject.  The causes for the decline in productivity are many and complex.  Some of the causes are external to R&D and therefore difficult to address, such as growing regulatory conservatism and lack of international regulatory harmonisation.  However, a number of the causes for the decline in productivity are internal to R&D groups and can be addressed by R&D managers, such as cost-containment and maximum use of resources.  This article focuses on some of the major issues that have caused productivity to decline, and some of the areas where those who manage large R&D organisations may focus to improve R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjTvDTmQimo9FxYDaSSP8XfW6udTcc2eaSiH-NoUZo8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svntVOqtA%253D%253D&md5=d7d0bad6b25ec13c9d48e86530a018ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1517%2F17460441.1.2.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.1.2.99%26sid%3Dliteratum%253Aachs%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26atitle%3DWhy%2520Has%2520R%2526D%2520Productivity%2520Declined%2520in%2520the%2520Pharmaceutical%2520Industry%253F%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2006%26volume%3D1%26issue%3D2%26spage%3D99%26epage%3D102%26doi%3D10.1517%2F17460441.1.2.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scannell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanckley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, B.</span></span> <span> </span><span class="NLM_article-title">Diagnosing the Decline in Pharmaceutical R&D Efficiency</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1038/nrd3681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&issue=3&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+Decline+in+Pharmaceutical+R%26D+Efficiency&doi=10.1038%2Fnrd3681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0lijjJbMlhx6hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520Decline%2520in%2520Pharmaceutical%2520R%2526D%2520Efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D191%26epage%3D200%26doi%3D10.1038%2Fnrd3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mytelka, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwiddie, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persinger, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munos, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindborg, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacht, A. L.</span></span> <span> </span><span class="NLM_article-title">How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/nrd3078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=20168317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=203-214&issue=3&author=S.+M.+Paulauthor=D.+S.+Mytelkaauthor=C.+T.+Dunwiddieauthor=C.+C.+Persingerauthor=B.+H.+Munosauthor=S.+R.+Lindborgauthor=A.+L.+Schacht&title=How+to+Improve+R%26D+Productivity%3A+The+Pharmaceutical+Industry%E2%80%99s+Grand+Challenge&doi=10.1038%2Fnrd3078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">How to improve R&D productivity: the pharmaceutical industry's grand challenge</span></div><div class="casAuthors">Paul, Steven M.; Mytelka, Daniel S.; Dunwiddie, Christopher T.; Persinger, Charles C.; Munos, Bernard H.; Lindborg, Stacy R.; Schacht, Aaron L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-214</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements.  In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the no. and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs.  However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a no. of years.  Here, we present a detailed anal. based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity.  We then propose specific strategies that could have the most substantial impact in improving R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY67PCIhaBVLVg90H21EOLACvtfcHk0liOJzb0ga21gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D&md5=2f32bcc48c869290eef18ff9400afcc5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3078%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DMytelka%26aufirst%3DD.%2BS.%26aulast%3DDunwiddie%26aufirst%3DC.%2BT.%26aulast%3DPersinger%26aufirst%3DC.%2BC.%26aulast%3DMunos%26aufirst%3DB.%2BH.%26aulast%3DLindborg%26aufirst%3DS.%2BR.%26aulast%3DSchacht%26aufirst%3DA.%2BL.%26atitle%3DHow%2520to%2520Improve%2520R%2526D%2520Productivity%253A%2520The%2520Pharmaceutical%2520Industry%25E2%2580%2599s%2520Grand%2520Challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D203%26epage%3D214%26doi%3D10.1038%2Fnrd3078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Lessons Learned from the Fate of AstraZeneca’s Drug Pipeline: A Five-Dimensional Framework</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&issue=6&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+AstraZeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0liOJzb0ga21gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520AstraZeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D6%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pammolli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magazzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccaboni, M.</span></span> <span> </span><span class="NLM_article-title">The Productivity Crisis in Pharmaceutical R&D</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1038/nrd3405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=21629293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVegt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=428-438&issue=6&author=F.+Pammolliauthor=L.+Magazziniauthor=M.+Riccaboni&title=The+Productivity+Crisis+in+Pharmaceutical+R%26D&doi=10.1038%2Fnrd3405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The productivity crisis in pharmaceutical R&D</span></div><div class="casAuthors">Pammolli, Fabio; Magazzini, Laura; Riccaboni, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">428-438</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis of diseases have expanded the no. of plausible therapeutic targets for the development of innovative agents in recent decades.  However, although investment in pharmaceutical research and development (R&D) has increased substantially in this time, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging.  Here, using a large database that contains information on R&D projects for more than 28,000 compds. investigated since 1990, we examine the decline of R&D productivity in pharmaceuticals in the past two decades and its determinants.  We show that this decline is assocd. with an increasing concn. of R&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biol. mechanisms.  We also investigate the potential variations in productivity with regard to the regional location of companies and find that although companies based in the United States and Europe differ in the compn. of their R&D portfolios, there is no evidence of any productivity gap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4lNnATFMYqLVg90H21EOLACvtfcHk0liOJzb0ga21gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVegt7o%253D&md5=8adb683913f6b27f212f05ee0220ff05</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3405%26sid%3Dliteratum%253Aachs%26aulast%3DPammolli%26aufirst%3DF.%26aulast%3DMagazzini%26aufirst%3DL.%26aulast%3DRiccaboni%26aufirst%3DM.%26atitle%3DThe%2520Productivity%2520Crisis%2520in%2520Pharmaceutical%2520R%2526D%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D6%26spage%3D428%26epage%3D438%26doi%3D10.1038%2Fnrd3405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span> </span><span class="NLM_article-title">The Decade’s Top 10 Patent Losses,
Worth a Whopping $915B
in Lifetime Sales</span>.  <i>FiercePharma</i>. <a href="https://www.fiercepharma.com/pharma/decade-s-top-10-patent-losses-featuring-seismic-sales-shifts" class="extLink">https://www.fiercepharma.com/pharma/decade-s-top-10-patent-losses-featuring-seismic-sales-shifts</a> (accessed <span class="NLM_year">2020</span>-04-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Decade%E2%80%99s+Top+10+Patent+Losses%2C%0AWorth+a+Whopping+%24915B%0Ain+Lifetime+Sales.+FiercePharma.+https%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fdecade-s-top-10-patent-losses-featuring-seismic-sales-shifts+%28accessed+2020-04-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Decade%25E2%2580%2599s%2520Top%252010%2520Patent%2520Losses%252C%250AWorth%2520a%2520Whopping%2520%2524915B%250Ain%2520Lifetime%2520Sales%26jtitle%3DFiercePharma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koyfman, H.</span></span> <span> </span><span class="NLM_article-title">Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA’s 2012 Draft Guidance for Industry</span>. <i>Biotechnol. Law Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1089/blr.2013.9884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1089%2Fblr.2013.9884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24761052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpvVSktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=238-251&issue=4&author=H.+Koyfman&title=Biosimilarity+and+Interchangeability+in+the+Biologics+Price+Competition+and+Innovation+Act+of+2009+and+FDA%E2%80%99s+2012+Draft+Guidance+for+Industry&doi=10.1089%2Fblr.2013.9884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry</span></div><div class="casAuthors">Koyfman Hannah</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology law report</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">238-251</span>
        ISSN:<span class="NLM_cas:issn">0730-031X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOJKb-2mmdz5NiNltV31zlfW6udTcc2eZxJpU39pGJjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpvVSktg%253D%253D&md5=43a4296e9621208038b8170fde206b75</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1089%2Fblr.2013.9884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fblr.2013.9884%26sid%3Dliteratum%253Aachs%26aulast%3DKoyfman%26aufirst%3DH.%26atitle%3DBiosimilarity%2520and%2520Interchangeability%2520in%2520the%2520Biologics%2520Price%2520Competition%2520and%2520Innovation%2520Act%2520of%25202009%2520and%2520FDA%25E2%2580%2599s%25202012%2520Draft%2520Guidance%2520for%2520Industry%26jtitle%3DBiotechnol.%2520Law%2520Rep.%26date%3D2013%26volume%3D32%26issue%3D4%26spage%3D238%26epage%3D251%26doi%3D10.1089%2Fblr.2013.9884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span> <i>What Is a Biosimilar?</i> <a href="https://www.fda.gov/media/108905/download" class="extLink">https://www.fda.gov/media/108905/download</a> (accessed <span class="NLM_year">2020</span>-11-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+What+Is+a+Biosimilar%3F+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F108905%2Fdownload+%28accessed+2020-11-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWhat%2520Is%2520a%2520Biosimilar%253F%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raedler, L. A.</span></span> <span> </span><span class="NLM_article-title">Zarxio (Filgrastim-Sndz): First Biosimilar Approved in the United States</span>. <i>Am. Health Drug Benefits</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27668063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2svjvFWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=150-154&author=L.+A.+Raedler&title=Zarxio+%28Filgrastim-Sndz%29%3A+First+Biosimilar+Approved+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States</span></div><div class="casAuthors">Raedler Lisa A</div><div class="citationInfo"><span class="NLM_cas:title">American health & drug benefits</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Spec Feature</span>),
    <span class="NLM_cas:pages">150-4</span>
        ISSN:<span class="NLM_cas:issn">1942-2962</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAmJOZnkDiwdenUz0lpNqnfW6udTcc2eZxJpU39pGJjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svjvFWqtQ%253D%253D&md5=979d15b0adb0d2d524cba0c73491312d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaedler%26aufirst%3DL.%2BA.%26atitle%3DZarxio%2520%2528Filgrastim-Sndz%2529%253A%2520First%2520Biosimilar%2520Approved%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520Health%2520Drug%2520Benefits%26date%3D2016%26volume%3D9%26spage%3D150%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span> </span><span class="NLM_article-title">How Many Biosimilars Have Been Approved in the United States?</span> <i>Drugs.com</i>. <a href="https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/" class="extLink">https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/</a> (accessed <span class="NLM_year">2020</span>-04-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=How+Many+Biosimilars+Have+Been+Approved+in+the+United+States%3F+Drugs.com.+https%3A%2F%2Fwww.drugs.com%2Fmedical-answers%2Fmany-biosimilars-approved-united-states-3463281%2F+%28accessed+2020-04-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHow%2520Many%2520Biosimilars%2520Have%2520Been%2520Approved%2520in%2520the%2520United%2520States%253F%26jtitle%3DDrugs.com%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span> </span><span class="NLM_article-title">New Molecular
Entity (NME) Drug and New Biologic Approvals (2009–2015)</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://wayback.archive-it.org/7993/20170404174205/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm" class="extLink">https://wayback.archive-it.org/7993/20170404174205/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm</a> (accessed <span class="NLM_year">2018</span>-08-30).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=New+Molecular%0AEntity+%28NME%29+Drug+and+New+Biologic+Approvals+%282009%E2%80%932015%29.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwayback.archive-it.org%2F7993%2F20170404174205%2Fhttps%3A%2F%2Fwww.fda.gov%2FDrugs%2FDevelopmentApprovalProcess%2FHowDrugsareDevelopedandApproved%2FDrugandBiologicApprovalReports%2FNDAandBLAApprovalReports%2Fucm373420.htm+%28accessed+2018-08-30%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNew%2520Molecular%250AEntity%2520%2528NME%2529%2520Drug%2520and%2520New%2520Biologic%2520Approvals%2520%25282009%25E2%2580%25932015%2529%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span> </span><span class="NLM_article-title">New Molecular
Entity (NME) Drug and New Biologic Approvals 2015–2017</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ndaandblaapprovalreports/ucm373420.htm" class="extLink">https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ndaandblaapprovalreports/ucm373420.htm</a> (accessed <span class="NLM_year">2018</span>-08-30).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=New+Molecular%0AEntity+%28NME%29+Drug+and+New+Biologic+Approvals+2015%E2%80%932017.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdevelopmentapprovalprocess%2Fhowdrugsaredevelopedandapproved%2Fdrugandbiologicapprovalreports%2Fndaandblaapprovalreports%2Fucm373420.htm+%28accessed+2018-08-30%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNew%2520Molecular%250AEntity%2520%2528NME%2529%2520Drug%2520and%2520New%2520Biologic%2520Approvals%25202015%25E2%2580%25932017%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span> </span><span class="NLM_article-title">Novel
Drug Approvals for 2019</span>.  <i>U.S. Food
and Drug Administration</i>. <a href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019" class="extLink">https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019</a> (accessed <span class="NLM_year">2020</span>-02-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novel%0ADrug+Approvals+for+2019.+U.S.+Food%0Aand+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fnew-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products%2Fnovel-drug-approvals-2019+%28accessed+2020-02-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNovel%250ADrug%2520Approvals%2520for%25202019%26jtitle%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">Drug Development and FDA Approval, 1938–2013</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">e39</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1402114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMp1402114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24963591" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=e39&issue=26&author=J.+J.+Darrowauthor=A.+S.+Kesselheim&title=Drug+Development+and+FDA+Approval%2C+1938%E2%80%932013&doi=10.1056%2FNEJMp1402114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1402114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1402114%26sid%3Dliteratum%253Aachs%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DDrug%2520Development%2520and%2520FDA%2520Approval%252C%25201938%25E2%2580%25932013%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D26%26spage%3De39%26doi%3D10.1056%2FNEJMp1402114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1d596f687a6e5d5b595c">[email protected]</a>: FDA-Approved Drugs</span>.  <i>U.S. Food
and Drug Administration</i>. <a href="https://www.accessdata.fda.gov/scripts/cder/daf/" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/</a> (accessed <span class="NLM_year">2018</span>-08-30).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40FDA%3A+FDA-Approved+Drugs.+U.S.+Food%0Aand+Drug+Administration.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2F+%28accessed+2018-08-30%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%2540FDA%253A%2520FDA-Approved%2520Drugs%26jtitle%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span> <i>Federal Register.
The Daily Journal of the United States Government</i>. <a href="https://www.federalregister.gov/" class="extLink">https://www.federalregister.gov/</a> (accessed <span class="NLM_year">2020</span>-10-17).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Federal+Register.%0AThe+Daily+Journal+of+the+United+States+Government.+https%3A%2F%2Fwww.federalregister.gov%2F+%28accessed+2020-10-17%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFederal%2520Register.%250AThe%2520Daily%2520Journal%2520of%2520the%2520United%2520States%2520Government%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&issue=2&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0ljQEnMgKBJRzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26issue%3D2%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehlings, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestronk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissel, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cwik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanasse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florence, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Deflazacort vs Prednisone and Placebo for Duchenne Muscular Dystrophy</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2123</span>– <span class="NLM_lpage">2131</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000003217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1212%2FWNL.0000000000003217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27566742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyhu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=2123-2131&issue=20&author=R.+C.+Griggsauthor=J.+P.+Millerauthor=C.+R.+Greenbergauthor=D.+L.+Fehlingsauthor=A.+Pestronkauthor=J.+R.+Mendellauthor=R.+T.+Moxleyauthor=W.+Kingauthor=J.+T.+Kisselauthor=V.+Cwikauthor=M.+Vanasseauthor=J.+M.+Florenceauthor=S.+Pandyaauthor=J.+S.+Dubowauthor=J.+M.+Meyer&title=Efficacy+and+Safety+of+Deflazacort+vs+Prednisone+and+Placebo+for+Duchenne+Muscular+Dystrophy&doi=10.1212%2FWNL.0000000000003217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy</span></div><div class="casAuthors">Griggs, Robert C.; Miller, J. Phillip; Greenberg, Cheryl R.; Fehlings, Darcy L.; Pestronk, Alan; Mendell, Jerry R.; Moxley, Richard T., III; King, Wendy; Kissel, John T.; Cwik, Valerie; Vanasse, Michel; Florence, Julaine M.; Pandya, Shree; Dubow, Jordan S.; Meyer, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2123-2131</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To assess safety and efficacy of deflazacort (DFZ) and prednisone (PRED) vs placebo in Duchenne muscular dystrophy (DMD).  Methods: This phase III, double-blind, randomized, placebo-controlled, multicenter study evaluated muscle strength among 196 boys aged 5-15 years with DMD during a 52-wk period.  In phase 1, participants were randomly assigned to receive treatment with DFZ 0.9 mg/kg/d, DFZ 1.2 mg/kg/d, PRED 0.75 mg/kg/d, or placebo for 12 wk.  In phase 2, placebo participants were randomly assigned to 1 of the 3 active treatment groups.  Participants originally assigned to an active treatment continued that treatment for an addnl. 40 wk.  The primary efficacy endpoint was av. change in muscle strength from baseline to week 12 compared with placebo.  The study was completed in 1995.  Results: All treatment groups (DFZ 0.9 mg/kg/d, DFZ 1.2 mg/kg/d, and PRED 0.75 mg/kg/d) demonstrated significant improvement in muscle strength compared with placebo at 12 wk.  Participants taking PRED had significantly more wt. gain than placebo or both doses of DFZ at 12 wk; at 52 wk, participants taking PRED had significantly more wt. gain than both DFZ doses.  The most frequent adverse events in all 3 active treatment arms were Cushingoid appearance, erythema, hirsutism, increased wt., headache, and nasopharyngitis.  Conclusions: After 12 wk of treatment, PRED and both doses of DFZ improved muscle strength compared with placebo.  Deflazacort was assocd. with less wt. gain than PRED.  Classification of evidence: This study provides Class I evidence that for boys with DMD, daily use of either DFZ and PRED is effective in preserving muscle strength over a 12-wk period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIoye0qYEzybVg90H21EOLACvtfcHk0ljQEnMgKBJRzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyhu7rO&md5=d58ea71c3c1b165ab4d992bd7b110dc8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000003217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000003217%26sid%3Dliteratum%253Aachs%26aulast%3DGriggs%26aufirst%3DR.%2BC.%26aulast%3DMiller%26aufirst%3DJ.%2BP.%26aulast%3DGreenberg%26aufirst%3DC.%2BR.%26aulast%3DFehlings%26aufirst%3DD.%2BL.%26aulast%3DPestronk%26aufirst%3DA.%26aulast%3DMendell%26aufirst%3DJ.%2BR.%26aulast%3DMoxley%26aufirst%3DR.%2BT.%26aulast%3DKing%26aufirst%3DW.%26aulast%3DKissel%26aufirst%3DJ.%2BT.%26aulast%3DCwik%26aufirst%3DV.%26aulast%3DVanasse%26aufirst%3DM.%26aulast%3DFlorence%26aufirst%3DJ.%2BM.%26aulast%3DPandya%26aufirst%3DS.%26aulast%3DDubow%26aufirst%3DJ.%2BS.%26aulast%3DMeyer%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Deflazacort%2520vs%2520Prednisone%2520and%2520Placebo%2520for%2520Duchenne%2520Muscular%2520Dystrophy%26jtitle%3DNeurology%26date%3D2016%26volume%3D87%26issue%3D20%26spage%3D2123%26epage%3D2131%26doi%3D10.1212%2FWNL.0000000000003217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span> <span> </span><span class="NLM_article-title">Taiwanese Company Wins FDA Approval for HIV Treatment with New Mechanism of Action</span>.  <i>FiercePharma</i>. <a href="https://www.fiercepharma.com/marketing/fda-approves-taimed-s-hiv-treatment-new-mechanism-action" class="extLink">https://www.fiercepharma.com/marketing/fda-approves-taimed-s-hiv-treatment-new-mechanism-action</a> (accessed <span class="NLM_year">2020</span>-04-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Liu&title=Taiwanese+Company+Wins+FDA+Approval+for+HIV+Treatment+with+New+Mechanism+of+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DA.%26atitle%3DTaiwanese%2520Company%2520Wins%2520FDA%2520Approval%2520for%2520HIV%2520Treatment%2520with%2520New%2520Mechanism%2520of%2520Action%26jtitle%3DFiercePharma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Win, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinheimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsolais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span> <span> </span><span class="NLM_article-title">Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1711460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1711460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30110589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKnsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=645-654&issue=7&author=B.+Emuauthor=J.+Fesselauthor=S.+Schraderauthor=P.+Kumarauthor=G.+Richmondauthor=S.+Winauthor=S.+Weinheimerauthor=C.+Marsolaisauthor=S.+Lewis&title=Phase+3+Study+of+Ibalizumab+for+Multidrug-Resistant+HIV-1&doi=10.1056%2FNEJMoa1711460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 study of ibalizumab for multidrug-resistant HIV-1</span></div><div class="casAuthors">Emu, Brinda; Fessel, Jeffrey; Schrader, Shannon; Kumar, Princy; Richmond, Gary; Win, Sandra; Weinheimer, Steven; Marsolais, Christian; Lewis, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">645-654</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ibalizumab, a humanized IgG4 monoclonal antibody, blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4.  In this single-group, open-label, phase 3 study, we enrolled 40 adults with multidrug-resistant (MDR) HIV-1 infection in whom multiple antiretroviral therapies had failed.  All the patients had a viral load of more than 1000 copies of HIV-1 RNA per mL.  After a 7-day control period in which patients continued to receive their current therapy, a loading dose of 2000 mg of ibalizumab was infused; the viral load was quantified 7 days later.  Through week 25 of the study, patients received 800 mg of ibalizumab every 14 days, combined with an individually optimized background regimen including at least one fully active agent.  The primary end point was the proportion of patients with a decrease in viral load of at least 0.5 log10 copies per mL from baseline (day 7) to day 14.  A total of 31 patients completed the study.  The mean baseline viral load was 4.5 log10 copies per mL, and the mean CD4 count was 150 per μL.  Of the 40 patients in the intention-to-treat population, 33 (83%) had a decrease in viral load of at least 0.5 log10 copies per mL from baseline (P<0.001 for the comparison with the control period).  The mean viral-load decrease was 1.1 log10 copies per mL.  During the control period, 1 patient, who received the optimized background regimen prematurely, had a decrease in viral load of 0.5 log10 copies per mL.  At week 25, patients who had received ibalizumab plus an optimized background regimen had a mean decrease of 1.6 log10 copies per mL from baseline; 43% of the patients had a viral load of less than 50 copies per mL, and 50% had a viral load of less than 200 copies per mL.  Among 10 patients who had virol. failure or rebound, in vitro testing identified 9 who had a lower degree of susceptibility to ibalizumab than at baseline.  The most common adverse event was diarrhea (in 20% of patients).  Four patients died from causes related to underlying illnesses; 1 had a serious adverse event (the immune reconstitution inflammatory syndrome) that was deemed to be related to ibalizumab therapy.  In patients with MDR HIV-1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25-wk study.  Evidence of the emergence of diminished ibalizumab susceptibility was obsd. in vitro in patients who had virol. failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxHWkfJ1Za7Vg90H21EOLACvtfcHk0ljQEnMgKBJRzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKnsrnF&md5=0a2bb3fbe6a637b371c1cd3c9c56ba89</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1711460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1711460%26sid%3Dliteratum%253Aachs%26aulast%3DEmu%26aufirst%3DB.%26aulast%3DFessel%26aufirst%3DJ.%26aulast%3DSchrader%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DWin%26aufirst%3DS.%26aulast%3DWeinheimer%26aufirst%3DS.%26aulast%3DMarsolais%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DS.%26atitle%3DPhase%25203%2520Study%2520of%2520Ibalizumab%2520for%2520Multidrug-Resistant%2520HIV-1%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D7%26spage%3D645%26epage%3D654%26doi%3D10.1056%2FNEJMoa1711460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Ibalizumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0907-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0907-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29675744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVeit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=781-785&issue=7&author=A.+Markham&title=Ibalizumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0907-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ibalizumab: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">781-785</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">TaiMed Biologics is developing ibalizumab (Trogarzo, ibalizumab-uiyk)-a humanised IgG4 monoclonal antibody-as a treatment for HIV-1 infection.  Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunol. function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS.  This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5TKBF_1RnbVg90H21EOLACvtfcHk0lh5QqmPrUrV6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVeit7o%253D&md5=7c66da702b532c85c7afaf6651ee0eb1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0907-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0907-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DIbalizumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D7%26spage%3D781%26epage%3D785%26doi%3D10.1007%2Fs40265-018-0907-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joffe, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easley, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrfeld, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slagle, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, J.</span></span> <span> </span><span class="NLM_article-title">FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1513686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMp1513686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26649985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC28vovVemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=101-104&issue=2&author=H.+V.+Joffeauthor=C.+Changauthor=C.+Sewellauthor=O.+Easleyauthor=C.+Nguyenauthor=S.+Dunnauthor=K.+Lehrfeldauthor=L.+Leeauthor=M.-J.+Kimauthor=A.+F.+Slagleauthor=J.+Beitz&title=FDA+Approval+of+Flibanserin%2D%2DTreating+Hypoactive+Sexual+Desire+Disorder&doi=10.1056%2FNEJMp1513686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder</span></div><div class="casAuthors">Joffe Hylton V; Chang Christina; Sewell Catherine; Easley Olivia; Nguyen Christine; Dunn Somya; Lehrfeld Kimberly; Lee LaiMing; Kim Myong-Jin; Slagle Ashley F; Beitz Julie</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXFy-UI4Wl4uQ4Pl9hzjQhfW6udTcc2eYG_ZpIP8uQsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vovVemtA%253D%253D&md5=b51c17fa51b2786a0b76c2733a4eb77f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1513686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1513686%26sid%3Dliteratum%253Aachs%26aulast%3DJoffe%26aufirst%3DH.%2BV.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DSewell%26aufirst%3DC.%26aulast%3DEasley%26aufirst%3DO.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DDunn%26aufirst%3DS.%26aulast%3DLehrfeld%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DM.-J.%26aulast%3DSlagle%26aufirst%3DA.%2BF.%26aulast%3DBeitz%26aufirst%3DJ.%26atitle%3DFDA%2520Approval%2520of%2520Flibanserin--Treating%2520Hypoactive%2520Sexual%2520Desire%2520Disorder%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26issue%3D2%26spage%3D101%26epage%3D104%26doi%3D10.1056%2FNEJMp1513686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitin, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCerbo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasagna, L.</span></span> <span> </span><span class="NLM_article-title">The New Drug Approvals of 1987, 1988, and 1989: Trends in Drug Development</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1991.tb03694.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fj.1552-4604.1991.tb03694.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=2010558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADyaK3M7osFKgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1991&pages=116-122&issue=2&author=K.+I.+Kaitinauthor=P.+A.+DiCerboauthor=L.+Lasagna&title=The+New+Drug+Approvals+of+1987%2C+1988%2C+and+1989%3A+Trends+in+Drug+Development&doi=10.1002%2Fj.1552-4604.1991.tb03694.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The new drug approvals of 1987, 1988, and 1989: trends in drug development</span></div><div class="casAuthors">Kaitin K I; DiCerbo P A; Lasagna L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-22</span>
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">The new drug approvals of 1987, 1988, and 1989 were analyzed to determine whether there are any emerging trends in the US drug development and review processes.  Sixty-four new drugs were approved by the FDA during this period, of which 55 met the Center for the Study of Drug Development's definition of a new chemical entity (NEC).  For the 55 NCEs, the mean length of the investigational new drug application (IND) phase (IND filing to NDA submission) was 5.2 years, the new drug application (NDA) phase (NDA submission to approval) was 2.9 years, and the total phase (IND filing to NDA approval) was 8.1 years.  Nine of the 55 NCEs were classified by the FDA as 1A (important therapeutic gain), 15 were classified as 1B (modest gain), 29 were classified as 1C (little or no gain), and 2 were classified as 1AA (drugs to treat AIDS and AIDS-related conditions); 10 drugs were granted orphan status.  The mean NDA phase for 1A drugs was 2.4 years; 1B drugs, 2.9 years; 1C drugs, 3.1 years; 1AA drugs, 1.4 years; and orphan drugs, 2.5 years.  Forty-four of the 55 NCEs (80%) were available in foreign markets before US approval was given, with a mean of 6.5 years of prior marketing.  These data are consistent with figures for previous years and suggest little change in the rate of new drug development and review in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG1LiGXyjMdrGbPKh4T9eAfW6udTcc2eYG_ZpIP8uQsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7osFKgtA%253D%253D&md5=0de45cc35ca4dfce576056a5e543c670</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1991.tb03694.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1991.tb03694.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaitin%26aufirst%3DK.%2BI.%26aulast%3DDiCerbo%26aufirst%3DP.%2BA.%26aulast%3DLasagna%26aufirst%3DL.%26atitle%3DThe%2520New%2520Drug%2520Approvals%2520of%25201987%252C%25201988%252C%2520and%25201989%253A%2520Trends%2520in%2520Drug%2520Development%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1991%26volume%3D31%26issue%3D2%26spage%3D116%26epage%3D122%26doi%3D10.1002%2Fj.1552-4604.1991.tb03694.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitin, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manocchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasagna, L.</span></span> <span> </span><span class="NLM_article-title">The New Drug Approvals of 1990, 1991, and 1992: Trends in Drug Development</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1994.tb03975.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fj.1552-4604.1994.tb03975.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=8163711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADyaK2c3hs1Gluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1994&pages=120-127&issue=2&author=K.+I.+Kaitinauthor=M.+Manocchiaauthor=M.+Seibringauthor=L.+Lasagna&title=The+New+Drug+Approvals+of+1990%2C+1991%2C+and+1992%3A+Trends+in+Drug+Development&doi=10.1002%2Fj.1552-4604.1994.tb03975.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The new drug approvals of 1990, 1991, and 1992: trends in drug development</span></div><div class="casAuthors">Kaitin K I; Manocchia M; Seibring M; Lasagna L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-7</span>
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">Efforts to speed the development and review of new drugs have increased sharply in recent years.  This report, which is the third in a series on trends in drug development, examines the new drug approvals of 1990, 1991, and 1992.  During the 3-year study period, the Food and Drug Administration (FDA) approved 79 new drugs, 74 of which met the Center for the Study of Drug Development's definition of a new chemical entity (NCE).  Of the 74 NCEs, 36 (49%) were considered by the FDA to represent notable therapeutic gains and were selected for "priority" review (i.e., drugs rated 1P, 1A, 1AA, and 1B), and 38 (51%) were considered to represent little or no gain and received "standard" reviews (i.e., drugs rated 1S and 1C).  Investigational new drug application (IND) filing and new drug application (NDA) submission dates on all 74 drugs were obtained from responses to our manufacturer surveys as well as from FDA and public sources.  The mean length of the clinical phase (IND filing to NDA submission) was 6.1 years and that of the review phase (NDA submission to approval) was 2.6 years.  Of the 74 NCEs, 43 (58%) were available in foreign markets at least 1 year before U.S. approval, with a mean of 5.6 years of foreign marketing.  In general, 1990 to 1992 figures are similar to those in the last half of the 1980s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQasH_KqiAkCLJzI8owOhpDfW6udTcc2eYpBvVlDoVhcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3hs1Gluw%253D%253D&md5=394edc4368c601e36ddc37fd88215fc7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1994.tb03975.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1994.tb03975.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaitin%26aufirst%3DK.%2BI.%26aulast%3DManocchia%26aufirst%3DM.%26aulast%3DSeibring%26aufirst%3DM.%26aulast%3DLasagna%26aufirst%3DL.%26atitle%3DThe%2520New%2520Drug%2520Approvals%2520of%25201990%252C%25201991%252C%2520and%25201992%253A%2520Trends%2520in%2520Drug%2520Development%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1994%26volume%3D34%26issue%3D2%26spage%3D120%26epage%3D127%26doi%3D10.1002%2Fj.1552-4604.1994.tb03975.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keyhani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener-West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, N.</span></span> <span> </span><span class="NLM_article-title">Are Development Times for Pharmaceuticals Increasing or Decreasing?</span>. <i>Health Aff. Proj. Hope</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1377/hlthaff.25.2.461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1377%2Fhlthaff.25.2.461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=16522587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BD287jsFWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=461-468&issue=2&author=S.+Keyhaniauthor=M.+Diener-Westauthor=N.+Powe&title=Are+Development+Times+for+Pharmaceuticals+Increasing+or+Decreasing%3F&doi=10.1377%2Fhlthaff.25.2.461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Are development times for pharmaceuticals increasing or decreasing?</span></div><div class="casAuthors">Keyhani Salomeh; Diener-West Marie; Powe Neil</div><div class="citationInfo"><span class="NLM_cas:title">Health affairs (Project Hope)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">461-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This study examines trends in drug development times.  Longer clinical trial times have been described as one factor leading to higher drug prices.  Previous reports on development times have been based on proprietary data.  We examined trends in development times for 168 drugs with data collected from publicly available sources.  The median clinical trial and regulatory review periods for drugs approved between 1992 and 2002 were 5.1 and 1.2 years, respectively.  Clinical trial periods have not increased during this time frame, and regulatory review periods have decreased.  Therefore, it is unlikely that longer clinical trial times are contributing to rising prescription drug prices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb6nwqk7-fKqe0F5ixvZgXfW6udTcc2eYpBvVlDoVhcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287jsFWjtQ%253D%253D&md5=c74b7687a7762a2b32ca41e4e43c3882</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1377%2Fhlthaff.25.2.461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1377%252Fhlthaff.25.2.461%26sid%3Dliteratum%253Aachs%26aulast%3DKeyhani%26aufirst%3DS.%26aulast%3DDiener-West%26aufirst%3DM.%26aulast%3DPowe%26aufirst%3DN.%26atitle%3DAre%2520Development%2520Times%2520for%2520Pharmaceuticals%2520Increasing%2520or%2520Decreasing%253F%26jtitle%3DHealth%2520Aff.%2520Proj.%2520Hope%26date%3D2006%26volume%3D25%26issue%3D2%26spage%3D461%26epage%3D468%26doi%3D10.1377%2Fhlthaff.25.2.461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitin, K. I.</span></span> <span> </span><span class="NLM_article-title">The Prescription Drug User Fee Act of 1992 and the New Drug Development Process</span>. <i>Am. J. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1097/00045391-199705000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1097%2F00045391-199705000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10423607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FptFajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=167-172&issue=5&author=K.+I.+Kaitin&title=The+Prescription+Drug+User+Fee+Act+of+1992+and+the+New+Drug+Development+Process&doi=10.1097%2F00045391-199705000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The prescription Drug User Fee Act of 1992 and the new drug development process</span></div><div class="casAuthors">Kaitin K I</div><div class="citationInfo"><span class="NLM_cas:title">American journal of therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">167-72</span>
        ISSN:<span class="NLM_cas:issn">1075-2765</span>.
    </div><div class="casAbstract">The Prescription Drug User Fee Act of 1992 (PDUFA) authorizes the US Food and Drug Administration (FDA) to levy user fees on manufacturers who submit applications to the agency.  Revenues are dedicated to the achievement of a set of specific performance goals, documented by the FDA Commissioner and referenced in the Act.  The FDA currently credits PDUFA with the agency's success in reducing new drug review times and eliminating the formidable new drug application (NDA) backlog.  To provide an independent assessment of PDUFA's impact on the new drug development process, the Tufts Center for the Study of Drug Development established an annual user fee survey of over 50 major pharmaceutical and biotechnology firms with operations in the United States.  As of December 31, 1996, survey data have been collected for fiscal years 1994, 1995, and 1996.  Data from a cohort of user fee drugs approved in 1993-1996 were compared with data from all non-user fee drugs approved in 1990-1992.  Whereas the mean approval phase (NDA submission to approval) for the user fee drugs was considerably shorter than that for the non-user fee drugs (14.5 versus 31.0 months, respectively), the mean clinical phase (investigational new drug application filing to NDA submission) was somewhat longer (88.0 versus 81.1 months, respectively).  As a result, the total time from the start of clinical testing to drug approval (total phase) was only marginally shorter for the user fee drugs (102.0 versus 112.1 months, respectively).  These results highlight the need for efforts to reduce lengthy drug development times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_oT-CMiv0s-2mnZh2OgS0fW6udTcc2eYpBvVlDoVhcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FptFajtA%253D%253D&md5=eefdb3ef2a276d86d93921752bd77994</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2F00045391-199705000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00045391-199705000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DKaitin%26aufirst%3DK.%2BI.%26atitle%3DThe%2520Prescription%2520Drug%2520User%2520Fee%2520Act%2520of%25201992%2520and%2520the%2520New%2520Drug%2520Development%2520Process%26jtitle%3DAm.%2520J.%2520Ther.%26date%3D1997%26volume%3D4%26issue%3D5%26spage%3D167%26epage%3D172%26doi%3D10.1097%2F00045391-199705000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span> <span> </span><span class="NLM_article-title">Trends in Utilization of FDA Expedited Drug Development and Approval Programs, 1987–2014: Cohort Study</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">h4633</span>, <span class="refDoi"> DOI: 10.1136/bmj.h4633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1136%2Fbmj.h4633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26400751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWgtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2015&pages=h4633&author=A.+S.+Kesselheimauthor=B.+Wangauthor=J.+M.+Franklinauthor=J.+J.+Darrow&title=Trends+in+Utilization+of+FDA+Expedited+Drug+Development+and+Approval+Programs%2C+1987%E2%80%932014%3A+Cohort+Study&doi=10.1136%2Fbmj.h4633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study</span></div><div class="casAuthors">Kesselheim, Aaron S.; Wang, Bo; Franklin, Jessica M.; Darrow, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">BMJ [British Medical Journal]</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">h4633/1-h4633/7</span>CODEN:
                <span class="NLM_cas:coden">BMJBFE</span>;
        ISSN:<span class="NLM_cas:issn">1756-1833</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective To evaluate the use of special expedited development and review pathways at the US Food and Drug Administration over the past two decades.  Design Cohort study.  Setting FDA approved novel therapeutics between 1987 and 2014.  Population Publicly available sources provided each drug's year of approval, their innovativeness (first in class vs. not first in class), World Health Organization Anat. Therapeutic Classification, and which (if any) of the FDA's four primary expedited development and review programs or designations were assocd. with each drug: orphan drug, fast track, accelerated approval, and priority review.  Main outcome measures Logistic regression models evaluated trends in the proportion of drugs assocd. with each of the four expedited development and review programs.  To evaluate the no. of programs assocd. with each approved drug over time, Poisson models were employed, with the no. of programs as the dependent variable and a linear term for year of approval.  The difference in trends was compared between drugs that were first in class and those that were not.  Results The FDA approved 774 drugs during the study period, with one third representing first in class agents.  Priority review (43%) was the most prevalent of the four programs, with accelerated approval (9%) the least common.  There was a significant increase of 2.6% per yr in the no. of expedited review and approval programs granted to each newly approved agent (incidence rate ratio 1.026, 95% confidence interval 1.017 to 1.035, P<0.001), and a 2.4% increase in the proportion of drugs assocd. with at least one such program (odds ratio 1.024, 95% confidence interval 1.006 to 1.043, P = 0.009).  Driving this trend was an increase in the proportion of approved, non-first in class drugs assocd. with at least one program for drugs (P = 0.03 for interaction).  Conclusions In the past two decades, drugs newly approved by the FDA have been assocd. with an increasing no. of expedited development or review programs.  Though expedited programs should be strictly limited to drugs providing noticeable clin. advances, this trend is being driven by drugs that are not first in class and thus potentially less innovative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopP9YYTUZJibVg90H21EOLACvtfcHk0ljfWXOz_9CJRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWgtrvE&md5=bd55b182d49474122a46bb75b0a7f108</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1136%2Fbmj.h4633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.h4633%26sid%3Dliteratum%253Aachs%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFranklin%26aufirst%3DJ.%2BM.%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26atitle%3DTrends%2520in%2520Utilization%2520of%2520FDA%2520Expedited%2520Drug%2520Development%2520and%2520Approval%2520Programs%252C%25201987%25E2%2580%25932014%253A%2520Cohort%2520Study%26jtitle%3DBMJ.%26date%3D2015%26volume%3D351%26spage%3Dh4633%26doi%3D10.1136%2Fbmj.h4633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chary, K. V.</span></span> <span> </span><span class="NLM_article-title">Expedited Drug Review Process: Fast, but Flawed</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.184768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.4103%2F0976-500X.184768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27440949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ivF2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=57-61&issue=2&author=K.+V.+Chary&title=Expedited+Drug+Review+Process%3A+Fast%2C+but+Flawed&doi=10.4103%2F0976-500X.184768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Expedited drug review process: Fast, but flawed</span></div><div class="casAuthors">Chary Krishnan Vengadaraga</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">57-61</span>
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXY9sT2o6-sZw7prLlxLOzfW6udTcc2eavT3gDPpOyyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ivF2gtw%253D%253D&md5=479c219b489e4a4289a71e7f5cc5d489</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.184768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.184768%26sid%3Dliteratum%253Aachs%26aulast%3DChary%26aufirst%3DK.%2BV.%26atitle%3DExpedited%2520Drug%2520Review%2520Process%253A%2520Fast%252C%2520but%2520Flawed%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2016%26volume%3D7%26issue%3D2%26spage%3D57%26epage%3D61%26doi%3D10.4103%2F0976-500X.184768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012–2016</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>318</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1001/jama.2017.14896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1001%2Fjama.2017.14896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29209711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1M3otl2ntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2017&pages=2137-2138&issue=21&author=T.+J.+Hwangauthor=J.+J.+Darrowauthor=A.+S.+Kesselheim&title=The+FDA%E2%80%99s+Expedited+Programs+and+Clinical+Development+Times+for+Novel+Therapeutics%2C+2012%E2%80%932016&doi=10.1001%2Fjama.2017.14896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016</span></div><div class="casAuthors">Hwang Thomas J; Darrow Jonathan J; Kesselheim Aaron S</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2137-2138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVkldKbp5_JP6BottYdIAWfW6udTcc2eavT3gDPpOyyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3otl2ntQ%253D%253D&md5=05a9b738737abf7f9c245695aba18fb7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1001%2Fjama.2017.14896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2017.14896%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DT.%2BJ.%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DThe%2520FDA%25E2%2580%2599s%2520Expedited%2520Programs%2520and%2520Clinical%2520Development%2520Times%2520for%2520Novel%2520Therapeutics%252C%25202012%25E2%2580%25932016%26jtitle%3DJAMA%26date%3D2017%26volume%3D318%26issue%3D21%26spage%3D2137%26epage%3D2138%26doi%3D10.1001%2Fjama.2017.14896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span> </span><span class="NLM_article-title">NDA and BLA Approval Times</span>.  <i>U.S. Food and
Drug Administration</i>. <a href="https://www.fda.gov/drugs/nda-and-bla-approvals/nda-and-bla-approval-times" class="extLink">https://www.fda.gov/drugs/nda-and-bla-approvals/nda-and-bla-approval-times</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NDA+and+BLA+Approval+Times.+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fnda-and-bla-approvals%2Fnda-and-bla-approval-times+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNDA%2520and%2520BLA%2520Approval%2520Times%26jtitle%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span> <span> </span><span class="NLM_article-title">Trial Watch: Clinical Trial Cycle Times Continue to Increase despite Industry Efforts</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2017.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28184041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisV2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=157&issue=3&author=L.+Martinauthor=M.+Hutchensauthor=C.+Hawkins&title=Trial+Watch%3A+Clinical+Trial+Cycle+Times+Continue+to+Increase+despite+Industry+Efforts&doi=10.1038%2Fnrd.2017.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Trial watch Clinical trial cycle times continue to increase despite industry efforts</span></div><div class="casAuthors">Martin, Linda; Hutchens, Melissa; Hawkins, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3cSq3i47XYLVg90H21EOLACvtfcHk0lj1BrWJ-9RBKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisV2qsro%253D&md5=c4b737bf882e134bf8af47da4058e9d6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.21%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DL.%26aulast%3DHutchens%26aufirst%3DM.%26aulast%3DHawkins%26aufirst%3DC.%26atitle%3DTrial%2520Watch%253A%2520Clinical%2520Trial%2520Cycle%2520Times%2520Continue%2520to%2520Increase%2520despite%2520Industry%2520Efforts%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D3%26spage%3D157%26doi%3D10.1038%2Fnrd.2017.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span> <i>2015 Novel Drugs Summary</i>. <a href="https://www.fda.gov/media/95661/download" class="extLink">https://www.fda.gov/media/95661/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2015+Novel+Drugs+Summary.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F95661%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2015%2520Novel%2520Drugs%2520Summary%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furberg, C. D.</span></span> <span> </span><span class="NLM_article-title">Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration: The Class of 2008</span>. <i>JAMA Int. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>174</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1001/jamainternmed.2013.11813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1001%2Fjamainternmed.2013.11813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24166236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2c7gsVWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2014&pages=90-95&issue=1&author=T.+J.+Mooreauthor=C.+D.+Furberg&title=Development+Times%2C+Clinical+Testing%2C+Postmarket+Follow-up%2C+and+Safety+Risks+for+the+New+Drugs+Approved+by+the+US+Food+and+Drug+Administration%3A+The+Class+of+2008&doi=10.1001%2Fjamainternmed.2013.11813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008</span></div><div class="casAuthors">Moore Thomas J; Furberg Curt D</div><div class="citationInfo"><span class="NLM_cas:title">JAMA internal medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  The US Food and Drug Administration (FDA) has advanced multiple proposals to promote biomedical innovation by making new drugs available more quickly but with shorter, smaller, and more selective clinical trials and less rigorous end points.  OBJECTIVE:  To inform the debate about appropriate standards, we studied the development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the FDA in 2008, when most provisions of current law, regulation, and policies were in effect.  DESIGN:  Descriptive study of the drugs classified as new molecular entities using preapproval FDA evaluation documents, agency drug information databases, prescribing information, and other primary data sources.  MAIN OUTCOMES AND MEASURES:  Comparison of drugs that received standard review and those deemed sufficiently innovative to receive expedited review with regard to clinical development and FDA review time, the size and duration of efficacy trials, safety issues, and postmarket follow-up.  RESULTS:  In 2008, the FDA approved 20 therapeutic drugs, 8 with expedited review and 12 with standard review.  The expedited drugs took a median of 5.1 years (range, 1.6-10.6 years) of clinical development to obtain marketing approval compared with 7.5 years (range, 4.7-19.4 years) for the standard review drugs (P = .05).  The expedited drugs were tested for efficacy in a median of 104 patients receiving the active drug (range, 23-599), compared with a median of 580 patients (range, 75-1207) for standard review drugs (P = .003).  Nonclinical testing showed that 6 therapeutic drugs were animal carcinogens, 5 were in vitro mutagens, and 14 were animal teratogens.  Other safety concerns resulted in 5 Boxed Warnings; 8 drugs required risk management plans.  The FDA required 85 postmarket commitments.  By 2013, 5 drugs acquired a new or expanded Boxed Warning; 26 of 85 (31%) of the postmarketing study commitments had been fulfilled, and 8 (9%) had been submitted for agency review.  CONCLUSIONS AND RELEVANCE:  For new drugs approved by the FDA in 2008, those that received expedited review were approved more rapidly than those that received standard review.  However, considerably fewer patients were studied prior to approval, and many safety questions remained unanswered.  By 2013, many postmarketing studies had not been completed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkudPyAJDRTLmQt-ICR3qNfW6udTcc2ebpmj4I-OaGjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7gsVWhuw%253D%253D&md5=b48bfd358d6ac1e236b56c767ab4119d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2013.11813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2013.11813%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DT.%2BJ.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DDevelopment%2520Times%252C%2520Clinical%2520Testing%252C%2520Postmarket%2520Follow-up%252C%2520and%2520Safety%2520Risks%2520for%2520the%2520New%2520Drugs%2520Approved%2520by%2520the%2520US%2520Food%2520and%2520Drug%2520Administration%253A%2520The%2520Class%2520of%25202008%26jtitle%3DJAMA%2520Int.%2520Med.%26date%3D2014%26volume%3D174%26issue%3D1%26spage%3D90%26epage%3D95%26doi%3D10.1001%2Fjamainternmed.2013.11813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span> <i>New Drug Therapy Approvals 2019</i>. <a href="https://www.fda.gov/media/134493/download" class="extLink">https://www.fda.gov/media/134493/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Drug+Therapy+Approvals+2019.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F134493%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Drug%2520Therapy%2520Approvals%25202019%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span> <i>New Drug Therapy
Approvals 2018</i>. <a href="https://www.fda.gov/media/120357/download" class="extLink">https://www.fda.gov/media/120357/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Drug+Therapy%0AApprovals+2018.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F120357%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Drug%2520Therapy%250AApprovals%25202018%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avorn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">FDA Approval and Regulation of Pharmaceuticals, 1983–2018</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>323</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1001/jama.2019.20288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1001%2Fjama.2019.20288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31935033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MbpvVGntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2020&pages=164-176&issue=2&author=J.+J.+Darrowauthor=J.+Avornauthor=A.+S.+Kesselheim&title=FDA+Approval+and+Regulation+of+Pharmaceuticals%2C+1983%E2%80%932018&doi=10.1001%2Fjama.2019.20288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval and Regulation of Pharmaceuticals, 1983-2018</span></div><div class="casAuthors">Darrow Jonathan J; Avorn Jerry; Kesselheim Aaron S</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-176</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  US law requires testing of new drugs before approval to ensure that they provide a well-defined benefit that is commensurate with their risks.  A major challenge for the US Food and Drug Administration (FDA) is to achieve an appropriate balance between rigorous testing and the need for timely approval of drugs that have benefits that outweigh their risks.  Objective:  To describe the evolution of laws and standards affecting drug testing, the use of new approval programs and standards, expansions of the role and authority of the FDA, and changes in the number of drugs approved from the 1980s to 2018.  Evidence:  Sources of evidence included principal federal laws and FDA regulations (1962-2018) and FDA databases of approved new drugs (1984-2018), generic drugs (1970-2018), biologics (1984-2018), and vaccines (1998-2018); special development and approval programs (Orphan drug [1984-2018], Fast-Track [1988-2018], Priority Review and its predecessors [1984-2018], Accelerated Approval [1992-2018], and Breakthrough Therapy [2012-2018]); expanded access (2010-2017) and Risk Evaluation and Mitigation Strategies (2008-2018); and user fees paid to the FDA by industry (1993-2018).  Findings:  From 1983 to 2018, legislation and regulatory initiatives have substantially changed drug approval at the FDA.  The mean annual number of new drug approvals, including biologics, was 34 from 1990-1999, 25 from 2000-2009, and 41 from 2010-2018.  New biologic product approvals increased from a median of 2.5 from 1990-1999, to 5 from 2000-2013, to 12 from 2014-2018.  The median annual number of generic drugs approved was 136 from 1970 to the enactment of the Hatch-Waxman Act in 1984; 284 from 1985 to the enactment of the Generic Drug User Fee Act in 2012; and 588 from 2013-2018.  Prescription drug user fee funding expanded from new drugs and biologics in 1992 to generic and biosimilar drugs in 2012.  The amount of Prescription Drug User Fee Act fees collected from industry increased from an annual mean of $66 million in 1993-1997 to $820 million in 2013-2017, and in 2018, user fees accounted for approximately 80% of the salaries of review personnel responsible for the approval of new drugs.  The proportion of drugs approved with an Orphan Drug Act designation increased from 18% (55/304) in 1984-1995, to 22% (82/379) in 1996-2007, to 41% (154/380) in 2008-2018.  Use of Accelerated Approval, Fast-Track, and Priority Review for new drugs has increased over time, with 81% (48/59) of new drugs benefiting from at least 1 such expedited program in 2018.  The proportion of new approvals supported by at least 2 pivotal trials decreased from 80.6% in 1995-1997 to 52.8% in 2015-2017, based on 124 and 106 approvals, respectively, while the median number of patients studied did not change significantly (774 vs 816).  FDA drug review times declined from more than 3 years in 1983 to less than 1 year in 2017, but total time from the authorization of clinical testing to approval has remained at approximately 8 years over that period.  Conclusions and Relevance:  Over the last 4 decades, the approval and regulation processes for pharmaceutical agents have evolved and increased in complexity as special programs have been added and as the use of surrogate measures has been encouraged.  The FDA funding needed to implement and manage these programs has been addressed by expanding industry-paid user fees.  The FDA has increasingly accepted less data and more surrogate measures, and has shortened its review times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQALVBvmUct2mHOrQ6qeX-mfW6udTcc2ebpmj4I-OaGjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbpvVGntQ%253D%253D&md5=5b1fd18963395a89e3865d4ebb430b16</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1001%2Fjama.2019.20288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2019.20288%26sid%3Dliteratum%253Aachs%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26aulast%3DAvorn%26aufirst%3DJ.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DFDA%2520Approval%2520and%2520Regulation%2520of%2520Pharmaceuticals%252C%25201983%25E2%2580%25932018%26jtitle%3DJAMA%26date%3D2020%26volume%3D323%26issue%3D2%26spage%3D164%26epage%3D176%26doi%3D10.1001%2Fjama.2019.20288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span> <i>FY 2011 Innovative Drug Approvals</i>. <a href="https://wayback.archive-it.org/7993/20170723162306/https:/www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf" class="extLink">https://wayback.archive-it.org/7993/20170723162306/https:/www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FY+2011+Innovative+Drug+Approvals.+https%3A%2F%2Fwayback.archive-it.org%2F7993%2F20170723162306%2Fhttps%3A%2Fwww.fda.gov%2Fdownloads%2FAboutFDA%2FReportsManualsForms%2FReports%2FUCM278358.pdf+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFY%25202011%2520Innovative%2520Drug%2520Approvals%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span> <i>FY 2012 Innovative
Drug Approvals</i>. <a href="https://www.fdanews.com/ext/resources/files/archives/1/12/12-7-12-approvals.pdf" class="extLink">https://www.fdanews.com/ext/resources/files/archives/1/12/12-7-12-approvals.pdf</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FY+2012+Innovative%0ADrug+Approvals.+https%3A%2F%2Fwww.fdanews.com%2Fext%2Fresources%2Ffiles%2Farchives%2F1%2F12%2F12-7-12-approvals.pdf+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFY%25202012%2520Innovative%250ADrug%2520Approvals%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span> <i>Approved Drugs
2013</i>. <a href="https://www.fda.gov/media/87579/download" class="extLink">https://www.fda.gov/media/87579/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Approved+Drugs%0A2013.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F87579%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DApproved%2520Drugs%250A2013%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span> <i>2014 FDA New Drug Approvals</i>. <a href="https://cellculturedish.com/2014-fda-new-drug-approvals-11-biologics-receive-approval/" class="extLink">https://cellculturedish.com/2014-fda-new-drug-approvals-11-biologics-receive-approval/</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2014+FDA+New+Drug+Approvals.+https%3A%2F%2Fcellculturedish.com%2F2014-fda-new-drug-approvals-11-biologics-receive-approval%2F+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2014%2520FDA%2520New%2520Drug%2520Approvals%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span> <i>2016 Novel Drugs
Summary</i>. <a href="https://www.fda.gov/media/102618/download" class="extLink">https://www.fda.gov/media/102618/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2016+Novel+Drugs%0ASummary.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F102618%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2016%2520Novel%2520Drugs%250ASummary%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span> <i>New Drug Therapy Approvals
2017</i>. <a href="https://www.fda.gov/files/about%20fda/published/2017-New-Drug-Therapy-Approvals-Report.pdf" class="extLink">https://www.fda.gov/files/about%20fda/published/2017-New-Drug-Therapy-Approvals-Report.pdf</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Drug+Therapy+Approvals%0A2017.+https%3A%2F%2Fwww.fda.gov%2Ffiles%2Fabout%2520fda%2Fpublished%2F2017-New-Drug-Therapy-Approvals-Report.pdf+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Drug%2520Therapy%2520Approvals%250A2017%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamrén, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matcham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Impact of a Five-Dimensional Framework on R&D Productivity at AstraZeneca</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2017.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29348681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=167-181&issue=3&author=P.+Morganauthor=D.+G.+Brownauthor=S.+Lennardauthor=M.+J.+Andertonauthor=J.+C.+Barrettauthor=U.+Erikssonauthor=M.+Fidockauthor=B.+Hamr%C3%A9nauthor=A.+Johnsonauthor=R.+E.+Marchauthor=J.+Matchamauthor=J.+Mettetalauthor=D.+J.+Nichollsauthor=S.+Platzauthor=S.+Reesauthor=M.+A.+Snowdenauthor=M.+N.+Pangalos&title=Impact+of+a+Five-Dimensional+Framework+on+R%26D+Productivity+at+AstraZeneca&doi=10.1038%2Fnrd.2017.244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of a five-dimensional framework on R&D productivity at AstraZeneca</span></div><div class="casAuthors">Morgan, Paul; Brown, Dean G.; Lennard, Simon; Anderton, Mark J.; Barrett, J. Carl; Eriksson, Ulf; Fidock, Mark; Hamren, Bengt; Johnson, Anthony; March, Ruth E.; Matcham, James; Mettetal, Jerome; Nicholls, David J.; Platz, Stefan; Rees, Steve; Snowden, Michael A.; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry avs. in 2005-2010.  A cornerstone of the revised strategy was to focus decision-making on five tech. determinants (the right target, right tissue, right safety, right patient and right com. potential).  In this article, we describe the progress made using this '5R framework' in the hope that our experience could be useful to other companies tackling R&D productivity issues.  We focus on the evolution of our approach to target validation, hit and lead optimization, pharmacokinetic/pharmacodynamic modeling and drug safety testing, which have helped improve the quality of candidate drug nomination, as well as the development of the right culture, where 'truth seeking' is encouraged by more rigorous and quant. decision-making.  We also discuss where the approach has failed and the lessons learned.  Overall, the continued evolution and application of the 5R framework are beginning to have an impact, with success rates from candidate drug nomination to phase III completion improving from 4% in 2005-2010 to 19% in 2012-2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdx6OlRZpzrVg90H21EOLACvtfcHk0lh4f9UU4qhGlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D&md5=06906e0bc59dc715941998660a514ffe</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.244%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DLennard%26aufirst%3DS.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DEriksson%26aufirst%3DU.%26aulast%3DFidock%26aufirst%3DM.%26aulast%3DHamr%25C3%25A9n%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DMarch%26aufirst%3DR.%2BE.%26aulast%3DMatcham%26aufirst%3DJ.%26aulast%3DMettetal%26aufirst%3DJ.%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DPlatz%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DSnowden%26aufirst%3DM.%2BA.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DImpact%2520of%2520a%2520Five-Dimensional%2520Framework%2520on%2520R%2526D%2520Productivity%2520at%2520AstraZeneca%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26issue%3D3%26spage%3D167%26epage%3D181%26doi%3D10.1038%2Fnrd.2017.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">Development of Immuno-Oncology Drugs - From CTLA4 to PD1 to the Next Generations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2015.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26965203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=235-247&issue=4&author=A.+Hoos&title=Development+of+Immuno-Oncology+Drugs+-+From+CTLA4+to+PD1+to+the+Next+Generations&doi=10.1038%2Fnrd.2015.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations</span></div><div class="casAuthors">Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-247</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance.  This success is based on progress in both preclin. and clin. science, including the development of new methods of investigation.  Immuno-oncol. has become a sub-specialty within oncol. owing to its unique science and its potential for substantial and long-term clin. benefit.  Immunotherapy agents do not directly attack the tumor but instead mobilize the immune system - this can be achieved through various approaches that utilize adaptive or innate immunity.  Therefore, immuno-oncol. drug development encompasses a broad range of agents, including antibodies, peptides, proteins, small mols., adjuvants, cytokines, oncolytic viruses, bi-specific mols. and cellular therapies.  This Perspective summarizes the recent history of cancer immunotherapy, including the factors that led to its success, provides an overview of novel drug-development considerations, summarizes three generations of immunotherapies that have been developed since 2011 and, thus, illustrates the breadth of opportunities these new generations of immunotherapies represent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8GBkFRW-5VLVg90H21EOLACvtfcHk0lh4f9UU4qhGlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D&md5=547a5ef71cf6e494ea3abeb8b2c2e463</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.35%26sid%3Dliteratum%253Aachs%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Immuno-Oncology%2520Drugs%2520-%2520From%2520CTLA4%2520to%2520PD1%2520to%2520the%2520Next%2520Generations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D4%26spage%3D235%26epage%3D247%26doi%3D10.1038%2Fnrd.2015.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1973</span>– <span class="NLM_lpage">1981</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0314-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-014-0314-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25331768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1973-1981&issue=16&author=R.+M.+Poole&title=Pembrolizumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0314-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1973-1981</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Pembrolizumab [Keytruda (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer.  Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic malignant melanoma in the US, for use in patients with disease progression after prior treatment with ipilimumab and, for BRAF V600 mutation-pos. patients, a BRAF inhibitor.  It is the first anti-PD-1 therapy to receive regulatory approval in the US, and is currently under regulatory review in the EU.  This article summarizes the milestones in the development of pembrolizumab leading to this first approval for the treatment of malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzneRbqZCmrVg90H21EOLACvtfcHk0lh4f9UU4qhGlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrK&md5=a7642d2b422ab8e58a7e49c7ba6cf1f8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0314-5%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DPembrolizumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D16%26spage%3D1973%26epage%3D1981%26doi%3D10.1007%2Fs40265-014-0314-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span> <span> </span><span class="NLM_article-title">Clinical Blockade of PD1 and LAG3--Potential Mechanisms of Action</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/nri3790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnri3790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25534622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=45-56&issue=1&author=L.+T.+Nguyenauthor=P.+S.+Ohashi&title=Clinical+Blockade+of+PD1+and+LAG3%2D%2DPotential+Mechanisms+of+Action&doi=10.1038%2Fnri3790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical blockade of PD1 and LAG3 - potential mechanisms of action</span></div><div class="casAuthors">Nguyen, Linh T.; Ohashi, Pamela S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-56</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysfunctional T cells can render the immune system unable to eliminate infections and cancer.  Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clin. trials.  In this Review, we discuss the potential mechanisms of action of the clin. agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3).  We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphrWsF__zKXLVg90H21EOLACvtfcHk0lh4f9UU4qhGlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb7I&md5=3802eef86152af75b7a7729b7c9a9050</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnri3790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3790%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BT.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26atitle%3DClinical%2520Blockade%2520of%2520PD1%2520and%2520LAG3--Potential%2520Mechanisms%2520of%2520Action%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2015%26volume%3D15%26issue%3D1%26spage%3D45%26epage%3D56%26doi%3D10.1038%2Fnri3790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span> <i>Pembrolizumab Label</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf</a> (accessed <span class="NLM_year">2020</span>-04-07).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pembrolizumab+Label.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2014%2F125514lbl.pdf+%28accessed+2020-04-07%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPembrolizumab%2520Label%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flower, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">7035</span>),  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&issue=7035&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+Killing+of+BRCA2-Deficient+Tumours+with+Inhibitors+of+Poly%28ADP-Ribose%29+Polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lgQOk79ENgeAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520Killing%2520of%2520BRCA2-Deficient%2520Tumours%2520with%2520Inhibitors%2520of%2520Poly%2528ADP-Ribose%2529%2520Polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26issue%3D7035%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J.</span></span> <span> </span><span class="NLM_article-title">Laying a Trap to Kill Cancer Cells: PARP Inhibitors and Their Mechanisms of Action</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">362</span>),  <span class="NLM_fpage">362ps17</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaf9246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscitranslmed.aaf9246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27797957" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=362ps17&issue=362&author=Y.+Pommierauthor=M.+J.+O%E2%80%99Connorauthor=J.+de+Bono&title=Laying+a+Trap+to+Kill+Cancer+Cells%3A+PARP+Inhibitors+and+Their+Mechanisms+of+Action&doi=10.1126%2Fscitranslmed.aaf9246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaf9246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaf9246%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%26atitle%3DLaying%2520a%2520Trap%2520to%2520Kill%2520Cancer%2520Cells%253A%2520PARP%2520Inhibitors%2520and%2520Their%2520Mechanisms%2520of%2520Action%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D362%26spage%3D362ps17%26doi%3D10.1126%2Fscitranslmed.aaf9246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorsell, A.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekblad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trésaugues, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüler, H.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Potency and Promiscuity in Poly(ADP-Ribose) Polymerase (PARP) and Tankyrase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1271</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2hu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1262-1271&issue=4&author=A.-G.+Thorsellauthor=T.+Ekbladauthor=T.+Karlbergauthor=M.+L%C3%B6wauthor=A.+F.+Pintoauthor=L.+Tr%C3%A9sauguesauthor=M.+Mocheauthor=M.+S.+Cohenauthor=H.+Sch%C3%BCler&title=Structural+Basis+for+Potency+and+Promiscuity+in+Poly%28ADP-Ribose%29+Polymerase+%28PARP%29+and+Tankyrase+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors</span></div><div class="casAuthors">Thorsell, Ann-Gerd; Ekblad, Torun; Karlberg, Tobias; Loew, Mirjam; Pinto, Ana Filipa; Tresaugues, Lionel; Moche, Martin; Cohen, Michael S.; Schuler, Herwig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1262-1271</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective inhibitors could help unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clin. benefits in cancer therapy.  The authors profiled ten clin. PARP inhibitors and commonly used research tools for their inhibition of multiple PARP enzymes.  The authors also detd. crystal structures of these compds. bound to PARP1 or PARP2.  Veliparib and Niraparib are selective inhibitors of PARP1 and PARP2; Olaparib, Rucaparib and Talazoparib are more potent inhibitors of PARP1, but are less selective.  PJ34 and UPF1069 are broad PARP inhibitors; PJ34 inserts a flexible moiety into hydrophobic subpockets in various ADP-ribosyltransferases.  XAV939 is a promiscuous tankyrase inhibitor, and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ6102 are tankyrase selective.  The authors' biochem. and structural anal. of PARP inhibitor potencies establishes a mol. basis for either selectivity or promiscuity and provides a benchmark for exptl. design in assessment of PARP inhibitor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQSmV0dV9abrVg90H21EOLACvtfcHk0lgQOk79ENgeAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2hu77E&md5=fce2c08efcf47cbc24929b62df782a39</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00990%26sid%3Dliteratum%253Aachs%26aulast%3DThorsell%26aufirst%3DA.-G.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DL%25C3%25B6w%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DA.%2BF.%26aulast%3DTr%25C3%25A9saugues%26aufirst%3DL.%26aulast%3DMoche%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26atitle%3DStructural%2520Basis%2520for%2520Potency%2520and%2520Promiscuity%2520in%2520Poly%2528ADP-Ribose%2529%2520Polymerase%2520%2528PARP%2529%2520and%2520Tankyrase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1262%26epage%3D1271%26doi%3D10.1021%2Facs.jmedchem.6b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span> </span><span class="NLM_article-title">Advances in Leukemia Research</span>.  <i>NIH National
Cancer Institute</i>. <a href="https://www.cancer.gov/types/leukemia/research" class="extLink">https://www.cancer.gov/types/leukemia/research</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Advances+in+Leukemia+Research.+NIH+National%0ACancer+Institute.+https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fleukemia%2Fresearch+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%2520in%2520Leukemia%2520Research%26jtitle%3DNIH%2520National%250ACancer%2520Institute%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalamegham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essioux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. A.</span></span> <span> </span><span class="NLM_article-title">Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1111/cts.12455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fcts.12455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28121072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ptFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=84-92&issue=2&author=H.+Scheerensauthor=A.+Malongauthor=K.+Bassettauthor=Z.+Boydauthor=V.+Guptaauthor=J.+Harrisauthor=C.+Mesickauthor=S.+Simnettauthor=H.+Stevensauthor=H.+Gilbertauthor=P.+Risserauthor=R.+Kalameghamauthor=J.+Jordanauthor=J.+Engelauthor=S.+Chenauthor=L.+Essiouxauthor=J.+A.+Williams&title=Current+Status+of+Companion+and+Complementary+Diagnostics%3A+Strategic+Considerations+for+Development+and+Launch&doi=10.1111%2Fcts.12455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch</span></div><div class="casAuthors">Scheerens H; Malong A; Bassett K; Boyd Z; Gupta V; Harris J; Mesick C; Simnett S; Gilbert H; Risser P; Kalamegham R; Williams J A; Stevens H; Jordan J; Engel J; Chen S; Essioux L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">84-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">US Food and Drug Administration (FDA)-approved diagnostic assays play an increasingly common role in managing patients to prolong lifespan while also enhancing quality of life.  Diagnostic assays can be essential for the safe and effective use of therapeutics (companion diagnostic), or may inform on improving the benefit/risk ratio without restricting drug access (complementary diagnostic).  This tutorial reviews strategic considerations for drug and assay development resulting in FDA-approved companion or complementary diagnostic status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtZkkpGtP-CyjiVMCqkKxVfW6udTcc2ebxC1LzquHJh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ptFSntA%253D%253D&md5=c1cff2deadbb709b04458ccea9081a21</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fcts.12455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12455%26sid%3Dliteratum%253Aachs%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DMalong%26aufirst%3DA.%26aulast%3DBassett%26aufirst%3DK.%26aulast%3DBoyd%26aufirst%3DZ.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DMesick%26aufirst%3DC.%26aulast%3DSimnett%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DH.%26aulast%3DGilbert%26aufirst%3DH.%26aulast%3DRisser%26aufirst%3DP.%26aulast%3DKalamegham%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DEssioux%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26atitle%3DCurrent%2520Status%2520of%2520Companion%2520and%2520Complementary%2520Diagnostics%253A%2520Strategic%2520Considerations%2520for%2520Development%2520and%2520Launch%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26issue%3D2%26spage%3D84%26epage%3D92%26doi%3D10.1111%2Fcts.12455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span> </span><span class="NLM_article-title">List of Cleared or Approved Companion Diagnostic
Devices (In Vitro
and Imaging Tools)</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools" class="extLink">https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools</a> (accessed <span class="NLM_year">2020</span>-10-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=List+of+Cleared+or+Approved+Companion+Diagnostic%0ADevices+%28In+Vitro%0Aand+Imaging+Tools%29.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Fvitro-diagnostics%2Flist-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools+%28accessed+2020-10-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DList%2520of%2520Cleared%2520or%2520Approved%2520Companion%2520Diagnostic%250ADevices%2520%2528In%2520Vitro%250Aand%2520Imaging%2520Tools%2529%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewlett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettischer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruebsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span> <span> </span><span class="NLM_article-title">The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">10884</span>– <span class="NLM_lpage">10893</span>, <span class="refDoi"> DOI: 10.1128/JVI.05265-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1128%2FJVI.05265-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=21752907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=10884-10893&issue=20&author=T.+Goldnerauthor=G.+Hewlettauthor=N.+Ettischerauthor=H.+Ruebsamen-Schaeffauthor=H.+Zimmermannauthor=P.+Lischka&title=The+Novel+Anticytomegalovirus+Compound+AIC246+%28Letermovir%29+Inhibits+Human+Cytomegalovirus+Replication+through+a+Specific+Antiviral+Mechanism+That+Involves+the+Viral+Terminase&doi=10.1128%2FJVI.05265-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase</span></div><div class="casAuthors">Goldner, Thomas; Hewlett, Guy; Ettischer, Nicole; Ruebsamen-Schaeff, Helga; Zimmermann, Holger; Lschka, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10884-10893</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) remains the leading viral cause of birth defects and life-threatening disease in transplant recipients.  All approved antiviral drugs target the viral DNA polymerase and are assocd. with severe toxicity issues and the emergence of drug resistance.  Attempts to discover improved anti-HCMV drugs led to the identification of the small-mol.-wt. compd. AIC246 (Letermovir).  AIC246 exhibits outstanding anti-HCMV activity in vitro and in vivo and currently is undergoing a clin. phase IIb trial.  The initial mode-of-action studies suggested that the drug acts late in the HCMV replication cycle via a mechanism distinct from that of polymerase inhibitors.  Here, we extend our mode-of-action analyses and report that AIC246 blocks viral replication without inhibiting the synthesis of progeny HCMV DNA or viral proteins.  The genotyping of mutant viruses that escaped AIC246 inhibition uncovered distinct point mutations in the UL56 subunit of the viral terminase complex.  Marker transfer analyses confirmed that these mutations were sufficient to mediate AIC246 resistance.  The mapping of drug resistance to open reading frame UL56 suggests that viral DNA processing and/or packaging is targeted by AIC246.  In line with this, we demonstrate that AIC246 affects the formation of proper unit-length genomes from viral DNA concatemers and interferes with virion maturation.  However, since AIC246-resistant viruses do not exhibit cross-resistance to previously published terminase inhibitors, our data suggest that AIC246 interferes with HCMV DNA cleavage/packaging via a mol. mechanism that is distinct from that of other compd. classes known to target the viral terminase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswkV2gibRBbVg90H21EOLACvtfcHk0lj5XpzBDyMIfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI&md5=63602456ebfb1cf9c2509d26d260487d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FJVI.05265-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.05265-11%26sid%3Dliteratum%253Aachs%26aulast%3DGoldner%26aufirst%3DT.%26aulast%3DHewlett%26aufirst%3DG.%26aulast%3DEttischer%26aufirst%3DN.%26aulast%3DRuebsamen-Schaeff%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DLischka%26aufirst%3DP.%26atitle%3DThe%2520Novel%2520Anticytomegalovirus%2520Compound%2520AIC246%2520%2528Letermovir%2529%2520Inhibits%2520Human%2520Cytomegalovirus%2520Replication%2520through%2520a%2520Specific%2520Antiviral%2520Mechanism%2520That%2520Involves%2520the%2520Viral%2520Terminase%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26issue%3D20%26spage%3D10884%26epage%3D10893%26doi%3D10.1128%2FJVI.05265-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Helou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razonable, R. R.</span></span> <span> </span><span class="NLM_article-title">Letermovir for the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients: An Evidence-Based Review</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.2147/IDR.S180908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.2147%2FIDR.S180908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31239725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Oqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=1481-1491&author=G.+El%0AHelouauthor=R.+R.+Razonable&title=Letermovir+for+the+Prevention+of+Cytomegalovirus+Infection+and+Disease+in+Transplant+Recipients%3A+An+Evidence-Based+Review&doi=10.2147%2FIDR.S180908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review</span></div><div class="casAuthors">El Helou, Guy; Razonable, Raymund R.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Drug Resistance</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1481-1491</span>CODEN:
                <span class="NLM_cas:coden">IDRNAV</span>;
        ISSN:<span class="NLM_cas:issn">1178-6973</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is assocd. with increased morbidity and mortality.  Antiviral drugs are the mainstay for the prevention of CMVinfection and disease, most commonly with valganciclovir.  However, valganciclovir use is often assocd. with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to emergence of antiviral resistance.  Foscarnet and cidofovir, however, are assocd. with nephrotoxicity.  Letermovir, a novel CMV viral terminase inhibitor drug, was recently approved for CMV prophylaxis in allogeneic HSCT recipients.  It has a favorable pharmacokinetic and tolerability profile.  The aim of this paper is to review the evidence supporting the use of letermovir in allogeneic HSCT recipients, and how the drug impacts our contemporary clin. practice.  In addn., we discuss the ongoing clin. trial of letermovir for the prevention of CMVin SOT recipients.  The use of letermovir for treatment of CMVinfection and disease is not yet approved.  However, because of a unique mechanism of activity, we provide our perspective on the potential role of letermovir in the treatment of ganciclovir-resistant CMV infection and disease.  Furthermore, drug-resistant CMV has emerged during use of letermovir for prophylaxis and treatment.  Caution is advised on its use in order to preserve its therapeutic lifespan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3AHrH5Zh9QbVg90H21EOLACvtfcHk0lj5XpzBDyMIfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Oqtbo%253D&md5=b0a0962a19e5bca04251b7cb43cf477f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2147%2FIDR.S180908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S180908%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BHelou%26aufirst%3DG.%26aulast%3DRazonable%26aufirst%3DR.%2BR.%26atitle%3DLetermovir%2520for%2520the%2520Prevention%2520of%2520Cytomegalovirus%2520Infection%2520and%2520Disease%2520in%2520Transplant%2520Recipients%253A%2520An%2520Evidence-Based%2520Review%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2019%26volume%3D12%26spage%3D1481%26epage%3D1491%26doi%3D10.2147%2FIDR.S180908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howe, A. Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Boceprevir: A Novel, First-Generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2013.002XX</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.14218%2FJCTH.2013.002XX" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26357603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC283htl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=22-32&issue=1&author=A.+Y.+M.+Howeauthor=S.+Venkatraman&title=The+Discovery+and+Development+of+Boceprevir%3A+A+Novel%2C+First-Generation+Inhibitor+of+the+Hepatitis+C+Virus+NS3%2F4A+Serine+Protease&doi=10.14218%2FJCTH.2013.002XX"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease</span></div><div class="casAuthors">Howe Anita Y M; Venkatraman Srikanth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-32</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">An estimated 2-3% of the world's population is infected with hepatitis C virus (HCV), making it a major global health problem.  Consequently, over the past 15 years, there has been a concerted effort to understand the pathophysiology of HCV infection and the molecular virology of replication, and to utilize this knowledge for the development of more effective treatments.  The virally encoded non-structural serine protease (NS3) is required to process the HCV polyprotein and release the individual proteins that form the viral RNA replication machinery.  Given its critical role in the replication of HCV, the NS3 protease has been recognized as a potential drug target for the development of selective HCV therapies.  In this review, we describe the key scientific discoveries that led to the approval of boceprevir, a first-generation, selective, small molecule inhibitor of the NS3 protease.  We highlight the early studies that reported the crystal structure of the NS3 protease, its role in the processing of the HCV polyprotein, and the structural requirements critical for substrate cleavage.  We also consider the novel attributes of the NS3 protease-binding pocket that challenged development of small molecule inhibitors, and the studies that ultimately yielded milligram quantities of this enzyme in a soluble, tractable form suitable for inhibitor screening programs.  Finally, we describe the discovery of boceprevir, from the early chemistry studies, through the development of high-throughput assays, to the phase III clinical development program that ultimately provided the basis for approval of this drug.  This latest phase in the development of boceprevir represents the culmination of a major global effort to understand the pathophysiology of HCV and develop small molecule inhibitors for the NS3 protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKJ8jZszU7eqNc3HjJRoFAfW6udTcc2eZzyLExSUY8C7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htl2lsg%253D%253D&md5=ec18c56586ad6b5c7fb5ccf47daaee68</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2013.002XX&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2013.002XX%26sid%3Dliteratum%253Aachs%26aulast%3DHowe%26aufirst%3DA.%2BY.%2BM.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Boceprevir%253A%2520A%2520Novel%252C%2520First-Generation%2520Inhibitor%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%252F4A%2520Serine%2520Protease%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2013%26volume%3D1%26issue%3D1%26spage%3D22%26epage%3D32%26doi%3D10.14218%2FJCTH.2013.002XX" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0179-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-014-0179-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24442794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=273-282&issue=2&author=G.+M.+Keatingauthor=A.+Vaidya&title=Sofosbuvir%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0179-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir: First Global Approval</span></div><div class="casAuthors">Keating, Gillian M.; Vaidya, Asha</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Sofosbuvir (Solvadi®), a nucleotide analog hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component of a combination antiviral regimen.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of sofosbuvir for the treatment of chronic hepatitis C. This article summarizes the milestones in the development of sofosbuvir leading to this first approval for chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpmuxvtmlMbVg90H21EOLACvtfcHk0ljtak3rs7pBhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7c%253D&md5=9a4835e0b3733e0a91e3dab36a24115c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0179-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0179-7%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DVaidya%26aufirst%3DA.%26atitle%3DSofosbuvir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D2%26spage%3D273%26epage%3D282%26doi%3D10.1007%2Fs40265-014-0179-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinestrosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuluvath, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symonds, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquinelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span> <span> </span><span class="NLM_article-title">AI444040 Study Group. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1306218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24428467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=211-221&issue=3&author=M.+S.+Sulkowskiauthor=D.+F.+Gardinerauthor=M.+Rodriguez-Torresauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=I.+Jacobsonauthor=E.+Lawitzauthor=A.+S.+Lokauthor=F.+Hinestrosaauthor=P.+J.+Thuluvathauthor=H.+Schwartzauthor=D.+R.+Nelsonauthor=G.+T.+Eversonauthor=T.+Eleyauthor=M.+Wind-Rotoloauthor=S.-P.+Huangauthor=M.+Gaoauthor=D.+Hernandezauthor=F.+McPheeauthor=D.+Shermanauthor=R.+Hindesauthor=W.+Symondsauthor=C.+Pasquinelliauthor=D.+M.+Grasela&title=AI444040+Study+Group.+Daclatasvir+plus+Sofosbuvir+for+Previously+Treated+or+Untreated+Chronic+HCV+Infection&doi=10.1056%2FNEJMoa1306218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span></div><div class="casAuthors">Sulkowski, Mark S.; Gardiner, David F.; Rodriguez-Torres, Maribel; Reddy, K. Rajender; Hassanein, Tarek; Jacobson, Ira; Lawitz, Eric; Lok, Anna S.; Hinestrosa, Federico; Thuluvath, Paul J.; Schwartz, Howard; Nelson, David R.; Everson, Gregory T.; Eley, Timothy; Wind-Rotolo, Megan; Huang, Shu-Pang; Gao, Min; Hernandez, Dennis; McPhee, Fiona; Sherman, Diane; Hindes, Robert; Symonds, William; Pasquinelli, Claudio; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.  We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analog HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.  METHODS In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without ribavirin, for 24 wk.  The study was expanded to include 123 addnl. patients with genotype 1 infection who were randomly assigned to daclatasvir plus sofosbuvir, with or without ribavirin, for 12 wk (82 previously untreated patients) or 24 wk (41 patients who had previous virol. failure with telaprevir or boceprevir plus peginterferon alfa ribavirin).  The primary end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) at week 12 after the end of therapy.  RESULTS Overall, 211 patients received treatment.  Among patients with genotype 1 infection, 98% of 126 previously untreated patients and 98% of 41 patients who did not have a sustained virol. response with HCV protease inhibitors had a sustained virol. response at week 12 after the end of therapy.  A total of 92% of 26 patients with genotype 2 infection and 89% of 18 patients with genotype 3 infection had a sustained virol. response at week 12.  High rates of sustained virol. response at week 12 were obsd. among patients with HCV subtypes 1a and 1b (98% and 100%, resp.) and those with CC and non-CC IL28B genotypes (93% and 98%, resp.), as well as among patients who received ribavirin and those who did not (94% and 98%, resp.).  The most common adverse events were fatigue, headache, and nausea.  CONCLUSIONS Once-daily oral daclatasvir plus sofosbuvir was assocd. with high rates of sustained virol. response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMiCkoKS-KUrVg90H21EOLACvtfcHk0ljtak3rs7pBhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D&md5=bc9eff52401d2f1e00505d30fcffd2c5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306218%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DAI444040%2520Study%2520Group.%2520Daclatasvir%2520plus%2520Sofosbuvir%2520for%2520Previously%2520Treated%2520or%2520Untreated%2520Chronic%2520HCV%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D3%26spage%3D211%26epage%3D221%26doi%3D10.1056%2FNEJMoa1306218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0381-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-015-0381-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25837989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlCksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=675-685&issue=6&author=G.+M.+Keating&title=Ledipasvir%2FSofosbuvir%3A+A+Review+of+Its+Use+in+Chronic+Hepatitis+C&doi=10.1007%2Fs40265-015-0381-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C</span></div><div class="casAuthors">Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">675-685</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The single-tablet regimen of the hepatitis C virus (HCV) NS5A inhibitor ledipasvir and the HCV NS5B polymerase inhibitor sofosbuvir (ledipasvir/sofosbuvir; Harvoni) was recently approved in the US and the EU.  The phase III ION trials included treatment-naive (ION-1 and -3) or treatment-experienced (ION-2) patients with chronic HCV genotype 1 infection (≈20 % of patients in ION-1 and -2 had cirrhosis, whereas no patient in ION-3 had cirrhosis).  A sustained virol. response 12 wk' post-treatment (SVR12) was seen in 99 % of treatment-naive patients receiving ledipasvir/sofosbuvir for 12 wk in ION-1, with no addnl. benefit conferred by the addn. of ribavirin or extending the treatment duration to 24 wk.  Moreover, in ION-3, an 8-wk regimen achieved an SVR12 rate of 94 % overall and 97 % in the subgroup of patients with a baseline HCV RNA level of <6 million IU/mL.  SVR12 rates of 94 and 99 % were seen in treatment-experienced patients who received ledipasvir/sofosbuvir for 12 and 24 wk in ION-2.  Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 infection, in HCV and HIV co-infection and, in combination with ribavirin, in patients with chronic HCV genotype 1 or 4 infection who have decompensated cirrhosis or are liver transplant recipients and in chronic HCV genotype 3 infection.  Oral ledipasvir/sofosbuvir was generally well tolerated.  In conclusion, ledipasvir/sofosbuvir is an important new single-tablet regimen that represents a significant advance in the treatment of chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqagM_RFKmFKLVg90H21EOLACvtfcHk0liIWgDVs1ZhlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlCksL8%253D&md5=137b610d65162620fccfeb3783469fb2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0381-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0381-2%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DLedipasvir%252FSofosbuvir%253A%2520A%2520Review%2520of%2520Its%2520Use%2520in%2520Chronic%2520Hepatitis%2520C%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26issue%3D6%26spage%3D675%26epage%3D685%26doi%3D10.1007%2Fs40265-015-0381-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curescu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledinghen, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habersetzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolakopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papatheodoridis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakalos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauss, S.</span></span> <span> </span><span class="NLM_article-title">PegBase Group Investigators. Efficacy and Safety Profile of Boceprevir- or Telaprevir-Based Triple Therapy or Dual Peginterferon Alfa-2a or Alfa-2b plus Ribavirin Therapy in Chronic Hepatitis C: The Real-World PegBase Observational Study</span>. <i>Ann. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.20524/aog.2017.0136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.20524%2Faog.2017.0136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28469364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1crjsl2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=327-343&issue=3&author=A.+Mangiaauthor=G.+R.+Fosterauthor=C.+P.+Bergauthor=M.+Curescuauthor=V.+D.+Ledinghenauthor=F.+Habersetzerauthor=S.+Manolakopoulosauthor=E.+Negriauthor=G.+Papatheodoridisauthor=S.+Ahlersauthor=M.+Castilloauthor=G.+Bakalosauthor=S.+Mauss&title=PegBase+Group+Investigators.+Efficacy+and+Safety+Profile+of+Boceprevir-+or+Telaprevir-Based+Triple+Therapy+or+Dual+Peginterferon+Alfa-2a+or+Alfa-2b+plus+Ribavirin+Therapy+in+Chronic+Hepatitis+C%3A+The+Real-World+PegBase+Observational+Study&doi=10.20524%2Faog.2017.0136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study</span></div><div class="casAuthors">Mangia Alessandra; Foster Graham R; Berg Christoph P; Curescu Manuela; Ledinghen Victor De; Habersetzer Francois; Manolakopoulos Spilios; Negri Elisa; Papatheodoridis George; Ahlers Silke; Castillo Marco; Bakalos Georgios; Mauss Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Annals of gastroenterology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-343</span>
        ISSN:<span class="NLM_cas:issn">1108-7471</span>.
    </div><div class="casAbstract">BACKGROUND:  The aim of the study was to determine the efficacy and safety of triple therapy with a first-generation protease inhibitor (PI; boceprevir, telaprevir) plus peginterferon alfa-2a or -2b plus ribavirin, and dual therapy (peginterferon alfa-2a or -2b plus ribavirin) in patients with chronic hepatitis C (CHC) in routine clinical practice.  METHODS:  PegBase was an international, prospective, observational study in which 4441 patients with CHC were enrolled in 27 countries.  This analysis focuses on results in 4100 treatment-naive and previously treated patients treated with PI-based triple therapy or dual therapy, according to the discretion of the investigator and local standards of practice.  The primary efficacy outcome was sustained virological response after 12-week follow up (SVR12).  RESULTS:  SVR12 rates in treatment-naive genotype (G) 1 patients were 56.6% and 62.9% for recipients of boceprevir plus peginterferon alfa-2a/ribavirin and boceprevir plus peginterferon alfa-2b/ribavirin, respectively, and 65.3% and 58.6% for recipients of telaprevir plus peginterferon alfa-2a/ribavirin and telaprevir plus peginterferon alfa-2b/ribavirin, respectively.  In previously treated patients assigned to these four regimens, SVR12 rates were 43.6%, 48.3%, 60.3% and 56.1%, respectively.  Among treatment-naive patients assigned to peginterferon alfa-2a/ribavirin and peginterferon alfa-2b/ribavirin, respectively, SVR12 rates were 49.2% and 41.9% in G1 patients, 75.7% and 83.3% in G2 patients, 65.9% and 65.9% in G3 patients, and 49.7%, and 51.1% in G4 patients.  The safety and tolerability of dual and triple therapy were consistent with previous reports.  CONCLUSION:  The efficacy and safety of first-generation PI-based triple-therapy and dual-therapy regimens in this real-world cohort were broadly comparable to those of previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcf_k-H9XLw9bHMBt0mMIXfW6udTcc2eamJfRvFS8Fgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjsl2rsQ%253D%253D&md5=cb6149b78a8550f2e3b9384865129d79</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.20524%2Faog.2017.0136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20524%252Faog.2017.0136%26sid%3Dliteratum%253Aachs%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBerg%26aufirst%3DC.%2BP.%26aulast%3DCurescu%26aufirst%3DM.%26aulast%3DLedinghen%26aufirst%3DV.%2BD.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DManolakopoulos%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DE.%26aulast%3DPapatheodoridis%26aufirst%3DG.%26aulast%3DAhlers%26aufirst%3DS.%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DBakalos%26aufirst%3DG.%26aulast%3DMauss%26aufirst%3DS.%26atitle%3DPegBase%2520Group%2520Investigators.%2520Efficacy%2520and%2520Safety%2520Profile%2520of%2520Boceprevir-%2520or%2520Telaprevir-Based%2520Triple%2520Therapy%2520or%2520Dual%2520Peginterferon%2520Alfa-2a%2520or%2520Alfa-2b%2520plus%2520Ribavirin%2520Therapy%2520in%2520Chronic%2520Hepatitis%2520C%253A%2520The%2520Real-World%2520PegBase%2520Observational%2520Study%26jtitle%3DAnn.%2520Gastroenterol.%26date%3D2017%26volume%3D30%26issue%3D3%26spage%3D327%26epage%3D343%26doi%3D10.20524%2Faog.2017.0136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zipfel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zablocki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Pan-Genotypic Hepatitis C Virus NS3/4A Protease Inhibitor Voxilaprevir (GS-9857): A Component of Vosevi</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.bmcl.2019.03.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31133531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKqu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2428-2436&issue=16&author=J.+G.+Taylorauthor=S.+Zipfelauthor=K.+Rameyauthor=R.+Vivianauthor=A.+Schrierauthor=K.+K.+Karkiauthor=A.+Katanaauthor=D.+Katoauthor=T.+Kobayashiauthor=R.+Martinezauthor=M.+Sangiauthor=D.+Siegelauthor=C.+V.+Tranauthor=Z.-Y.+Yangauthor=J.+Zablockiauthor=C.+Y.+Yangauthor=Y.+Wangauthor=K.+Wangauthor=K.+Chanauthor=O.+Barauskasauthor=G.+Chengauthor=D.+Jinauthor=B.+E.+Schultzauthor=T.+Applebyauthor=A.+G.+Villase%C3%B1orauthor=J.+O.+Link&title=Discovery+of+the+Pan-Genotypic+Hepatitis+C+Virus+NS3%2F4A+Protease+Inhibitor+Voxilaprevir+%28GS-9857%29%3A+A+Component+of+Vosevi&doi=10.1016%2Fj.bmcl.2019.03.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi</span></div><div class="casAuthors">Taylor, James G.; Zipfel, Sheila; Ramey, Kyla; Vivian, Randy; Schrier, Adam; Karki, Kapil K.; Katana, Ashley; Kato, Darryl; Kobayashi, Tetsuya; Martinez, Ruben; Sangi, Michael; Siegel, Dustin; Tran, Chinh V.; Yang, Zheng-Yu; Zablocki, Jeff; Yang, Cheng Y.; Wang, Yujin; Wang, Kelly; Chan, Katie; Barauskas, Ona; Cheng, Guofeng; Jin, Debi; Schultz, Brian E.; Appleby, Todd; Villasenor, Armando G.; Link, John O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2428-2436</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Treatment of hepatitis C virus (HCV) infection has been historically challenging due the high viral genetic complexity wherein there are eight distinct genotypes and at least 86 viral subtypes.  While HCV NS3/4A protease inhibitors are an established treatment option for genotype 1 infection, limited coverage of genotypes 2 and/or 3 combined with serum alanine transaminase (ALT) elevations for some compds. has limited the broad utility of this therapeutic class.  Our discovery efforts were focused on identifying an NS3/4A protease inhibitor with pan-genotypic antiviral activity, improved coverage of resistance assocd. substitutions, and a decreased risk of hepatotoxicity.  Towards this goal, distinct interactions with the conserved catalytic triad of the NS3/4A protease were identified that improved genotype 3 antiviral activity.  We further discovered that protein adduct formation strongly correlated with clin. ALT elevation for this therapeutic class.  Improving metabolic stability and decreasing protein adduct formation through structural modifications ultimately resulted in voxilaprevir.  Voxilaprevir, in combination with sofosbuvir and velpatasvir, has demonstrated pan-genotypic antiviral clin. activity.  Furthermore, hepatotoxicity was not obsd. in Phase 3 clin. trials with voxilaprevir, consistent with our design strategy.  Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) is now an approved pan-genotypic treatment option for the most difficult-to-cure individuals who have previously failed direct acting antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeOT2WnMaWbVg90H21EOLACvtfcHk0liP2dVigykCDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKqu77P&md5=19fb49e30634e8e95d17009cbc81a1a6</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DZipfel%26aufirst%3DS.%26aulast%3DRamey%26aufirst%3DK.%26aulast%3DVivian%26aufirst%3DR.%26aulast%3DSchrier%26aufirst%3DA.%26aulast%3DKarki%26aufirst%3DK.%2BK.%26aulast%3DKatana%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DSangi%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DC.%2BV.%26aulast%3DYang%26aufirst%3DZ.-Y.%26aulast%3DZablocki%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DK.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DD.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DLink%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520Pan-Genotypic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4A%2520Protease%2520Inhibitor%2520Voxilaprevir%2520%2528GS-9857%2529%253A%2520A%2520Component%2520of%2520Vosevi%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2428%26epage%3D2436%26doi%3D10.1016%2Fj.bmcl.2019.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenstein, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harney, C.</span></span> <span> </span><span class="NLM_article-title">The Evolution of the Regulatory Framework for Antibacterial Agents</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1323</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1111/nyas.12441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fnyas.12441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24797794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2cjgtVWntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1323&publication_year=2014&pages=11-21&author=J.+H.+Rexauthor=M.+Goldbergerauthor=B.+I.+Eisensteinauthor=C.+Harney&title=The+Evolution+of+the+Regulatory+Framework+for+Antibacterial+Agents&doi=10.1111%2Fnyas.12441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of the regulatory framework for antibacterial agents</span></div><div class="casAuthors">Rex John H; Goldberger Mark; Eisenstein Barry I; Harney Carrie</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1323</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The rising tide of antibacterial resistance and the lack of a diverse, vibrant pipeline of novel antibacterial agents is a global crisis that impairs our ability to treat life-threatening infections.  The recent introduction of a tiered approach to the regulatory framework in this area offers one path to resolving some of the challenges.  By drawing heavily on the predictive power of the related sciences of pharmacokinetics and pharmacodynamics, smaller, focused clinical trial programs have become possible for agents that might not otherwise have been possible to progress.  There are limitations to these pathways, and they are not easy to implement, but making reliable noninferiority-based approaches available is critical to reinvigorating the global antibiotic pipeline.  With the recognition of these ideas by key regulatory authorities in recent guidance, the next challenges in this area will focus on interpretive breakpoints, the extent of data in the prescribing information, ensuring that multiple agents can be progressed, and the challenge of the antibiotic business model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRITYa0NchRHCEJCPKhJPuqfW6udTcc2ebVGtAptJ4DFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjgtVWntw%253D%253D&md5=44b33008c61d157f599e76b3260c1e52</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12441%26sid%3Dliteratum%253Aachs%26aulast%3DRex%26aufirst%3DJ.%2BH.%26aulast%3DGoldberger%26aufirst%3DM.%26aulast%3DEisenstein%26aufirst%3DB.%2BI.%26aulast%3DHarney%26aufirst%3DC.%26atitle%3DThe%2520Evolution%2520of%2520the%2520Regulatory%2520Framework%2520for%2520Antibacterial%2520Agents%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1323%26spage%3D11%26epage%3D21%26doi%3D10.1111%2Fnyas.12441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manchester, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span> <span> </span><span class="NLM_article-title">ESKAPEing the Labyrinth of Antibacterial Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1038/nrd4572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd4572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26139286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyks77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=529-542&issue=8&author=R.+Tommasiauthor=D.+G.+Brownauthor=G.+K.+Walkupauthor=J.+I.+Manchesterauthor=A.+A.+Miller&title=ESKAPEing+the+Labyrinth+of+Antibacterial+Discovery&doi=10.1038%2Fnrd4572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">ESKAPEing the labyrinth of antibacterial discovery</span></div><div class="casAuthors">Tommasi, Ruben; Brown, Dean G.; Walkup, Grant K.; Manchester, John I.; Miller, Alita A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">529-542</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antimicrobial drug resistance is a growing threat to global public health.  Multidrug resistance among the 'ESKAPE' organisms - encompassing Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. - is of particular concern because they are responsible for many serious infections in hospitals.  Although some promising agents are in the pipeline, there is an urgent need for new antibiotic scaffolds.  However, antibacterial researchers have struggled to identify new small mols. with meaningful cellular activity, esp. those effective against multidrug-resistant Gram-neg. pathogens.  This difficulty ultimately stems from an incomplete understanding of efflux systems and compd. permeation through bacterial membranes.  This Opinion article describes findings from target-based and phenotypic screening efforts carried out at AstraZeneca over the past decade, discusses some of the subsequent chem. challenges and concludes with a description of new approaches comprising a combination of computational modeling and advanced biol. tools which may pave the way towards the discovery of new antibacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolJg6HXnn7BLVg90H21EOLACvtfcHk0liP2dVigykCDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyks77M&md5=0d3159250e27926ab280c305ea5fb9ef</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnrd4572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4572%26sid%3Dliteratum%253Aachs%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DWalkup%26aufirst%3DG.%2BK.%26aulast%3DManchester%26aufirst%3DJ.%2BI.%26aulast%3DMiller%26aufirst%3DA.%2BA.%26atitle%3DESKAPEing%2520the%2520Labyrinth%2520of%2520Antibacterial%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D8%26spage%3D529%26epage%3D542%26doi%3D10.1038%2Fnrd4572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span> </span><span class="NLM_article-title">GAIN act: H.R.2182 - Generating Antibiotic
Incentives Now Act of
2011 112th Congress (2011–2012)</span>.  <i>Congress.gov</i>. <a href="https://www.congress.gov/bill/112th-congress/house-bill/2182" class="extLink">https://www.congress.gov/bill/112th-congress/house-bill/2182</a> (accessed <span class="NLM_year">2020</span>-04-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GAIN+act%3A+H.R.2182+-+Generating+Antibiotic%0AIncentives+Now+Act+of%0A2011+112th+Congress+%282011%E2%80%932012%29.+Congress.gov.+https%3A%2F%2Fwww.congress.gov%2Fbill%2F112th-congress%2Fhouse-bill%2F2182+%28accessed+2020-04-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGAIN%2520act%253A%2520H.R.2182%2520-%2520Generating%2520Antibiotic%250AIncentives%2520Now%2520Act%2520of%250A2011%2520112th%2520Congress%2520%25282011%25E2%2580%25932012%2529%26jtitle%3DCongress.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0966-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0966-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30128699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGjt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1259-1270&issue=12&author=S.+Dhillon&title=Meropenem%2FVaborbactam%3A+A+Review+in+Complicated+Urinary+Tract+Infections&doi=10.1007%2Fs40265-018-0966-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1259-1270</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials.  I.v. meropenem/vaborbactam (Vabomere) is the first carbapenem/β-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis.  Vaborbactam is a potent inhibitor of class A serine carbapenemases, which, when combined with the antibacterial meropenem, restores the activity of meropenem against β-lactamase producing Enterobacteriaceae, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.  In the phase 3, noninferiority TANGO I trial in patients with cUTIs, i.v. meropenem/vaborbactam was noninferior to i.v. piperacillin/tazobactam for overall success (composite of clin. cure and microbial eradication; FDA primary endpoint) and microbial eradication (EMA primary endpoint).  Meropenem/vaborbactam was generally well tolerated, with a tolerability profile generally similar to that of piperacillin/tazobactam.  TANGO I did not assess the efficacy of meropenem/vaborbactam for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae and meropenem/vaborbactam is currently not indicated for these patients.  Available evidence indicates that meropenem/vaborbactam is a useful treatment option for patients with cUTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfbl_iY8DrWrVg90H21EOLACvtfcHk0lhFpY2ghreL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGjt7vE&md5=61025d2c50c93af20f96fc70cbf60a32</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0966-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0966-7%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DMeropenem%252FVaborbactam%253A%2520A%2520Review%2520in%2520Complicated%2520Urinary%2520Tract%2520Infections%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D12%26spage%3D1259%26epage%3D1270%26doi%3D10.1007%2Fs40265-018-0966-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0902-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0902-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29671219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFCmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=675-692&issue=6&author=M.+Shirley&title=Ceftazidime-Avibactam%3A+A+Review+in+the+Treatment+of+Serious+Gram-Negative+Bacterial+Infections&doi=10.1007%2Fs40265-018-0902-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">675-692</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ceftazidime-avibactam (Zavicefta) is an i.v. administered combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam.  In the EU, ceftazidime-avibactam is approved for the treatment of adults with complicated urinary tract infections (cUTIs) [including pyelonephritis], complicated intra-abdominal infections (cIAIs), hospital-acquired pneumonia (HAP) [including ventilator-assocd. pneumonia (VAP)], and other infections caused by aerobic Gram-neg. organisms in patients with limited treatment options.  This article discusses the in vitro activity and pharmacol. properties of ceftazidime-avibactam, and reviews data on the agent's clin. efficacy and tolerability relating to use in these indications, with a focus on the EU label.  Ceftazidime-avibactam has excellent in vitro activity against many important Gram-neg. pathogens, including many extended-spectrum β-lactamase-, AmpC-, Klebsiella pneumoniae carbapenemase- and OXA-48-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa isolates; it is not active against metallo-β-lactamase-producing strains.  The clin. efficacy of ceftazidime-avibactam in the treatment of cUTI, cIAI and HAP (including VAP) in adults was demonstrated in pivotal phase III non-inferiority trials with carbapenem comparators.  Ceftazidime-avibactam treatment was assocd. with high response rates at the test-of-cure visit in patients with infections caused by ceftazidime-susceptible and -nonsusceptible Gram-neg. pathogens.  Ceftazidime-avibactam was generally well tolerated, with a safety and tolerability profile consistent with that of ceftazidime alone and that was generally typical of the injectable cephalosporins.  Thus, ceftazidime-avibactam represents a valuable new treatment option for these serious and difficult-to-treat infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkrfnUfU_goLVg90H21EOLACvtfcHk0lhFpY2ghreL9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFCmtLc%253D&md5=f29a308a645b8cf7ec0089d07a1932a4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0902-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0902-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DCeftazidime-Avibactam%253A%2520A%2520Review%2520in%2520the%2520Treatment%2520of%2520Serious%2520Gram-Negative%2520Bacterial%2520Infections%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D6%26spage%3D675%26epage%3D692%26doi%3D10.1007%2Fs40265-018-0902-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span> </span><span class="NLM_article-title">First Antibiotic with New Mechanisms of Action Approved
in Almost
20 Years</span>.  <i>BioSpace</i>. <a href="https://www.biospace.com/article/fda-approves-nabriva-s-xenleta-for-bacterial-pneumonia/" class="extLink">https://www.biospace.com/article/fda-approves-nabriva-s-xenleta-for-bacterial-pneumonia/</a> (accessed <span class="NLM_year">2020</span>-07-05).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=First+Antibiotic+with+New+Mechanisms+of+Action+Approved%0Ain+Almost%0A20+Years.+BioSpace.+https%3A%2F%2Fwww.biospace.com%2Farticle%2Ffda-approves-nabriva-s-xenleta-for-bacterial-pneumonia%2F+%28accessed+2020-07-05%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFirst%2520Antibiotic%2520with%2520New%2520Mechanisms%2520of%2520Action%2520Approved%250Ain%2520Almost%250A20%2520Years%26jtitle%3DBioSpace%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&issue=16&author=S.+J.+Keam&title=Pretomanid%3A+First+Approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eZ-SodJm7QjoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D16%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maheu-Giroux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. A.</span></span> <span> </span><span class="NLM_article-title">Moxidectin for Deworming: From Trials to Implementation</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30270-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1473-3099%2818%2930270-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29858152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1MbivFSgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=817-819&issue=8&author=M.+Maheu-Girouxauthor=S.+A.+Joseph&title=Moxidectin+for+Deworming%3A+From+Trials+to+Implementation&doi=10.1016%2FS1473-3099%2818%2930270-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Moxidectin for deworming: from trials to implementation</span></div><div class="casAuthors">Maheu-Giroux Mathieu; Joseph Serene A</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">817-819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzbFcp8DttpMjl5L8hwNX0fW6udTcc2eaUMCsLunx_h7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbivFSgtA%253D%253D&md5=a7134981ab65a1ba013df050d00754da</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930270-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930270-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaheu-Giroux%26aufirst%3DM.%26aulast%3DJoseph%26aufirst%3DS.%2BA.%26atitle%3DMoxidectin%2520for%2520Deworming%253A%2520From%2520Trials%2520to%2520Implementation%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26issue%3D8%26spage%3D817%26epage%3D819%26doi%3D10.1016%2FS1473-3099%2818%2930270-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, J. E.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0979-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0979-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30229442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCjurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1517-1523&issue=14&author=J.+E.+Frampton&title=Tafenoquine%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0979-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine: First Global Approval</span></div><div class="casAuthors">Frampton, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1517-1523</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Tafenoquine (Krintafel, Arakoda), an orally-active 8-aminoquinoline anti-malarial drug, is a long-acting analog of primaquine with activity against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include Plasmodium vivax (P. vivax) and Plasmodium falciparum.  It has been developed by GlaxoSmithKline (formerly SmithKline Beecham) for the radical cure of P. vivax malaria and by 60 Degrees Pharmaceuticals for the prophylaxis of malaria.  The exact mechanism(s) of action underlying the anti-Plasmodium activity of tafenoquine are unknown, although it may exert its effect by inhibiting haematin polymn. and, addnl., by inducing mitochondrial dysfunction leading to the apoptotic-like death of the organism.  In July 2018, tafenoquine was approved in the USA for the radical cure of P. vivax malaria in patients aged ≥ 16 years who are receiving appropriate antimalarial therapy for acute P. vivax malaria.  Subsequently, in August 2018, tafenoquine was approved in the USA for the prophylaxis of malaria in patients aged ≥ 18 years.  This article primarily summarizes the milestones in the development of tafenoquine leading to its first global approval for the radical cure of P. vivax malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrplYl7bXI8L7Vg90H21EOLACvtfcHk0lgz9EwXcbzvdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCjurvM&md5=4e8b6afc2abcb893eb7c428aebe0f152</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0979-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0979-2%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26atitle%3DTafenoquine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D14%26spage%3D1517%26epage%3D1523%26doi%3D10.1007%2Fs40265-018-0979-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novaes, R. D.</span></span> <span> </span><span class="NLM_article-title">An Evaluation of Benznidazole as a Chagas Disease Therapeutic</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1807</span>, <span class="refDoi"> DOI: 10.1080/14656566.2019.1650915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1080%2F14656566.2019.1650915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31456439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OhsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1797-1807&issue=15&author=I.+S.+Caldasauthor=E.+G.+Santosauthor=R.+D.+Novaes&title=An+Evaluation+of+Benznidazole+as+a+Chagas+Disease+Therapeutic&doi=10.1080%2F14656566.2019.1650915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of benznidazole as a Chagas disease therapeutic</span></div><div class="casAuthors">Caldas, Ivo S.; Santos, Elda G.; Novaes, Romulo D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1797-1807</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: As benznidazole is the first-line treatment for patients with Chagas disease, rational chemotherapy strategies are required based on the crit. anal. of the evidence on the relevance and applicability of this drug at different disease stages.: The authors discuss the current understanding of benznidazole-based chemotherapy for Chagas disease, focusing specifically on epidemiol., pharmacokinetics, mechanism of action, clin. recommendations, cure criteria, and therapeutic efficacy in different phases of the disease.: Benznidazole shows high bioavailability after oral administration.  Benznidazole at 5-8 mg/kg/day and 5-10 mg/kg/day for 30-60 days are consistent clin. recommendations for children and adults, resp.  A high correlation between neg. parasitol., serol., and polymerase chain reaction (PCR) assays in long-term post-therapeutic follow-up has been consistently used to evaluate therapeutic efficacy.  These methods support the evidence that the success of benznidazole-based chemotherapy is closely correlated with the phase of infection in which the treatment is administered.  The greater therapeutic efficacy is obtained in acute infections, gradually worsening as the infection becomes chronic.  When therapeutic failure is confirmed by any diagnostic assay, benznidazole treatment does not always ensure better long-term prognosis, and Chagas cardiomyopathy may develop as well as in untreated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4X8uwosJCYLVg90H21EOLACvtfcHk0lgz9EwXcbzvdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OhsLzK&md5=9e811af7be3789c0a2f2318e04991fb6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1080%2F14656566.2019.1650915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2019.1650915%26sid%3Dliteratum%253Aachs%26aulast%3DCaldas%26aufirst%3DI.%2BS.%26aulast%3DSantos%26aufirst%3DE.%2BG.%26aulast%3DNovaes%26aufirst%3DR.%2BD.%26atitle%3DAn%2520Evaluation%2520of%2520Benznidazole%2520as%2520a%2520Chagas%2520Disease%2520Therapeutic%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26issue%3D15%26spage%3D1797%26epage%3D1807%26doi%3D10.1080%2F14656566.2019.1650915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span> </span><span class="NLM_article-title">FDA Approves
New Drug for Treatment-Resistant Forms of Tuberculosis
That Affects the Lungs</span>.  <i>U.S. Food and Drug
Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs</a> (accessed <span class="NLM_year">2020</span>-10-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves%0ANew+Drug+for+Treatment-Resistant+Forms+of+Tuberculosis%0AThat+Affects+the+Lungs.+U.S.+Food+and+Drug%0AAdministration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs+%28accessed+2020-10-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%250ANew%2520Drug%2520for%2520Treatment-Resistant%2520Forms%2520of%2520Tuberculosis%250AThat%2520Affects%2520the%2520Lungs%26jtitle%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span> </span><span class="NLM_article-title">US FDA
Approves Krintafel (Tafenoquine) for the Radical Cure of <i>P.
vivax</i> malaria</span>.  <i>Medicines for
Malaria Venture</i>. <a href="https://www.mmv.org/newsroom/press-releases/us-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malaria" class="extLink">https://www.mmv.org/newsroom/press-releases/us-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malaria</a> (accessed <span class="NLM_year">2020</span>-10-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+FDA%0AApproves+Krintafel+%28Tafenoquine%29+for+the+Radical+Cure+of+P.%0Avivax+malaria.+Medicines+for%0AMalaria+Venture.+https%3A%2F%2Fwww.mmv.org%2Fnewsroom%2Fpress-releases%2Fus-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malaria+%28accessed+2020-10-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DUS%2520FDA%250AApproves%2520Krintafel%2520%2528Tafenoquine%2529%2520for%2520the%2520Radical%2520Cure%2520of%2520P.%250Avivax%2520malaria%26jtitle%3DMedicines%2520for%250AMalaria%2520Venture%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rujescu, D.</span></span> <span> </span><span class="NLM_article-title">The Current Development of CNS Drug Research</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1687</span>– <span class="NLM_lpage">1693</span>, <span class="refDoi"> DOI: 10.1017/S1461145713000345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1017%2FS1461145713000345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=23651558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC3snhsFGjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=1687-1693&issue=7&author=G.+Wegenerauthor=D.+Rujescu&title=The+Current+Development+of+CNS+Drug+Research&doi=10.1017%2FS1461145713000345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The current development of CNS drug research</span></div><div class="casAuthors">Wegener Gregers; Rujescu Dan</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1687-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the past few years, several high profiled pharmaceutical companies have decided to shut down major research activities within the central nervous system (CNS) area.  For example, in December 2011 Novartis announced that the company is closing its neuroscience facility in Basel, Switzerland, where Novartis is headquartered (Abbott, 2011).  It follows similar moves by GlaxoSmithKline and AstraZeneca, both based in the UK, which in 2010 announced the closure of major parts of their neuroscience research divisions globally (Jack, Financial Times, 4 February 2010).  Also companies primarily based in the USA, Pfizer and Merck, as well as the French company Sanofi, have pulled back on research into brain disorders.  This development is still proceeding, as e.g.  AstraZeneca closed their CNS/pain centres (Fiercebiotech, press release, 2 February 2012).  Several of the companies have launched smaller new initiatives based on studies of genetics and biomarkers, but as mental disorders such as unipolar depression impose the largest disease burden worldwide, e.g. 6.2% disability-adjusted life year of total (WHO, 2008), and current treatments do not work particularly well for many patients, this has obviously raised a number of concerns related to how the future developments should be carried out, and whether the genetic approach may be sufficient.  In June 2012, the International College of Neuropsychopharmacology (http://www.cinp.org) hosted an international workshop in order to discuss and consider the consequences and implications of the withdrawal of these research activities.  This paper presents the problem background together with a summary of the viewpoints of the invited speakers and recommendations for future intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEM4WnxGgp54JKJbLTgsvCfW6udTcc2eaUMCsLunx_h7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snhsFGjsw%253D%253D&md5=4e666ce86adcc0563589563a520a401f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1017%2FS1461145713000345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713000345%26sid%3Dliteratum%253Aachs%26aulast%3DWegener%26aufirst%3DG.%26aulast%3DRujescu%26aufirst%3DD.%26atitle%3DThe%2520Current%2520Development%2520of%2520CNS%2520Drug%2520Research%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D16%26issue%3D7%26spage%3D1687%26epage%3D1693%26doi%3D10.1017%2FS1461145713000345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, J. D.</span></span> <span> </span><span class="NLM_article-title">Edaravone: A New Drug Approved for ALS</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">725</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.cell.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29100067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyhurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=725&issue=4&author=J.+D.+Rothstein&title=Edaravone%3A+A+New+Drug+Approved+for+ALS&doi=10.1016%2Fj.cell.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Edaravone: A new drug approved for ALS</span></div><div class="casAuthors">Rothstein, Jeffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">725</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal.  The history of ALS drug discovery is fraught with many stops and starts.  It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3cmo73s5DoLVg90H21EOLACvtfcHk0lg2PV86VHlsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyhurvP&md5=70a3840ab2e174873dbfe2a73334cd28</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DRothstein%26aufirst%3DJ.%2BD.%26atitle%3DEdaravone%253A%2520A%2520New%2520Drug%2520Approved%2520for%2520ALS%26jtitle%3DCell%26date%3D2017%26volume%3D171%26issue%3D4%26spage%3D725%26doi%3D10.1016%2Fj.cell.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Writing
Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group</span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Edaravone
in Well Defined Patients with Amyotrophic Lateral Sclerosis: A Randomised,
Double-Blind, Placebo-Controlled Trial</span>. <i>Lancet
Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(17)30115-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1474-4422%2817%2930115-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28522181" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=505-512&issue=7&author=Writing%0AGroup+on+behalf+of+the+Edaravone+%28MCI-186%29+ALS+19+Study+Group&title=Safety+and+Efficacy+of+Edaravone%0Ain+Well+Defined+Patients+with+Amyotrophic+Lateral+Sclerosis%3A+A+Randomised%2C%0ADouble-Blind%2C+Placebo-Controlled+Trial&doi=10.1016%2FS1474-4422%2817%2930115-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2817%2930115-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252817%252930115-1%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Edaravone%250Ain%2520Well%2520Defined%2520Patients%2520with%2520Amyotrophic%2520Lateral%2520Sclerosis%253A%2520A%2520Randomised%252C%250ADouble-Blind%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%250ANeurol.%26date%3D2017%26volume%3D16%26issue%3D7%26spage%3D505%26epage%3D512%26doi%3D10.1016%2FS1474-4422%2817%2930115-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiriboga, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servais, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topaloglu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulinius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanzman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheuens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farwell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, D. C.</span></span> <span> </span><span class="NLM_article-title">ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1702752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1702752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29091570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFChtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1723-1732&issue=18&author=R.+S.+Finkelauthor=E.+Mercuriauthor=B.+T.+Darrasauthor=A.+M.+Connollyauthor=N.+L.+Kuntzauthor=J.+Kirschnerauthor=C.+A.+Chiribogaauthor=K.+Saitoauthor=L.+Servaisauthor=E.+Tizzanoauthor=H.+Topalogluauthor=M.+Tuliniusauthor=J.+Montesauthor=A.+M.+Glanzmanauthor=K.+Bishopauthor=Z.+J.+Zhongauthor=S.+Gheuensauthor=C.+F.+Bennettauthor=E.+Schneiderauthor=W.+Farwellauthor=D.+C.+De+Vivo&title=ENDEAR+Study+Group.+Nusinersen+versus+Sham+Control+in+Infantile-Onset+Spinal+Muscular+Atrophy&doi=10.1056%2FNEJMoa1702752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Nusinersen versus sham control in infantile-onset spinal muscular atrophy</span></div><div class="casAuthors">Finkel, R. S.; Mercuri, E.; Darras, B. T.; Connolly, A. M.; Kuntz, N. L.; Kirschner, J.; Chiriboga, C. A.; Saito, K.; Servais, L.; Tizzano, E.; Topaloglu, H.; Tulinius, M.; Montes, J.; Glanzman, A. M.; Bishop, K.; Zhong, Z. J.; Gheuens, S.; Bennett, C. F.; Schneider, E.; Farwell, W.; De Vivo, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1723-1732</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein.  Nusinersen is an antisense oligonucleotide drug that modifies pre-mRNA splicing of the SMN2 gene and thus promotes increased prodn. of full-length SMN protein. methods We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy.  The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurol. Examn.) and event-free survival (time to death or the use of permanent assisted ventilation).  Secondary end points included overall survival and subgroup analyses of event-free survival according to disease duration at screening.  Only the first primary end point was tested in a prespecified interim anal.  To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final anal. results In the interim anal., a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41%] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial.  In the final anal., a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P = 0.005).  The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P = 0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen.  The incidence and severity of adverse events were similar in the two groups. conclusions Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group.  Early treatment may be necessary to maximize the benefit of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGybyEEOo-zrVg90H21EOLACvtfcHk0lg2PV86VHlsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFChtbfF&md5=552d3c84f644aee68c96d39c1b5eb280</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1702752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1702752%26sid%3Dliteratum%253Aachs%26aulast%3DFinkel%26aufirst%3DR.%2BS.%26aulast%3DMercuri%26aufirst%3DE.%26aulast%3DDarras%26aufirst%3DB.%2BT.%26aulast%3DConnolly%26aufirst%3DA.%2BM.%26aulast%3DKuntz%26aufirst%3DN.%2BL.%26aulast%3DKirschner%26aufirst%3DJ.%26aulast%3DChiriboga%26aufirst%3DC.%2BA.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DServais%26aufirst%3DL.%26aulast%3DTizzano%26aufirst%3DE.%26aulast%3DTopaloglu%26aufirst%3DH.%26aulast%3DTulinius%26aufirst%3DM.%26aulast%3DMontes%26aufirst%3DJ.%26aulast%3DGlanzman%26aufirst%3DA.%2BM.%26aulast%3DBishop%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DZ.%2BJ.%26aulast%3DGheuens%26aufirst%3DS.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DSchneider%26aufirst%3DE.%26aulast%3DFarwell%26aufirst%3DW.%26aulast%3DDe%2BVivo%26aufirst%3DD.%2BC.%26atitle%3DENDEAR%2520Study%2520Group.%2520Nusinersen%2520versus%2520Sham%2520Control%2520in%2520Infantile-Onset%2520Spinal%2520Muscular%2520Atrophy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D18%26spage%3D1723%26epage%3D1732%26doi%3D10.1056%2FNEJMoa1702752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissel, J. T.</span></span> <span> </span><span class="NLM_article-title">Spinal Muscular Atrophy</span>. <i>Neurol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1016/j.ncl.2015.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.ncl.2015.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26515624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC28zntVGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=831-846&issue=4&author=S.+J.+Kolbauthor=J.+T.+Kissel&title=Spinal+Muscular+Atrophy&doi=10.1016%2Fj.ncl.2015.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal Muscular Atrophy</span></div><div class="casAuthors">Kolb Stephen J; Kissel John T</div><div class="citationInfo"><span class="NLM_cas:title">Neurologic clinics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">831-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal muscular atrophy is an autosomal-recessive disorder characterized by degeneration of motor neurons in the spinal cord and caused by mutations in the survival motor neuron 1 gene, SMN1.  The severity of SMA is variable.  The SMN2 gene produces a fraction of the SMN messenger RNA (mRNA) transcript produced by the SMN1 gene.  There is an inverse correlation between SMN2 gene copy number and clinical severity.  Clinical management focuses on multidisciplinary care.  Preclinical models of SMA have led to an explosion of SMA clinical trials that hold great promise of effective therapy in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ21r5CsgpXTkcLvDNbOD4DfW6udTcc2eYsMWiVzHxRe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zntVGmsA%253D%253D&md5=9f3a2143e5c0bb515d4850a63edeed58</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2015.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2015.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DS.%2BJ.%26aulast%3DKissel%26aufirst%3DJ.%2BT.%26atitle%3DSpinal%2520Muscular%2520Atrophy%26jtitle%3DNeurol.%2520Clin.%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D831%26epage%3D846%26doi%3D10.1016%2Fj.ncl.2015.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span> <i>Spinraza Information Sheet</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Spinraza+Information+Sheet.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2016%2F209531lbl.pdf+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DSpinraza%2520Information%2520Sheet%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Galcanezumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1769</span>– <span class="NLM_lpage">1775</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1002-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-1002-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30378008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVChsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1769-1775&issue=16&author=Y.+N.+Lamb&title=Galcanezumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1002-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Galcanezumab: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1769-1775</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Galcanezumab-gnlm (Emgality; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand.  A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis.  In Sept. 2018, the US FDA approved galcanezumab as a once-monthly s.c. injection for the preventive treatment of migraine in adults.  In the same month, the EMA issued a pos. opinion for galcanezumab for the prophylaxis of migraine in adults who have at least 4 migraine days per mo.  Galcanezumab is also undergoing phase III evaluation for the preventive treatment of cluster headache in North America and Europe.  This article summarizes the milestones in the development of galcanezumab leading to its first approval for the preventive treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL2marTaXqkrVg90H21EOLACvtfcHk0lhKJ_0XBTwSgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVChsr3F&md5=3fa40419d417fed604f0c050d674edea</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1002-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1002-7%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DGalcanezumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D16%26spage%3D1769%26epage%3D1775%26doi%3D10.1007%2Fs40265-018-1002-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Erenumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0944-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0944-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29968151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ygur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1157-1161&issue=11&author=A.+Markham&title=Erenumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0944-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Erenumab: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1157-1161</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Amgen and Novartis are developing erenumab (AIMOVIG, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine.  CGRP is a vasodilatory neuropeptide implicated in the pathophysiol. of migraine and treatment with erenumab was assocd. with significant redns. in migraine frequency in phase II and III clin. trials.  Based on these pos. results erenumab was recently approved in the US for the preventive treatment of migraine in adults and has received a pos. opinion in the EU for the prophylaxis of migraines in adults who have at least 4 migraine days per mo.  This article summarizes the milestones in the development of erenumab leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouU__bWPgx77Vg90H21EOLACvtfcHk0lhKJ_0XBTwSgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ygur7P&md5=d4334e9510d167c037bb1e08dbc49d19</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0944-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0944-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DErenumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D11%26spage%3D1157%26epage%3D1161%26doi%3D10.1007%2Fs40265-018-0944-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Fremanezumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1829</span>– <span class="NLM_lpage">1834</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1004-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-1004-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30406901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnvVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1829-1834&issue=17&author=S.+M.+Hoy&title=Fremanezumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1004-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Fremanezumab: First Global Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1829-1834</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY®] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine).  Its use has been associated with significant reductions in migraine frequency, the requirement for acute headache medication use and headache-related disability compared with placebo in multinational, phase III studies, and in September 2018 fremanezumab was approved by the US FDA for the preventive treatment of migraine in adults.  A regulatory assessment for fremanezumab as a preventive treatment of migraine in adults is underway in the EU.  Fremanezumab is also undergoing phase III development for the preventive treatment of cluster headache (although a phase III chronic cluster headache study has been suspended due to the results of a prespecified futility analysis) and phase II development for the preventive treatment of post-traumatic headache disorder.  This article summarizes the milestones in the development of fremanezumab leading to this first approval in the USA for the preventive treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA3j7grvNR8O2mnZh2OgS0fW6udTcc2eacfPePJ1gERrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnvVOqsg%253D%253D&md5=ec04ab0132663db66059da430afc9b77</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1004-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1004-5%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DFremanezumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D17%26spage%3D1829%26epage%3D1834%26doi%3D10.1007%2Fs40265-018-1004-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searles, J. W.</span></span> <span> </span><span class="NLM_article-title">The Market for Migraine Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1038/d41573-018-00014-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fd41573-018-00014-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=333-334&author=A.+M.+Sparrowauthor=J.+W.+Searles&title=The+Market+for+Migraine+Drugs&doi=10.1038%2Fd41573-018-00014-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fd41573-018-00014-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-018-00014-3%26sid%3Dliteratum%253Aachs%26aulast%3DSparrow%26aufirst%3DA.%2BM.%26aulast%3DSearles%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520Market%2520for%2520Migraine%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D333%26epage%3D334%26doi%3D10.1038%2Fd41573-018-00014-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-020-01264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32020557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=323-328&issue=3&author=L.+J.+Scott&title=Ubrogepant%3A+First+Approval&doi=10.1007%2Fs40265-020-01264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ubrogepant (Ubrelvy®) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine.  In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults.  This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFMvLc4ARHEmzfW6udTcc2eaR-IfZbDEv-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D&md5=dee277e0c6d6835ea105dbb4024f8a92</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01264-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DUbrogepant%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D3%26spage%3D323%26epage%3D328%26doi%3D10.1007%2Fs40265-020-01264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Lasmiditan: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1996</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01225-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-019-01225-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31749059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1989-1996&issue=18&author=Y.+N.+Lamb&title=Lasmiditan%3A+First+Approval&doi=10.1007%2Fs40265-019-01225-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Lasmiditan: First Approval</span></div><div class="casAuthors">Lamb Yvette N</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1989-1996</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lasmiditan (REYVOW®; Eli Lilly and Company) is an orally available serotonin (5-HT)1F receptor agonist.  In October 2019, the US FDA approved lasmiditan 50 mg and 100 mg tablets for the acute treatment of migraine with or without aura in adults.  Approval was based on positive results from two pivotal phase III trials, in which lasmiditan significantly improved the proportions of patients achieving freedom from headache pain and freedom from the most bothersome symptom (photophobia, phonophobia or nausea), relative to placebo, when used to treat a migraine with moderate to severe pain.  Lasmiditan is not for use in the preventive treatment of migraine.  This article summarizes the milestones in the development of lasmiditan leading to its first approval for the acute treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrg8vE0Fvv8VvAgqb2vdc5fW6udTcc2eaR-IfZbDEv-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D&md5=54ba4498e8b1a3f567f0e56b56e04322</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01225-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01225-7%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DLasmiditan%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D18%26spage%3D1989%26epage%3D1996%26doi%3D10.1007%2Fs40265-019-01225-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span> </span><span class="NLM_article-title">How the Orphan Drug Act Opened the Door
for Rare Disease Research</span>.  <i>Rare Genomics Institute</i>. <a href="https://www.raregenomics.org/blog/2019/1/8/how-the-orphan-drug-act-opened-the-door-for-rare-disease-research" class="extLink">https://www.raregenomics.org/blog/2019/1/8/how-the-orphan-drug-act-opened-the-door-for-rare-disease-research</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=How+the+Orphan+Drug+Act+Opened+the+Door%0Afor+Rare+Disease+Research.+Rare+Genomics+Institute.+https%3A%2F%2Fwww.raregenomics.org%2Fblog%2F2019%2F1%2F8%2Fhow-the-orphan-drug-act-opened-the-door-for-rare-disease-research+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHow%2520the%2520Orphan%2520Drug%2520Act%2520Opened%2520the%2520Door%250Afor%2520Rare%2520Disease%2520Research%26jtitle%3DRare%2520Genomics%2520Institute%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germain, D. P.</span></span> <span> </span><span class="NLM_article-title">Fabry Disease</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.1186/1750-1172-5-30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2F1750-1172-5-30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=21092187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FmsVShtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=30&author=D.+P.+Germain&title=Fabry+Disease&doi=10.1186%2F1750-1172-5-30"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Fabry disease</span></div><div class="casAuthors">Germain Dominique P</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A activity.  FD is pan-ethnic and the reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease.  Classically affected hemizygous males, with no residual α-galactosidase A activity may display all the characteristic neurological (pain), cutaneous (angiokeratoma), renal (proteinuria, kidney failure), cardiovascular (cardiomyopathy, arrhythmia), cochleo-vestibular and cerebrovascular (transient ischemic attacks, strokes) signs of the disease while heterozygous females have symptoms ranging from very mild to severe.  Deficient activity of lysosomal α-galactosidase A results in progressive accumulation of globotriaosylceramide within lysosomes, believed to trigger a cascade of cellular events.  Demonstration of marked α-galactosidase A deficiency is the definitive method for the diagnosis of hemizygous males.  Enzyme analysis may occasionnally help to detect heterozygotes but is often inconclusive due to random X-chromosomal inactivation so that molecular testing (genotyping) of females is mandatory.  In childhood, other possible causes of pain such as rheumatoid arthritis and 'growing pains' must be ruled out.  In adulthood, multiple sclerosis is sometimes considered.  Prenatal diagnosis, available by determination of enzyme activity or DNA testing in chorionic villi or cultured amniotic cells is, for ethical reasons, only considered in male fetuses.  Pre-implantation diagnosis is possible.  The existence of atypical variants and the availability of a specific therapy singularly complicate genetic counseling.  A disease-specific therapeutic option - enzyme replacement therapy using recombinant human α-galactosidase A - has been recently introduced and its long term outcome is currently still being investigated.  Conventional management consists of pain relief with analgesic drugs, nephroprotection (angiotensin converting enzyme inhibitors and angiotensin receptors blockers) and antiarrhythmic agents, whereas dialysis or renal transplantation are available for patients experiencing end-stage renal failure.  With age, progressive damage to vital organ systems develops and at some point, organs may start to fail in functioning.  End-stage renal disease and life-threatening cardiovascular or cerebrovascular complications limit life-expectancy of untreated males and females with reductions of 20 and 10 years, respectively, as compared to the general population.  While there is increasing evidence that long-term enzyme therapy can halt disease progression, the importance of adjunctive therapies should be emphasized and the possibility of developing an oral therapy drives research forward into active site specific chaperones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGSVbCPou-cuWhZTslLrfffW6udTcc2ea8EXNm2IAWaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FmsVShtg%253D%253D&md5=9501521191fc72a2325936b5f29c5f8e</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1186%2F1750-1172-5-30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1172-5-30%26sid%3Dliteratum%253Aachs%26aulast%3DGermain%26aufirst%3DD.%2BP.%26atitle%3DFabry%2520Disease%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2010%26volume%3D5%26spage%3D30%26doi%3D10.1186%2F1750-1172-5-30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span> </span><span class="NLM_article-title">How Many
People Have Fabry Disease?</span> <i>National
Fabry Disease Foundation</i>.  <a href="https://www.fabrydisease.org/index.php/about-fabry-disease/how-many-people-have-fabry-disease" class="extLink">https://www.fabrydisease.org/index.php/about-fabry-disease/how-many-people-have-fabry-disease</a> (accessed <span class="NLM_year">2020</span>-04-04).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=How+Many%0APeople+Have+Fabry+Disease%3F+National%0AFabry+Disease+Foundation.+https%3A%2F%2Fwww.fabrydisease.org%2Findex.php%2Fabout-fabry-disease%2Fhow-many-people-have-fabry-disease+%28accessed+2020-04-04%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHow%2520Many%250APeople%2520Have%2520Fabry%2520Disease%253F%26jtitle%3DNational%250AFabry%2520Disease%2520Foundation%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bichet, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giugliani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliciani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezgu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amartino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldt-Rasmussen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf El Din, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lourenco, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banikazemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasouki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finegold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goker-Alpan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovanovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludington, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viereck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skuban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span> <span> </span><span class="NLM_article-title">Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1510198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1510198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27509102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=545-555&issue=6&author=D.+P.+Germainauthor=D.+A.+Hughesauthor=K.+Nichollsauthor=D.+G.+Bichetauthor=R.+Giuglianiauthor=W.+R.+Wilcoxauthor=C.+Felicianiauthor=S.+P.+Shankarauthor=F.+Ezguauthor=H.+Amartinoauthor=D.+Bratkovicauthor=U.+Feldt-Rasmussenauthor=K.+Neddauthor=U.+Sharaf+El+Dinauthor=C.+M.+Lourencoauthor=M.+Banikazemiauthor=J.+Charrowauthor=M.+Dasoukiauthor=D.+Finegoldauthor=P.+Giraldoauthor=O.+Goker-Alpanauthor=N.+Longoauthor=C.+R.+Scottauthor=R.+Torraauthor=A.+Tuffahaauthor=A.+Jovanovicauthor=S.+Waldekauthor=S.+Packmanauthor=E.+Ludingtonauthor=C.+Viereckauthor=J.+Kirkauthor=J.+Yuauthor=E.+R.+Benjaminauthor=F.+Johnsonauthor=D.+J.+Lockhartauthor=N.+Skubanauthor=J.+Castelliauthor=J.+Barthauthor=C.+Barlowauthor=R.+Schiffmann&title=Treatment+of+Fabry%E2%80%99s+Disease+with+the+Pharmacologic+Chaperone+Migalastat&doi=10.1056%2FNEJMoa1510198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of fabry's disease with the pharmacologic chaperone migalastat</span></div><div class="casAuthors">Germain, D. P.; Hughes, D. A.; Nicholls, K.; Bichet, D. G.; Giugliani, R.; Wilcox, W. R.; Feliciani, C.; Shankar, S. P.; Ezgu, F.; Amartino, H.; Bratkovic, D.; Feldt-Rasmussen, U.; Nedd, K.; El Din, U. Sharaf; Lourenco, C. M.; Banikazemi, M.; Charrow, J.; Dasouki, M.; Finegold, D.; Giraldo, P.; Goker-Alpan, O.; Longo, N.; Scott, C. R.; Torra, R.; Tuffaha, A.; Jovanovic, A.; Waldek, S.; Packman, S.; Ludington, E.; Viereck, C.; Kirk, J.; Yu, J.; Benjamin, E. R.; Johnson, F.; Lockhart, D. J.; Skuban, N.; Castelli, J.; Barth, J.; Barlow, C.; Schiffmann, R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs.  Migalastat, an oral pharmacol. chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes.  METHODS: The initial assay of mutant α-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 mo of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 mo (stage 2) plus an addnl. year, had certain limitations.  Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant α-galactosidase forms suitable for targeting by migalastat.  The primary end point was the percentage of patients who had a response (≥50% redn. in the no. of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 mo.  We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes.  RESULTS: The primary end-point anal., involving patients with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41%) who received migalastat and 9 of 32 patients (28%) who received placebo had a response at 6 mo (P = 0.30).  Among patients with suitable mutant α-galactosidase who received migalastat for up to 24 mo, the annualized changes from baseline in the estd. glomerular filtration rate (GFR) and measured GFR were -0.30±0.66 and -1.51±1.33 mL per min per 1.73 m2 of body-surface area, resp.  The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95% confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95% CI, -38.2 to 1.0).  The severity of diarrhea, reflux, and indigestion decreased.  CONCLUSIONS: Among all randomly assigned patients (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 mo did not differ significantly between the migalastat group and the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryg3_Q8v07YrVg90H21EOLACvtfcHk0liloYYFtQEMMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks77E&md5=451941d2d3b712d1bb5085e681368f6c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1510198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1510198%26sid%3Dliteratum%253Aachs%26aulast%3DGermain%26aufirst%3DD.%2BP.%26aulast%3DHughes%26aufirst%3DD.%2BA.%26aulast%3DNicholls%26aufirst%3DK.%26aulast%3DBichet%26aufirst%3DD.%2BG.%26aulast%3DGiugliani%26aufirst%3DR.%26aulast%3DWilcox%26aufirst%3DW.%2BR.%26aulast%3DFeliciani%26aufirst%3DC.%26aulast%3DShankar%26aufirst%3DS.%2BP.%26aulast%3DEzgu%26aufirst%3DF.%26aulast%3DAmartino%26aufirst%3DH.%26aulast%3DBratkovic%26aufirst%3DD.%26aulast%3DFeldt-Rasmussen%26aufirst%3DU.%26aulast%3DNedd%26aufirst%3DK.%26aulast%3DSharaf%2BEl%2BDin%26aufirst%3DU.%26aulast%3DLourenco%26aufirst%3DC.%2BM.%26aulast%3DBanikazemi%26aufirst%3DM.%26aulast%3DCharrow%26aufirst%3DJ.%26aulast%3DDasouki%26aufirst%3DM.%26aulast%3DFinegold%26aufirst%3DD.%26aulast%3DGiraldo%26aufirst%3DP.%26aulast%3DGoker-Alpan%26aufirst%3DO.%26aulast%3DLongo%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DC.%2BR.%26aulast%3DTorra%26aufirst%3DR.%26aulast%3DTuffaha%26aufirst%3DA.%26aulast%3DJovanovic%26aufirst%3DA.%26aulast%3DWaldek%26aufirst%3DS.%26aulast%3DPackman%26aufirst%3DS.%26aulast%3DLudington%26aufirst%3DE.%26aulast%3DViereck%26aufirst%3DC.%26aulast%3DKirk%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DJohnson%26aufirst%3DF.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSkuban%26aufirst%3DN.%26aulast%3DCastelli%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DBarlow%26aufirst%3DC.%26aulast%3DSchiffmann%26aufirst%3DR.%26atitle%3DTreatment%2520of%2520Fabry%25E2%2580%2599s%2520Disease%2520with%2520the%2520Pharmacologic%2520Chaperone%2520Migalastat%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D6%26spage%3D545%26epage%3D555%26doi%3D10.1056%2FNEJMoa1510198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imel, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Högler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linglart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padidela, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t Hoff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrinar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portale, A. A.</span></span> <span> </span><span class="NLM_article-title">Burosumab Therapy in Children with X-Linked Hypophosphatemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">1987</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1714641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1714641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29791829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGmt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1987-1998&issue=21&author=T.+O.+Carpenterauthor=M.+P.+Whyteauthor=E.+A.+Imelauthor=A.+M.+Bootauthor=W.+H%C3%B6glerauthor=A.+Linglartauthor=R.+Padidelaauthor=W.+Van%E2%80%99t+Hoffauthor=M.+Maoauthor=C.-Y.+Chenauthor=A.+Skrinarauthor=E.+Kakkisauthor=J.+San+Martinauthor=A.+A.+Portale&title=Burosumab+Therapy+in+Children+with+X-Linked+Hypophosphatemia&doi=10.1056%2FNEJMoa1714641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Burosumab therapy in children with x-linked hypophosphatemia</span></div><div class="casAuthors">Carpenter, Thomas O.; Whyte, Michael P.; Imel, Erik A.; Boot, Annemieke M.; Hogler, Wolfgang; Linglart, Agnes; Padidela, Raja; van't Hoff, William; Mao, Meng; Chen, Chao-Yin; Skrinar, Alison; Kakkis, Emil; Martin, Javier San; Portale, Anthony A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1987-1998</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity).  In addn., the Radiog. Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64.  Addnl. end points were changes in pharmacodynamic markers, linear growth, phys. ability, and patient-reported outcomes and the incidence of adverse events. results The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-wk dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-wk dosing (P<0.001 for both comparisons); these improvements persisted at week 64.  The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per dL [1.0 to 2.0 mmol per L]) by week 6.  Stable serum phosphorus levels were maintained through week 64 with every-2-wk dosing.  Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per dL (0.32 mmol per L).  The mean dose of burosumab at week 40 was 0.98 mg per kg of body wt. with every-2-wk dosing and 1.50 mg per kg with every-4-wk dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqgwdwHG6u1LVg90H21EOLACvtfcHk0liAaxjHnLfttQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGmt7bK&md5=0c600953279acdfd503ac8a3ea86a390</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1714641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1714641%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DT.%2BO.%26aulast%3DWhyte%26aufirst%3DM.%2BP.%26aulast%3DImel%26aufirst%3DE.%2BA.%26aulast%3DBoot%26aufirst%3DA.%2BM.%26aulast%3DH%25C3%25B6gler%26aufirst%3DW.%26aulast%3DLinglart%26aufirst%3DA.%26aulast%3DPadidela%26aufirst%3DR.%26aulast%3DVan%25E2%2580%2599t%2BHoff%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.-Y.%26aulast%3DSkrinar%26aufirst%3DA.%26aulast%3DKakkis%26aufirst%3DE.%26aulast%3DSan%2BMartin%26aufirst%3DJ.%26aulast%3DPortale%26aufirst%3DA.%2BA.%26atitle%3DBurosumab%2520Therapy%2520in%2520Children%2520with%2520X-Linked%2520Hypophosphatemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D21%26spage%3D1987%26epage%3D1998%26doi%3D10.1056%2FNEJMoa1714641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, T. O.</span></span> <span> </span><span class="NLM_article-title">New Perspectives on the Biology and Treatment of X-Linked Hypophosphatemic Rickets</span>. <i>Pediatr. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/S0031-3955(05)70485-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS0031-3955%2805%2970485-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=9130929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADyaK2s3nslGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1997&pages=443-466&issue=2&author=T.+O.+Carpenter&title=New+Perspectives+on+the+Biology+and+Treatment+of+X-Linked+Hypophosphatemic+Rickets&doi=10.1016%2FS0031-3955%2805%2970485-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives on the biology and treatment of X-linked hypophosphatemic rickets</span></div><div class="casAuthors">Carpenter T O</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric clinics of North America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">443-66</span>
        ISSN:<span class="NLM_cas:issn">0031-3955</span>.
    </div><div class="casAbstract">This article updates the practicing pediatrician's knowledge of the hypophophatemic disorders that may occur in children.  The classic X-linked disorder is emphasized.  Details of clinical manifestations, the wide spectrum of disease severity, and complications of the disorder in adults are reviewed.  Recent research, new genetic findings, and speculations regarding pathophysiology are discussed.  A strategy for approaching medical treatment of X-linked hypophosphatemic rickets is provided, together with complications of treatment and treatment after cessation of growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTTSBc9Wfxur0AGQpJZWpJfW6udTcc2eYsoFxG-_oqArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3nslGntw%253D%253D&md5=feb0dfedd9ba8f566abfdcd1627e474d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0031-3955%2805%2970485-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0031-3955%252805%252970485-5%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DT.%2BO.%26atitle%3DNew%2520Perspectives%2520on%2520the%2520Biology%2520and%2520Treatment%2520of%2520X-Linked%2520Hypophosphatemic%2520Rickets%26jtitle%3DPediatr.%2520Clin.%2520North%2520Am.%26date%3D1997%26volume%3D44%26issue%3D2%26spage%3D443%26epage%3D466%26doi%3D10.1016%2FS0031-3955%2805%2970485-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span> </span><span class="NLM_article-title">Paroxysmal Nocturnal Hemoglobinuria</span>.  <i>National
Organization for Rare Diseases</i>. <a href="https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/" class="extLink">https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Paroxysmal+Nocturnal+Hemoglobinuria.+National%0AOrganization+for+Rare+Diseases.+https%3A%2F%2Frarediseases.org%2Frare-diseases%2Fparoxysmal-nocturnal-hemoglobinuria%2F+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DParoxysmal%2520Nocturnal%2520Hemoglobinuria%26jtitle%3DNational%250AOrganization%2520for%2520Rare%2520Diseases%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicre
de Fontbrune, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong Lee Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualandro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Füreder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptushkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottinghaus, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguzzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrezenmeier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span> <span> </span><span class="NLM_article-title">Ravulizumab (ALXN1210) vs Eculizumab in Adult Patients with PNH Naive to Complement Inhibitors: The 301 Study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-09-876136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1182%2Fblood-2018-09-876136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30510080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFart78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2019&pages=530-539&issue=6&author=J.+W.+Leeauthor=F.+Sicre%0Ade+Fontbruneauthor=L.+Wong+Lee+Leeauthor=V.+Pessoaauthor=S.+Gualandroauthor=W.+F%C3%BCrederauthor=V.+Ptushkinauthor=S.+T.+Rottinghausauthor=L.+Vollesauthor=L.+Shafnerauthor=R.+Aguzziauthor=R.+Pradhanauthor=H.+Schrezenmeierauthor=A.+Hill&title=Ravulizumab+%28ALXN1210%29+vs+Eculizumab+in+Adult+Patients+with+PNH+Naive+to+Complement+Inhibitors%3A+The+301+Study&doi=10.1182%2Fblood-2018-09-876136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study</span></div><div class="casAuthors">Lee, Jong Wook; Sicre de Fontbrune, Flore; Lee, Lily Wong Lee; Pessoa, Viviani; Gualandro, Sandra; Fureder, Wolfgang; Ptushkin, Vadim; Rottinghaus, Scott T.; Volles, Lori; Shafner, Lori; Aguzzi, Rasha; Pradhan, Rajendra; Schrezenmeier, Hubert; Hill, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">530-539</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition.  This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor-naive adults with paroxysmal nocturnal hemoglobinuria (PNH).  Patients with lactate dehydrogenase (LDH)≥ 1.5 times the upper limit of normal and at least 1 PNH symptom were randomized 1:1 to receive ravulizumab or eculizumab for 183 days (N = 246).  Coprimary efficacy end points were proportion of patients remaining transfusion-free and LDH normalization.  Secondary end points were percent change from baseline in LDH, change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, proportion of patients with breakthrough hemolysis, stabilized Hb, and change in serum free C5.  Ravulizumab was noninferior to eculizumab for both coprimary and all key secondary end points (Pinf less than .0001): transfusion avoidance (73.6% vs 66.1%; difference of 6.8% [95% confidence interval (CI), -4.66, 18.14]), LDH normalization (53.6% vs 49.4%; odds ratio, 1.19 [0.80, 1.77]), percent redn. in LDH (-76.8% vs -76.0%; difference [95% CI], -0.83% [-5.21, 3.56]), change in FACIT-Fatigue score (7.07 vs 6.40; difference [95% CI], 0.67 [-1.21, 2.55]), breakthrough hemolysis (4.0% vs 10.7%; difference [95% CI], -6.7% [-14.21, 0.18]), and stabilized Hb (68.0% vs 64.5%; difference [95% CI], 2.9 [-8.80, 14.64]).  The safety and tolerability of ravulizumab and eculizumab were similar; no meningococcal infections occurred.  In conclusion, ravulizumab given every 8 wk achieved noninferiority compared with eculizumab given every 2 wk for all efficacy end points, with a similar safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOeGCVtTx-ObVg90H21EOLACvtfcHk0liAaxjHnLfttQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFart78%253D&md5=356dc8a9951fcb54b215c2c88b4ab87c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-09-876136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-09-876136%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DSicre%2Bde%2BFontbrune%26aufirst%3DF.%26aulast%3DWong%2BLee%2BLee%26aufirst%3DL.%26aulast%3DPessoa%26aufirst%3DV.%26aulast%3DGualandro%26aufirst%3DS.%26aulast%3DF%25C3%25BCreder%26aufirst%3DW.%26aulast%3DPtushkin%26aufirst%3DV.%26aulast%3DRottinghaus%26aufirst%3DS.%2BT.%26aulast%3DVolles%26aufirst%3DL.%26aulast%3DShafner%26aufirst%3DL.%26aulast%3DAguzzi%26aufirst%3DR.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DSchrezenmeier%26aufirst%3DH.%26aulast%3DHill%26aufirst%3DA.%26atitle%3DRavulizumab%2520%2528ALXN1210%2529%2520vs%2520Eculizumab%2520in%2520Adult%2520Patients%2520with%2520PNH%2520Naive%2520to%2520Complement%2520Inhibitors%253A%2520The%2520301%2520Study%26jtitle%3DBlood%26date%3D2019%26volume%3D133%26issue%3D6%26spage%3D530%26epage%3D539%26doi%3D10.1182%2Fblood-2018-09-876136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condren, M.</span></span> <span> </span><span class="NLM_article-title">Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy</span>. <i>J. Pediatr. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.5863/1551-6776-25.3.192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.5863%2F1551-6776-25.3.192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32265602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38zislKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=192-197&issue=3&author=K.+Ridleyauthor=M.+Condren&title=Elexacaftor-Tezacaftor-Ivacaftor%3A+The+First+Triple-Combination+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulating+Therapy&doi=10.5863%2F1551-6776-25.3.192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy</span></div><div class="casAuthors">Ridley Kaden; Condren Michelle</div><div class="citationInfo"><span class="NLM_cas:title">The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">192-197</span>
        ISSN:<span class="NLM_cas:issn">1551-6776</span>.
    </div><div class="casAbstract">Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel.  Its labeled indication for use is for persons 12 years of age and older with at least 1 F508del mutation for the CFTR gene.  This drug combination provides potential therapy to many patients who had previously been excluded from CFTR modulation therapy due to the nature of their genetic mutations.  The efficacy demonstrated in clinical trials surpasses the currently available therapies related to lung function, quality of life, sweat chloride reduction, and reducing exacerbations.  The most common adverse events seen in clinical trials included rash and headache, and laboratory monitoring is recommended to evaluate liver function.  Continued evaluation of patient data is needed to confirm its long-term safety and efficacy.  Elexacaftor-tezacaftor-ivacaftor is a monumental and encouraging therapy for cystic fibrosis; however, approximately 10% of the CF population are not candidates for this or any other CFTR modulation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDe8STwgEhUhKDYG3bNImrfW6udTcc2eb7c8FndICOLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zislKhsQ%253D%253D&md5=af7bf873365bdb46bb54f0b1ff972255</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.5863%2F1551-6776-25.3.192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5863%252F1551-6776-25.3.192%26sid%3Dliteratum%253Aachs%26aulast%3DRidley%26aufirst%3DK.%26aulast%3DCondren%26aufirst%3DM.%26atitle%3DElexacaftor-Tezacaftor-Ivacaftor%253A%2520The%2520First%2520Triple-Combination%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulating%2520Therapy%26jtitle%3DJ.%2520Pediatr.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D25%26issue%3D3%26spage%3D192%26epage%3D197%26doi%3D10.5863%2F1551-6776-25.3.192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span> <i>Application NUMBER: 212273Orig1s000, Risk Assessment
and Risk Mitigation
Review(s)</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000RiskR.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000RiskR.pdf</a> (accessed <span class="NLM_year">2020</span>-04-01).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Application+NUMBER%3A+212273Orig1s000%2C+Risk+Assessment%0Aand+Risk+Mitigation%0AReview%28s%29.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2019%2F212273Orig1s000RiskR.pdf+%28accessed+2020-04-01%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DApplication%2520NUMBER%253A%2520212273Orig1s000%252C%2520Risk%2520Assessment%250Aand%2520Risk%2520Mitigation%250AReview%2528s%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span> </span><span class="NLM_article-title">FDA Approves
New Breakthrough Therapy for Cystic Fibrosis</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves%0ANew+Breakthrough+Therapy+for+Cystic+Fibrosis.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-breakthrough-therapy-cystic-fibrosis+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%250ANew%2520Breakthrough%2520Therapy%2520for%2520Cystic%2520Fibrosis%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekoroski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zepeda, M. L.</span></span> <span> </span><span class="NLM_article-title">Recombinant Human Hyaluronidase PH20 (RHuPH20) Facilitates Subcutaneous Infusions of Large Volumes of Immunoglobulin in a Swine Model</span>. <i>Drug Delivery Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1007/s13346-012-0065-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs13346-012-0065-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25787031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Omtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=254-264&issue=4&author=D.+W.+Kangauthor=L.+Jadinauthor=T.+Nekoroskiauthor=F.+H.+Drakeauthor=M.+L.+Zepeda&title=Recombinant+Human+Hyaluronidase+PH20+%28RHuPH20%29+Facilitates+Subcutaneous+Infusions+of+Large+Volumes+of+Immunoglobulin+in+a+Swine+Model&doi=10.1007%2Fs13346-012-0065-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model</span></div><div class="casAuthors">Kang, David W.; Jadin, Laurence; Nekoroski, Tara; Drake, Fred H.; Zepeda, Monica L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery and Translational Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">254-264</span>CODEN:
                <span class="NLM_cas:coden">DDTRCY</span>;
        ISSN:<span class="NLM_cas:issn">2190-3948</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Many patients with primary immunodeficiency disease (PIDD) require lifelong Ig (Ig) replacement therapy.  Home-based s.c. (SC) infusion provides advantages to patients with PIDD compared to hospital-based i.v. infusion.  One limitation of current practice with SCIg infusion is the need for small-vol. infusions at multiple injection sites on a frequent basis.  A method was developed for large-vol. SC infusion that uses preinfusion of recombinant human hyaluronidase (rHuPH20) to facilitate fluid dispersion.  Miniature swine was used as a preclin. model to assess the effects of rHuPH20-facilitated infusions, of a single monthly dose, on fluid dispersion, infusion-related pressure, swelling, induration, and tissue damage.  Preinfusion of vehicle (control) or rHuPH20 (75 U/g Ig) was performed simultaneously on contralateral abdominal sites on each animal, followed by infusion of 300 mL 10 % Ig (30 g) at each site.  Compared to control infusions, rHuPH20 significantly reduced infusion pressure and induration (p < 0.05) and accelerated postinfusion Ig dispersion.  Histol. evaluation of infusion site tissue showed moderate to severe swelling for the control.  Swelling after rHuPH20-facilitated infusion was mild on day 1 and had completely resolved shortly thereafter.  Laser Doppler imaging of control infusion sites revealed local cutaneous hypoperfusion during Ig infusion, which was reduced almost 7-fold (p < 0.05) with the use of rHuPH20.  These results demonstrate that rHuPH20-facilitated Ig infusion is assocd. with improved dispersion of Ig, resulting in reduced tissue pressure, induration, and reduced risk of tissue damage from mech. trauma or local ischemia, thus enabling SC administration of large vols. of Ig at a single site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp937Ld1IXemLVg90H21EOLACvtfcHk0ljd7mPh5c0HRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Omtb3N&md5=545baf8bf2b547f8dcb0eaffa6d870c4</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1007%2Fs13346-012-0065-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13346-012-0065-3%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%2BW.%26aulast%3DJadin%26aufirst%3DL.%26aulast%3DNekoroski%26aufirst%3DT.%26aulast%3DDrake%26aufirst%3DF.%2BH.%26aulast%3DZepeda%26aufirst%3DM.%2BL.%26atitle%3DRecombinant%2520Human%2520Hyaluronidase%2520PH20%2520%2528RHuPH20%2529%2520Facilitates%2520Subcutaneous%2520Infusions%2520of%2520Large%2520Volumes%2520of%2520Immunoglobulin%2520in%2520a%2520Swine%2520Model%26jtitle%3DDrug%2520Delivery%2520Transl.%2520Res.%26date%3D2012%26volume%3D2%26issue%3D4%26spage%3D254%26epage%3D264%26doi%3D10.1007%2Fs13346-012-0065-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppal, P.</span></span> <span> </span><span class="NLM_article-title">Trifluridine/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer</span>. <i>P T</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27162472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC28botFSgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=314-325&issue=5&author=T.+Kishauthor=P.+Uppal&title=Trifluridine%2FTipiracil+%28Lonsurf%29+for+the+Treatment+of+Metastatic+Colorectal+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluridine/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer</span></div><div class="casAuthors">Kish Troy; Uppal Priyasha</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">314-25</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0cDLBzgdho5QHPYJuLg8TfW6udTcc2eb7c8FndICOLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28botFSgtg%253D%253D&md5=d7790ae85861a512980553044df99f4d</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKish%26aufirst%3DT.%26aulast%3DUppal%26aufirst%3DP.%26atitle%3DTrifluridine%252FTipiracil%2520%2528Lonsurf%2529%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Colorectal%2520Cancer%26jtitle%3DP%2520T%26date%3D2016%26volume%3D41%26issue%3D5%26spage%3D314%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, L.</span>; <span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">The Role of Black Box Warnings In Safe Prescribing Practices</span>.  <i>Health Affairs</i>. <a href="https://www.healthaffairs.org/do/10.1377/hblog20140820.040875/full/" class="extLink">https://www.healthaffairs.org/do/10.1377/hblog20140820.040875/full/</a> (accessed <span class="NLM_year">2020</span>-08-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Maggs&author=A.+S.+Kesselheim&title=The+Role+of+Black+Box+Warnings+In+Safe+Prescribing+Practices"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520Black%2520Box%2520Warnings%2520In%2520Safe%2520Prescribing%2520Practices%26jtitle%3DHealth%2520Affairs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanne, J. H.</span></span> <span> </span><span class="NLM_article-title">FDA Adds “Black Box” Warning Label to Fluoroquinolone Antibiotics</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">a816</span>, <span class="refDoi"> DOI: 10.1136/bmj.a816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1136%2Fbmj.a816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=18632714" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2008&pages=a816&author=J.+H.+Tanne&title=FDA+Adds+%E2%80%9CBlack+Box%E2%80%9D+Warning+Label+to+Fluoroquinolone+Antibiotics&doi=10.1136%2Fbmj.a816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1136%2Fbmj.a816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.a816%26sid%3Dliteratum%253Aachs%26aulast%3DTanne%26aufirst%3DJ.%2BH.%26atitle%3DFDA%2520Adds%2520%25E2%2580%259CBlack%2520Box%25E2%2580%259D%2520Warning%2520Label%2520to%2520Fluoroquinolone%2520Antibiotics%26jtitle%3DBMJ.%26date%3D2008%26volume%3D337%26spage%3Da816%26doi%3D10.1136%2Fbmj.a816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baddley, J. W.</span></span> <span> </span><span class="NLM_article-title">Opportunistic Infections in Biological Therapy, Risk and Prevention</span>. <i>Rheum. Dis. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.rdc.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.rdc.2016.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27890172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2017&pages=27-41&issue=1&author=P.+A.+Bryantauthor=J.+W.+Baddley&title=Opportunistic+Infections+in+Biological+Therapy%2C+Risk+and+Prevention&doi=10.1016%2Fj.rdc.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunistic Infections in Biological Therapy, Risk and Prevention</span></div><div class="casAuthors">Bryant Paul A; Baddley John W</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatic diseases clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients being treated with biological therapies are at increased risk for serious infections, including opportunistic infections.  Although more is known about opportunistic infection risk with older biologics, such as antitumor necrosis factor drugs, there is less knowledge of opportunistic infection risk with newer biological therapies.  The incidence of certain opportunistic infections (tuberculosis, herpes zoster, pneumocystosis) has been rigorously evaluated in large observational studies.  However, data are more limited for other infections (histoplasmosis, nontuberculous mycobacteria).  Infectious morbidity and mortality may be preventable with screening and prophylaxis in select populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmopmDE8yyttts4TFFB11gfW6udTcc2eboyHBSpcrS2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgslWgug%253D%253D&md5=d0ad7a4ffd74e475b85027591800f1bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.rdc.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rdc.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DP.%2BA.%26aulast%3DBaddley%26aufirst%3DJ.%2BW.%26atitle%3DOpportunistic%2520Infections%2520in%2520Biological%2520Therapy%252C%2520Risk%2520and%2520Prevention%26jtitle%3DRheum.%2520Dis.%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D43%26issue%3D1%26spage%3D27%26epage%3D41%26doi%3D10.1016%2Fj.rdc.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvana, E. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salata, R. A.</span></span> <span> </span><span class="NLM_article-title">Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1128/CMR.00040-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1128%2FCMR.00040-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=19366915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVSqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=274-290&issue=2&author=E.+M.+T.+Salvanaauthor=R.+A.+Salata&title=Infectious+Complications+Associated+with+Monoclonal+Antibodies+and+Related+Small+Molecules&doi=10.1128%2FCMR.00040-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Infectious complications associated with monoclonal antibodies and related small molecules</span></div><div class="casAuthors">Salvana, Edsel Maurice T.; Salata, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-290</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Biologics are increasingly becoming part of routine disease management.  As more agents are developed, the challenge of keeping track of indications and side effects is growing.  While biologics represent a milestone in targeted and specific therapy, they are not without drawbacks, and the judicious use of these "magic bullets" is essential if their full potential is to be realized.  Infectious complications in particular are not an uncommon side effect of therapy, whether as a direct consequence of the agent or because of the underlying disease process.  With this in mind, we have reviewed and summarized the risks of infection and the infectious disease-related complications for all FDA-approved monoclonal antibodies and some related small mols., and we discuss the probable mechanisms involved in immunosuppression as well as recommendations for prophylaxis and treatment of specific disease entities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn07Dvbh3x3LVg90H21EOLACvtfcHk0ljtLp2-raviyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVSqt7Y%253D&md5=9d253f89e22dadca0381572722158190</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1128%2FCMR.00040-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00040-08%26sid%3Dliteratum%253Aachs%26aulast%3DSalvana%26aufirst%3DE.%2BM.%2BT.%26aulast%3DSalata%26aufirst%3DR.%2BA.%26atitle%3DInfectious%2520Complications%2520Associated%2520with%2520Monoclonal%2520Antibodies%2520and%2520Related%2520Small%2520Molecules%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2009%26volume%3D22%26issue%3D2%26spage%3D274%26epage%3D290%26doi%3D10.1128%2FCMR.00040-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular Property Design: Does Everyone Get It?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=722-725&issue=7&author=P.+D.+Leesonauthor=R.+J.+Young&title=Molecular+Property+Design%3A+Does+Everyone+Get+It%3F&doi=10.1021%2Facsmedchemlett.5b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0ljtLp2-raviyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Property%2520Design%253A%2520Does%2520Everyone%2520Get%2520It%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D7%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0liCd0R7ArShUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobritzsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2312</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2312-2327&issue=6&author=B.+C.+Doakauthor=J.+Zhengauthor=D.+Dobritzschauthor=J.+Kihlberg&title=How+Beyond+Rule+of+5+Drugs+and+Clinical+Candidates+Bind+to+Their+Targets&doi=10.1021%2Facs.jmedchem.5b01286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span></div><div class="casAuthors">Doak, Bradley C.; Zheng, Jie; Dobritzsch, Doreen; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve discovery of drugs for difficult targets, the opportunities of chem. space beyond the rule of 5 (bRo5) were examd. by retrospective anal. of a comprehensive set of structures for complexes between drugs and clin. candidates and their targets.  The anal. illustrates the potential of compds. far beyond rule of 5 space to modulate novel and difficult target classes that have large, flat, and groove-shaped binding sites.  However, ligand efficiencies are significantly reduced for flat- and groove-shape binding sites, suggesting that adjustments of how to use such metrics are required.  Ligands bRo5 appear to benefit from an appropriate balance between rigidity and flexibility to bind with sufficient affinity to their targets, with macrocycles and nonmacrocycles being found to have similar flexibility.  However, macrocycles were more disk- and spherelike, which may contribute to their superior binding to flat sites, while rigidification of nonmacrocycles lead to rodlike ligands that bind well to groove-shaped binding sites.  These insights should contribute to altering perceptions of what targets are considered "druggable" and provide support for drug design in beyond rule of 5 space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZD-h9VodiPLVg90H21EOLACvtfcHk0liCd0R7ArShUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F&md5=a417b605d1a3ffbc7ee84706401f01f4</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01286%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DDobritzsch%26aufirst%3DD.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DHow%2520Beyond%2520Rule%2520of%25205%2520Drugs%2520and%2520Clinical%2520Candidates%2520Bind%2520to%2520Their%2520Targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2312%26epage%3D2327%26doi%3D10.1021%2Facs.jmedchem.5b01286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&issue=4&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0liCd0R7ArShUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tinworth, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">10091</span>– <span class="NLM_lpage">10108</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01596</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01596" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslShtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10091-10108&issue=18&author=C.+P.+Tinworthauthor=R.+J.+Young&title=Facts%2C+Patterns%2C+and+Principles+in+Drug+Discovery%3A+Appraising+the+Rule+of+5+with+Measured+Physicochemical+Data&doi=10.1021%2Facs.jmedchem.9b01596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data</span></div><div class="casAuthors">Tinworth, Christopher P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10091-10108</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The rule of 5 was designed to est. the likelihood of poor absorption or permeation, noting the impact of poor soly.  This Perspective explores the impact of various physicochem. descriptors and contemporary lipophilicity measurements on permeability and soly., showing that the distribution coeff. log D7.4 (rather than log P) is the most impactful parameter.  Mol. wt., almost invariably the defining characteristic of "beyond the rule of 5" compds., has little impact on soly. when log D7.4 measurements and aromaticity are considered.  Predicting permeation is more complex, given passive and carrier transport mechanisms; however, notable patterns of behavior are apparent, giving insight even "beyond the rule of 5".  Recommended best practices should involve using the facts (measurements) and the patterns they reveal to establish informative principles rather than fastidious rules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBT9kzvTWdTbVg90H21EOLACvtfcHk0liCd0R7ArShUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslShtb4%253D&md5=c93bbcd944dcb41c0d38d2a3881b8593</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01596%26sid%3Dliteratum%253Aachs%26aulast%3DTinworth%26aufirst%3DC.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DFacts%252C%2520Patterns%252C%2520and%2520Principles%2520in%2520Drug%2520Discovery%253A%2520Appraising%2520the%2520Rule%2520of%25205%2520with%2520Measured%2520Physicochemical%2520Data%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D18%26spage%3D10091%26epage%3D10108%26doi%3D10.1021%2Facs.jmedchem.9b01596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6421</span>– <span class="NLM_lpage">6467</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6421-6467&issue=15&author=R.+J.+Youngauthor=P.+D.+Leeson&title=Mapping+the+Efficiency+and+Physicochemical+Trajectories+of+Successful+Optimizations&doi=10.1021%2Facs.jmedchem.8b00180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations</span></div><div class="casAuthors">Young, Robert J.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6421-6467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The practices and tactics employed in successful optimizations are examd., judged from the trajectories of ligand efficiency and property evolution.  A wide range of targets is analyzed, encompassing a variety of hit finding methods (HTS, fragments, encoded library technol.) and types of mols., including those beyond the rule of five.  The wider employment of efficiency metrics and lipophilicity control is evident in contemporary practice and the impact on quality demonstrable.  What is clear is that while targets are different, successful mols. are almost invariably among the most efficient for their target, even at the extremes.  Trajectory mapping, based on principles rather than rules, is useful in assessing quality and progress in optimizations while benchmarking against competitors and assessing property-dependent risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCQtcLKSk7q7Vg90H21EOLACvtfcHk0lgvRGlBrtyMnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D&md5=f040ef02d161e070bb5021fde1585e66</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DMapping%2520the%2520Efficiency%2520and%2520Physicochemical%2520Trajectories%2520of%2520Successful%2520Optimizations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467%26doi%3D10.1021%2Facs.jmedchem.8b00180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&issue=21&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Where+Do+Recent+Small+Molecule+Clinical+Development+Candidates+Come+From%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0lgvRGlBrtyMnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DWhere%2520Do%2520Recent%2520Small%2520Molecule%2520Clinical%2520Development%2520Candidates%2520Come%2520From%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span> <span> </span><span class="NLM_article-title">Why Some Targets Benefit from beyond Rule of Five Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10005</span>– <span class="NLM_lpage">10025</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01732</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01732" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKktr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10005-10025&issue=22&author=M.+Egbertauthor=A.+Whittyauthor=G.+M.+Keser%C5%B1author=S.+Vajda&title=Why+Some+Targets+Benefit+from+beyond+Rule+of+Five+Drugs&doi=10.1021%2Facs.jmedchem.8b01732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Why Some Targets Benefit from beyond Rule of Five Drugs</span></div><div class="casAuthors">Egbert, Megan; Whitty, Adrian; Keseru, Gyorgy M.; Vajda, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10005-10025</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Beyond rule-of-five (bRo5) compds. are increasingly used in drug discovery.  Here we analyze 37 target proteins that have bRo5 drugs or clin. candidates.  Targets can benefit from bRo5 drugs if they have "complex" hot spot structure with four or more hots spots, including some strong ones.  Complex I targets show pos. correlation between binding affinity and mol. wt.  These targets are conventionally druggable, but reaching addnl. hot spots enables improved pharmaceutical properties.  Complex II targets, mostly protein kinases, also have strong hot spots but show no correlation between affinity and ligand mol. wt., and the primary motivation for creating larger drugs is to increase selectivity.  Each target considered as complex III has some specific reason for requiring bRo5 drugs.  Finally, targets with "simple" hot spot structure, i.e., three or fewer weak hot spots, must use larger compds. that interact with surfaces beyond the hot spot region to achieve acceptable affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZIR5KB1PgHLVg90H21EOLACvtfcHk0lgvRGlBrtyMnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKktr%252FE&md5=cef48829657115db9d8d48e6d54d2398</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01732%26sid%3Dliteratum%253Aachs%26aulast%3DEgbert%26aufirst%3DM.%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26aulast%3DVajda%26aufirst%3DS.%26atitle%3DWhy%2520Some%2520Targets%2520Benefit%2520from%2520beyond%2520Rule%2520of%2520Five%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10005%26epage%3D10025%26doi%3D10.1021%2Facs.jmedchem.8b01732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&issue=7&author=D.+A.+DeGoeyauthor=H.-J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+Rule+of+5%3A+Lessons+Learned+from+AbbVie%E2%80%99s+Drugs+and+Compound+Collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0lgvRGlBrtyMnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.-J.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520Rule%2520of%25205%253A%2520Lessons%2520Learned%2520from%2520AbbVie%25E2%2580%2599s%2520Drugs%2520and%2520Compound%2520Collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanotto, D.</span></span> <span> </span><span class="NLM_article-title">FDA-Approved Oligonucleotide Therapies in 2017</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.ymthe.2017.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28366767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1069-1075&issue=5&author=C.+A.+Steinauthor=D.+Castanotto&title=FDA-Approved+Oligonucleotide+Therapies+in+2017&doi=10.1016%2Fj.ymthe.2017.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-Approved Oligonucleotide Therapies in 2017</span></div><div class="casAuthors">Stein, Cy A.; Castanotto, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1075</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oligonucleotides (oligos) have been under clin. development for approx. the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs.  During that lengthy period of time, numerous clin. trials have been performed and thousands of trial participants accrued onto studies.  Of all the mols. evaluated as of Jan. 2017, the regulatory authorities assessed that six provided clear clin. benefit in rigorously controlled trials.  The story of these six is given in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNtVeb7iVOxrVg90H21EOLACvtfcHk0lgjJDMhaRT43g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D&md5=d9f556e813d1070c6af77b34fe051fd2</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DC.%2BA.%26aulast%3DCastanotto%26aufirst%3DD.%26atitle%3DFDA-Approved%2520Oligonucleotide%2520Therapies%2520in%25202017%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26issue%3D5%26spage%3D1069%26epage%3D1075%26doi%3D10.1016%2Fj.ymthe.2017.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddington-Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polydefkis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planté-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannagan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchy, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conceição, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campistol, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorevic, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwoh, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span> <span> </span><span class="NLM_article-title">Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1716793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29972757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=22-31&issue=1&author=M.+D.+Bensonauthor=M.+Waddington-Cruzauthor=J.+L.+Berkauthor=M.+Polydefkisauthor=P.+J.+Dyckauthor=A.+K.+Wangauthor=V.+Plant%C3%A9-Bordeneuveauthor=F.+A.+Barrosoauthor=G.+Merliniauthor=L.+Obiciauthor=M.+Scheinbergauthor=T.+H.+Brannaganauthor=W.+J.+Litchyauthor=C.+Whelanauthor=B.+M.+Drachmanauthor=D.+Adamsauthor=S.+B.+Heitnerauthor=I.+Concei%C3%A7%C3%A3oauthor=H.+H.+Schmidtauthor=G.+Vitaauthor=J.+M.+Campistolauthor=J.+Gamezauthor=P.+D.+Gorevicauthor=E.+Ganeauthor=A.+M.+Shahauthor=S.+D.+Solomonauthor=B.+P.+Moniaauthor=S.+G.+Hughesauthor=T.+J.+Kwohauthor=B.+W.+McEvoyauthor=S.+W.+Jungauthor=B.+F.+Bakerauthor=E.+J.+Ackermannauthor=M.+A.+Gertzauthor=T.+Coelho&title=Inotersen+Treatment+for+Patients+with+Hereditary+Transthyretin+Amyloidosis&doi=10.1056%2FNEJMoa1716793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Inotersen treatment for patients with hereditary transthyretin amyloidosis</span></div><div class="casAuthors">Benson, M. D.; Waddington-Cruz, M.; Berk, J. L.; Polydefkis, M.; Dyck, P. J.; Wang, A. K.; Plante-Bordeneuve, V.; Barroso, F. A.; Merlini, G.; Obici, L.; Scheinberg, M.; Brannagan, T. H., III; Litchy, W. J.; Whelan, C.; Drachman, B. M.; Adams, D.; Heitner, S. B.; Conceicao, I.; Schmidt, H. H.; Vita, G.; Campistol, J. M.; Gamez, J.; Gorevic, P. D.; Gane, E.; Shah, A. M.; Solomon, S. D.; Monia, B. P.; Hughes, S. G.; Kwoh, T. J.; McEvoy, B. W.; Jung, S. W.; Baker, B. F.; Ackermann, E. J.; Gertz, M. A.; Coelho, T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-31</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin (TTR) that induce transthyretin misfolding and systemic deposition of amyloid.  Progressive amyloid accumulation leads to multiorgan dysfunction and death.  Inotersen, a 2'-O-methoxyethyl-modified antisense oligonucleotide, inhibits hepatic prodn. of transthyretin.  Methods: We conducted an international, randomized, double-blind, placebo-controlled, 15-mo, phase 3 trial of inotersen in adults with stage 1 (patient is ambulatory) or stage 2 (patient is ambulatory with assistance) hereditary transthyretin amyloidosis with polyneuropathy.  Patients were randomly assigned, in a 2:1 ratio, to receive weekly s.c. injections of inotersen (300 mg) or placebo.  The primary end points were the change in the modified Neuropathy Impairment Score + 7 (mNIS + 7; range, -22.3 to 346.3, with higher scores indicating poorer function; minimal clin. meaningful change, 2 points) and the change in the score on the patient-reported Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating poorer quality of life).  A decrease in scores indicated improvement.  Results: A total of 172 patients (112 in the inotersen group and 60 in the placebo group) received at least one dose of a trial regimen, and 139 (81%) completed the intervention period.  Both primary efficacy assessments favored inotersen: the difference in the least-squares mean change from baseline to week 66 between the two groups (inotersen minus placebo) was -19.7 points (95% confidence interval [CI], -26.4 to -13.0; P<0.001) for the mNIS + 7 and -11.7 points (95% CI, -18.3 to -5.1; P<0.001) for the Norfolk QOL-DN score.  These improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.  There were five deaths in the inotersen group and none in the placebo group.  The most frequent serious adverse events in the inotersen group were glomerulonephritis (in 3 patients [3%]) and thrombocytopenia (in 3 patients [3%]), with one death assocd. with one of the cases of grade 4 thrombocytopenia.  Thereafter, all patients received enhanced monitoring.  Conclusions: Inotersen improved the course of neurol. disease and quality of life in patients with hereditary transthyretin amyloidosis.  Thrombocytopenia and glomerulonephritis were managed with enhanced monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBEWIP8nbbdbVg90H21EOLACvtfcHk0lgjJDMhaRT43g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zK&md5=f22e3bc79225bb739cff9e32d3630ab4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716793%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DM.%2BD.%26aulast%3DWaddington-Cruz%26aufirst%3DM.%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DPolydefkis%26aufirst%3DM.%26aulast%3DDyck%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DA.%2BK.%26aulast%3DPlant%25C3%25A9-Bordeneuve%26aufirst%3DV.%26aulast%3DBarroso%26aufirst%3DF.%2BA.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DObici%26aufirst%3DL.%26aulast%3DScheinberg%26aufirst%3DM.%26aulast%3DBrannagan%26aufirst%3DT.%2BH.%26aulast%3DLitchy%26aufirst%3DW.%2BJ.%26aulast%3DWhelan%26aufirst%3DC.%26aulast%3DDrachman%26aufirst%3DB.%2BM.%26aulast%3DAdams%26aufirst%3DD.%26aulast%3DHeitner%26aufirst%3DS.%2BB.%26aulast%3DConcei%25C3%25A7%25C3%25A3o%26aufirst%3DI.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DVita%26aufirst%3DG.%26aulast%3DCampistol%26aufirst%3DJ.%2BM.%26aulast%3DGamez%26aufirst%3DJ.%26aulast%3DGorevic%26aufirst%3DP.%2BD.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DShah%26aufirst%3DA.%2BM.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DHughes%26aufirst%3DS.%2BG.%26aulast%3DKwoh%26aufirst%3DT.%2BJ.%26aulast%3DMcEvoy%26aufirst%3DB.%2BW.%26aulast%3DJung%26aufirst%3DS.%2BW.%26aulast%3DBaker%26aufirst%3DB.%2BF.%26aulast%3DAckermann%26aufirst%3DE.%2BJ.%26aulast%3DGertz%26aufirst%3DM.%2BA.%26aulast%3DCoelho%26aufirst%3DT.%26atitle%3DInotersen%2520Treatment%2520for%2520Patients%2520with%2520Hereditary%2520Transthyretin%2520Amyloidosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D1%26spage%3D22%26epage%3D31%26doi%3D10.1056%2FNEJMoa1716793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D. R.</span></span> <span> </span><span class="NLM_article-title">Chemistry, Mechanism and Clinical Status of Antisense Oligonucleotides and Duplex RNAs</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1584</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1093%2Fnar%2Fgkx1239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29240946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1584-1600&issue=4&author=X.+Shenauthor=D.+R.+Corey&title=Chemistry%2C+Mechanism+and+Clinical+Status+of+Antisense+Oligonucleotides+and+Duplex+RNAs&doi=10.1093%2Fnar%2Fgkx1239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs</span></div><div class="casAuthors">Shen, Xiulong; Corey, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1584-1600</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  RNA plays a central role in the expression of all genes.  Because any sequence within RNA can be recognized by complementary base pairing, synthetic oligonucleotides and oligonucleotide mimics offer a general strategy for controlling processes that affect disease.  The two primary antisense approaches for regulating expression through recognition of cellular RNAs are single-stranded antisense oligonucleotides and duplex RNAs.  This review will discuss the chem. modifications and mol. mechanisms that make synthetic nucleic acid drugs possible.  Lessons learned from recent clin. trials will be summarized.  Ongoing clin. trials are likely to decisively test the adequacy of our current generation of antisense nucleic acid technologies and highlight areas where more basic research is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHfDaQwcmtD7Vg90H21EOLACvtfcHk0lgjJDMhaRT43g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F&md5=b5bdec984635f12162386b6f8a6f6fe0</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1239%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DCorey%26aufirst%3DD.%2BR.%26atitle%3DChemistry%252C%2520Mechanism%2520and%2520Clinical%2520Status%2520of%2520Antisense%2520Oligonucleotides%2520and%2520Duplex%2520RNAs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D1584%26epage%3D1600%26doi%3D10.1093%2Fnar%2Fgkx1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keefe, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellington, A.</span></span> <span> </span><span class="NLM_article-title">Aptamers as Therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrd3141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=20592747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotFelsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=537-550&issue=7&author=A.+D.+Keefeauthor=S.+Paiauthor=A.+Ellington&title=Aptamers+as+Therapeutics&doi=10.1038%2Fnrd3141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamers as therapeutics</span></div><div class="casAuthors">Keefe, Anthony D.; Pai, Supriya; Ellington, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">537-550</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with affinities and specificities that are comparable to antibodies.  Aptamers exhibit significant advantages relative to protein therapeutics in terms of size, synthetic accessibility and modification by medicinal chem.  Despite these properties, aptamers have been slow to reach the marketplace, with only one aptamer-based drug receiving approval so far.  A series of aptamers currently in development may change how nucleic acid therapeutics are perceived.  It is likely that in the future, aptamers will increasingly find use in concert with other therapeutic mols. and modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHt9O_VBa_rLVg90H21EOLACvtfcHk0lgQs7C3Bb6YdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotFelsLY%253D&md5=37135269c7c403087bd0e992d981fd31</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnrd3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3141%26sid%3Dliteratum%253Aachs%26aulast%3DKeefe%26aufirst%3DA.%2BD.%26aulast%3DPai%26aufirst%3DS.%26aulast%3DEllington%26aufirst%3DA.%26atitle%3DAptamers%2520as%2520Therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D7%26spage%3D537%26epage%3D550%26doi%3D10.1038%2Fnrd3141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, J.</span></span> <span> </span><span class="NLM_article-title">Aptamers as Targeted Therapeutics: Current Potential and Challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2016.199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27807347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOqtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=181-202&issue=3&author=J.+Zhouauthor=J.+Rossi&title=Aptamers+as+Targeted+Therapeutics%3A+Current+Potential+and+Challenges&doi=10.1038%2Fnrd.2016.199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamers as targeted therapeutics: current potential and challenges</span></div><div class="casAuthors">Zhou, Jiehua; Rossi, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-202</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nucleic acid aptamers, often termed 'chem. antibodies', are functionally comparable to traditional antibodies, but offer several advantages, including their relatively small phys. size, flexible structure, quick chem. prodn., versatile chem. modification, high stability and lack of immunogenicity.  In addn., many aptamers are internalized upon binding to cellular receptors, making them useful targeted delivery agents for small interfering RNAs (siRNAs), microRNAs and conventional drugs.  However, several crucial factors have delayed the clin. translation of therapeutic aptamers, such as their inherent physicochem. characteristics and lack of safety data.  This Review discusses these challenges, highlighting recent clin. developments and technol. advances that have revived the impetus for this promising class of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KSEhC4dW0LVg90H21EOLACvtfcHk0lgQs7C3Bb6YdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOqtr3I&md5=3d79942589e20829b3e8de582a08d6e1</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.199%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DJ.%26atitle%3DAptamers%2520as%2520Targeted%2520Therapeutics%253A%2520Current%2520Potential%2520and%2520Challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D3%26spage%3D181%26epage%3D202%26doi%3D10.1038%2Fnrd.2016.199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Patisiran: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0983-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0983-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30251172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1625-1631&issue=15&author=S.+M.+Hoy&title=Patisiran%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0983-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1625-1631</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Patisiran (ONPATTRO) is a double-stranded small interfering RNA encapsulated in a lipid nanoparticle for delivery to hepatocytes.  By specifically binding to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type transthyretin (TTR) mRNA, patisiran causes its degrdn. (via RNA interference) and subsequently a redn. in serum TTR protein levels and tissue TTR protein deposits.  Patisiran has been developed by Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and subsequently approved in the EU for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy.  The recommended dosage, administered as a single i.v. infusion over approx. 80 min, is 0.3 mg/kg once every 3 wk for patients weighing < 100 kg and 30 mg once every 3 wk for patients weighing ≥ 100 kg.  This article summarizes the milestones in the development of patisiran leading to these approvals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69gWrTaxHmLVg90H21EOLACvtfcHk0lgQs7C3Bb6YdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI&md5=94abed01abbe7ba7b679224a42338810</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0983-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0983-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DPatisiran%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D15%26spage%3D1625%26epage%3D1631%26doi%3D10.1007%2Fs40265-018-0983-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Golodirsen: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01267-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-020-01267-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32026421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FovFGjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=329-333&issue=3&author=Y.-A.+Heo&title=Golodirsen%3A+First+Approval&doi=10.1007%2Fs40265-020-01267-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Golodirsen: First Approval</span></div><div class="casAuthors">Heo Young-A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-333</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Golodirsen (Vyondys 53(®)), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD).  In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial.  Golodirsen is in phase III clinical development for the treatment of DMD worldwide.  This article summarizes the milestones in the development of golodirsen leading to this first approval for DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfkeM-ZqSk0wxyojvcjibhfW6udTcc2eaczP1RtRrI_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FovFGjuw%253D%253D&md5=8c87286872bea509d97f40bc4cdbc042</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01267-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01267-2%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DGolodirsen%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D3%26spage%3D329%26epage%3D333%26doi%3D10.1007%2Fs40265-020-01267-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Givosiran: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01269-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-020-01269-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32034693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=335-339&issue=3&author=L.+J.+Scott&title=Givosiran%3A+First+Approval&doi=10.1007%2Fs40265-020-01269-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Givosiran: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-339</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Givosiran (Givlaari®) is an aminolevulinate synthase 1 (ALAS1)-directed small interfering RNA (siRNA) covalently linked to a ligand to enable specific delivery of the siRNA to hepatocytes.  This results in downregulation of ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels that are associated with acute porphyria attacks.  Givosiran is being developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP).  In November 2019, givosiran was approved in the USA for the treatment of adults with AHP based on the positive results from the multinational, phase III ENVISION trial.  In the EU, givosiran received a positive opinion in January 2020 for the treatment of AHP in adults and adolescents aged 12 years and older.  This article summarizes the milestones in the development of givosiran leading to this first approval for the treatment of adults with AHP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDp3euVwlvRZw7prLlxLOzfW6udTcc2eZytexkMdHL7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D&md5=d3d9d673974d3c8f9525c37fae4b7f80</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01269-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01269-0%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DGivosiran%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D3%26spage%3D335%26epage%3D339%26doi%3D10.1007%2Fs40265-020-01269-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denduluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span> <span> </span><span class="NLM_article-title">DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1914510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1914510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31825192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=610-621&issue=7&author=S.+Modiauthor=C.+Sauraauthor=T.+Yamashitaauthor=Y.+H.+Parkauthor=S.-B.+Kimauthor=K.+Tamuraauthor=F.+Andreauthor=H.+Iwataauthor=Y.+Itoauthor=J.+Tsurutaniauthor=J.+Sohnauthor=N.+Denduluriauthor=C.+Perrinauthor=K.+Aogiauthor=E.+Tokunagaauthor=S.-A.+Imauthor=K.+S.+Leeauthor=S.+A.+Hurvitzauthor=J.+Cortesauthor=C.+Leeauthor=S.+Chenauthor=L.+Zhangauthor=J.+Shahidiauthor=A.+Yverauthor=I.+Krop&title=DESTINY-Breast01+Investigators.+Trastuzumab+Deruxtecan+in+Previously+Treated+HER2-Positive+Breast+Cancer&doi=10.1056%2FNEJMoa1914510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span></div><div class="casAuthors">Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.-A.; Lee, K. S.; Hurvitz, S. A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathol. documented HER2-pos. metastatic breast cancer who had received previous treatment with trastuzumab emtansine.  In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose.  Key secondary end points were the disease-control rate, clin.-benefit rate, duration of response and progression-free survival, and safety. results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kg of body wt.).  During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%).  On independent adjudication, the trial drug was assocd. with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-pos. metastatic breast cancer.  In addn. to nausea and myelosuppression, interstitial lung disease was obsd. in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Uc2NDB76h7Vg90H21EOLACvtfcHk0ljY8efFNq-6uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D&md5=0b142802a47c4f50f0b2cdc82f22ce87</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1914510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1914510%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DS.-B.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DDenduluri%26aufirst%3DN.%26aulast%3DPerrin%26aufirst%3DC.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DDESTINY-Breast01%2520Investigators.%2520Trastuzumab%2520Deruxtecan%2520in%2520Previously%2520Treated%2520HER2-Positive%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26issue%3D7%26spage%3D610%26epage%3D621%26doi%3D10.1056%2FNEJMoa1914510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrétien, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasnovas, R.-O.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/s11523-018-0558-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs11523-018-0558-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29556925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1MnivVyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=287-308&issue=3&author=C.+Rossiauthor=M.-L.+Chr%C3%A9tienauthor=R.-O.+Casasnovas&title=Antibody-Drug+Conjugates+for+the+Treatment+of+Hematological+Malignancies%3A+A+Comprehensive+Review&doi=10.1007%2Fs11523-018-0558-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review</span></div><div class="casAuthors">Rossi Cedric; Rossi Cedric; Chretien Marie-Lorraine; Casasnovas Rene-Olivier; Chretien Marie-Lorraine; Casasnovas Rene-Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are an emerging class of therapeutic agents that bring new opportunities for the treatment of hematological malignancies by meeting unmet medical needs.  These drugs consist of a cytotoxic agent connected by a linker to a human, humanized, or chimeric antibody targeting a surface antigen specifically expressed by tumor cells.  These ADCs are being developed to specifically deliver the cytotoxic agent into tumor cells.  The cytotoxic payload is released from the ADC after internalization and cleavage of the linker, ultimately triggering the death of the cancer cell.  Second- and even third-generation ADCs are currently being developed and have more stable linkers and more potent payloads, which should improve ADC efficacy even further.  In this review, we analyze the results for the main ADCs currently developed and discuss the advantages and drawbacks of this therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqmuXC7xz1NKcY7HFp97qMfW6udTcc2eZytexkMdHL7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnivVyqtQ%253D%253D&md5=508db14c33f1f4f38f7c688e35d53f83</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs11523-018-0558-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-018-0558-1%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DC.%26aulast%3DChr%25C3%25A9tien%26aufirst%3DM.-L.%26aulast%3DCasasnovas%26aufirst%3DR.-O.%26atitle%3DAntibody-Drug%2520Conjugates%2520for%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%253A%2520A%2520Comprehensive%2520Review%26jtitle%3DTarget.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D3%26spage%3D287%26epage%3D308%26doi%3D10.1007%2Fs11523-018-0558-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1490</span>– <span class="NLM_lpage">1496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=11410481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1490-1496&issue=6&author=P.+F.+Brossauthor=J.+Beitzauthor=G.+Chenauthor=X.+H.+Chenauthor=E.+Duffyauthor=L.+Kiefferauthor=S.+Royauthor=R.+Sridharaauthor=A.+Rahmanauthor=G.+Williamsauthor=R.+Pazdur&title=Approval+Summary%3A+Gemtuzumab+Ozogamicin+in+Relapsed+Acute+Myeloid+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia</span></div><div class="casAuthors">Bross, Peter F.; Beitz, Julie; Chen, Gang; Chen, Xiao Hong; Duffy, Eric; Kieffer, Lydia; Roy, Sandip; Sridhara, Rajeshwari; Rahman, Atiqur; Williams, Grant; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1490-1496</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review with refs.  Gemtuzumab ozogamicin (Mylotarg; Wyeth Labs., Philadelphia, PA) consists of a semisynthetic deriv. of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).  In this study, we review the preclin. and clin. profiles of this immuno-conjugate and the regulatory review that led to marketing approval by the United States Food and Drug Administration.  From the literature and manufacturer's data, we review the activity, tolerability, and pharmacokinetics of gemtuzumab ozogamicin in preclin. and Phase I studies and its activity, efficacy, and side effects in three Phase 2 trials of 142 patients with relapsed AML.  In Phase I studies, the major toxicity was myelosuppression, esp. neutropenia and thrombocytopenia, resulting from the expression of CD33 on myeloid progenitor cells.  The Phase 2 dose was 9 mg/m2 infused i.v. over 4 h, repeated on day 14.  A minority of patients experienced acute infusion-related symptoms, usually transient and occasionally requiring hospitalization.  The complete response (CR) rate with full recovery of hematopoiesis was 16%.  A subset of patients [CRs with incomplete platelet recovery (CRps)] was identified with blast clearance and neutrophil recovery but incomplete platelet recovery.  The duration of responses of CRps appeared to be similar to those of the CRs, although the nos. were small.  The question of the equivalence of these response groups was a central issue in the review of this new drug application (NDA).  After considerable discussion, the Oncol. Drugs Advisory Committee recommended allowing inclusion of CRps resulting in an overall response rate in the Phase 2 studies of 30%.  In the subgroup of patients over 60 yr of age, the overall response rate was 26%.  Response duration was difficult to establish because of the high prevalence of postremission therapies.  Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes.  One patient died of liver failure in the Phase 2 trials.  Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by the United States Food and Drug Administration under the Accelerated Approval regulations.  Gemtuzumab ozogamicin is indicated for the treatment of patients with CD33 pos. AML in first relapse who are 60 yr of age or older and who are not considered candidates for cytotoxic chemotherapy.  The approved dose was 9 mg/m2 i.v. over 4 h and repeated in 14 days.  Completion of the ongoing studies of gemtuzumab ozogamicin in relapsed AML and initiation of randomized clin. trials comparing the effects of gemtuzumab ozogamicin in combination with conventional induction chemotherapy to conventional chemotherapy alone on survival are mandated to confirm clin. benefit under the accelerated approval Subpart H regulations.  Postmarketing reports of fatal anaphylaxis, adult respiratory distress syndrome (ARDS), and hepatotoxicity, esp. venoocclusive disease (VOD) in patients treated with gemtuzumab ozogamicin, with and without assocd. hematopoietic stem cell transplantation (HSCT), have required labeling revisions and the initiation of a registration surveillance program.  Tumor lysis and ARDS have been reported in patients with leukocytes above 30,000/mL treated with gemtuzumab ozogamicin; therefore, the redn. of leukocyte counts to below 30,000/mL is recommended prior to treatment.  Patients should be carefully monitored for acute hypersensitivity, hypoxia, and delayed hepatotoxicity following treatment with gemtuzumab ozogamicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxE3VNYYST67Vg90H21EOLACvtfcHk0ljY8efFNq-6uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D&md5=8a85e32e3113034e98f05dfbd119110b</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DBeitz%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DDuffy%26aufirst%3DE.%26aulast%3DKieffer%26aufirst%3DL.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520Summary%253A%2520Gemtuzumab%2520Ozogamicin%2520in%2520Relapsed%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26issue%3D6%26spage%3D1490%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span> </span><span class="NLM_article-title">Top Drugs by Sales in 2017: Who Sold the Blockbuster Drugs?</span> <i>PharmaCompass</i>. <a href="https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-in-2017-who-sold-the-blockbuster-drugs" class="extLink">https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-in-2017-who-sold-the-blockbuster-drugs</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Top+Drugs+by+Sales+in+2017%3A+Who+Sold+the+Blockbuster+Drugs%3F+PharmaCompass.+https%3A%2F%2Fwww.pharmacompass.com%2Fradio-compass-blog%2Ftop-drugs-by-sales-in-2017-who-sold-the-blockbuster-drugs+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DTop%2520Drugs%2520by%2520Sales%2520in%25202017%253A%2520Who%2520Sold%2520the%2520Blockbuster%2520Drugs%253F%26jtitle%3DPharmaCompass%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span> </span><span class="NLM_article-title">Top Drugs
and Pharmaceutical Companies of 2018 by Revenues</span>.  <i>PharmaCompass</i>. <a href="https://www.pharmacompass.com/radio-compass-blog/top-drugs-and-pharmaceutical-companies-of-2018-by-revenues" class="extLink">https://www.pharmacompass.com/radio-compass-blog/top-drugs-and-pharmaceutical-companies-of-2018-by-revenues</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Top+Drugs%0Aand+Pharmaceutical+Companies+of+2018+by+Revenues.+PharmaCompass.+https%3A%2F%2Fwww.pharmacompass.com%2Fradio-compass-blog%2Ftop-drugs-and-pharmaceutical-companies-of-2018-by-revenues+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DTop%2520Drugs%250Aand%2520Pharmaceutical%2520Companies%2520of%25202018%2520by%2520Revenues%26jtitle%3DPharmaCompass%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urquhart, L.</span></span> <span> </span><span class="NLM_article-title">Top Product Forecasts for 2019</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">91</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00012-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fd41573-019-00012-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30710137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3cjotFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=91&issue=2&author=L.+Urquhart&title=Top+Product+Forecasts+for+2019&doi=10.1038%2Fd41573-019-00012-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Top product forecasts for 2019</span></div><div class="casAuthors">Urquhart Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9BeM5inOu_8ScOqQTSkOffW6udTcc2eYKIp3e_1hHsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjotFantw%253D%253D&md5=93896dd3e52db4657adf9f9872b08a68</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00012-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00012-z%26sid%3Dliteratum%253Aachs%26aulast%3DUrquhart%26aufirst%3DL.%26atitle%3DTop%2520Product%2520Forecasts%2520for%25202019%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26issue%3D2%26spage%3D91%26doi%3D10.1038%2Fd41573-019-00012-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gammon, K.</span></span> <span> </span><span class="NLM_article-title">Neurodegenerative Disease: Brain Windfall</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span> (<span class="NLM_issue">7526</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/nj7526-299a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnj7526-299a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25396246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2M3ot12kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=299-300&issue=7526&author=K.+Gammon&title=Neurodegenerative+Disease%3A+Brain+Windfall&doi=10.1038%2Fnj7526-299a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Neurodegenerative disease: brain windfall</span></div><div class="casAuthors">Gammon Katharine</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7526</span>),
    <span class="NLM_cas:pages">299-300</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDfOo1BTaCdG52AMpI4GK2fW6udTcc2eYKIp3e_1hHsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3ot12kuw%253D%253D&md5=1ee40ff6fc8fab21a70d1df7a0b12674</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnj7526-299a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnj7526-299a%26sid%3Dliteratum%253Aachs%26aulast%3DGammon%26aufirst%3DK.%26atitle%3DNeurodegenerative%2520Disease%253A%2520Brain%2520Windfall%26jtitle%3DNature%26date%3D2014%26volume%3D515%26issue%3D7526%26spage%3D299%26epage%3D300%26doi%3D10.1038%2Fnj7526-299a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wobst, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shorter, J.</span></span> <span> </span><span class="NLM_article-title">The Clinical Trial Landscape in Amyotrophic Lateral Sclerosis-Past, Present, and Future</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1352</span>, <span class="refDoi"> DOI: 10.1002/med.21661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fmed.21661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32043626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CrtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=1352&author=H.+J.+Wobstauthor=K.+L.+Mackauthor=D.+G.+Brownauthor=N.+J.+Brandonauthor=J.+Shorter&title=The+Clinical+Trial+Landscape+in+Amyotrophic+Lateral+Sclerosis-Past%2C+Present%2C+and+Future&doi=10.1002%2Fmed.21661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future</span></div><div class="casAuthors">Wobst, Heike J.; Mack, Korrie L.; Brown, Dean G.; Brandon, Nicholas J.; Shorter, James</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1352-1384</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by progressive loss of muscle function.  It is the most common adult-onset form of motor neuron disease, affecting about 16 000 people in the United States alone.  The av. survival is about 3 years.  Only two interventional drugs, the antiglutamatergic small-mol. riluzole and the more recent antioxidant edaravone, have been approved for the treatment of ALS to date.  Therapeutic strategies under investigation in clin. trials cover a range of different modalities and targets, and more than 70 different drugs have been tested in the clinic to date.  Here, we summarize and classify interventional therapeutic strategies based on their mol. targets and phenotypic effects.  We also discuss possible reasons for the failure of clin. trials in ALS and highlight emerging preclin. strategies that could provide a breakthrough in the battle against this relentless disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6iM59ajg057Vg90H21EOLACvtfcHk0li6Mg7wGH5MYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CrtLvJ&md5=4457c1fdc5f5d2257185e22ca507321d</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fmed.21661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21661%26sid%3Dliteratum%253Aachs%26aulast%3DWobst%26aufirst%3DH.%2BJ.%26aulast%3DMack%26aufirst%3DK.%2BL.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26aulast%3DShorter%26aufirst%3DJ.%26atitle%3DThe%2520Clinical%2520Trial%2520Landscape%2520in%2520Amyotrophic%2520Lateral%2520Sclerosis-Past%252C%2520Present%252C%2520and%2520Future%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D1352%26doi%3D10.1002%2Fmed.21661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span> </span><span class="NLM_article-title">After 190 Tries, Are We Any Closer to a
Cure for Alzheimer’s?</span> <i>Bloomberg Businessweek</i>. <a href="https://www.bloomberg.com/news/articles/2016-06-27/after-190-tries-are-we-any-closer-to-a-cure-for-alzheimer-s" class="extLink">https://www.bloomberg.com/news/articles/2016-06-27/after-190-tries-are-we-any-closer-to-a-cure-for-alzheimer-s</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=After+190+Tries%2C+Are+We+Any+Closer+to+a%0ACure+for+Alzheimer%E2%80%99s%3F+Bloomberg+Businessweek.+https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2016-06-27%2Fafter-190-tries-are-we-any-closer-to-a-cure-for-alzheimer-s+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAfter%2520190%2520Tries%252C%2520Are%2520We%2520Any%2520Closer%2520to%2520a%250ACure%2520for%2520Alzheimer%25E2%2580%2599s%253F%26jtitle%3DBloomberg%2520Businessweek%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sevigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussière, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunstan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Gorman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chollate, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintero-Monzon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandrock, A.</span></span> <span> </span><span class="NLM_article-title">The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span> (<span class="NLM_issue">7618</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/nature19323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnature19323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27582220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCqur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=50-56&issue=7618&author=J.+Sevignyauthor=P.+Chiaoauthor=T.+Bussi%C3%A8reauthor=P.+H.+Weinrebauthor=L.+Williamsauthor=M.+Maierauthor=R.+Dunstanauthor=S.+Sallowayauthor=T.+Chenauthor=Y.+Lingauthor=J.+O%E2%80%99Gormanauthor=F.+Qianauthor=M.+Arastuauthor=M.+Liauthor=S.+Chollateauthor=M.+S.+Brennanauthor=O.+Quintero-Monzonauthor=R.+H.+Scannevinauthor=H.+M.+Arnoldauthor=T.+Engberauthor=K.+Rhodesauthor=J.+Ferreroauthor=Y.+Hangauthor=A.+Mikulskisauthor=J.+Grimmauthor=C.+Hockauthor=R.+M.+Nitschauthor=A.+Sandrock&title=The+Antibody+Aducanumab+Reduces+A%CE%B2+Plaques+in+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fnature19323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The antibody aducanumab reduces Aβ plaques in Alzheimer's disease</span></div><div class="casAuthors">Sevigny, Jeff; Chiao, Ping; Bussiere, Thierry; Weinreb, Paul H.; Williams, Leslie; Maier, Marcel; Dunstan, Robert; Salloway, Stephen; Chen, Tianle; Ling, Yan; O'Gorman, John; Qian, Fang; Arastu, Mahin; Li, Mingwei; Chollate, Sowmya; Brennan, Melanie S.; Quintero-Monzon, Omar; Scannevin, Robert H.; Arnold, H. Moore; Engber, Thomas; Rhodes, Kenneth; Ferrero, James; Hang, Yaming; Mikulskis, Alvydas; Grimm, Jan; Hock, Christoph; Nitsch, Roger M.; Sandrock, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7618</span>),
    <span class="NLM_cas:pages">50-56</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration.  Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful.  Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ.  In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce sol. and insol. Aβ in a dose-dependent manner.  In patients with prodromal or mild AD, one year of monthly i.v. infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner.  This is accompanied by a slowing of clin. decline measured by Clin. Dementia Rating-Sum of Boxes and Mini Mental State Examn. scores.  The main safety and tolerability findings are amyloid-related imaging abnormalities.  These results justify further development of aducanumab for the treatment of AD.  Should the slowing of clin. decline be confirmed in ongoing phase 3 clin. trials, it would provide compelling support for the amyloid hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojFdrufBYOgbVg90H21EOLACvtfcHk0lgR1Fc_H5pOGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCqur%252FJ&md5=62aa713f842093cead6b40cb523417a7</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnature19323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19323%26sid%3Dliteratum%253Aachs%26aulast%3DSevigny%26aufirst%3DJ.%26aulast%3DChiao%26aufirst%3DP.%26aulast%3DBussi%25C3%25A8re%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DP.%2BH.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DMaier%26aufirst%3DM.%26aulast%3DDunstan%26aufirst%3DR.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Gorman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DArastu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DChollate%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BS.%26aulast%3DQuintero-Monzon%26aufirst%3DO.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DArnold%26aufirst%3DH.%2BM.%26aulast%3DEngber%26aufirst%3DT.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DFerrero%26aufirst%3DJ.%26aulast%3DHang%26aufirst%3DY.%26aulast%3DMikulskis%26aufirst%3DA.%26aulast%3DGrimm%26aufirst%3DJ.%26aulast%3DHock%26aufirst%3DC.%26aulast%3DNitsch%26aufirst%3DR.%2BM.%26aulast%3DSandrock%26aufirst%3DA.%26atitle%3DThe%2520Antibody%2520Aducanumab%2520Reduces%2520A%25CE%25B2%2520Plaques%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNature%26date%3D2016%26volume%3D537%26issue%3D7618%26spage%3D50%26epage%3D56%26doi%3D10.1038%2Fnature19323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L.</span></span> <span> </span><span class="NLM_article-title">A Resurrection of Aducanumab for Alzheimer’s Disease</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30480-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1474-4422%2819%2930480-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31978357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=111-112&issue=2&author=L.+Schneider&title=A+Resurrection+of+Aducanumab+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2FS1474-4422%2819%2930480-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A resurrection of aducanumab for Alzheimer's disease</span></div><div class="casAuthors">Schneider Lon</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtdxhWBoi5aDQLBVDQn4bCfW6udTcc2eZogYBiR-bMnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D&md5=5ce903ac47c76caa5954b1d7feafdb97</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930480-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930480-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%26atitle%3DA%2520Resurrection%2520of%2520Aducanumab%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26issue%3D2%26spage%3D111%26epage%3D112%26doi%3D10.1016%2FS1474-4422%2819%2930480-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Servick, K.</span></span> <span> </span><span class="NLM_article-title">Doubts Persist for Claimed Alzheimer’s Drug</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">6471</span>),  <span class="NLM_fpage">1298</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1126/science.366.6471.1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscience.366.6471.1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31831649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=1298-1298&issue=6471&author=K.+Servick&title=Doubts+Persist+for+Claimed+Alzheimer%E2%80%99s+Drug&doi=10.1126%2Fscience.366.6471.1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Doubts persist for claimed Alzheimer's drug</span></div><div class="casAuthors">Servick, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">6471</span>),
    <span class="NLM_cas:pages">1298</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Last week, Biogen gave its first scientific presentation in defense of its startling claim to have developed the first drug that can change the devastating course of Alzheimer's disease.  At the Clin. Trials on Alzheimer's Disease congress in San Diego, California, Samantha Budd Haeberlein, Biogen's head of clin. development, tried to clarify what had emboldened the Cambridge, Massachusetts-based biotech to say in Oct. it would soon ask the U.S. Food and Drug Administration to approve its antibody drug, aducanumab, even though the company publicly declared the drug a failure back in March.  After examg. more patient data, she explained, investigators found in one trial that the higher of two tested doses led to 22% less cognitive decline after 78 wk than a placebo.  However, the small margins sepg. the treated and placebo groups and the failure of a second trial leave some researchers skeptical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJILt9Omfja7Vg90H21EOLACvtfcHk0lgR1Fc_H5pOGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLbO&md5=21cd0c17fb44dbb076eb950e2a1bd38a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1126%2Fscience.366.6471.1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.366.6471.1298%26sid%3Dliteratum%253Aachs%26aulast%3DServick%26aufirst%3DK.%26atitle%3DDoubts%2520Persist%2520for%2520Claimed%2520Alzheimer%25E2%2580%2599s%2520Drug%26jtitle%3DScience%26date%3D2019%26volume%3D366%26issue%3D6471%26spage%3D1298%26epage%3D1298%26doi%3D10.1126%2Fscience.366.6471.1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dearment, A.</span></span> <span> </span><span class="NLM_article-title">Biogen Presents Data on Controversial Alzheimer’s Drug, but Doesn’t Sway Analysts</span>.  <i>MedCity News</i>. <a href="https://medcitynews.com/2019/12/biogen-presents-data-on-controversial-alzheimers-drug-but-doesnt-dampen-analyst-skepticism/" class="extLink">https://medcitynews.com/2019/12/biogen-presents-data-on-controversial-alzheimers-drug-but-doesnt-dampen-analyst-skepticism/</a> (accessed <span class="NLM_year">2020</span>-07-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Dearment&title=Biogen+Presents+Data+on+Controversial+Alzheimer%E2%80%99s+Drug%2C+but+Doesn%E2%80%99t+Sway+Analysts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDearment%26aufirst%3DA.%26atitle%3DBiogen%2520Presents%2520Data%2520on%2520Controversial%2520Alzheimer%25E2%2580%2599s%2520Drug%252C%2520but%2520Doesn%25E2%2580%2599t%2520Sway%2520Analysts%26jtitle%3DMedCity%2520News%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, S. J.</span></span> <span> </span><span class="NLM_article-title">Antisense Oligonucleotides for Neurodegeneration</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">6485</span>),  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1126/science.aba4624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscience.aba4624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32217715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslymsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&pages=1428-1429&issue=6485&author=B.+R.+Leavittauthor=S.+J.+Tabrizi&title=Antisense+Oligonucleotides+for+Neurodegeneration&doi=10.1126%2Fscience.aba4624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense oligonucleotides for neurodegeneration</span></div><div class="casAuthors">Leavitt, Blair R.; Tabrizi, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6485</span>),
    <span class="NLM_cas:pages">1428-1429</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Antisense oligonucleotides (ASOs) have the potential to reduce, restore, or modify RNA and protein expression.  Thus, they can target disease pathogenesis by altering the expression of mutant proteins ().  The recent regulatory approval of ASOs for the pediatric motor neuron disease spinal muscular atrophy has provided a regulatory pathway for addnl. ASO therapies in other central nervous system (CNS) diseases.  Developments in ASO chem. and advances in CNS delivery methods have enabled ASOs to enter clin. trials to treat Huntington's disease (HD).  There are currently no available treatments that slow or prevent progression of HD, but two ongoing ASO-based clin. programs have shown promising results.  Addnl., clin. trials of ASOs to treat amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease are under way, with more in development for other neurodegenerative diseases.  It is hoped that ASO-based approaches will provide effective diseasemodifying therapies for HD and similar neurodegenerative diseases soon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlOZAc9MJOQ7Vg90H21EOLACvtfcHk0lgR1Fc_H5pOGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslymsbs%253D&md5=1b131a781357016dad46d764fff19d05</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1126%2Fscience.aba4624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aba4624%26sid%3Dliteratum%253Aachs%26aulast%3DLeavitt%26aufirst%3DB.%2BR.%26aulast%3DTabrizi%26aufirst%3DS.%2BJ.%26atitle%3DAntisense%2520Oligonucleotides%2520for%2520Neurodegeneration%26jtitle%3DScience%26date%3D2020%26volume%3D367%26issue%3D6485%26spage%3D1428%26epage%3D1429%26doi%3D10.1126%2Fscience.aba4624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span> </span><span class="NLM_article-title">A Study to Evaluate the Safety, Tolerability,
and Pharmacokinetics
of BIIB094 in Adults with Parkinson’s Disease</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT03976349" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03976349</a> (accessed <span class="NLM_year">2020</span>-07-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+to+Evaluate+the+Safety%2C+Tolerability%2C%0Aand+Pharmacokinetics%0Aof+BIIB094+in+Adults+with+Parkinson%E2%80%99s+Disease.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03976349+%28accessed+2020-07-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520to%2520Evaluate%2520the%2520Safety%252C%2520Tolerability%252C%250Aand%2520Pharmacokinetics%250Aof%2520BIIB094%2520in%2520Adults%2520with%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, S. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Antisense Targeting of Huntingtin</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1089/dna.2019.5188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1089%2Fdna.2019.5188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31821021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=154-158&issue=2&author=A.+V.+Smithauthor=S.+J.+Tabrizi&title=Therapeutic+Antisense+Targeting+of+Huntingtin&doi=10.1089%2Fdna.2019.5188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Antisense Targeting of Huntingtin</span></div><div class="casAuthors">Smith, Anne V.; Tabrizi, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-158</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  This brief review summarizes the preclin., translational, and early clin. development of an ASO designed to reduce the prodn. of the disease-causing protein in Huntington's disease, an inherited neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoieL_bom1-3bVg90H21EOLACvtfcHk0lgKplvSJuH30g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVGns7Y%253D&md5=848089afbe53785607d24a94bbc356b2</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1089%2Fdna.2019.5188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2019.5188%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BV.%26aulast%3DTabrizi%26aufirst%3DS.%2BJ.%26atitle%3DTherapeutic%2520Antisense%2520Targeting%2520of%2520Huntingtin%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2020%26volume%3D39%26issue%3D2%26spage%3D154%26epage%3D158%26doi%3D10.1089%2Fdna.2019.5188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cudkowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atassi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucelli, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludolph, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestronk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salachas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houshyar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCampbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestorov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, T. A.</span></span> <span> </span><span class="NLM_article-title">Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2003715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa2003715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32640130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeis7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=109-119&issue=2&author=T.+Millerauthor=M.+Cudkowiczauthor=P.+J.+Shawauthor=P.+M.+Andersenauthor=N.+Atassiauthor=R.+C.+Bucelliauthor=A.+Gengeauthor=J.+Glassauthor=S.+Ladhaauthor=A.+L.+Ludolphauthor=N.+J.+Maragakisauthor=C.+J.+McDermottauthor=A.+Pestronkauthor=J.+Ravitsauthor=F.+Salachasauthor=R.+Trudellauthor=P.+Van+Dammeauthor=L.+Zinmanauthor=C.+F.+Bennettauthor=R.+Laneauthor=A.+Sandrockauthor=H.+Runzauthor=D.+Grahamauthor=H.+Houshyarauthor=A.+McCampbellauthor=I.+Nestorovauthor=I.+Changauthor=M.+McNeillauthor=L.+Fanningauthor=S.+Fradetteauthor=T.+A.+Ferguson&title=Phase+1%E2%80%932+Trial+of+Antisense+Oligonucleotide+Tofersen+for+SOD1+ALS&doi=10.1056%2FNEJMoa2003715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS</span></div><div class="casAuthors">Miller, T.; Cudkowicz, M.; Shaw, P. J.; Andersen, P. M.; Atassi, N.; Bucelli, R. C.; Genge, A.; Glass, J.; Ladha, S.; Ludolph, A. L.; Maragakis, N. J.; McDermott, C. J.; Pestronk, A.; Ravits, J.; Salachas, F.; Trudell, R.; Van Damme, P.; Zinman, L.; Bennett, C. F.; Lane, R.; Sandrock, A.; Runz, H.; Graham, D.; Houshyar, H.; McCampbell, A.; Nestorov, I.; Chang, I.; McNeill, M.; Fanning, L.; Fradette, S.; Ferguson, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-119</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tofersen is an antisense oligonucleotide that mediates the degrdn. of superoxide dismutase 1 (SOD1) mRNA to reduce SOD1 protein synthesis.  Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.  We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS due to SOD1 mutations.  In each dose cohort (20, 40, 60, or 100 mg), participants were randomly assigned in a 3:1 ratio to receive five doses of tofersen or placebo, administered intrathecally for 12 wk.  The primary outcomes were safety and pharmacokinetics.  The secondary outcome was the change from baseline in the cerebrospinal fluid (CSF) SOD1 concn. at day 85.  Clin. function and vital capacity were measured.  A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses.  Lumbar puncture-related adverse events were obsd. in most participants.  Elevations in CSF white-cell count and protein were reported as adverse events in 4 and 5 participants, resp., who received tofersen.  Among participants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the placebo group died from respiratory failure on day 52.  The difference at day 85 in the change from baseline in the CSF SOD1 concn. between the tofersen groups and the placebo group was 2 percentage points (95% confidence interval [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16) for the 100-mg dose.  In adults with ALS due to SOD1 mutations, CSF SOD1 concns. decreased at the highest concn. of tofersen administered intrathecally over a period of 12 wk.  CSF pleocytosis occurred in some participants receiving tofersen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlGCCoE7Z6hrVg90H21EOLACvtfcHk0lgKplvSJuH30g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeis7jE&md5=9bd3795b9300a32f6278efe78d3f5b8f</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2003715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2003715%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCudkowicz%26aufirst%3DM.%26aulast%3DShaw%26aufirst%3DP.%2BJ.%26aulast%3DAndersen%26aufirst%3DP.%2BM.%26aulast%3DAtassi%26aufirst%3DN.%26aulast%3DBucelli%26aufirst%3DR.%2BC.%26aulast%3DGenge%26aufirst%3DA.%26aulast%3DGlass%26aufirst%3DJ.%26aulast%3DLadha%26aufirst%3DS.%26aulast%3DLudolph%26aufirst%3DA.%2BL.%26aulast%3DMaragakis%26aufirst%3DN.%2BJ.%26aulast%3DMcDermott%26aufirst%3DC.%2BJ.%26aulast%3DPestronk%26aufirst%3DA.%26aulast%3DRavits%26aufirst%3DJ.%26aulast%3DSalachas%26aufirst%3DF.%26aulast%3DTrudell%26aufirst%3DR.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DZinman%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DLane%26aufirst%3DR.%26aulast%3DSandrock%26aufirst%3DA.%26aulast%3DRunz%26aufirst%3DH.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DHoushyar%26aufirst%3DH.%26aulast%3DMcCampbell%26aufirst%3DA.%26aulast%3DNestorov%26aufirst%3DI.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DFanning%26aufirst%3DL.%26aulast%3DFradette%26aufirst%3DS.%26aulast%3DFerguson%26aufirst%3DT.%2BA.%26atitle%3DPhase%25201%25E2%2580%25932%2520Trial%2520of%2520Antisense%2520Oligonucleotide%2520Tofersen%2520for%2520SOD1%2520ALS%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26issue%3D2%26spage%3D109%26epage%3D119%26doi%3D10.1056%2FNEJMoa2003715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span> </span><span class="NLM_article-title">Safety, Tolerability, Pharmacokinetics,
and Pharmacodynamics of IONIS-MAPTRx
in Patients with Mild Alzheimer’s Disease</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT03186989" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03186989</a> (accessed <span class="NLM_year">2020</span>-11-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C+Tolerability%2C+Pharmacokinetics%2C%0Aand+Pharmacodynamics+of+IONIS-MAPTRx%0Ain+Patients+with+Mild+Alzheimer%E2%80%99s+Disease.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03186989+%28accessed+2020-11-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSafety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%250Aand%2520Pharmacodynamics%2520of%2520IONIS-MAPTRx%250Ain%2520Patients%2520with%2520Mild%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moufawad El Achkar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douville, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergast, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldkind, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuniholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belur, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojkovska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsytsykova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustine, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genetti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dies, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodlett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflock, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beggs, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urion, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waisbren, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poduri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biffi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzulli, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodamer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berde, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T. W.</span></span> <span> </span><span class="NLM_article-title">Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1652</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1813279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31597037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1644-1652&issue=17&author=J.+Kimauthor=C.+Huauthor=C.+Moufawad+El+Achkarauthor=L.+E.+Blackauthor=J.+Douvilleauthor=A.+Larsonauthor=M.+K.+Pendergastauthor=S.+F.+Goldkindauthor=E.+A.+Leeauthor=A.+Kuniholmauthor=A.+Soucyauthor=J.+Vazeauthor=N.+R.+Belurauthor=K.+Fredriksenauthor=I.+Stojkovskaauthor=A.+Tsytsykovaauthor=M.+Armantauthor=R.+L.+DiDonatoauthor=J.+Choiauthor=L.+Cornelissenauthor=L.+M.+Pereiraauthor=E.+F.+Augustineauthor=C.+A.+Genettiauthor=K.+Diesauthor=B.+Bartonauthor=L.+Williamsauthor=B.+D.+Goodlettauthor=B.+L.+Rileyauthor=A.+Pasternakauthor=E.+R.+Berryauthor=K.+A.+Pflockauthor=S.+Chuauthor=C.+Reedauthor=K.+Tyndallauthor=P.+B.+Agrawalauthor=A.+H.+Beggsauthor=P.+E.+Grantauthor=D.+K.+Urionauthor=R.+O.+Snyderauthor=S.+E.+Waisbrenauthor=A.+Poduriauthor=P.+J.+Parkauthor=A.+Pattersonauthor=A.+Biffiauthor=J.+R.+Mazzulliauthor=O.+Bodamerauthor=C.+B.+Berdeauthor=T.+W.+Yu&title=Patient-Customized+Oligonucleotide+Therapy+for+a+Rare+Genetic+Disease&doi=10.1056%2FNEJMoa1813279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Patient-customized oligonucleotide therapy for a rare genetic disease</span></div><div class="casAuthors">Kim, J.; Hu, C.; El Achkar, C. Moufawad; Black, L. E.; Douville, J.; Larson, A.; Pendergast, M. K.; Goldkind, S. F.; Lee, E. A.; Kuniholm, A.; Soucy, A.; Vaze, J.; Belur, N. R.; Fredriksen, K.; Stojkovska, I.; Tsytsykova, A.; Armant, M.; DiDonato, R. L.; Choi, J.; Cornelissen, L.; Pereira, L. M.; Augustine, E. F.; Genetti, C. A.; Dies, K.; Barton, B.; Williams, L.; Goodlett, B. D.; Riley, B. L.; Pasternak, A.; Berry, E. R.; Pflock, K. A.; Chu, S.; Reed, C.; Tyndall, K.; Agrawal, P. B.; Beggs, A. H.; Grant, P. E.; Urion, D. K.; Snyder, R. O.; Waisbren, S. E.; Poduri, A.; Park, P. J.; Patterson, A.; Biffi, A.; Mazzulli, J. R.; Bodamer, O.; Berde, C. B.; Yu, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1644-1652</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Genome sequencing is often pivotal in the diagnosis of rare diseases, but many of these conditions lack specific treatments.  We describe how mol. diagnosis of a rare, fatal neurodegenerative condition led to the rational design, testing, and manuf. of milasen, a splice-modulating antisense oligonucleotide drug tailored to a particular patient.  Proof-of-concept expts. in cell lines from the patient served as the basis for launching an "N-of-1" study of milasen within 1 yr after first contact with the patient.  There were no serious adverse events, and treatment was assocd. with objective redn. in seizures (detd. by electroencephalog. and parental reporting).  This study offers a possible template for the rapid development of patient-customized treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEdC1RDufqFLVg90H21EOLACvtfcHk0ljXIZkT6HZzVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWkt73I&md5=bb1983cc9dc5932d35346d16e68b974d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813279%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DMoufawad%2BEl%2BAchkar%26aufirst%3DC.%26aulast%3DBlack%26aufirst%3DL.%2BE.%26aulast%3DDouville%26aufirst%3DJ.%26aulast%3DLarson%26aufirst%3DA.%26aulast%3DPendergast%26aufirst%3DM.%2BK.%26aulast%3DGoldkind%26aufirst%3DS.%2BF.%26aulast%3DLee%26aufirst%3DE.%2BA.%26aulast%3DKuniholm%26aufirst%3DA.%26aulast%3DSoucy%26aufirst%3DA.%26aulast%3DVaze%26aufirst%3DJ.%26aulast%3DBelur%26aufirst%3DN.%2BR.%26aulast%3DFredriksen%26aufirst%3DK.%26aulast%3DStojkovska%26aufirst%3DI.%26aulast%3DTsytsykova%26aufirst%3DA.%26aulast%3DArmant%26aufirst%3DM.%26aulast%3DDiDonato%26aufirst%3DR.%2BL.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DCornelissen%26aufirst%3DL.%26aulast%3DPereira%26aufirst%3DL.%2BM.%26aulast%3DAugustine%26aufirst%3DE.%2BF.%26aulast%3DGenetti%26aufirst%3DC.%2BA.%26aulast%3DDies%26aufirst%3DK.%26aulast%3DBarton%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DGoodlett%26aufirst%3DB.%2BD.%26aulast%3DRiley%26aufirst%3DB.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DBerry%26aufirst%3DE.%2BR.%26aulast%3DPflock%26aufirst%3DK.%2BA.%26aulast%3DChu%26aufirst%3DS.%26aulast%3DReed%26aufirst%3DC.%26aulast%3DTyndall%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DP.%2BB.%26aulast%3DBeggs%26aufirst%3DA.%2BH.%26aulast%3DGrant%26aufirst%3DP.%2BE.%26aulast%3DUrion%26aufirst%3DD.%2BK.%26aulast%3DSnyder%26aufirst%3DR.%2BO.%26aulast%3DWaisbren%26aufirst%3DS.%2BE.%26aulast%3DPoduri%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DPatterson%26aufirst%3DA.%26aulast%3DBiffi%26aufirst%3DA.%26aulast%3DMazzulli%26aufirst%3DJ.%2BR.%26aulast%3DBodamer%26aufirst%3DO.%26aulast%3DBerde%26aufirst%3DC.%2BB.%26aulast%3DYu%26aufirst%3DT.%2BW.%26atitle%3DPatient-Customized%2520Oligonucleotide%2520Therapy%2520for%2520a%2520Rare%2520Genetic%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D17%26spage%3D1644%26epage%3D1652%26doi%3D10.1056%2FNEJMoa1813279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keshavan, M.</span></span> <span> </span><span class="NLM_article-title">Saving Mila: How a Tailor-Made Therapy, Developed in a Flash, May Have Halted a Young Girl’s Rare Disease</span>.  <i>STAT</i>. <a href="https://www.statnews.com/2018/10/22/a-tailor-made-therapy-may-have-halted-a-rare-disease/" class="extLink">https://www.statnews.com/2018/10/22/a-tailor-made-therapy-may-have-halted-a-rare-disease/</a> (accessed <span class="NLM_year">2020</span>-07-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Keshavan&title=Saving+Mila%3A+How+a+Tailor-Made+Therapy%2C+Developed+in+a+Flash%2C+May+Have+Halted+a+Young+Girl%E2%80%99s+Rare+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKeshavan%26aufirst%3DM.%26atitle%3DSaving%2520Mila%253A%2520How%2520a%2520Tailor-Made%2520Therapy%252C%2520Developed%2520in%2520a%2520Flash%252C%2520May%2520Have%2520Halted%2520a%2520Young%2520Girl%25E2%2580%2599s%2520Rare%2520Disease%26jtitle%3DSTAT%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booth, B.</span></span> <span> </span><span class="NLM_article-title">Venturing Boldly Into Neuroscience</span>.  <i>Life Sci VC</i>. <a href="https://lifescivc.com/2017/09/venturing-boldly-neuroscience/" class="extLink">https://lifescivc.com/2017/09/venturing-boldly-neuroscience/</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+Booth&title=Venturing+Boldly+Into+Neuroscience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBooth%26aufirst%3DB.%26atitle%3DVenturing%2520Boldly%2520Into%2520Neuroscience%26jtitle%3DLife%2520Sci%2520VC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span> </span><span class="NLM_article-title">CNS drugs
take 20% longer to develop and to approve vs. non-CNS drugs</span>.  <i>Tufts Center for the Study of Drug Development</i>. <a href="https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5b97b8f5575d1f202ba413c3/1536669941287/summary_septoct18.pdf" class="extLink">https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5b97b8f5575d1f202ba413c3/1536669941287/summary_septoct18.pdf</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CNS+drugs%0Atake+20%25+longer+to+develop+and+to+approve+vs.+non-CNS+drugs.+Tufts+Center+for+the+Study+of+Drug+Development.+https%3A%2F%2Fstatic1.squarespace.com%2Fstatic%2F5a9eb0c8e2ccd1158288d8dc%2Ft%2F5b97b8f5575d1f202ba413c3%2F1536669941287%2Fsummary_septoct18.pdf+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCNS%2520drugs%250Atake%252020%2525%2520longer%2520to%2520develop%2520and%2520to%2520approve%2520vs.%2520non-CNS%2520drugs%26jtitle%3DTufts%2520Center%2520for%2520the%2520Study%2520of%2520Drug%2520Development%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span> <span> </span><span class="NLM_article-title">Strategies to Address Challenges in Neuroscience Drug Discovery and Development</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyz027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1093%2Fijnp%2Fpyz027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31139821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gvVGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2019&pages=445-448&issue=7&author=P.+O%E2%80%99Donnellauthor=L.+Rosenauthor=R.+Alexanderauthor=V.+Murthyauthor=C.+H.+Daviesauthor=E.+Ratti&title=Strategies+to+Address+Challenges+in+Neuroscience+Drug+Discovery+and+Development&doi=10.1093%2Fijnp%2Fpyz027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to Address Challenges in Neuroscience Drug Discovery and Development</span></div><div class="casAuthors">O'Donnell Patricio; Rosen Laura; Alexander Robert; Murthy Venkatesha; Ratti Emiliangelo; Davies Ceri H</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">445-448</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The paucity of novel drugs for neuropsychiatric indications contrasts with the remarkable recent advances in neuroscience research.  We have identified 5 challenges the field needs to address and recommend potential solutions.  First, we need to drive discovery efforts based on human data.  Second, we need to think more carefully about animal models, embracing them as tools to test pathophysiological alterations.  Third, we need to develop strategies to select more homogenous groups of patients in our clinical trials.  Fourth, we need to develop and validate translational biomarkers, which can be used for pharmacodynamic assessments as well as for patient selection.  Fifth, we need to adopt more reliable and objective measures to capture clinical efficacy.  The tools that will allow these solutions to be implemented may already be in place but not routinely adopted or are still being developed.  Overall, a change in mindset to adopt science- and data-driven paths is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRpfI4sEPq943yKPtYViAGfW6udTcc2ebY_MjUe1SBpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gvVGgtQ%253D%253D&md5=d86c1f4aac93062adaf7dc17f0f39c7e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyz027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyz027%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMurthy%26aufirst%3DV.%26aulast%3DDavies%26aufirst%3DC.%2BH.%26aulast%3DRatti%26aufirst%3DE.%26atitle%3DStrategies%2520to%2520Address%2520Challenges%2520in%2520Neuroscience%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2019%26volume%3D22%26issue%3D7%26spage%3D445%26epage%3D448%26doi%3D10.1093%2Fijnp%2Fpyz027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span> </span><span class="NLM_article-title">Opioid Overdose</span>.  <i>Center for Disease Control
and Prevention</i>. <a href="https://www.cdc.gov/drugoverdose/epidemic/index.html" class="extLink">https://www.cdc.gov/drugoverdose/epidemic/index.html</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Opioid+Overdose.+Center+for+Disease+Control%0Aand+Prevention.+https%3A%2F%2Fwww.cdc.gov%2Fdrugoverdose%2Fepidemic%2Findex.html+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DOpioid%2520Overdose%26jtitle%3DCenter%2520for%2520Disease%2520Control%250Aand%2520Prevention%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doughty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, T.</span></span> <span> </span><span class="NLM_article-title">Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1177/1060028019828954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1177%2F1060028019828954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30724094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=746-753&issue=7&author=B.+Doughtyauthor=D.+Morgensonauthor=T.+Brooks&title=Lofexidine%3A+A+Newly+FDA-Approved%2C+Nonopioid+Treatment+for+Opioid+Withdrawal&doi=10.1177%2F1060028019828954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal</span></div><div class="casAuthors">Doughty, Bennett; Morgenson, Daralyn; Brooks, Tracy</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">746-753</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., efficacy, and safety of lofexidine for the treatment of opioid withdrawal secondary to the recent Food and Drug Administration (FDA) approval.  Data Sources: A literature search using PubMed was conducted (inception to Dec. 2018) using the terms lofexidine, opioid, opiate, and withdrawal.  Refs. from retrieved articles and the prescribing information were reviewed for any addnl. material.  Study Selection/Data Extn.: The literature search was limited to human studies published in English that pertained to human pharmacol., pharmacokinetics, pharmacodynamics, dosing, efficacy, and safety regarding opioid withdrawal.  Phase I, II, and III studies of lofexidine for opioid withdrawal were reviewed for inclusion.  Data Synthesis: Lofexidine is newly FDA approved in the United States for the treatment of opioid withdrawal symptoms in adults.  Several randomized controlled trials and a Cochrane review noted the effectiveness of lofexidine vs. placebo for this indication.  The efficacy of lofexidine has also been shown to be comparable to that of other indicated first- and second-line pharmacol. agents.  Relevance to Patient Care and Clin. Practice: This article examines the trials that led to lofexidine's new FDA-approved indication as well as other recent literature published since its last major review, seeking to guide providers in the appropriate use of lofexidine for its new indication.  Conclusions: Lofexidine is an effective and safe agent in treating symptoms related to opioid withdrawal in adults when compared with placebo; although it is more widely accessible than other first-line therapies, its use in practice may be limited by cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohcyqmCUKki7Vg90H21EOLACvtfcHk0lhGc9iTNSrG_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfF&md5=1e7755a13d9a6fee8cbac7e9a41152e0</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1177%2F1060028019828954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019828954%26sid%3Dliteratum%253Aachs%26aulast%3DDoughty%26aufirst%3DB.%26aulast%3DMorgenson%26aufirst%3DD.%26aulast%3DBrooks%26aufirst%3DT.%26atitle%3DLofexidine%253A%2520A%2520Newly%2520FDA-Approved%252C%2520Nonopioid%2520Treatment%2520for%2520Opioid%2520Withdrawal%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2019%26volume%3D53%26issue%3D7%26spage%3D746%26epage%3D753%26doi%3D10.1177%2F1060028019828954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span> </span><span class="NLM_article-title">FDA Approves the First Non-Opioid Treatment
for Management of Opioid
Withdrawal Symptoms in Adults</span>.  <i>U.S. Food and
Drug Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+the+First+Non-Opioid+Treatment%0Afor+Management+of+Opioid%0AWithdrawal+Symptoms+in+Adults.+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520the%2520First%2520Non-Opioid%2520Treatment%250Afor%2520Management%2520of%2520Opioid%250AWithdrawal%2520Symptoms%2520in%2520Adults%26jtitle%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span> <i>Reviving the
Pipeline of Live-saving Antibiotics: Exploring Solutions
to Spur Innovation</i>. <a href="https://www.pewtrusts.org/-/media/legacy/uploadedfiles/phg/content_level_pages/issue_briefs/aippipelineproceedings9webpdf.pdf" class="extLink">https://www.pewtrusts.org/-/media/legacy/uploadedfiles/phg/content_level_pages/issue_briefs/aippipelineproceedings9webpdf.pdf</a> (accessed <span class="NLM_year">2020</span>-10-24).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Reviving+the%0APipeline+of+Live-saving+Antibiotics%3A+Exploring+Solutions%0Ato+Spur+Innovation.+https%3A%2F%2Fwww.pewtrusts.org%2F-%2Fmedia%2Flegacy%2Fuploadedfiles%2Fphg%2Fcontent_level_pages%2Fissue_briefs%2Faippipelineproceedings9webpdf.pdf+%28accessed+2020-10-24%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DReviving%2520the%250APipeline%2520of%2520Live-saving%2520Antibiotics%253A%2520Exploring%2520Solutions%250Ato%2520Spur%2520Innovation%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span> </span><span class="NLM_article-title">Rick
Brown</span>.  <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">18</span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">11</span>.<span class="refDoi"> DOI: 10.1038/nrd.2018.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2018.237" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Rick%0ABrown.+Nat.+Rev.+Drug+Discovery+2019%2C+18+%281%29%2C+10%E2%80%9311.+10.1038%2Fnrd.2018.237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.237%26sid%3Dliteratum%253Aachs%26atitle%3DRick%250ABrown%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26issue%3D1%26spage%3D10%26epage%3D11%26doi%3D10.1038%2Fnrd.2018.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbarth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulcini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahlmeter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluytmans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmeli, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Outterson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaleri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houchens, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theuretzbacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magrini, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">WHO Pathogens Priority List Working Group. Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30753-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1473-3099%2817%2930753-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29276051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1MzkvFOgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=318-327&issue=3&author=E.+Tacconelliauthor=E.+Carraraauthor=A.+Savoldiauthor=S.+Harbarthauthor=M.+Mendelsonauthor=D.+L.+Monnetauthor=C.+Pulciniauthor=G.+Kahlmeterauthor=J.+Kluytmansauthor=Y.+Carmeliauthor=M.+Ouelletteauthor=K.+Outtersonauthor=J.+Patelauthor=M.+Cavaleriauthor=E.+M.+Coxauthor=C.+R.+Houchensauthor=M.+L.+Graysonauthor=P.+Hansenauthor=N.+Singhauthor=U.+Theuretzbacherauthor=N.+Magrini&title=WHO+Pathogens+Priority+List+Working+Group.+Discovery%2C+Research%2C+and+Development+of+New+Antibiotics%3A+The+WHO+Priority+List+of+Antibiotic-Resistant+Bacteria+and+Tuberculosis&doi=10.1016%2FS1473-3099%2817%2930753-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</span></div><div class="casAuthors">Tacconelli Evelina; Carrara Elena; Savoldi Alessia; Harbarth Stephan; Mendelson Marc; Monnet Dominique L; Pulcini Celine; Kahlmeter Gunnar; Kluytmans Jan; Carmeli Yehuda; Ouellette Marc; Outterson Kevin; Patel Jean; Cavaleri Marco; Cox Edward M; Houchens Chris R; Grayson M Lindsay; Hansen Paul; Singh Nalini; Theuretzbacher Ursula; Magrini Nicola</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-327</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide.  Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs.  In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs.  METHODS:  We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated.  The final priority ranking of the antibiotic-resistant bacteria was established after a preference-based survey was used to obtain expert weighting of criteria.  FINDINGS:  We selected 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority: mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline.  We stratified the priority list into three tiers (critical, high, and medium priority), using the 33rd percentile of the bacterium's total scores as the cutoff.  Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae.  The highest ranked Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin-resistant Staphylococcus aureus.  Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori, and fluoroquinolone-resistant Campylobacter spp, Neisseria gonorrhoeae, and Salmonella typhi were included in the high-priority tier.  INTERPRETATION:  Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria.  The global strategy should include antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, N gonorrhoeae, and H pylori.  FUNDING:  World Health Organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkARC7DR8uZLGbPKh4T9eAfW6udTcc2ebY_MjUe1SBpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzkvFOgsA%253D%253D&md5=14021ec57670b29fec6a88226a6a1fdd</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930753-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930753-3%26sid%3Dliteratum%253Aachs%26aulast%3DTacconelli%26aufirst%3DE.%26aulast%3DCarrara%26aufirst%3DE.%26aulast%3DSavoldi%26aufirst%3DA.%26aulast%3DHarbarth%26aufirst%3DS.%26aulast%3DMendelson%26aufirst%3DM.%26aulast%3DMonnet%26aufirst%3DD.%2BL.%26aulast%3DPulcini%26aufirst%3DC.%26aulast%3DKahlmeter%26aufirst%3DG.%26aulast%3DKluytmans%26aufirst%3DJ.%26aulast%3DCarmeli%26aufirst%3DY.%26aulast%3DOuellette%26aufirst%3DM.%26aulast%3DOutterson%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DCavaleri%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DE.%2BM.%26aulast%3DHouchens%26aufirst%3DC.%2BR.%26aulast%3DGrayson%26aufirst%3DM.%2BL.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DTheuretzbacher%26aufirst%3DU.%26aulast%3DMagrini%26aufirst%3DN.%26atitle%3DWHO%2520Pathogens%2520Priority%2520List%2520Working%2520Group.%2520Discovery%252C%2520Research%252C%2520and%2520Development%2520of%2520New%2520Antibiotics%253A%2520The%2520WHO%2520Priority%2520List%2520of%2520Antibiotic-Resistant%2520Bacteria%2520and%2520Tuberculosis%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26issue%3D3%26spage%3D318%26epage%3D327%26doi%3D10.1016%2FS1473-3099%2817%2930753-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, D. L.</span></span> <span> </span><span class="NLM_article-title">Antibiotics in the Clinical Pipeline in October 2019</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1038/s41429-020-0291-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41429-020-0291-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32152527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2020&pages=329-364&issue=6&author=M.+S.+Butlerauthor=D.+L.+Paterson&title=Antibiotics+in+the+Clinical+Pipeline+in+October+2019&doi=10.1038%2Fs41429-020-0291-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotics in the clinical pipeline in October 2019</span></div><div class="casAuthors">Butler, Mark S.; Paterson, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">329-364</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR) bacteria, esp. Gram-neg. (G-ve) pathogens, is acknowledged as one of the world's most pressing health issues; however, the discovery and development of new, nontoxic antibacterials is not a straightforward scientific task, which is compounded by a challenging economic model.  This review lists the antibacterials, β-lactamase/β-lactam inhibitor (BLI) combinations, and monoclonal antibodies (mAbs) first launched around the world since 2009 and details the seven new antibiotics and two new β-lactam/BLI combinations launched since 2016.  The development status, mode of action, spectra of activity, lead source, and administration route for the 44 small mol. antibacterials, eight β-lactamase/BLI combinations, and one antibody drug conjugate (ADC) being evaluated in worldwide clin. trials at the end of Oct. 2019 are described.  Compds. discontinued from clin. development since 2016 and new antibacterial pharmacophores are also reviewed.  There has been an increase in the no. of early stage clin. candidates, which has been fueled by antibiotic-focused funding agencies; however, there is still a significant gap in the pipeline for the development of new antibacterials with activity against β-metallolactamases, orally administered with broad spectrum G-ve activity, and new treatments for MDR Acinetobacter and gonorrhea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDTAYv4MlaorVg90H21EOLACvtfcHk0lidRD5e_d6piQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeqsb8%253D&md5=8144b41888383c0bf8af6d6e0d7dc1c4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fs41429-020-0291-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41429-020-0291-8%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DPaterson%26aufirst%3DD.%2BL.%26atitle%3DAntibiotics%2520in%2520the%2520Clinical%2520Pipeline%2520in%2520October%25202019%26jtitle%3DJ.%2520Antibiot.%26date%3D2020%26volume%3D73%26issue%3D6%26spage%3D329%26epage%3D364%26doi%3D10.1038%2Fs41429-020-0291-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Triguero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonardelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavel, J. A.</span></span> <span> </span><span class="NLM_article-title">A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus Aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e02588</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1128/AAC.02588-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1128%2FAAC.02588-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30910894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1SgsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e02588-18&issue=6&author=M.+Peckauthor=M.+E.+Rothenbergauthor=R.+Dengauthor=N.+Lewin-Kohauthor=G.+Sheauthor=A.+V.+Kamathauthor=M.+Carrasco-Trigueroauthor=O.+Saadauthor=A.+Castroauthor=L.+Teufelauthor=D.+S.+Dickersonauthor=M.+Leonardelliauthor=J.+A.+Tavel&title=A+Phase+1%2C+Randomized%2C+Single-Ascending-Dose+Study+To+Investigate+the+Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+DSTA4637S%2C+an+Anti-Staphylococcus+Aureus+Thiomab+Antibody-Antibiotic+Conjugate%2C+in+Healthy+Volunteers&doi=10.1128%2FAAC.02588-18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti- Staphylococcus aureus Thiomab antibody-antibiotic conjugate, in healthy volunteers</span></div><div class="casAuthors">Peck, Melicent; Rothenberg, Michael E.; Deng, Rong; Lewin-Koh, Nicholas; She, Gaohong; Kamath, Amrita V.; Carrasco-Triguero, Montserrat; Saad, Ola; Castro, Aide; Teufel, Lisa; Dickerson, Daniel S.; Leonardelli, Marisa; Tavel, Jorge A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e02588-18</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Staphylococcus aureus causes serious bacterial infections with high morbidity and mortality, necessitating the discovery of new antibiotics.  DSTA4637S is a novel antibody-antibiotic conjugate designed to target intracellular S. aureus that is not adequately eliminated by current std.-of-care antibiotics.  Phagocytic cells ingest DSTA4637S-bound S. aureus, and intracellular cathepsins cleave the linker, releasing dmDNA31and killing intracellular S. aureus.  This first-in-human, randomized, doubleblind, placebo-controlled, single-ascending-dose phase 1 trial analyzed the safety, pharmacokinetics, and immunogenicity of DSTA4637S in healthy volunteers.  Thirty healthy male and female volunteers, 18-65 years old, subjects were followed for 85 days after dosing.  No subject withdrew from the study, and no serious or severe adverse events.  One moderate infusion-related reaction (150 mg/kg DSTA4637S).  No clin. meaningful or dose-related changes in lab. parameters or vital signs.  Pharmacokinetics of plasma DSTA4637S conjugate and serum DSTA4637S total antibody were dose proportional.  Systemic exposure of unconjugated dmDNA31 was low.  No DSTA4637S-induced anti-drug antibody responses were obsd.  DSTA4637S was generally safe and well tolerated as a single i.v. dose in healthy volunteers.  DSTA4637S has a favorable safety and pharmacokinetic profile that supports future development as a novel therapeutic for S. aureus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdRbuoylerrLVg90H21EOLACvtfcHk0lidRD5e_d6piQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1SgsrfN&md5=81b5b5182885d6ff7192290ecf16990b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1128%2FAAC.02588-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02588-18%26sid%3Dliteratum%253Aachs%26aulast%3DPeck%26aufirst%3DM.%26aulast%3DRothenberg%26aufirst%3DM.%2BE.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DShe%26aufirst%3DG.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DCarrasco-Triguero%26aufirst%3DM.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DTeufel%26aufirst%3DL.%26aulast%3DDickerson%26aufirst%3DD.%2BS.%26aulast%3DLeonardelli%26aufirst%3DM.%26aulast%3DTavel%26aufirst%3DJ.%2BA.%26atitle%3DA%2520Phase%25201%252C%2520Randomized%252C%2520Single-Ascending-Dose%2520Study%2520To%2520Investigate%2520the%2520Safety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520DSTA4637S%252C%2520an%2520Anti-Staphylococcus%2520Aureus%2520Thiomab%2520Antibody-Antibiotic%2520Conjugate%252C%2520in%2520Healthy%2520Volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26issue%3D6%26spage%3De02588%26epage%3D18%26doi%3D10.1128%2FAAC.02588-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theuretzbacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbarth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, G. E.</span></span> <span> </span><span class="NLM_article-title">Critical Analysis of Antibacterial Agents in Clinical Development</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/s41579-020-0340-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41579-020-0340-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32152509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXks1Kgur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=286-298&issue=5&author=U.+Theuretzbacherauthor=K.+Bushauthor=S.+Harbarthauthor=M.+Paulauthor=J.+H.+Rexauthor=E.+Tacconelliauthor=G.+E.+Thwaites&title=Critical+Analysis+of+Antibacterial+Agents+in+Clinical+Development&doi=10.1038%2Fs41579-020-0340-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Critical analysis of antibacterial agents in clinical development</span></div><div class="casAuthors">Theuretzbacher, Ursula; Bush, Karen; Harbarth, Stephan; Paul, Mical; Rex, John H.; Tacconelli, Evelina; Thwaites, Guy E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">286-298</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The antibacterial agents currently in clin. development are predominantly derivs. of well-established antibiotic classes and were selected to address the class-specific resistance mechanisms and determinants that were known at the time of their discovery.  Many of these agents aim to target the antibiotic-resistant priority pathogens listed by the WHO, including Gram-neg. bacteria in the crit. priority category, such as carbapenem-resistant Acinetobacter, Pseudomonas and Enterobacterales.  Although some current compds. in the pipeline have exhibited increased susceptibility rates in surveillance studies that depend on geog., pre-existing cross-resistance both within and across antibacterial classes limits the activity of many of the new agents against the most extensively drug-resistant (XDR) and pan-drug-resistant (PDR) Gram-neg. pathogens.  In particular, cross-resistance to unrelated classes may occur by co-selection of resistant strains, thus leading to the rapid emergence and subsequent spread of resistance.  There is a continued need for innovation and new-class antibacterial agents in order to provide effective therapeutic options against infections specifically caused by XDR and PDR Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPNVOvIzBXbVg90H21EOLACvtfcHk0lidRD5e_d6piQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXks1Kgur0%253D&md5=2fb35747299e6fc8a6bea5e4619968a5</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fs41579-020-0340-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41579-020-0340-0%26sid%3Dliteratum%253Aachs%26aulast%3DTheuretzbacher%26aufirst%3DU.%26aulast%3DBush%26aufirst%3DK.%26aulast%3DHarbarth%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DJ.%2BH.%26aulast%3DTacconelli%26aufirst%3DE.%26aulast%3DThwaites%26aufirst%3DG.%2BE.%26atitle%3DCritical%2520Analysis%2520of%2520Antibacterial%2520Agents%2520in%2520Clinical%2520Development%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2020%26volume%3D18%26issue%3D5%26spage%3D286%26epage%3D298%26doi%3D10.1038%2Fs41579-020-0340-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batteiger, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seña, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzbicki, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span> <span> </span><span class="NLM_article-title">Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1845</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1706988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30403954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1835-1845&issue=19&author=S.+N.+Taylorauthor=J.+Marrazzoauthor=B.+E.+Batteigerauthor=E.+W.+Hookauthor=A.+C.+Se%C3%B1aauthor=J.+Longauthor=M.+R.+Wierzbickiauthor=H.+Kwakauthor=S.+M.+Johnsonauthor=K.+Lawrenceauthor=J.+Mueller&title=Single-Dose+Zoliflodacin+%28ETX0914%29+for+Treatment+of+Urogenital+Gonorrhea&doi=10.1056%2FNEJMoa1706988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea</span></div><div class="casAuthors">Taylor, Stephanie N.; Marrazzo, Jeanne; Batteiger, Byron E.; Hook, Edward W.; Sena, Arlene C.; Long, Jill; Wierzbicki, Michael R.; Kwak, Hannah; Johnson, Shacondra M.; Lawrence, Kenneth; Mueller, John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1835-1845</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this multi-center, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated gonorrhea.  We randomly assigned eligible men and women who had signs or symptoms of uncomplicated urogenital gonorrhea or untreated urogenital gonorrhea or who had had sexual contact in the preceding 14 days with a person who had gonorrhea to receive a single oral dose of zoliflodacin (2 g or 3 g) or a single 500-mg i.m. dose of ceftriaxone in a ratio of approx. 70:70:40.  Among the 141 participants in the micro-ITT population who could be evaluated, microbiol. cure at urogenital sites was documented in 55 of 57 (96%) who received 2 g of zoliflodacin, 54 of 56 (96%) who received 3 g of zoliflodacin, and 28 of 28 (100%) who received ceftriaxone.  Pharyngeal infections were cured in 4 of 8 participants (50%), 9 of 11 participants (82%), and 4 of 4 participants (100%) in the groups that received 2 g of zoliflodacin, 3 g of zoliflodacin, and ceftriaxone, resp.  A total of 84 adverse events were reported: 24 in the group that received 2 g of zoliflodacin, 37 in the group that received 3 g of zoliflodacin, and 23 in the group that received ceftriaxone.  The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin, but this agent was less efficacious in the treatment of pharyngeal infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohoirIrYFf7Vg90H21EOLACvtfcHk0lgJGNtNVl19WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN&md5=f26717391c8d3764114c8fee2a359b8b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706988%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BN.%26aulast%3DMarrazzo%26aufirst%3DJ.%26aulast%3DBatteiger%26aufirst%3DB.%2BE.%26aulast%3DHook%26aufirst%3DE.%2BW.%26aulast%3DSe%25C3%25B1a%26aufirst%3DA.%2BC.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DWierzbicki%26aufirst%3DM.%2BR.%26aulast%3DKwak%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DJ.%26atitle%3DSingle-Dose%2520Zoliflodacin%2520%2528ETX0914%2529%2520for%2520Treatment%2520of%2520Urogenital%2520Gonorrhea%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D19%26spage%3D1835%26epage%3D1845%26doi%3D10.1056%2FNEJMoa1706988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Activity of Artefenomel (OZ439), a Novel Synthetic Antimalarial Endoperoxide, in Patients with Plasmodium Falciparum and Plasmodium Vivax Malaria: An Open-Label Phase 2 Trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)00320-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1473-3099%2815%2900320-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26448141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=61-69&issue=1&author=A.+P.+Phyoauthor=P.+Jittamalaauthor=F.+H.+Nostenauthor=S.+Pukrittayakameeauthor=M.+Imwongauthor=N.+J.+Whiteauthor=S.+Duparcauthor=F.+Macintyreauthor=M.+Bakerauthor=J.+J.+M%C3%B6hrle&title=Antimalarial+Activity+of+Artefenomel+%28OZ439%29%2C+a+Novel+Synthetic+Antimalarial+Endoperoxide%2C+in+Patients+with+Plasmodium+Falciparum+and+Plasmodium+Vivax+Malaria%3A+An+Open-Label+Phase+2+Trial&doi=10.1016%2FS1473-3099%2815%2900320-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial</span></div><div class="casAuthors">Phyo, Aung Pyae; Jittamala, Podjanee; Nosten, Francois H.; Pukrittayakamee, Sasithon; Imwong, Mallika; White, Nicholas J.; Duparc, Stephan; MacIntyre, Fiona; Baker, Mark; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared with other antimalarial drugs with the artemisinin pharmacophore.  Artefenomel has been generally well tolerated in volunteers at doses up to 1600 mg and is being developed as a partner drug in an antimalarial combination treatment.  We investigated the efficacy, tolerability, and pharmacokinetics of artefenomel at different doses in patients with Plasmodium falciparum or Plasmodium vivax malaria.  This phase 2a exploratory, open-label trial was done at the Hospital for Tropical Diseases, Bangkok, and the Shoklo Malaria Research Unit in Thailand.  Adult patients with acute, uncomplicated P falciparum or P vivax malaria received artefenomel in a single oral dose (200 mg, 400 mg, 800 mg, or 1200 mg).  The first cohort received 800 mg.  Testing of a new dose of artefenomel in a patient cohort was decided on after safety and efficacy assessment of the preceding cohort.  The primary endpoint was the natural log parasite redn. per 24 h.  Definitive oral treatment was given at 36 h.  This trial is registered with ClinicalTrials.gov, no. NCT01213966.  Between Oct 24, 2010, and May 25, 2012, 82 patients were enrolled (20 in each of the 200 mg, 400 mg, and 800 mg cohorts, and 21 in the 1200 mg cohort).  One patient withdrew consent (before the administration of artefenomel) but there were no further dropouts.  The parasite redn. rates per 24 h ranged from 0·90 to 1·88 for P falciparum, and 2·09 to 2·53 for P vivax.  All doses were equally effective in both P falciparum and P vivax malaria, with median parasite clearance half-lives of 4·1 h (range 1·3-6·7) to 5·6 h (2·0-8·5) for P falciparum and 2·3 h (1·2-3·9) to 3·2 h (0·9-15·0) for P vivax.  Maximum plasma concns., dose-proportional to 800 mg, occurred at 4 h (median).  The estd. elimination half-life was 46-62 h.  No serious drug-related adverse effects were reported; other adverse effects were generally mild and reversible, with the highest no. in the 1200 mg cohort (17 [81%] patients with at least one adverse event).  The most frequently reported adverse effect was an asymptomatic increase in plasma creatine phosphokinase concn. (200 mg, n=5; 400 mg, n=3; 800 mg, n=1; 1200 mg, n=3).  Artefenomel is a new synthetic antimalarial peroxide with a good safety profile that clears parasitemia rapidly in both P falciparum and P vivax malaria.  Its long half-life suggests a possible use in a single-dose treatment in combination with other drugs.  Bill & Melinda Gates Foundation, Wellcome Trust, and UK Department for International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_OEYJuv5VVrVg90H21EOLACvtfcHk0lgJGNtNVl19WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP&md5=368550e5ec73242c603c8abdc6a66f12</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900320-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900320-5%26sid%3Dliteratum%253Aachs%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DNosten%26aufirst%3DF.%2BH.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26atitle%3DAntimalarial%2520Activity%2520of%2520Artefenomel%2520%2528OZ439%2529%252C%2520a%2520Novel%2520Synthetic%2520Antimalarial%2520Endoperoxide%252C%2520in%2520Patients%2520with%2520Plasmodium%2520Falciparum%2520and%2520Plasmodium%2520Vivax%2520Malaria%253A%2520An%2520Open-Label%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26issue%3D1%26spage%3D61%26epage%3D69%26doi%3D10.1016%2FS1473-3099%2815%2900320-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthaisin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuthasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1602250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27653565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1152-1160&issue=12&author=N.+J.+Whiteauthor=T.+T.+Duongauthor=C.+Uthaisinauthor=F.+Nostenauthor=A.+P.+Phyoauthor=B.+Hanboonkunupakarnauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chuthasmitauthor=M.+S.+Cheungauthor=Y.+Fengauthor=R.+Liauthor=B.+Magnussonauthor=M.+Sultanauthor=D.+Wieserauthor=X.+Xunauthor=R.+Zhaoauthor=T.+T.+Diaganaauthor=P.+Pertelauthor=F.+J.+Leong&title=Antimalarial+Activity+of+KAF156+in+Falciparum+and+Vivax+Malaria&doi=10.1056%2FNEJMoa1602250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of KAF156 in falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Duong, Tran T.; Uthaisin, Chirapong; Nosten, Francois; Phyo, Aung P.; Hanboonkunupakarn, Borimas; Pukrittayakamee, Sasithon; Jittamala, Podjanee; Chuthasmit, Kittiphum; Cheung, Ming S.; Feng, Yiyan; Li, Ruobing; Magnusson, Baldur; Sultan, Marc; Wieser, Daniela; Xun, Xiaolei; Zhao, Rong; Diagana, Thierry T.; Pertel, Peter; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1152-1160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.  METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria.  Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a sep. cohort of patients with falciparum malaria who received a single dose (800 mg).  RESULTS: Median parasite clearance times were 45 h (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 h (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 h (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.  Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84).  The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 h.  There were no serious adverse events in this small study.  The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia.  Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose.  More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts.  CONCLUSIONS: KAF156 showed antimalarial activity without evident safety concerns in a small no. of adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHzWNldN2RLbVg90H21EOLACvtfcHk0lgJGNtNVl19WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN&md5=24d0943da6d583f8c0fe4fe9f380ec99</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602250%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DUthaisin%26aufirst%3DC.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChuthasmit%26aufirst%3DK.%26aulast%3DCheung%26aufirst%3DM.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DSultan%26aufirst%3DM.%26aulast%3DWieser%26aufirst%3DD.%26aulast%3DXun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DAntimalarial%2520Activity%2520of%2520KAF156%2520in%2520Falciparum%2520and%2520Vivax%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D12%26spage%3D1152%26epage%3D1160%26doi%3D10.1056%2FNEJMoa1602250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adoke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiono, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mombo-Ngoma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouyou-Akotet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassat, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issifou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demarest, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurijssens, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biguenet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibuuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipoldt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phuc, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouedraogo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramharter, M.</span></span> <span> </span><span class="NLM_article-title">OZ-Piperaquine Study Group. A Randomised, Double-Blind Clinical Phase II Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Combination Treatment with Artefenomel and Piperaquine in Adults and Children with Uncomplicated Plasmodium Falciparum Malaria</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">181</span>, <span class="refDoi"> DOI: 10.1186/s12916-017-0940-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2Fs12916-017-0940-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28988541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=181&issue=1&author=F.+Macintyreauthor=Y.+Adokeauthor=A.+B.+Tionoauthor=T.+T.+Duongauthor=G.+Mombo-Ngomaauthor=M.+Bouyou-Akotetauthor=H.+Tintoauthor=Q.+Bassatauthor=S.+Issifouauthor=M.+Adamyauthor=H.+Demarestauthor=S.+Duparcauthor=D.+Leroyauthor=B.+E.+Laurijssensauthor=S.+Biguenetauthor=A.+Kibuukaauthor=A.+K.+Tshefuauthor=M.+Smithauthor=C.+Fosterauthor=I.+Leipoldtauthor=P.+G.+Kremsnerauthor=B.+Q.+Phucauthor=A.+Ouedraogoauthor=M.+Ramharter&title=OZ-Piperaquine+Study+Group.+A+Randomised%2C+Double-Blind+Clinical+Phase+II+Trial+of+the+Efficacy%2C+Safety%2C+Tolerability+and+Pharmacokinetics+of+a+Single+Dose+Combination+Treatment+with+Artefenomel+and+Piperaquine+in+Adults+and+Children+with+Uncomplicated+Plasmodium+Falciparum+Malaria&doi=10.1186%2Fs12916-017-0940-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria</span></div><div class="casAuthors">Macintyre, Fiona; Adoke, Yeka; Tiono, Alfred B.; Duong, Tran Thanh; Mombo-Ngoma, Ghyslain; Bouyou-Akotet, Marielle; Tinto, Halidou; Bassat, Quique; Issifou, Saadou; Adamy, Marc; Demarest, Helen; Duparc, Stephan; Leroy, Didier; Laurijssens, Bart E.; Biguenet, Sophie; Kibuuka, Afizi; Tshefu, Antoinette Kitoto; Smith, Melnick; Foster, Chanelle; Leipoldt, Illse; Kremsner, Peter G.; Phuc, Bui Quang; Ouedraogo, Alphonse; Ramharter, Michael</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181/1-181/19</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The clin. development of a single encounter treatment for uncomplicated malaria has the potential to significantly improve the effectiveness of antimalarials.  Exploratory data suggested that the combination of artefenomel and piperaquine phosphate (PQP) has the potential to achieve satisfactory cure rates as a single dose therapy.  The primary objective of the study was to det. whether a single dose of artefenomel (800 mg) plus PQP in ascending doses is an efficacious treatment for uncomplicated Plasmodium falciparum malaria in the 'target' population of children ≤ 5 years of age in Africa as well as Asian patients of all ages.  Methods: Patients in six African countries and in Vietnam were randomised to treatment with follow-up for 42 - 63 days.  Efficacy, tolerability, safety and pharmacokinetics were assessed.  Addnl. key objectives were to characterize the exposure - response relationship for polymerase chain reaction (PCR)-adjusted adequate clin. and parasitol. response at day 28 post-dose (ACPR28) and to further investigate Kelch13 mutations.  Patients in Africa (n = 355) and Vietnam (n = 82) were included, with 85% of the total population being children < 5 years of age.  Results: ACPR28 in the per protocol population (95% confidence interval) was 70.8% (61.13 - 79.19), 68.4% (59.13 - 76.66) and 78.6% (70.09 - 85.67) for doses of 800 mg artefenomel with 640 mg, 960 mg and 1440 mg of PQP resp.  ACPR28 was lower in Vietnamese than in African patients (66.2%; 54.55 - 76.62 and 74.5%; 68.81 - 79.68) resp.  Within the African population, efficacy was lowest in the youngest age group of ≥ 0.5 to ≤ 2 years, 52.7% (38.80 - 66.35).  Initial parasite clearance was twice as long in Vietnam than in Africa.  Within Vietnam, the frequency of the Kelch13 mutation was 70.1% and was clearly assocd. with parasite clearance half-life (PCt1/2).  The most significant tolerability finding was vomiting (28.8%).  Conclusions: In this first clin. trial evaluating a single encounter antimalarial therapy, none of the treatment arms reached the target efficacy of > 95% PCR-adjusted ACPR at day 28.  Achieving very high efficacy following single dose treatment is challenging, since > 95% of the population must have sufficient concns. to achieve cure across a range of parasite sensitivities and baseline parasitemia levels.  While challenging, the development of tools suitable for deployment as single encounter curative treatments for adults and children in Africa and to support elimination strategies remains a key development goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopmM9eSHRjJbVg90H21EOLACvtfcHk0ljZJJ0o-NfWBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgsLvP&md5=2329f0f780c46d2fbf9e648171b9459c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs12916-017-0940-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-017-0940-3%26sid%3Dliteratum%253Aachs%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DAdoke%26aufirst%3DY.%26aulast%3DTiono%26aufirst%3DA.%2BB.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DMombo-Ngoma%26aufirst%3DG.%26aulast%3DBouyou-Akotet%26aufirst%3DM.%26aulast%3DTinto%26aufirst%3DH.%26aulast%3DBassat%26aufirst%3DQ.%26aulast%3DIssifou%26aufirst%3DS.%26aulast%3DAdamy%26aufirst%3DM.%26aulast%3DDemarest%26aufirst%3DH.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DLaurijssens%26aufirst%3DB.%2BE.%26aulast%3DBiguenet%26aufirst%3DS.%26aulast%3DKibuuka%26aufirst%3DA.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DLeipoldt%26aufirst%3DI.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DPhuc%26aufirst%3DB.%2BQ.%26aulast%3DOuedraogo%26aufirst%3DA.%26aulast%3DRamharter%26aufirst%3DM.%26atitle%3DOZ-Piperaquine%2520Study%2520Group.%2520A%2520Randomised%252C%2520Double-Blind%2520Clinical%2520Phase%2520II%2520Trial%2520of%2520the%2520Efficacy%252C%2520Safety%252C%2520Tolerability%2520and%2520Pharmacokinetics%2520of%2520a%2520Single%2520Dose%2520Combination%2520Treatment%2520with%2520Artefenomel%2520and%2520Piperaquine%2520in%2520Adults%2520and%2520Children%2520with%2520Uncomplicated%2520Plasmodium%2520Falciparum%2520Malaria%26jtitle%3DBMC%2520Med.%26date%3D2017%26volume%3D15%26issue%3D1%26spage%3D181%26doi%3D10.1186%2Fs12916-017-0940-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sen Nag, O.</span></span> <span> </span><span class="NLM_article-title">The Deadliest Epidemics of the 21st Century So Far</span>.  <i>WorldAtlas</i>. <a href="https://www.worldatlas.com/articles/the-deadliest-epidemics-of-the-21st-century-till-date.html" class="extLink">https://www.worldatlas.com/articles/the-deadliest-epidemics-of-the-21st-century-till-date.html</a> (accessed <span class="NLM_year">2020</span>-01-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=O.+Sen+Nag&title=The+Deadliest+Epidemics+of+the+21st+Century+So+Far"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSen%2BNag%26aufirst%3DO.%26atitle%3DThe%2520Deadliest%2520Epidemics%2520of%2520the%252021st%2520Century%2520So%2520Far%26jtitle%3DWorldAtlas%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span> <i>Johns Hopkins
Coronavirus Resource Center</i>. <a href="https://coronavirus.jhu.edu" class="extLink">https://coronavirus.jhu.edu</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Johns+Hopkins%0ACoronavirus+Resource+Center.+https%3A%2F%2Fcoronavirus.jhu.edu+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJohns%2520Hopkins%250ACoronavirus%2520Resource%2520Center%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span> </span><span class="NLM_article-title">Coronavirus
Treatment Acceleration Program (CTAP)</span>.  <i>U.S.
Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap" class="extLink">https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Coronavirus%0ATreatment+Acceleration+Program+%28CTAP%29.+U.S.%0AFood+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fcoronavirus-covid-19-drugs%2Fcoronavirus-treatment-acceleration-program-ctap+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCoronavirus%250ATreatment%2520Acceleration%2520Program%2520%2528CTAP%2529%26jtitle%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlIbrahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hijazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkalamouni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaraket, H.</span></span> <span> </span><span class="NLM_article-title">COVID-19 Therapeutic Options Under Investigation</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1196</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.01196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.3389%2Ffphar.2020.01196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32848795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlSitbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1196&author=M.+Kaddouraauthor=M.+AlIbrahimauthor=G.+Hijaziauthor=N.+Soudaniauthor=A.+Audiauthor=H.+Alkalamouniauthor=S.+Haddadauthor=A.+Eidauthor=H.+Zaraket&title=COVID-19+Therapeutic+Options+Under+Investigation&doi=10.3389%2Ffphar.2020.01196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 therapeutic options under investigation</span></div><div class="casAuthors">Kaddoura, Malak; Alibrahim, Malak; Hijazi, Ghina; Soudani, Nadia; Audi, Amani; Alkalamouni, Habib; Haddad, Salame; Eid, Ali; Zaraket, Hassan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1196</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Since its emergence in China in Dec. 2019, COVID-19 has quickly spread around the globe causing a pandemic.  Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future.  Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed.  Preclin. and clin. studies of potential antiviral and immunomodulatory compds. and mols. to identify safe and efficacious therapeutics for COVID-19 are ongoing.  Two compds., remdesivir, and dexamethasone have been so far shown to reduce COVID-19-assocd. death.  Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvKrqvys1A4rVg90H21EOLACvtfcHk0ljZJJ0o-NfWBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlSitbzK&md5=d52c134dc91a76f7c2c7ddb3e196ff49</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.01196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.01196%26sid%3Dliteratum%253Aachs%26aulast%3DKaddoura%26aufirst%3DM.%26aulast%3DAlIbrahim%26aufirst%3DM.%26aulast%3DHijazi%26aufirst%3DG.%26aulast%3DSoudani%26aufirst%3DN.%26aulast%3DAudi%26aufirst%3DA.%26aulast%3DAlkalamouni%26aufirst%3DH.%26aulast%3DHaddad%26aufirst%3DS.%26aulast%3DEid%26aufirst%3DA.%26aulast%3DZaraket%26aufirst%3DH.%26atitle%3DCOVID-19%2520Therapeutic%2520Options%2520Under%2520Investigation%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D1196%26doi%3D10.3389%2Ffphar.2020.01196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouanounou, A.</span></span> <span> </span><span class="NLM_article-title">COVID-19: A Review of the Proposed Pharmacological Treatments</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>886</i></span>,  <span class="NLM_fpage">173451</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2020.173451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.ejphar.2020.173451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32768505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2qt7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=886&publication_year=2020&pages=173451&author=S.+Lamauthor=A.+Lombardiauthor=A.+Ouanounou&title=COVID-19%3A+A+Review+of+the+Proposed+Pharmacological+Treatments&doi=10.1016%2Fj.ejphar.2020.173451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19: A review of the proposed pharmacological treatments</span></div><div class="casAuthors">Lam, Sarah; Lombardi, Andrew; Ouanounou, Aviv</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">886</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173451</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The emerging pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge for healthcare systems globally.  The clin. course of COVID-19 and its ability to rapidly create widespread infection has major implications, warranting vigorous infection prevention and control measures.  As the confirmed no. of cases has surpassed 5.6 million worldwide and continues to grow, the potential severity of the disease and its deadly complications requires urgent development of novel therapeutic agents to both prevent and treat COVID-19.  Although vaccines and specific drug therapies have yet to be discovered, ongoing research and clin. trials are being conducted to investigate the efficacy of repurposed drugs for treating COVID-19.  In the present review, the drug candidates that have been suggested to treat COVID-19 will be discussed.  These include anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, chloroquine, hydroxychloroquine, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other misc. agents.  The mechanisms of action and further pharmacol. properties will be explored, with a particular focus on the evidence-based safety and efficacy of each agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfXWuFsC1wyrVg90H21EOLACvtfcHk0li8_vV2oFuktA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2qt7nF&md5=a16e77fe6eb4ce4b01611c7197a8a78d</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2020.173451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2020.173451%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DS.%26aulast%3DLombardi%26aufirst%3DA.%26aulast%3DOuanounou%26aufirst%3DA.%26atitle%3DCOVID-19%253A%2520A%2520Review%2520of%2520the%2520Proposed%2520Pharmacological%2520Treatments%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D886%26spage%3D173451%26doi%3D10.1016%2Fj.ejphar.2020.173451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span> </span><span class="NLM_article-title">Emergency Use Authorization</span>.  <i>U.S. Food and
Drug Administration</i>. <a href="https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs" class="extLink">https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Emergency+Use+Authorization.+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Femergency-preparedness-and-response%2Fmcm-legal-regulatory-and-policy-framework%2Femergency-use-authorization%23coviddrugs+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEmergency%2520Use%2520Authorization%26jtitle%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">RECOVERY Collaborative
Group</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emberson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mafham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staplin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustianowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmahi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rege, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juszczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landray, M. J.</span></span> <span> </span><span class="NLM_article-title">Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">NEJMoa2021436</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2021436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa2021436" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=NEJMoa2021436&author=RECOVERY+Collaborative%0AGroupauthor=P.+Horbyauthor=W.+S.+Limauthor=J.+R.+Embersonauthor=M.+Mafhamauthor=J.+L.+Bellauthor=L.+Linsellauthor=N.+Staplinauthor=C.+Brightlingauthor=A.+Ustianowskiauthor=E.+Elmahiauthor=B.+Prudonauthor=C.+Greenauthor=T.+Feltonauthor=D.+Chadwickauthor=K.+Regeauthor=C.+Feganauthor=L.+C.+Chappellauthor=S.+N.+Faustauthor=T.+Jakiauthor=K.+Jefferyauthor=A.+Montgomeryauthor=K.+Rowanauthor=E.+Juszczakauthor=J.+K.+Baillieauthor=R.+Haynesauthor=M.+J.+Landray&title=Dexamethasone+in+Hospitalized+Patients+with+Covid-19+-+Preliminary+Report&doi=10.1056%2FNEJMoa2021436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2021436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2021436%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DHorby%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DW.%2BS.%26aulast%3DEmberson%26aufirst%3DJ.%2BR.%26aulast%3DMafham%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DJ.%2BL.%26aulast%3DLinsell%26aufirst%3DL.%26aulast%3DStaplin%26aufirst%3DN.%26aulast%3DBrightling%26aufirst%3DC.%26aulast%3DUstianowski%26aufirst%3DA.%26aulast%3DElmahi%26aufirst%3DE.%26aulast%3DPrudon%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DFelton%26aufirst%3DT.%26aulast%3DChadwick%26aufirst%3DD.%26aulast%3DRege%26aufirst%3DK.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DChappell%26aufirst%3DL.%2BC.%26aulast%3DFaust%26aufirst%3DS.%2BN.%26aulast%3DJaki%26aufirst%3DT.%26aulast%3DJeffery%26aufirst%3DK.%26aulast%3DMontgomery%26aufirst%3DA.%26aulast%3DRowan%26aufirst%3DK.%26aulast%3DJuszczak%26aufirst%3DE.%26aulast%3DBaillie%26aufirst%3DJ.%2BK.%26aulast%3DHaynes%26aufirst%3DR.%26aulast%3DLandray%26aufirst%3DM.%2BJ.%26atitle%3DDexamethasone%2520in%2520Hospitalized%2520Patients%2520with%2520Covid-19%2520-%2520Preliminary%2520Report%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26spage%3DNEJMoa2021436%26doi%3D10.1056%2FNEJMoa2021436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span> </span><span class="NLM_article-title">FDA Approves First Treatment for COVID-19.
FDA News Release</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+First+Treatment+for+COVID-19.%0AFDA+News+Release.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-treatment-covid-19+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520First%2520Treatment%2520for%2520COVID-19.%250AFDA%2520News%2520Release%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessoku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imajo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, A.</span></span> <span> </span><span class="NLM_article-title">Present and Emerging Pharmacotherapies for Non-Alcoholic Steatohepatitis in Adults</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1543403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1080%2F14656566.2018.1543403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30411635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=69-82&issue=1&author=Y.+Ogawaauthor=M.+Yonedaauthor=T.+Kobayashiauthor=Y.+Hondaauthor=T.+Kessokuauthor=K.+Imajoauthor=S.+Saitoauthor=A.+Nakajima&title=Present+and+Emerging+Pharmacotherapies+for+Non-Alcoholic+Steatohepatitis+in+Adults&doi=10.1080%2F14656566.2018.1543403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults</span></div><div class="casAuthors">Ogawa, Yuji; Yoneda, Masato; Kobayashi, Takashi; Honda, Yasushi; Kessoku, Takaomi; Imajo, Kento; Saito, Satoru; Nakajima, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-82</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Multiple parallel factors are implicated in the pathogenesis and progression of non-alc. fatty liver disease (NAFLD)/non-alc. steatohepatitis (NASH).  Currently recommended therapies for NASH include vitamin E and pioglitazone, besides dietary and lifestyle changes.: This review focuses on the clin. development of several emerging drugs for the treatment of NASH and the impact of these drugs on current treatment stds.: Four drug classes (FXR agonists, CCR2/CCR5 antagonists, ASK1 inhibitors, and PPARα/δ agonists) have moved into phase 3 trials for their investigation as NASH treatments.  Results from phase 2 trials of other therapeutic agents with other pharmacol. actions are also expected.  The importance of combinational therapies with synergistic benefits engaging different targets, is now understood.  Furthermore, studies have detd. that the Mediterranean diet is beneficial for patients with NAFLD, while the traditional Okinawan diet is also considered useful.  In the future, it will be important to establish new biomarkers to assess NAFLD activity, furthermore non-invasive diagnostic methods will promote the development of new drugs for NASH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsG9wiycgi3LVg90H21EOLACvtfcHk0li8_vV2oFuktA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOjtbrP&md5=4a21ba29982206798c7bd98c7307ae0b</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1543403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1543403%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DYoneda%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DY.%26aulast%3DKessoku%26aufirst%3DT.%26aulast%3DImajo%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DA.%26atitle%3DPresent%2520and%2520Emerging%2520Pharmacotherapies%2520for%2520Non-Alcoholic%2520Steatohepatitis%2520in%2520Adults%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26issue%3D1%26spage%3D69%26epage%3D82%26doi%3D10.1080%2F14656566.2018.1543403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attia, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Softic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouzaki, M.</span></span> <span> </span><span class="NLM_article-title">Evolving Role for Pharmacotherapy in NAFLD/NASH</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi"> DOI: 10.1111/cts.12839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fcts.12839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32583961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3MXksV2hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2021&pages=11&author=S.+L.+Attiaauthor=S.+Softicauthor=M.+Mouzaki&title=Evolving+Role+for+Pharmacotherapy+in+NAFLD%2FNASH&doi=10.1111%2Fcts.12839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving Role for Pharmacotherapy in NAFLD/NASH</span></div><div class="casAuthors">Attia, Suzanna L.; Softic, Samir; Mouzaki, Marialena</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma.  There are currently no US Food and Drug Administration (FDA) approved treatments for NAFLD; however, this is a field of active research.  This review summarizes emerging pharmacotherapies for the treatment of adult and pediatric NAFLD.  Investigated pharmacotherapies predominantly target bile acid signaling, insulin resistance, and lipid handling within the liver.  Three drugs have gone on to phase III trials for which results are available.  Of those, obeticholic acid is the single agent that demonstrates promise according to the interim analyses of the REGENERATE trial.  Obeticholic acid showed redn. of fibrosis in adults with nonalcoholic steatohepatitis (NASH) taking 25 mg daily for 18 mo (n = 931, redn. in fibrosis in 25% vs. 12% placebo, P < 0.01).  Ongoing phase III trials include REGENERATE and MAESTRO-NASH, which investigates thyroid hormone receptor-β agonist MGL-3196.  Outcomes of promising phase II trials in adults with NASH are also available and those have investigated agents, including the fibroblast growth factor (FGF)19 analog NGM282, the GLP1 agonist liraglutide, the FGF21 analog Pegbelfermin, the sodium glucose co-transporter 2 inhibitor Empagliflozin, the ketohexokinase inhibitor PF-06835919, the acetyl-CoA carboxylase inhibitor GS-0976, and the chemokine receptor antagonist Cenicriviroc.  Completed and ongoing clin. trials emphasize the need for a more nuanced understanding of the phenotypes of subgroups within NAFLD that may respond to an individualized approach to pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwIV4TUPWqMLVg90H21EOLACvtfcHk0lgVS7ZxV2TqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXksV2hsLw%253D&md5=912b1c8438d22b43661271da9314d43c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1111%2Fcts.12839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12839%26sid%3Dliteratum%253Aachs%26aulast%3DAttia%26aufirst%3DS.%2BL.%26aulast%3DSoftic%26aufirst%3DS.%26aulast%3DMouzaki%26aufirst%3DM.%26atitle%3DEvolving%2520Role%2520for%2520Pharmacotherapy%2520in%2520NAFLD%252FNASH%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2021%26volume%3D14%26spage%3D11%26doi%3D10.1111%2Fcts.12839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younossi, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratziu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anstee, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckebaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapple, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalek, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano-Loza, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boursier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathurin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugianesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olveira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez-Pinto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graupera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluud, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shringarpure, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">REGENERATE Study Investigators. Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">10215</span>),  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2196</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)33041-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS0140-6736%2819%2933041-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31813633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlegsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=2184-2196&issue=10215&author=Z.+M.+Younossiauthor=V.+Ratziuauthor=R.+Loombaauthor=M.+Rinellaauthor=Q.+M.+Ansteeauthor=Z.+Goodmanauthor=P.+Bedossaauthor=A.+Geierauthor=S.+Beckebaumauthor=P.+N.+Newsomeauthor=D.+Sheridanauthor=M.+Y.+Sheikhauthor=J.+Trotterauthor=W.+Knappleauthor=E.+Lawitzauthor=M.+F.+Abdelmalekauthor=K.+V.+Kowdleyauthor=A.+J.+Montano-Lozaauthor=J.+Boursierauthor=P.+Mathurinauthor=E.+Bugianesiauthor=G.+Mazzellaauthor=A.+Olveiraauthor=H.+Cortez-Pintoauthor=I.+Grauperaauthor=D.+Orrauthor=L.+L.+Gluudauthor=J.-F.+Dufourauthor=D.+Shapiroauthor=J.+Campagnaauthor=L.+Zaruauthor=L.+MacConellauthor=R.+Shringarpureauthor=S.+Harrisonauthor=A.+J.+Sanyal&title=REGENERATE+Study+Investigators.+Obeticholic+Acid+for+the+Treatment+of+Non-Alcoholic+Steatohepatitis%3A+Interim+Analysis+from+a+Multicentre%2C+Randomised%2C+Placebo-Controlled+Phase+3+Trial&doi=10.1016%2FS0140-6736%2819%2933041-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial</span></div><div class="casAuthors">Younossi, Zobair M.; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M.; Goodman, Zachary; Bedossa, Pierre; Geier, Andreas; Beckebaum, Susanne; Newsome, Philip N.; Sheridan, David; Sheikh, Muhammad Y.; Trotter, James; Knapple, Whitfield; Lawitz, Eric; Abdelmalek, Manal F.; Kowdley, Kris V.; Montano-Loza, Aldo J.; Boursier, Jerome; Mathurin, Philippe; Bugianesi, Elisabetta; Mazzella, Giuseppe; Olveira, Antonio; Cortez-Pinto, Helena; Graupera, Isabel; Orr, David; Gluud, Lise Lotte; Dufour, Jean-Francois; Shapiro, David; Campagna, Jason; Zaru, Luna; MacConell, Leigh; Shringarpure, Reshma; Harrison, Stephen; Sanyal, Arun J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10215</span>),
    <span class="NLM_cas:pages">2184-2196</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Non-alc. steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis.  Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histol. features of NASH.  Here we report results from a planned interim anal. of an ongoing, phase 3 study of obeticholic acid for NASH.  In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alc. fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily.  Patients were excluded if cirrhosis, other chronic liver disease, elevated alc. consumption, or confounding conditions were present.  The primary endpoints for the month-18 interim anal. were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resoln. with no worsening of fibrosis, with the study considered successful if either primary endpoint was met.  Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim anal. cutoff date.  The study also evaluated other histol. and biochem. markers of NASH and fibrosis, and safety.  This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6.  Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary anal. (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group).  The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002).  The NASH resoln. endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]).  In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity.  The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group).  Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH.  The results from this planned interim anal. show clin. significant histol. improvement that is reasonably likely to predict clin. benefit.  This study is ongoing to assess clin. outcomes.Intercept Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWL0KDSXp0urVg90H21EOLACvtfcHk0lgVS7ZxV2TqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlegsLfP&md5=debf7f9209691d856c4e489cd766affd</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2933041-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252933041-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounossi%26aufirst%3DZ.%2BM.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DRinella%26aufirst%3DM.%26aulast%3DAnstee%26aufirst%3DQ.%2BM.%26aulast%3DGoodman%26aufirst%3DZ.%26aulast%3DBedossa%26aufirst%3DP.%26aulast%3DGeier%26aufirst%3DA.%26aulast%3DBeckebaum%26aufirst%3DS.%26aulast%3DNewsome%26aufirst%3DP.%2BN.%26aulast%3DSheridan%26aufirst%3DD.%26aulast%3DSheikh%26aufirst%3DM.%2BY.%26aulast%3DTrotter%26aufirst%3DJ.%26aulast%3DKnapple%26aufirst%3DW.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DAbdelmalek%26aufirst%3DM.%2BF.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DMontano-Loza%26aufirst%3DA.%2BJ.%26aulast%3DBoursier%26aufirst%3DJ.%26aulast%3DMathurin%26aufirst%3DP.%26aulast%3DBugianesi%26aufirst%3DE.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DOlveira%26aufirst%3DA.%26aulast%3DCortez-Pinto%26aufirst%3DH.%26aulast%3DGraupera%26aufirst%3DI.%26aulast%3DOrr%26aufirst%3DD.%26aulast%3DGluud%26aufirst%3DL.%2BL.%26aulast%3DDufour%26aufirst%3DJ.-F.%26aulast%3DShapiro%26aufirst%3DD.%26aulast%3DCampagna%26aufirst%3DJ.%26aulast%3DZaru%26aufirst%3DL.%26aulast%3DMacConell%26aufirst%3DL.%26aulast%3DShringarpure%26aufirst%3DR.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DSanyal%26aufirst%3DA.%2BJ.%26atitle%3DREGENERATE%2520Study%2520Investigators.%2520Obeticholic%2520Acid%2520for%2520the%2520Treatment%2520of%2520Non-Alcoholic%2520Steatohepatitis%253A%2520Interim%2520Analysis%2520from%2520a%2520Multicentre%252C%2520Randomised%252C%2520Placebo-Controlled%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26issue%3D10215%26spage%3D2184%26epage%3D2196%26doi%3D10.1016%2FS0140-6736%2819%2933041-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span> </span><span class="NLM_article-title">Genfit’s
Elafibranor En Route to NASH Graveyard with Phase
3 Flop</span>.  <i>Fierce Biotech</i>. <a href="https://www.fiercebiotech.com/biotech/genfit-s-elafibranor-en-route-to-nash-graveyard-phase-3-flop" class="extLink">https://www.fiercebiotech.com/biotech/genfit-s-elafibranor-en-route-to-nash-graveyard-phase-3-flop</a> (accessed <span class="NLM_year">2020</span>-07-16).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Genfit%E2%80%99s%0AElafibranor+En+Route+to+NASH+Graveyard+with+Phase%0A3+Flop.+Fierce+Biotech.+https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fgenfit-s-elafibranor-en-route-to-nash-graveyard-phase-3-flop+%28accessed+2020-07-16%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGenfit%25E2%2580%2599s%250AElafibranor%2520En%2520Route%2520to%2520NASH%2520Graveyard%2520with%2520Phase%250A3%2520Flop%26jtitle%3DFierce%2520Biotech%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span> </span><span class="NLM_article-title">Gilead’s
Selonsertib Flunks Another NASH Phase 3</span>.  <i>Fierce
Biotech</i>. <a href="https://www.fiercebiotech.com/biotech/gilead-s-selonsertib-flunks-another-nash-phase-3" class="extLink">https://www.fiercebiotech.com/biotech/gilead-s-selonsertib-flunks-another-nash-phase-3</a> (accessed <span class="NLM_year">2020</span>-07-16).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gilead%E2%80%99s%0ASelonsertib+Flunks+Another+NASH+Phase+3.+Fierce%0ABiotech.+https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fgilead-s-selonsertib-flunks-another-nash-phase-3+%28accessed+2020-07-16%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGilead%25E2%2580%2599s%250ASelonsertib%2520Flunks%2520Another%2520NASH%2520Phase%25203%26jtitle%3DFierce%250ABiotech%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span> </span><span class="NLM_article-title">Allergan
| Cenicriviroc</span>.  <i>Fierce Biotech</i>. <a href="https://www.fiercebiotech.com/special-report/allergan-cenicriviroc" class="extLink">https://www.fiercebiotech.com/special-report/allergan-cenicriviroc</a> (accessed <span class="NLM_year">2020</span>-07-16).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allergan%0A%7C+Cenicriviroc.+Fierce+Biotech.+https%3A%2F%2Fwww.fiercebiotech.com%2Fspecial-report%2Fallergan-cenicriviroc+%28accessed+2020-07-16%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAllergan%250A%257C%2520Cenicriviroc%26jtitle%3DFierce%2520Biotech%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span> </span><span class="NLM_article-title">Cardiovascular
Diseases</span>.  <i>World Health Organization</i>. <a href="https://www.who.int/health-topics/cardiovascular-diseases/" class="extLink">https://www.who.int/health-topics/cardiovascular-diseases/</a> (accessed <span class="NLM_year">2020</span>-07-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cardiovascular%0ADiseases.+World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fhealth-topics%2Fcardiovascular-diseases%2F+%28accessed+2020-07-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCardiovascular%250ADiseases%26jtitle%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallend, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijngaard, P. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastelein, J. J. P.</span></span> <span> </span><span class="NLM_article-title">ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1912387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1912387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32187462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvV2iurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=1507-1519&issue=16&author=K.+K.+Rayauthor=R.+S.+Wrightauthor=D.+Kallendauthor=W.+Koenigauthor=L.+A.+Leiterauthor=F.+J.+Raalauthor=J.+A.+Bischauthor=T.+Richardsonauthor=M.+Jarosauthor=P.+L.+J.+Wijngaardauthor=J.+J.+P.+Kastelein&title=ORION-10+and+ORION-11+Investigators.+Two+Phase+3+Trials+of+Inclisiran+in+Patients+with+Elevated+LDL+Cholesterol&doi=10.1056%2FNEJMoa1912387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol</span></div><div class="casAuthors">Ray, Kausik K.; Wright, R. Scott; Kallend, David; Koenig, Wolfgang; Leiter, Lawrence A.; Raal, Frederick J.; Bisch, Jenna A.; Richardson, Tara; Jaros, Mark; Wijngaard, Peter L. J.; Kastelein, John J. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1507-1519</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9.  Previous studies suggest that inclisiran might provide sustained redns. in low-d. lipoprotein (LDL) cholesterol levels with infrequent dosing. methods We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equiv. (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the max. tolerated dose.  Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by s.c. injection on day 1, day 90, and every 6 mo thereafter over a period of 540 days.  The coprimary end points in each trial were the placebo-cor. percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. results A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, resp.  Mean (±SD) LDL cholesterol levels at baseline were 104.7 ± 38.3 mg per dL (2.71 ± 0.99 mmol per L) and 105.5 ± 39.1 mg per dL (2.73 ± 1.01 mmol per L), resp.  At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted redns. of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo).  Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. conclusions Redns. in LDL cholesterol levels of approx. 50% were obtained with inclisiran, administered s.c. every 6 mo.  More injection-site adverse events occurred with inclisiran than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod5zBwqvm-aLVg90H21EOLACvtfcHk0ljq-SP3Cv6HCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvV2iurg%253D&md5=0fc3b30b322cf3a1b785abf8057c40cb</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1912387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1912387%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DK.%2BK.%26aulast%3DWright%26aufirst%3DR.%2BS.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DKoenig%26aufirst%3DW.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DRaal%26aufirst%3DF.%2BJ.%26aulast%3DBisch%26aufirst%3DJ.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%26aulast%3DJaros%26aufirst%3DM.%26aulast%3DWijngaard%26aufirst%3DP.%2BL.%2BJ.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DORION-10%2520and%2520ORION-11%2520Investigators.%2520Two%2520Phase%25203%2520Trials%2520of%2520Inclisiran%2520in%2520Patients%2520with%2520Elevated%2520LDL%2520Cholesterol%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26issue%3D16%26spage%3D1507%26epage%3D1519%26doi%3D10.1056%2FNEJMoa1912387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span> <i>Science Global
Oncology Trends 2019</i>; <span class="NLM_publisher-name">IQVIA
Institute for Human Data</span>, 2019. <a href="https://intelligencepharma.files.wordpress.com/2019/05/global-oncology-trends-2019-report.pdf" class="extLink">https://intelligencepharma.files.wordpress.com/2019/05/global-oncology-trends-2019-report.pdf</a> (accessed <span class="NLM_year">2020</span>-04-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Science+Global%0AOncology+Trends+2019%3B+IQVIA%0AInstitute+for+Human+Data%2C+2019.+https%3A%2F%2Fintelligencepharma.files.wordpress.com%2F2019%2F05%2Fglobal-oncology-trends-2019-report.pdf+%28accessed+2020-04-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Global%250AOncology%2520Trends%25202019%26pub%3DIQVIA%250AInstitute%2520for%2520Human%2520Data%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, O.</span></span> <span> </span><span class="NLM_article-title">CD19 as an Attractive Target for Antibody-Based Therapy</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.4161/mabs.21338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.4161%2Fmabs.21338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=22820352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC38fhvF2jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=571-577&issue=5&author=O.+Hammer&title=CD19+as+an+Attractive+Target+for+Antibody-Based+Therapy&doi=10.4161%2Fmabs.21338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">CD19 as an attractive target for antibody-based therapy</span></div><div class="casAuthors">Hammer Ohad</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">571-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite progress in the treatment of B cell disorders, novel treatment approaches are still highly needed.  CD19 is a pan-B cell marker that is recognized as a potential immunotherapy target for B cell disorders, including blood-borne malignancies and autoimmune diseases.  Although initial attempts to target CD19 were unsuccessful, a new wave of investigational agents is currently in development.  These agents are based on novel antibody-based technologies and formats that appear to better exploit CD19's therapeutic potential, and some promising clinical study data has already been reported.  This review provides an overview and the rationale for the most advanced CD19-targeting programs in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdTLA0ViNPxD69zv1FsJFMfW6udTcc2ebQQdtckArkZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fhvF2jtQ%253D%253D&md5=401d1bde023e96c3d7e8974e57888002</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.4161%2Fmabs.21338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.21338%26sid%3Dliteratum%253Aachs%26aulast%3DHammer%26aufirst%3DO.%26atitle%3DCD19%2520as%2520an%2520Attractive%2520Target%2520for%2520Antibody-Based%2520Therapy%26jtitle%3DmAbs%26date%3D2012%26volume%3D4%26issue%3D5%26spage%3D571%26epage%3D577%26doi%3D10.4161%2Fmabs.21338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span> </span><span class="NLM_article-title">FDA Grants Accelerated Approval to Tafasitamab-cxix for Diffuse large
B-Cell Lymphoma</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma" class="extLink">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma</a> (accessed <span class="NLM_year">2020</span>-08-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Grants+Accelerated+Approval+to+Tafasitamab-cxix+for+Diffuse+large%0AB-Cell+Lymphoma.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Ffda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma+%28accessed+2020-08-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Grants%2520Accelerated%2520Approval%2520to%2520Tafasitamab-cxix%2520for%2520Diffuse%2520large%250AB-Cell%2520Lymphoma%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaplon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, J. M.</span></span> <span> </span><span class="NLM_article-title">Antibodies to Watch in 2020</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1703531</span>, <span class="refDoi"> DOI: 10.1080/19420862.2019.1703531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1080%2F19420862.2019.1703531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31847708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyqs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1703531&issue=1&author=H.+Kaplonauthor=M.+Muralidharanauthor=Z.+Schneiderauthor=J.+M.+Reichert&title=Antibodies+to+Watch+in+2020&doi=10.1080%2F19420862.2019.1703531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Antibodies to watch in 2020</span></div><div class="casAuthors">Kaplon, Helene; Muralidharan, Mrinalini; Schneider, Zita; Reichert, Janice M.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1703531/1</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  This 2020 installment of the annual 'Antibodies to Watch' series documents the antibody therapeutics approved in 2019 and in regulatory review in the United States or European Union, as well as those in late-stage clin. studies, as of Nov. 2019*.  At this time, a total of 5 novel antibody therapeutics (romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, and crizanlizumab) had been granted a first approval in either the US or EU, and marketing applications for 13 novel antibody therapeutics (eptinezumab, teprotumumab, enfortumab vedotin, isatuximab, [fam-]trastuzumab deruxtecan, inebilizumab, leronlimab, sacituzumab govitecan, satralizumab, narsoplimab, tafasitamab, REGNEB3 and naxituximab) were undergoing review in these regions, which represent the major markets for antibody therapeutics.  Also as of Nov. 2019, 79 novel antibodies were undergoing evaluation in late-stage clin. studies.  Of the 79 antibodies, 39 were undergoing evaluation in late-stage studies for non-cancer indications, with 2 of these (ublituximab, pamrevlumab) also in late-stage studies for cancer indications.  Companies developing 7 (tanezumab, aducanumab, evinacumab, etrolizumab, sutimlimab, anifrolumab, and teplizumab) of the 39 drugs have indicated that they may submit a marketing application in either the US or EU in 2020.  Of the 79 antibodies in late-stage studies, 40 were undergoing evaluation as treatments for cancer, and potentially 9 of these (belantamab mafodotin, oportuzumab monatox, margetuximab, dostarlimab, spartalizumab, 131I-omburtamab, loncastuximab tesirine, balstilimab, and zalifrelimab) may enter regulatory review in late 2019 or in 2020.  Overall, the biopharmaceutical industry's clin. pipeline of antibody therapeutics is robust, and should provide a continuous supply of innovative products for patients in the future. *Note on key updates through Dec. 18, 2019: 1) the US Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev) on Dec. 18, 2019, bringing the ; 2) the European Commission approved romosozumab on Dec. 9, 2019; 3) the European Medicines Agency issued a pos. opinion for brolucizumab; 4) Sesen Bio initiated a rolling biologics license application (BLA) on Dec. 6, 2019; 5) GlaxoSmithKline submitted a BLA for belantamab mafodotin; and 6) the status of the Phase 3 study (NCT04128696) of GSK3359609, a humanized IgG4 anti-ICOS antibody, in patients with head and neck squamous cell carcinoma was updated to recruiting from not yet recruiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK1XTnR9QLarVg90H21EOLACvtfcHk0ljq-SP3Cv6HCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyqs7vM&md5=39480ff4c59bba9a5a935e6872c46f4e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1080%2F19420862.2019.1703531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2019.1703531%26sid%3Dliteratum%253Aachs%26aulast%3DKaplon%26aufirst%3DH.%26aulast%3DMuralidharan%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DZ.%26aulast%3DReichert%26aufirst%3DJ.%2BM.%26atitle%3DAntibodies%2520to%2520Watch%2520in%25202020%26jtitle%3DmAbs%26date%3D2020%26volume%3D12%26issue%3D1%26spage%3D1703531%26doi%3D10.1080%2F19420862.2019.1703531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span> </span><span class="NLM_article-title">FDA Approves Brexucabtagene Autoleucel
for Relapsed or Refractory
Mantle Cell Lymphoma</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma" class="extLink">https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma</a> (accessed <span class="NLM_year">2020</span>-04-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Brexucabtagene+Autoleucel%0Afor+Relapsed+or+Refractory%0AMantle+Cell+Lymphoma.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Ffda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma+%28accessed+2020-04-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Brexucabtagene%2520Autoleucel%250Afor%2520Relapsed%2520or%2520Refractory%250AMantle%2520Cell%2520Lymphoma%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phiphatwatchara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">The Promising Immune Checkpoint LAG-3: From Tumor Microenvironment to Cancer Immunotherapy</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.18632/genesandcancer.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.18632%2Fgenesandcancer.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30603054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ejsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=176-189&issue=5%E2%80%936&author=L.+Longauthor=X.+Zhangauthor=F.+Chenauthor=Q.+Panauthor=P.+Phiphatwatcharaauthor=Y.+Zengauthor=H.+Chen&title=The+Promising+Immune+Checkpoint+LAG-3%3A+From+Tumor+Microenvironment+to+Cancer+Immunotherapy&doi=10.18632%2Fgenesandcancer.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy</span></div><div class="casAuthors">Long, Long; Zhang, Xue; Chen, Fuchun; Pan, Qi; Phiphatwatchara, Pronnaphat; Zeng, Yuyang; Chen, Honglei</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">176-189</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades.  Targeting immune checkpoints esp. programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) has made a breakthrough in treating advanced malignancies.  However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets.  Strikingly, the inhibitory immune checkpoint lymphocyte activation gene-3 (LAG-3) holds considerable potential.  LAG-3 suppresses T cells activation and cytokines secretion, thereby ensuring immune homeostasis.  It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses.  Targeting LAG-3 immunotherapy is moving forward in active clin. trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 has shown exciting efficacy in fighting PD-1 resistance.  Herein, we shed light on the significance of LAG-3 in the tumor microenvironment, highlight its role to regulate different lymphocytes, interplay with other immune checkpoints esp. PD-1, and emphasize new advances in LAG-3-targeted immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu9ifqDRBr7Vg90H21EOLACvtfcHk0lgVWCHLgAU3Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ejsrrP&md5=4ed25333c2909d45f2ed673651551893</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.18632%2Fgenesandcancer.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Fgenesandcancer.180%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DPhiphatwatchara%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DThe%2520Promising%2520Immune%2520Checkpoint%2520LAG-3%253A%2520From%2520Tumor%2520Microenvironment%2520to%2520Cancer%2520Immunotherapy%26jtitle%3DGenes%2520Cancer%26date%3D2018%26volume%3D9%26issue%3D5%25E2%2580%25936%26spage%3D176%26epage%3D189%26doi%3D10.18632%2Fgenesandcancer.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciscano, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignali, D. A. A.</span></span> <span> </span><span class="NLM_article-title">LAG3 (CD223) as a Cancer Immunotherapy Target</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1111/imr.12519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fimr.12519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28258692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1elurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2017&pages=80-96&issue=1&author=L.+P.+Andrewsauthor=A.+E.+Marciscanoauthor=C.+G.+Drakeauthor=D.+A.+A.+Vignali&title=LAG3+%28CD223%29+as+a+Cancer+Immunotherapy+Target&doi=10.1111%2Fimr.12519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">LAG3 (CD223) as a cancer immunotherapy target</span></div><div class="casAuthors">Andrews, Lawrence P.; Marciscano, Ariel E.; Drake, Charles G.; Vignali, Dario A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-96</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Despite the impressive impact of CTLA4 and PD1-PDL1-targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond.  Consequently, the focus has shifted to targeting alternative inhibitory receptors (IRs) and suppressive mechanisms within the tumor microenvironment.  Lymphocyte activation gene-3 (LAG3) (CD223) is the third IR to be targeted in the clinic, consequently garnering considerable interest and scrutiny.  LAG3 upregulation is required to control overt activation and prevent the onset of autoimmunity.  However, persistent antigen exposure in the tumor microenvironment results in sustained LAG3 expression, contributing to a state of exhaustion manifest in impaired proliferation and cytokine prodn.  The exact signaling mechanisms downstream of LAG3 and interplay with other IRs remain largely unknown.  However, the striking synergy between LAG3 and PD1 obsd. in multiple settings, coupled with the contrasting intracellular cytoplasmic domain of LAG3 as compared with other IRs, highlights the potential uniqueness of LAG3.  There are now four LAG3-targeted therapies in the clinic with many more in preclin. development, emphasizing the broad interest in this IR.  Given the translational relevance of LAG3 and the heightened interest in the impact of dual LAG3/PD1 targeting in the clinic, the outcome of these trials could serve as a nexus; significantly increasing or dampening enthusiasm for subsequent targets in the cancer immunotherapeutic pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMEKswM_iiVbVg90H21EOLACvtfcHk0lgVWCHLgAU3Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1elurY%253D&md5=3b7c9895ff7c60df5c9f172ddd9b4f27</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1111%2Fimr.12519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12519%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DL.%2BP.%26aulast%3DMarciscano%26aufirst%3DA.%2BE.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DVignali%26aufirst%3DD.%2BA.%2BA.%26atitle%3DLAG3%2520%2528CD223%2529%2520as%2520a%2520Cancer%2520Immunotherapy%2520Target%26jtitle%3DImmunol.%2520Rev.%26date%3D2017%26volume%3D276%26issue%3D1%26spage%3D80%26epage%3D96%26doi%3D10.1111%2Fimr.12519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span> </span><span class="NLM_article-title">Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016
in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy
in the Metastatic Setting</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT03743766" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03743766</a> (accessed <span class="NLM_year">2020</span>-04-13).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nivolumab%2C+BMS-936558+in+Combination+with+Relatlimab%2C+BMS-986016%0Ain+Patients+with+Metastatic+Melanoma+Na%C3%AFve+to+Prior+Immunotherapy%0Ain+the+Metastatic+Setting.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03743766+%28accessed+2020-04-13%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNivolumab%252C%2520BMS-936558%2520in%2520Combination%2520with%2520Relatlimab%252C%2520BMS-986016%250Ain%2520Patients%2520with%2520Metastatic%2520Melanoma%2520Na%25C3%25AFve%2520to%2520Prior%2520Immunotherapy%250Ain%2520the%2520Metastatic%2520Setting%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">328</span>),  <span class="NLM_fpage">328rv4</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad7118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscitranslmed.aad7118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26936508" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=328rv4&issue=328&author=W.+Zouauthor=J.+D.+Wolchokauthor=L.+Chen&title=PD-L1+%28B7-H1%29+and+PD-1+Pathway+Blockade+for+Cancer+Therapy%3A+Mechanisms%2C+Response+Biomarkers+and+Combinations&doi=10.1126%2Fscitranslmed.aad7118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad7118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad7118%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DPD-L1%2520%2528B7-H1%2529%2520and%2520PD-1%2520Pathway%2520Blockade%2520for%2520Cancer%2520Therapy%253A%2520Mechanisms%252C%2520Response%2520Biomarkers%2520and%2520Combinations%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D328%26spage%3D328rv4%26doi%3D10.1126%2Fscitranslmed.aad7118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span> <span> </span><span class="NLM_article-title">PD-L1 and Emerging Biomarkers in PD-1/PD-L1 Blockade Therapy</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1097/PPO.0000000000000301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1097%2FPPO.0000000000000301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29360727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=41-46&issue=1&author=T.+Cottrellauthor=J.+M.+Taube&title=PD-L1+and+Emerging+Biomarkers+in+PD-1%2FPD-L1+Blockade+Therapy&doi=10.1097%2FPPO.0000000000000301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy</span></div><div class="casAuthors">Cottrell, Tricia R.; Taube, Janis M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-46</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">PD-L1 checkpoint blockade is revolutionizing cancer therapy, and biomarkers capable of predicting which patients are most likely to respond are highly desired.  The detection of PD-L1 protein expression by immunohistochem. can enrich for response to anti-PD-(L)1 blockade in a variety of tumor types, but is not abs.  Limitations of current com. PD-L1 immunohistochem. (IHC) assays and improvements anticipated in next-generation PD-L1 testing are reviewed.  Assessment of tumor-infiltrating lymphocytes in conjunction with PD-L1 testing could improve specificity by distinguishing adaptive (interferon γ driven and cytotoxic T-lymphocyte assocd.) from constitutive (non-immune mediated) expression.  The presence of a high tumor mutational burden also enriches for response to therapy, and early data indicate that this may provide additive predictive value beyond PD-L1 IHC alone.  As candidate biomarkers continue to emerge, the pathologist's assessment of the tumor microenvironment on hematoxylin-eosin stain combined with PD-L1 IHC remains a rapid and robust way to evaluate the tumor-immune dynamic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsTIilwNojorVg90H21EOLACvtfcHk0liAf5i9Pukyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrk%253D&md5=15c61479a78a8dcc4f010551dfc9c38c</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000301%26sid%3Dliteratum%253Aachs%26aulast%3DCottrell%26aufirst%3DT.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26atitle%3DPD-L1%2520and%2520Emerging%2520Biomarkers%2520in%2520PD-1%252FPD-L1%2520Blockade%2520Therapy%26jtitle%3DCancer%2520J.%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D41%26epage%3D46%26doi%3D10.1097%2FPPO.0000000000000301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.3389%2Ffimmu.2020.00339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32226426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=339&author=Y.+Jiangauthor=X.+Zhaoauthor=J.+Fuauthor=H.+Wang&title=Progress+and+Challenges+in+Precise+Treatment+of+Tumors+With+PD-1%2FPD-L1+Blockade&doi=10.3389%2Ffimmu.2020.00339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and challenges in precisetreatment of tumors withPD-1/PD-L1 blockade</span></div><div class="casAuthors">Jiang, Youhai; Zhao, Xiaofang; Fu, Jing; Wang, Hongyang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their antitumor ability and have shown significant efficacy in treating various cancers.  However, because of tumor heterogeneity and many other uncover reasons, the objective response rate for programmed death 1 and programmed death-ligand 1 (PD-1/PD-L1) blockade is only 20 to 30%; its response rate in solid tumors is relatively low, and different degrees of side effects have occurred.  There are still many unknown factors affecting the therapeutic effectiveness of PD-1/PD-L1 blockade.  Addnl., screening the responding tumor patients accurately and improving the response rate and efficacy are huge challenges for tumor precise treatment.  Here, we attempt to summarize the recent progress in response prediction and combined application of PD-1/PD-L1 blockade and briefly discuss the methods and evaluations combined with PD-1/PD-L1 blockade to improve the implementation of precision immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHpj67N22cXLVg90H21EOLACvtfcHk0liAf5i9Pukyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7%252FF&md5=bf7f484e6ccb566221b04eb20ed9dae4</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00339%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DProgress%2520and%2520Challenges%2520in%2520Precise%2520Treatment%2520of%2520Tumors%2520With%2520PD-1%252FPD-L1%2520Blockade%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D339%26doi%3D10.3389%2Ffimmu.2020.00339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">Biomarkers for Predicting Efficacy of PD-1/PD-L1 Inhibitors</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">129</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0864-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2Fs12943-018-0864-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30139382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslSmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=129&issue=1&author=M.+Yiauthor=D.+Jiaoauthor=H.+Xuauthor=Q.+Liuauthor=W.+Zhaoauthor=X.+Hanauthor=K.+Wu&title=Biomarkers+for+Predicting+Efficacy+of+PD-1%2FPD-L1+Inhibitors&doi=10.1186%2Fs12943-018-0864-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers for predicting efficacy of pd-1/ pd-l1 inhibitors</span></div><div class="casAuthors">Yi, Ming; Jiao, Dechao; Xu, Hanxiao; Liu, Qian; Zhao, Weiheng; Han, Xinwei; Wu, Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129/1-129/14</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a neg. modulatory signaling pathway for activation of T cell.  It is acknowledged that PD-1/PD-L1 axis plays a crucial role in the progression of tumor by altering status of immune surveillance.  As one of the most promising immune therapy strategies, PD-1/ PD-L1 inhibitor is a breakthrough for the therapy of some refractory tumors.  However, response rate of PD-1/PD-L1 inhibitors in overall patients is unsatisfactory, which limits the application in clin. practice.  Therefore, biomarkers which could effectively predict the efficacy of PD-1/PD-L1 inhibitors are crucial for patient selection.  Biomarkers reflecting tumor immune microenvironment and tumor cell intrinsic features, such as PD-L1 expression, d. of tumor infiltrating lymphocyte (TIL), tumor mutational burden, and mismatch-repair (MMR) deficiency, have been noticed to assoc. with treatment effect of anti-PD-1/anti-PD-L1 therapy.  Furthermore, gut microbiota, circulating biomarkers, and patient previous history have been found as valuable predictors as well.  Therefore establishing a comprehensive assessment framework involving multiple biomarkers would be meaningful to interrogate tumor immune landscape and select sensitive patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCaje2gngEbVg90H21EOLACvtfcHk0liAf5i9Pukyrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslSmtrw%253D&md5=62be2968466cad48add2aeb07bda7e2c</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0864-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0864-3%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DBiomarkers%2520for%2520Predicting%2520Efficacy%2520of%2520PD-1%252FPD-L1%2520Inhibitors%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D129%26doi%3D10.1186%2Fs12943-018-0864-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Carrigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA Repair in Cancer: Beyond PARP Inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1158%2F2159-8290.CD-16-0860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28003236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsF2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=20-37&issue=1&author=J.+S.+Brownauthor=B.+O%E2%80%99Carriganauthor=S.+P.+Jacksonauthor=T.+A.+Yap&title=Targeting+DNA+Repair+in+Cancer%3A+Beyond+PARP+Inhibitors&doi=10.1158%2F2159-8290.CD-16-0860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA Repair in Cancer: Beyond PARP Inhibitors</span></div><div class="casAuthors">Brown, Jessica S.; O'Carrigan, Brent; Jackson, Stephen P.; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-37</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Germline aberrations in crit. DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair.  The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers.  Herein, we detail how cellular DDR processes engage various proteins that sense DNA damage, initiate signaling pathways to promote cell-cycle checkpoint activation, trigger apoptosis, and coordinate DNA repair.  We focus on novel therapeutic strategies targeting promising DDR targets and discuss challenges of patient selection and the development of rational drug combinations.  Significance: Various inhibitors of DDR components are in preclin. and clin. development.  A thorough understanding of DDR pathway complexities must now be combined with strategies and lessons learned from the successful registration of PARP inhibitors in order to fully exploit the potential of DDR inhibitors and to ensure their long-term clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKRh_Xp_7H7Vg90H21EOLACvtfcHk0lh-XtSZcCz_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsF2mtA%253D%253D&md5=ce622565880cf0186abc9af39a5e82c4</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0860%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BS.%26aulast%3DO%25E2%2580%2599Carrigan%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DTargeting%2520DNA%2520Repair%2520in%2520Cancer%253A%2520Beyond%2520PARP%2520Inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D20%26epage%3D37%26doi%3D10.1158%2F2159-8290.CD-16-0860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lecona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Capetillo, O.</span></span> <span> </span><span class="NLM_article-title">Targeting ATR in Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">586</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0034-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41568-018-0034-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29899559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFelsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=586-595&issue=9&author=E.+Leconaauthor=O.+Fernandez-Capetillo&title=Targeting+ATR+in+Cancer&doi=10.1038%2Fs41568-018-0034-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ATR in cancer</span></div><div class="casAuthors">Lecona, Emilio; Fernandez-Capetillo, Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">586-595</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The chem. treatment of cancer started with the realization that DNA damaging agents such as mustard gas present notable antitumoral properties.  Consequently, early drug development focused on genotoxic chems., some of which are still widely used in the clinic.  However, the efficacy of such therapies is often limited by the side effects of these drugs on healthy cells.  A refinement to this approach is to use compds. that can exploit the presence of DNA damage in cancer cells.  Given that replication stress (RS) is a major source of genomic instability in cancer, targeting the RS-response kinase ataxia telangiectasia and Rad3-related protein (ATR) has emerged as a promising alternative.  With ATR inhibitors now entering clin. trials, we here revisit the biol. behind this strategy and discuss potential biomarkers that could be used for a better selection of patients who respond to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvSqZUpGo6e7Vg90H21EOLACvtfcHk0lh-XtSZcCz_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFelsrbN&md5=502575a5e0cc75d42968bed402611c1d</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0034-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0034-3%26sid%3Dliteratum%253Aachs%26aulast%3DLecona%26aufirst%3DE.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26atitle%3DTargeting%2520ATR%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26issue%3D9%26spage%3D586%26epage%3D595%26doi%3D10.1038%2Fs41568-018-0034-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahner Hendrickson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumer, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duska, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispens, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olawaiye, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroilhet, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilder, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Färkkilä, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span> <span> </span><span class="NLM_article-title">Berzosertib plus Gemcitabine versus Gemcitabine Alone in Platinum-Resistant High-Grade Serous Ovarian Cancer: A Multicentre, Open-Label, Randomised, Phase 2 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">968</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(20)30180-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1470-2045%2820%2930180-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32553118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Skt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=957-968&issue=7&author=P.+A.+Konstantinopoulosauthor=S.-C.+Chengauthor=A.+E.+Wahner+Hendricksonauthor=R.+T.+Pensonauthor=S.+T.+Schumerauthor=L.+A.+Doyleauthor=E.+K.+Leeauthor=E.+C.+Kohnauthor=L.+R.+Duskaauthor=M.+A.+Crispensauthor=A.+B.+Olawaiyeauthor=I.+S.+Winerauthor=L.+M.+Barroilhetauthor=S.+Fuauthor=M.+T.+McHaleauthor=R.+J.+Schilderauthor=A.+F%C3%A4rkkil%C3%A4author=D.+Chowdhuryauthor=J.+Curtisauthor=R.+S.+Quinnauthor=B.+Bowesauthor=A.+D.+D%E2%80%99Andreaauthor=G.+I.+Shapiroauthor=U.+A.+Matulonis&title=Berzosertib+plus+Gemcitabine+versus+Gemcitabine+Alone+in+Platinum-Resistant+High-Grade+Serous+Ovarian+Cancer%3A+A+Multicentre%2C+Open-Label%2C+Randomised%2C+Phase+2+Trial&doi=10.1016%2FS1470-2045%2820%2930180-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial</span></div><div class="casAuthors">Konstantinopoulos, Panagiotis A.; Cheng, Su-Chun; Wahner Hendrickson, Andrea E.; Penson, Richard T.; Schumer, Susan T.; Doyle, L. Austin; Lee, Elizabeth K.; Kohn, Elise C.; Duska, Linda R.; Crispens, Marta A.; Olawaiye, Alexander B.; Winer, Ira S.; Barroilhet, Lisa M.; Fu, Siqing; McHale, Michael T.; Schilder, Russell J.; Farkkila, Anniina; Chowdhury, Dipanjan; Curtis, Jennifer; Quinn, Roxanne S.; Bowes, Brittany; D'Andrea, Alan D.; Shapiro, Geoffrey I.; Matulonis, Ursula A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">957-968</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S phase entry (due to CCNE1 amplification, RB1 loss, or CDKN2A mRNA downregulation), alterations of homologous recombination repair genes, and expression of oncogenic drivers (through MYC amplification and other mechanisms).  We hypothesised that the combination of the selective ATR inhibitor, berzosertib, and gemcitabine could show acceptable toxicity and superior efficacy to gemcitabine alone in high-grade serous ovarian cancer.  In this multicentre, open-label, randomised, phase 2 study, 11 different centers in the US Exptl. Therapeutics Clin. Trials Network enrolled women (aged ≥18 years) with recurrent, platinum-resistant high-grade serous ovarian cancer (detd. histol.) and Eastern Cooperative Oncol. Group performance status of 0 or 1, who had unlimited previous lines of cytotoxic therapy in the platinum-sensitive setting but no more than one line of cytotoxic therapy in the platinum-resistant setting.  Eligible patients were randomly assigned (1:1) to receive i.v. gemcitabine (1000 mg/m2) on day 1 and day 8, or gemcitabine plus i.v. berzosertib (210 mg/m2) on day 2 and day 9 of a 21-day cycle until disease progression or intolerable toxicity.  Randomisation was done centrally using the Theradex Interactive Web Response System, stratified by platinum-free interval, and with a permuted block size of six.  Following central randomisation, patients and investigators were not masked to treatment assignment.  The primary endpoint was investigator-assessed progression-free survival, and analyses included all patients who received at least one dose of the study drugs.  The study is registered with ClinicalTrials.gov, NCT02595892, and is active but closed to enrolment.  Between Feb 14, 2017, and Sept 7, 2018, 88 patients were assessed for eligibility, of whom 70 were randomly assigned to treatment with gemcitabine alone (36 patients) or gemcitabine plus berzosertib (34 patients).  At the data cutoff date (Feb 21, 2020), the median follow-up was 53·2 wk (25·6-81·8) in the gemcitabine plus berzosertib group and 43·0 wk (IQR 23·2-69·1) in the gemcitabine alone group.  Median progression-free survival was 22·9 wk (17·9-72·0) for gemcitabine plus berzosertib and 14·7 wk (90% CI 9·7-36·7) for gemcitabine alone (hazard ratio 0·57, 90% CI 0·33-0·98; one-sided log-rank test p=0·044).  The most common treatment-related grade 3 or 4 adverse events were decreased neutrophil count (14 [39%] of 36 patients in the gemcitabine alone group vs 16 [47%] of 34 patients in the gemcitabine plus berzosertib group) and decreased platelet count (two [6%] vs eight [24%]).  Serious adverse events were obsd. in ten (28%) patients in the gemcitabine alone group and nine (26%) patients in the gemcitabine plus berzosertib group.  There was one treatment-related death in the gemcitabine alone group due to sepsis and one treatment-related death in the gemcitabine plus berzosertib group due to pneumonitis.  To our knowledge, this is the first randomised study of an ATR inhibitor in any tumor type.  This study shows a benefit of adding berzosertib to gemcitabine in platinum-resistant high-grade serous ovarian cancer.  This combination warrants further investigation in this setting.US National Cancer Institute.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI8--FOraDYbVg90H21EOLACvtfcHk0lh-XtSZcCz_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Skt73O&md5=afc762e5a18335c80840251765f08556</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2820%2930180-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252820%252930180-7%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DCheng%26aufirst%3DS.-C.%26aulast%3DWahner%2BHendrickson%26aufirst%3DA.%2BE.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DSchumer%26aufirst%3DS.%2BT.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DDuska%26aufirst%3DL.%2BR.%26aulast%3DCrispens%26aufirst%3DM.%2BA.%26aulast%3DOlawaiye%26aufirst%3DA.%2BB.%26aulast%3DWiner%26aufirst%3DI.%2BS.%26aulast%3DBarroilhet%26aufirst%3DL.%2BM.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DM.%2BT.%26aulast%3DSchilder%26aufirst%3DR.%2BJ.%26aulast%3DF%25C3%25A4rkkil%25C3%25A4%26aufirst%3DA.%26aulast%3DChowdhury%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DR.%2BS.%26aulast%3DBowes%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DBerzosertib%2520plus%2520Gemcitabine%2520versus%2520Gemcitabine%2520Alone%2520in%2520Platinum-Resistant%2520High-Grade%2520Serous%2520Ovarian%2520Cancer%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%252C%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26issue%3D7%26spage%3D957%26epage%3D968%26doi%3D10.1016%2FS1470-2045%2820%2930180-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Ataxia Telangiectasia and Rad3-Related Inhibitors and Cancer Therapy: Where We Stand</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/s13045-019-0733-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2Fs13045-019-0733-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31018854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FovVSntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=43&issue=1&author=L.+Meiauthor=J.+Zhangauthor=K.+Heauthor=J.+Zhang&title=Ataxia+Telangiectasia+and+Rad3-Related+Inhibitors+and+Cancer+Therapy%3A+Where+We+Stand&doi=10.1186%2Fs13045-019-0733-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand</span></div><div class="casAuthors">Mei Lin; Zhang Junran; He Kai; Zhang Jingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase 1 (CHK1) pathway plays an essential role in suppressing replication stress from DNA damage and oncogene activation.  MAIN BODY:  Preclinical studies have shown that cancer cells with defective DNA repair mechanisms or cell cycle checkpoints may be particularly sensitive to ATR inhibitors.  Preclinical and clinical data from early-phase trials on three ATR inhibitors (M6620, AZD6738, and BAY1895344), either as monotherapy or in combination, were reviewed.  CONCLUSION:  Data from ATR inhibitor-based combinational trials might lead to future expansion of this therapy to homologous recombination repair pathway-proficient cancers and potentially serve as a rescue therapy for patients who have progressed through poly ADP-ribose polymerase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1hnSigdvKH_xQvRxYU81tfW6udTcc2eb8p9GXw82g4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FovVSntw%253D%253D&md5=375804d5e67e7aa87c2d8509ab12b513</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1186%2Fs13045-019-0733-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-019-0733-6%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DAtaxia%2520Telangiectasia%2520and%2520Rad3-Related%2520Inhibitors%2520and%2520Cancer%2520Therapy%253A%2520Where%2520We%2520Stand%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D12%26issue%3D1%26spage%3D43%26doi%3D10.1186%2Fs13045-019-0733-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span> </span><span class="NLM_article-title">Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent
Protein
Kinase, in Combination With Radiotherapy</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT02516813" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02516813</a> (accessed <span class="NLM_year">2020</span>-08-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+1+Trial+of+MSC2490484A%2C+an+Inhibitor+of+a+DNA-dependent%0AProtein%0AKinase%2C+in+Combination+With+Radiotherapy.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02516813+%28accessed+2020-08-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%25201%2520Trial%2520of%2520MSC2490484A%252C%2520an%2520Inhibitor%2520of%2520a%2520DNA-dependent%250AProtein%250AKinase%252C%2520in%2520Combination%2520With%2520Radiotherapy%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fok, J. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Montoya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Chantada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnhoven, P. W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmokar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikkilä, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span> <span> </span><span class="NLM_article-title">AZD7648 Is a Potent and Selective DNA-PK Inhibitor That Enhances Radiation, Chemotherapy and Olaparib Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5065</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-12836-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41467-019-12836-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31699977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5065&issue=1&author=J.+H.+L.+Fokauthor=A.+Ramos-Montoyaauthor=M.+Vazquez-Chantadaauthor=P.+W.+G.+Wijnhovenauthor=V.+Folliaauthor=N.+Jamesauthor=P.+M.+Farringtonauthor=A.+Karmokarauthor=S.+E.+Willisauthor=J.+Cairnsauthor=J.+Nikkil%C3%A4author=D.+Beattieauthor=G.+M.+Lamontauthor=M.+R.+V.+Finlayauthor=J.+Wilsonauthor=A.+Smithauthor=L.+O.+O%E2%80%99Connorauthor=S.+Lingauthor=S.+E.+Fawellauthor=M.+J.+O%E2%80%99Connorauthor=S.+J.+Hollingsworthauthor=E.+Deanauthor=F.+W.+Goldbergauthor=B.+R.+Daviesauthor=E.+B.+Cadogan&title=AZD7648+Is+a+Potent+and+Selective+DNA-PK+Inhibitor+That+Enhances+Radiation%2C+Chemotherapy+and+Olaparib+Activity&doi=10.1038%2Fs41467-019-12836-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity</span></div><div class="casAuthors">Fok Jacqueline H L; Ramos-Montoya Antonio; Wijnhoven Paul W G; Follia Valeria; James Neil; Farrington Paul M; Karmokar Ankur; Nikkila Jenni; Fawell Stephen E; O'Connor Mark J; Davies Barry R; Cadogan Elaine B; Vazquez-Chantada Mercedes; Ling Stephanie; Willis Sophie E; O'Connor Lenka Oplustil; Cairns Jonathan; Beattie David; Lamont Gillian M; Finlay M Raymond V; Goldberg Frederick W; Wilson Joanne; Smith Aaron; Hollingsworth Simon J; Dean Emma</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5065</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">DNA-dependent protein kinase (DNA-PK) is a critical player in the DNA damage response (DDR) and instrumental in the non-homologous end-joining pathway (NHEJ) used to detect and repair DNA double-strand breaks (DSBs).  We demonstrate that the potent and highly selective DNA-PK inhibitor, AZD7648, is an efficient sensitizer of radiation- and doxorubicin-induced DNA damage, with combinations in xenograft and patient-derived xenograft (PDX) models inducing sustained regressions.  Using ATM-deficient cells, we demonstrate that AZD7648, in combination with the PARP inhibitor olaparib, increases genomic instability, resulting in cell growth inhibition and apoptosis.  AZD7648 enhanced olaparib efficacy across a range of doses and schedules in xenograft and PDX models, enabling sustained tumour regression and providing a clear rationale for its clinical investigation.  Through its differentiated mechanism of action as an NHEJ inhibitor, AZD7648 complements the current armamentarium of DDR-targeted agents and has potential in combination with these agents to achieve deeper responses to current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQf_5P1MX4JaXtlzo9xastyfW6udTcc2eb8p9GXw82g4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D&md5=b41d0e83963ad440f12b93fbdeed861e</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-12836-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-12836-9%26sid%3Dliteratum%253Aachs%26aulast%3DFok%26aufirst%3DJ.%2BH.%2BL.%26aulast%3DRamos-Montoya%26aufirst%3DA.%26aulast%3DVazquez-Chantada%26aufirst%3DM.%26aulast%3DWijnhoven%26aufirst%3DP.%2BW.%2BG.%26aulast%3DFollia%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DN.%26aulast%3DFarrington%26aufirst%3DP.%2BM.%26aulast%3DKarmokar%26aufirst%3DA.%26aulast%3DWillis%26aufirst%3DS.%2BE.%26aulast%3DCairns%26aufirst%3DJ.%26aulast%3DNikkil%25C3%25A4%26aufirst%3DJ.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DLamont%26aufirst%3DG.%2BM.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DL.%2BO.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DHollingsworth%26aufirst%3DS.%2BJ.%26aulast%3DDean%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DF.%2BW.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26atitle%3DAZD7648%2520Is%2520a%2520Potent%2520and%2520Selective%2520DNA-PK%2520Inhibitor%2520That%2520Enhances%2520Radiation%252C%2520Chemotherapy%2520and%2520Olaparib%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D5065%26doi%3D10.1038%2Fs41467-019-12836-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span> <span> </span><span class="NLM_article-title">ATM in DNA Repair in Cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">107391</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.pharmthera.2019.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31299316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtl2isrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2019&pages=107391&author=M.+H.+Jinauthor=D.-Y.+Oh&title=ATM+in+DNA+Repair+in+Cancer&doi=10.1016%2Fj.pharmthera.2019.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">ATM in DNA repair in cancer</span></div><div class="casAuthors">Jin, Mei Hua; Oh, Do-Youn</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107391</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Alterations in DNA damage response (DDR) pathways are hallmarks of cancer.  Incorrect repair of DNA lesions often leads to genomic instability.  Ataxia telangiectasia mutated (ATM), a core component of the DNA repair system, is activated to enhance the homologous recombination (HR) repair pathway upon DNA double-strand breaks.  Although ATM signaling has been widely studied in different types of cancer, its research is still lacking compared with other DDR-involved mols. such as PARP and ATR.  There is still a vast research opportunity for the development of ATM inhibitors as anticancer agents.  Here, we focus on the recent findings of ATM signaling in DNA repair of cancer.  Previous studies have identified several partners of ATM, some of which promote ATM signaling, while others have the opposite effect.  ATM inhibitors, including KU-55933, KU-60019, KU-59403, CP-466722, AZ31, AZ32, AZD0156, and AZD1390, have been evaluated for their antitumor effects.  It has been revealed that ATM inhibition increases a cancer cell's sensitivity to radiotherapy.  Moreover, the combination with PARP or ATR inhibitors has synergistic lethality in some cancers.  Of note, among these ATM inhibitors, AZD0156 and AZD1390 achieve potent and highly selective ATM kinase inhibition and have an excellent ability to penetrate the blood-brain barrier.  Currently, AZD0156 and AZD1390 are under investigation in phase I clin. trials.  Taken together, targeting ATM may be a promising strategy for cancer treatment.  Hence, further development of ATM inhibitors is urgently needed in cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxD2jj0D2fArVg90H21EOLACvtfcHk0li-cZ74k57qzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtl2isrrJ&md5=1ab2f96461142d9913d5859c309e853e</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%2BH.%26aulast%3DOh%26aufirst%3DD.-Y.%26atitle%3DATM%2520in%2520DNA%2520Repair%2520in%2520Cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D203%26spage%3D107391%26doi%3D10.1016%2Fj.pharmthera.2019.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witztum, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. F.</span></span> <span> </span><span class="NLM_article-title">RNA-Targeted Therapeutics</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.cmet.2018.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29617640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=714-739&issue=4&author=S.+T.+Crookeauthor=J.+L.+Witztumauthor=C.+F.+Bennettauthor=B.+F.+Baker&title=RNA-Targeted+Therapeutics&doi=10.1016%2Fj.cmet.2018.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Targeted Therapeutics</span></div><div class="casAuthors">Crooke, Stanley T.; Witztum, Joseph L.; Bennett, C. Frank; Baker, Brenda F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">714-739</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">RNA-targeted therapies represent a platform for drug discovery involving chem. modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif, Watson-Crick base pairing.  Numerous hurdles considered by many to be impassable have been overcome.  Today, four RNA-targeted therapies are approved for com. use for indications as diverse as Spinal Muscular Atrophy (SMA) and redn. of low-d. lipoprotein cholesterol (LDL-C) and by routes of administration including s.c., intravitreal, and intrathecal delivery.  The technol. is efficient and supports approaching "undruggable" targets.  Three addnl. agents are progressing through registration, and more are in clin. development, representing several chem. and structural classes.  Moreover, progress in understanding the mol. mechanisms by which these drugs work has led to steadily better clin. performance and a wide range of mechanisms that may be exploited for therapeutic purposes.  Here we summarize the progress, future challenges, and opportunities for this drug discovery platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYy4nInax5iLVg90H21EOLACvtfcHk0li-cZ74k57qzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D&md5=81de41b2b10fcab31787b830932d5b64</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26aulast%3DWitztum%26aufirst%3DJ.%2BL.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DBaker%26aufirst%3DB.%2BF.%26atitle%3DRNA-Targeted%2520Therapeutics%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26issue%3D4%26spage%3D714%26epage%3D739%26doi%3D10.1016%2Fj.cmet.2018.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span> </span><span class="NLM_article-title">FDA Approves Emicizumab-kxwh for Prevention
and Reduction of Bleeding
in Patients with Hemophilia A with Factor VIII Inhibitors</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Emicizumab-kxwh+for+Prevention%0Aand+Reduction+of+Bleeding%0Ain+Patients+with+Hemophilia+A+with+Factor+VIII+Inhibitors.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii+%28accessed+2020-08-08%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Emicizumab-kxwh%2520for%2520Prevention%250Aand%2520Reduction%2520of%2520Bleeding%250Ain%2520Patients%2520with%2520Hemophilia%2520A%2520with%2520Factor%2520VIII%2520Inhibitors%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, J. M.</span></span> <span> </span><span class="NLM_article-title">Bispecific Antibodies Come to the Fore</span>.  <i>Antibody Society</i>. <a href="https://www.antibodysociety.org/tag/bispecific/" class="extLink">https://www.antibodysociety.org/tag/bispecific/</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+M.+Reichert&title=Bispecific+Antibodies+Come+to+the+Fore"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DReichert%26aufirst%3DJ.%2BM.%26atitle%3DBispecific%2520Antibodies%2520Come%2520to%2520the%2520Fore%26jtitle%3DAntibody%2520Society%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suurs, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lub-de Hooge, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, D. J. A.</span></span> <span> </span><span class="NLM_article-title">A Review of Bispecific Antibodies and Antibody Constructs in Oncology and Clinical Challenges</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.pharmthera.2019.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31028837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVynsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2019&pages=103-119&author=F.+V.+Suursauthor=M.+N.+Lub-de+Hoogeauthor=E.+G.+E.+de+Vriesauthor=D.+J.+A.+de%0AGroot&title=A+Review+of+Bispecific+Antibodies+and+Antibody+Constructs+in+Oncology+and+Clinical+Challenges&doi=10.1016%2Fj.pharmthera.2019.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">A review of bispecific antibodies and antibody constructs in oncology and clinical challenges</span></div><div class="casAuthors">Suurs, Frans V.; Lub-de Hooge, Marjolijn N.; de Vries, Elisabeth G. E.; de Groot, Derk Jan A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-119</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to can target cancer.  For use in oncol., one bsAb has been approved and 57 bsAbs are in clin. trials, none of which has reached phase 3.  These bsAbs show great variability in design and mechanism of action.  The various designs are often linked to the mechanisms of actions.  The majority of bsAbs engage immune cells to destroy tumor cells.  However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways.  This review provides insight into the choice of construct for bsAbs, summarizes the clin. development of bsAbs in oncol. and identifies subsequent challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBPP04rWjOQLVg90H21EOLACvtfcHk0li-cZ74k57qzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVynsbvM&md5=bc858d195fb3c7b202f3e91c15c1f427</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DSuurs%26aufirst%3DF.%2BV.%26aulast%3DLub-de%2BHooge%26aufirst%3DM.%2BN.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26aulast%3Dde%2BGroot%26aufirst%3DD.%2BJ.%2BA.%26atitle%3DA%2520Review%2520of%2520Bispecific%2520Antibodies%2520and%2520Antibody%2520Constructs%2520in%2520Oncology%2520and%2520Clinical%2520Challenges%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D201%26spage%3D103%26epage%3D119%26doi%3D10.1016%2Fj.pharmthera.2019.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luh, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheib, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juenemann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span> <span> </span><span class="NLM_article-title">Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist’s Perspective</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">15448</span>, <span class="refDoi"> DOI: 10.1002/anie.202004310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fanie.202004310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyisL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=15448&author=L.+M.+Luhauthor=U.+Scheibauthor=K.+Juenemannauthor=L.+Wortmannauthor=M.+Brandsauthor=P.+M.+Cromm&title=Prey+for+the+Proteasome%3A+Targeted+Protein+Degradation-A+Medicinal+Chemist%E2%80%99s+Perspective&doi=10.1002%2Fanie.202004310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective</span></div><div class="casAuthors">Luh, Laura M.; Scheib, Ulrike; Juenemann, Katrin; Wortmann, Lars; Brands, Michael; Cromm, Philipp M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">15448-15466</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn. (TPD), the ability to control a proteins fate by triggering its degrdn. in a highly selective and effective manner, has created tremendous excitement in chem. biol. and drug discovery within the past decades.  The TPD field is spearheaded by small mol. induced protein degrdn. with mol. glues and proteolysis targeting chimeras (PROTACs) paving the way to expand the druggable space and to create a new paradigm in drug discovery.  However, besides the therapeutic angle of TPD a plethora of novel techniques to modulate and control protein levels have been developed.  This enables chem. biologists to better understand protein function and to discover and verify new therapeutic targets.  This Review gives a comprehensive overview of chem. biol. techniques inducing TPD.  It explains the strengths and weaknesses of these methods in the context of drug discovery and discusses their future potential from a medicinal chemist's perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWPsv2tjJdobVg90H21EOLACvtfcHk0li-cZ74k57qzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyisL7M&md5=e7585296878017cd5394a5345b07e047</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1002%2Fanie.202004310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202004310%26sid%3Dliteratum%253Aachs%26aulast%3DLuh%26aufirst%3DL.%2BM.%26aulast%3DScheib%26aufirst%3DU.%26aulast%3DJuenemann%26aufirst%3DK.%26aulast%3DWortmann%26aufirst%3DL.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DCromm%26aufirst%3DP.%2BM.%26atitle%3DPrey%2520for%2520the%2520Proteasome%253A%2520Targeted%2520Protein%2520Degradation-A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D15448%26doi%3D10.1002%2Fanie.202004310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span> <i>PharmiWeb</i>. <a href="https://www.pharmiweb.com/press-release/2020-03-10/with-over-usd-35-billion-in-capital-investment-and-numerous-high-value-licensing-deals-the-target" class="extLink">https://www.pharmiweb.com/press-release/2020-03-10/with-over-usd-35-billion-in-capital-investment-and-numerous-high-value-licensing-deals-the-target</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PharmiWeb.+https%3A%2F%2Fwww.pharmiweb.com%2Fpress-release%2F2020-03-10%2Fwith-over-usd-35-billion-in-capital-investment-and-numerous-high-value-licensing-deals-the-target+%28accessed+2020-08-08%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmiWeb%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">Targeted Degraders Clear First Safety Hurdles</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">435</span>, <span class="refDoi"> DOI: 10.1038/d41573-020-00109-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fd41573-020-00109-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlShtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=435&author=A.+Mullard&title=Targeted+Degraders+Clear+First+Safety+Hurdles&doi=10.1038%2Fd41573-020-00109-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted degraders clear first safety hurdles</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">435</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nHwwDZKMr7Vg90H21EOLACvtfcHk0lgvwVvBJCWxYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlShtbrM&md5=122b44714339e8b38fc418c2f8732706</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1038%2Fd41573-020-00109-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-020-00109-w%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DTargeted%2520Degraders%2520Clear%2520First%2520Safety%2520Hurdles%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26spage%3D435%26doi%3D10.1038%2Fd41573-020-00109-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirakawa, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnakumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timlin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. S.</span></span> <span> </span><span class="NLM_article-title">Gene Editing and CRISPR in the Clinic: Current and Future Perspectives</span>. <i>Biosci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">BSR20200127</span>, <span class="refDoi"> DOI: 10.1042/BSR20200127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1042%2FBSR20200127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32207531" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=BSR20200127&issue=4&author=M.+P.+Hirakawaauthor=R.+Krishnakumarauthor=J.+A.+Timlinauthor=J.+P.+Carneyauthor=K.+S.+Butler&title=Gene+Editing+and+CRISPR+in+the+Clinic%3A+Current+and+Future+Perspectives&doi=10.1042%2FBSR20200127"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1042%2FBSR20200127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20200127%26sid%3Dliteratum%253Aachs%26aulast%3DHirakawa%26aufirst%3DM.%2BP.%26aulast%3DKrishnakumar%26aufirst%3DR.%26aulast%3DTimlin%26aufirst%3DJ.%2BA.%26aulast%3DCarney%26aufirst%3DJ.%2BP.%26aulast%3DButler%26aufirst%3DK.%2BS.%26atitle%3DGene%2520Editing%2520and%2520CRISPR%2520in%2520the%2520Clinic%253A%2520Current%2520and%2520Future%2520Perspectives%26jtitle%3DBiosci.%2520Rep.%26date%3D2020%26volume%3D40%26issue%3D4%26spage%3DBSR20200127%26doi%3D10.1042%2FBSR20200127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span> </span><span class="NLM_article-title">Allergan and Editas Medicine Initiate the
Brilliance Phase 1/2 Clinical
Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10</span>.  <i>GlobeNewsWire</i>. <a href="https://www.globenewswire.com/news-release/2019/07/25/1888031/0/en/Allergan-and-Editas-Medicine-Initiate-the-Brilliance-Phase-1-2-Clinical-Trial-of-AGN-151587-EDIT-101-for-the-Treatment-of-LCA10.html" class="extLink">https://www.globenewswire.com/news-release/2019/07/25/1888031/0/en/Allergan-and-Editas-Medicine-Initiate-the-Brilliance-Phase-1-2-Clinical-Trial-of-AGN-151587-EDIT-101-for-the-Treatment-of-LCA10.html</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allergan+and+Editas+Medicine+Initiate+the%0ABrilliance+Phase+1%2F2+Clinical%0ATrial+of+AGN-151587+%28EDIT-101%29+for+the+Treatment+of+LCA10.+GlobeNewsWire.+https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2019%2F07%2F25%2F1888031%2F0%2Fen%2FAllergan-and-Editas-Medicine-Initiate-the-Brilliance-Phase-1-2-Clinical-Trial-of-AGN-151587-EDIT-101-for-the-Treatment-of-LCA10.html+%28accessed+2020-08-08%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAllergan%2520and%2520Editas%2520Medicine%2520Initiate%2520the%250ABrilliance%2520Phase%25201%252F2%2520Clinical%250ATrial%2520of%2520AGN-151587%2520%2528EDIT-101%2529%2520for%2520the%2520Treatment%2520of%2520LCA10%26jtitle%3DGlobeNewsWire%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munos, B. H.</span></span> <span> </span><span class="NLM_article-title">2018 New Drugs Approvals: An All-Time Record, And A Watershed</span>.  <i>Forbes</i>. <a href="https://www.forbes.com/sites/bernardmunos/2019/01/14/2018-new-drugs-approvals-an-all-time-record-and-a-watershed/amp" class="extLink">https://www.forbes.com/sites/bernardmunos/2019/01/14/2018-new-drugs-approvals-an-all-time-record-and-a-watershed/amp</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+H.+Munos&title=2018+New+Drugs+Approvals%3A+An+All-Time+Record%2C+And+A+Watershed"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DMunos%26aufirst%3DB.%2BH.%26atitle%3D2018%2520New%2520Drugs%2520Approvals%253A%2520An%2520All-Time%2520Record%252C%2520And%2520A%2520Watershed%26jtitle%3DForbes%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Paul D. Leeson, A. Patricia Bento, Anna Gaulton, Anne Hersey, Emma J. Manners, Chris J. Radoux, <span class="NLM_string-name hlFld-ContribAuthor">Andrew R. Leach</span>. </span><span class="cited-content_cbyCitation_article-title">Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7210-7230. <a href="https://doi.org/10.1021/acs.jmedchem.1c00416" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00416%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTarget-Based%252BEvaluation%252Bof%252B%2525E2%252580%25259CDrug-Like%2525E2%252580%25259D%252BProperties%252Band%252BLigand%252BEfficiencies%26aulast%3DLeeson%26aufirst%3DPaul%2BD.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D13052021%26volume%3D64%26issue%3D11%26spage%3D7210%26epage%3D7230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zai-Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">K. P.  Rakesh</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Qin</span>, <span class="hlFld-ContribAuthor ">Haolin  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">A general approach to nitrile- and sulfonyl fluoride-substituted cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (27)
                                     , 6021-6024. <a href="https://doi.org/10.1039/D1OB01043C" title="DOI URL">https://doi.org/10.1039/D1OB01043C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB01043C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB01043C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DA%252Bgeneral%252Bapproach%252Bto%252Bnitrile-%252Band%252Bsulfonyl%252Bfluoride-substituted%252Bcyclopropanes%26aulast%3DZhang%26aufirst%3DZai-Wei%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D27%26spage%3D6021%26epage%3D6024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicki  Frederiksen</span>, <span class="hlFld-ContribAuthor ">Stavroula  Louka</span>, <span class="hlFld-ContribAuthor ">Chirag  Mudaliar</span>, <span class="hlFld-ContribAuthor ">Ilona  Domraceva</span>, <span class="hlFld-ContribAuthor ">Agrita  Kreicberga</span>, <span class="hlFld-ContribAuthor ">Osvalds  Pugovics</span>, <span class="hlFld-ContribAuthor ">Dorota  Żabicka</span>, <span class="hlFld-ContribAuthor ">Magdalena  Tomczak</span>, <span class="hlFld-ContribAuthor ">Weronika  Wygoda</span>, <span class="hlFld-ContribAuthor ">Fredrik  Björkling</span>, <span class="hlFld-ContribAuthor ">Henrik  Franzyk</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide/β-Peptoid Hybrids with Ultrashort PEG-Like Moieties: Effects on Hydrophobicity, Antibacterial Activity and Hemolytic Properties. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (13)
                                     , 7041. <a href="https://doi.org/10.3390/ijms22137041" title="DOI URL">https://doi.org/10.3390/ijms22137041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22137041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22137041%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPeptide%25252F%2525CE%2525B2-Peptoid%252BHybrids%252Bwith%252BUltrashort%252BPEG-Like%252BMoieties%25253A%252BEffects%252Bon%252BHydrophobicity%25252C%252BAntibacterial%252BActivity%252Band%252BHemolytic%252BProperties%26aulast%3DFrederiksen%26aufirst%3DNicki%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D13%26spage%3D7041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hidetoshi  Arima</span>. </span><span class="cited-content_cbyCitation_article-title">Twenty Years of Research on Cyclodextrin Conjugates with PAMAM Dendrimers. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 697. <a href="https://doi.org/10.3390/pharmaceutics13050697" title="DOI URL">https://doi.org/10.3390/pharmaceutics13050697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13050697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13050697%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DTwenty%252BYears%252Bof%252BResearch%252Bon%252BCyclodextrin%252BConjugates%252Bwith%252BPAMAM%252BDendrimers%26aulast%3DArima%26aufirst%3DHidetoshi%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. NME and BLA approvals from 2010 to 2019. Number of new molecular entities (NME), biological license applications (BLA), and biosimilars approved from 2010 to 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Time from IND filing to drug approval. Approved drugs (<i>n</i> = 268) from 2010 to 2019. Drugs were included where IND filing times were accessible from FDA regulatory documents on <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="86c2f4f3e1f5c6c0c2c7">[email protected]</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> or from patent restoration documents on the federal register.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Mean and median times are included in the figure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of NMEs with examples of fastest (<b>1</b>, <b>2</b>) and slow (<b>3</b>) times from IND filing to NDA approval in the past decade. Osimertinib <b>1</b> (NSCLC with EGFR-T790 M mutation), 2.2 years; deflazacort <b>2</b> (DMD), 2.3 years; flibanserin <b>3</b> (hypoactive sexual desire disorder in females), 18 years. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Drug designation summary.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Expedited review categories of FDA-approved drugs 2010–2019.<a onclick="showRef(event, 'ref14 ref32 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref14 ref32 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42">(14,32,34−42)</a> Each bar graph represents the percentage in each category against all drugs approved in a given year. A drug may be designated in multiple categories.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Accelerated NME small molecule drug approvals in 2018 and 2019. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Approved drugs by therapy area 2010–2019. (a) Percentage of approvals by disease area based on 378 approved NMEs and BLAs 2010–2019. The category “other” was used to capture diseases which did not fit into any one of the other categories listed on the <i>X</i>-axis. A list of all the categories against each drug can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf" class="ext-link">Supporting Information</a>. (b) Therapy area approvals binned into 2010–2014 (orange) and 2015–2019 (green). The 2010–2014 percentage was based on an overall count of 158 drug approvals, and the 2015–2019 percentage based on 220 drug approvals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Approved inhibitors of poly(ADP-ribose) polymerases (PARP). Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. First-in-class (FIC) approvals in oncology for leukemia (2010–2019). Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Example FIC approvals in oncology with a diagnostic FDA-approved companion test. Year of approval in parentheses. Other NME approvals with a diagnostic FDA-approved companion test incude larotrectinib <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), olaparib <b>13</b>, (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), ivosidenib <b>17</b>, enasidenib <b>18</b>, midostaurin <b>19</b>, and ventoclax <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Examples of recently FDA-approved antiviral drugs. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Examples of recently FDA-approved HCV NS3/4A protease inhibitors. Year of approval in parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Examples of recently FDA-approved antibacterial drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. FIC approvals for CNS drugs 2010–2019. Ubrogepant <b>47</b> is not officially a FIC drug since erenumab-aooe was the first approved CGRP receptor blocker, but it is included since it is the first small molecule with such a mechanism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Orphan designations per year as a fraction of approved NME and BLA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. First-in-class approvals by year.<a onclick="showRef(event, 'ref32 ref34 ref35 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref32 ref34 ref35 ref37 ref38 ref39 ref40 ref41 ref42">(32,34,35,37−42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (a) FDA approvals from 2010 to 2019 based on route of administration and (b) FDA approvals from 2010 to 2019 categorized into single administration or fixed dose combination. Only the approval for the original route of administration was included in the analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Example of FDA-approved fixed dose combination drug for HIV (2012).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Example of recently FDA-approved fixed dose combination drug for CF (2019).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Example of oncology drug approved as a fixed-dose combination (2015).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Percent of approved drugs with black box warning.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. (a) Total analysis of Ro5 violations for 204 approved oral drugs and (b) Ro5 violations per year on 204 approved oral drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Examples of recently FDA-approved ADCs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. (a) Number of BLA vs NME (2010–2019). (b) Sales categorized by BLA and NME. Marketed sales for 2018 were taken from PharmaCompass and curated using the methods described in the text.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a> For simplicity, all similar products were combined where sales were shared across multiple companies (e.g., apixaban is comarketed by Pfizer and BMS). Vaccines were not included in the analysis. Only drugs with FDA approval were included in the analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/medium/jm0c01516_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. 2018 Sales (billions of USD) according to year of approval and orphan designation status. Sales figures taken from Pharmacompass.<a onclick="showRef(event, 'ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref123 ref124">(123,124)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01516/20210305/images/large/jm0c01516_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01516&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 200 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruffolo, R. R.</span></span> <span> </span><span class="NLM_article-title">Why Has R&D Productivity Declined in the Pharmaceutical Industry?</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1517/17460441.1.2.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1517%2F17460441.1.2.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=23495793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC3svntVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=99-102&issue=2&author=R.+R.+Ruffolo&title=Why+Has+R%26D+Productivity+Declined+in+the+Pharmaceutical+Industry%3F&doi=10.1517%2F17460441.1.2.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Why has R&D productivity declined in the pharmaceutical industry?</span></div><div class="casAuthors">Ruffolo Robert R</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-102</span>
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    </div><div class="casAbstract">Productivity in pharmaceutical R&D has been on the decline for the past several years, and much has been written on the subject.  The causes for the decline in productivity are many and complex.  Some of the causes are external to R&D and therefore difficult to address, such as growing regulatory conservatism and lack of international regulatory harmonisation.  However, a number of the causes for the decline in productivity are internal to R&D groups and can be addressed by R&D managers, such as cost-containment and maximum use of resources.  This article focuses on some of the major issues that have caused productivity to decline, and some of the areas where those who manage large R&D organisations may focus to improve R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjTvDTmQimo9FxYDaSSP8XfW6udTcc2ebf4Bgb1oQKdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svntVOqtA%253D%253D&md5=d7d0bad6b25ec13c9d48e86530a018ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1517%2F17460441.1.2.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.1.2.99%26sid%3Dliteratum%253Aachs%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26atitle%3DWhy%2520Has%2520R%2526D%2520Productivity%2520Declined%2520in%2520the%2520Pharmaceutical%2520Industry%253F%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2006%26volume%3D1%26issue%3D2%26spage%3D99%26epage%3D102%26doi%3D10.1517%2F17460441.1.2.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scannell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanckley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, B.</span></span> <span> </span><span class="NLM_article-title">Diagnosing the Decline in Pharmaceutical R&D Efficiency</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1038/nrd3681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&issue=3&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+Decline+in+Pharmaceutical+R%26D+Efficiency&doi=10.1038%2Fnrd3681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0li7K1O7ieG4mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520Decline%2520in%2520Pharmaceutical%2520R%2526D%2520Efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D191%26epage%3D200%26doi%3D10.1038%2Fnrd3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mytelka, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwiddie, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persinger, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munos, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindborg, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacht, A. L.</span></span> <span> </span><span class="NLM_article-title">How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/nrd3078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=20168317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=203-214&issue=3&author=S.+M.+Paulauthor=D.+S.+Mytelkaauthor=C.+T.+Dunwiddieauthor=C.+C.+Persingerauthor=B.+H.+Munosauthor=S.+R.+Lindborgauthor=A.+L.+Schacht&title=How+to+Improve+R%26D+Productivity%3A+The+Pharmaceutical+Industry%E2%80%99s+Grand+Challenge&doi=10.1038%2Fnrd3078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">How to improve R&D productivity: the pharmaceutical industry's grand challenge</span></div><div class="casAuthors">Paul, Steven M.; Mytelka, Daniel S.; Dunwiddie, Christopher T.; Persinger, Charles C.; Munos, Bernard H.; Lindborg, Stacy R.; Schacht, Aaron L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-214</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements.  In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the no. and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs.  However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a no. of years.  Here, we present a detailed anal. based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity.  We then propose specific strategies that could have the most substantial impact in improving R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY67PCIhaBVLVg90H21EOLACvtfcHk0lgjTgDfmYmjWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D&md5=2f32bcc48c869290eef18ff9400afcc5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3078%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DMytelka%26aufirst%3DD.%2BS.%26aulast%3DDunwiddie%26aufirst%3DC.%2BT.%26aulast%3DPersinger%26aufirst%3DC.%2BC.%26aulast%3DMunos%26aufirst%3DB.%2BH.%26aulast%3DLindborg%26aufirst%3DS.%2BR.%26aulast%3DSchacht%26aufirst%3DA.%2BL.%26atitle%3DHow%2520to%2520Improve%2520R%2526D%2520Productivity%253A%2520The%2520Pharmaceutical%2520Industry%25E2%2580%2599s%2520Grand%2520Challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D203%26epage%3D214%26doi%3D10.1038%2Fnrd3078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Lessons Learned from the Fate of AstraZeneca’s Drug Pipeline: A Five-Dimensional Framework</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&issue=6&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+AstraZeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0lgjTgDfmYmjWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520AstraZeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D6%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pammolli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magazzini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccaboni, M.</span></span> <span> </span><span class="NLM_article-title">The Productivity Crisis in Pharmaceutical R&D</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1038/nrd3405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=21629293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVegt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=428-438&issue=6&author=F.+Pammolliauthor=L.+Magazziniauthor=M.+Riccaboni&title=The+Productivity+Crisis+in+Pharmaceutical+R%26D&doi=10.1038%2Fnrd3405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The productivity crisis in pharmaceutical R&D</span></div><div class="casAuthors">Pammolli, Fabio; Magazzini, Laura; Riccaboni, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">428-438</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis of diseases have expanded the no. of plausible therapeutic targets for the development of innovative agents in recent decades.  However, although investment in pharmaceutical research and development (R&D) has increased substantially in this time, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging.  Here, using a large database that contains information on R&D projects for more than 28,000 compds. investigated since 1990, we examine the decline of R&D productivity in pharmaceuticals in the past two decades and its determinants.  We show that this decline is assocd. with an increasing concn. of R&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biol. mechanisms.  We also investigate the potential variations in productivity with regard to the regional location of companies and find that although companies based in the United States and Europe differ in the compn. of their R&D portfolios, there is no evidence of any productivity gap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4lNnATFMYqLVg90H21EOLACvtfcHk0lgysp4r6S4a8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVegt7o%253D&md5=8adb683913f6b27f212f05ee0220ff05</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3405%26sid%3Dliteratum%253Aachs%26aulast%3DPammolli%26aufirst%3DF.%26aulast%3DMagazzini%26aufirst%3DL.%26aulast%3DRiccaboni%26aufirst%3DM.%26atitle%3DThe%2520Productivity%2520Crisis%2520in%2520Pharmaceutical%2520R%2526D%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D6%26spage%3D428%26epage%3D438%26doi%3D10.1038%2Fnrd3405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span> </span><span class="NLM_article-title">The Decade’s Top 10 Patent Losses,
Worth a Whopping $915B
in Lifetime Sales</span>.  <i>FiercePharma</i>. <a href="https://www.fiercepharma.com/pharma/decade-s-top-10-patent-losses-featuring-seismic-sales-shifts" class="extLink">https://www.fiercepharma.com/pharma/decade-s-top-10-patent-losses-featuring-seismic-sales-shifts</a> (accessed <span class="NLM_year">2020</span>-04-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Decade%E2%80%99s+Top+10+Patent+Losses%2C%0AWorth+a+Whopping+%24915B%0Ain+Lifetime+Sales.+FiercePharma.+https%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fdecade-s-top-10-patent-losses-featuring-seismic-sales-shifts+%28accessed+2020-04-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Decade%25E2%2580%2599s%2520Top%252010%2520Patent%2520Losses%252C%250AWorth%2520a%2520Whopping%2520%2524915B%250Ain%2520Lifetime%2520Sales%26jtitle%3DFiercePharma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koyfman, H.</span></span> <span> </span><span class="NLM_article-title">Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA’s 2012 Draft Guidance for Industry</span>. <i>Biotechnol. Law Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1089/blr.2013.9884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1089%2Fblr.2013.9884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24761052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpvVSktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=238-251&issue=4&author=H.+Koyfman&title=Biosimilarity+and+Interchangeability+in+the+Biologics+Price+Competition+and+Innovation+Act+of+2009+and+FDA%E2%80%99s+2012+Draft+Guidance+for+Industry&doi=10.1089%2Fblr.2013.9884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry</span></div><div class="casAuthors">Koyfman Hannah</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology law report</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">238-251</span>
        ISSN:<span class="NLM_cas:issn">0730-031X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOJKb-2mmdz5NiNltV31zlfW6udTcc2eZP2mIACmHsA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpvVSktg%253D%253D&md5=43a4296e9621208038b8170fde206b75</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1089%2Fblr.2013.9884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fblr.2013.9884%26sid%3Dliteratum%253Aachs%26aulast%3DKoyfman%26aufirst%3DH.%26atitle%3DBiosimilarity%2520and%2520Interchangeability%2520in%2520the%2520Biologics%2520Price%2520Competition%2520and%2520Innovation%2520Act%2520of%25202009%2520and%2520FDA%25E2%2580%2599s%25202012%2520Draft%2520Guidance%2520for%2520Industry%26jtitle%3DBiotechnol.%2520Law%2520Rep.%26date%3D2013%26volume%3D32%26issue%3D4%26spage%3D238%26epage%3D251%26doi%3D10.1089%2Fblr.2013.9884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span> <i>What Is a Biosimilar?</i> <a href="https://www.fda.gov/media/108905/download" class="extLink">https://www.fda.gov/media/108905/download</a> (accessed <span class="NLM_year">2020</span>-11-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+What+Is+a+Biosimilar%3F+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F108905%2Fdownload+%28accessed+2020-11-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DWhat%2520Is%2520a%2520Biosimilar%253F%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raedler, L. A.</span></span> <span> </span><span class="NLM_article-title">Zarxio (Filgrastim-Sndz): First Biosimilar Approved in the United States</span>. <i>Am. Health Drug Benefits</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27668063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2svjvFWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=150-154&author=L.+A.+Raedler&title=Zarxio+%28Filgrastim-Sndz%29%3A+First+Biosimilar+Approved+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States</span></div><div class="casAuthors">Raedler Lisa A</div><div class="citationInfo"><span class="NLM_cas:title">American health & drug benefits</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Spec Feature</span>),
    <span class="NLM_cas:pages">150-4</span>
        ISSN:<span class="NLM_cas:issn">1942-2962</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAmJOZnkDiwdenUz0lpNqnfW6udTcc2eZP2mIACmHsA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svjvFWqtQ%253D%253D&md5=979d15b0adb0d2d524cba0c73491312d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaedler%26aufirst%3DL.%2BA.%26atitle%3DZarxio%2520%2528Filgrastim-Sndz%2529%253A%2520First%2520Biosimilar%2520Approved%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520Health%2520Drug%2520Benefits%26date%3D2016%26volume%3D9%26spage%3D150%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span> </span><span class="NLM_article-title">How Many Biosimilars Have Been Approved in the United States?</span> <i>Drugs.com</i>. <a href="https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/" class="extLink">https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/</a> (accessed <span class="NLM_year">2020</span>-04-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=How+Many+Biosimilars+Have+Been+Approved+in+the+United+States%3F+Drugs.com.+https%3A%2F%2Fwww.drugs.com%2Fmedical-answers%2Fmany-biosimilars-approved-united-states-3463281%2F+%28accessed+2020-04-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHow%2520Many%2520Biosimilars%2520Have%2520Been%2520Approved%2520in%2520the%2520United%2520States%253F%26jtitle%3DDrugs.com%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span> </span><span class="NLM_article-title">New Molecular
Entity (NME) Drug and New Biologic Approvals (2009–2015)</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://wayback.archive-it.org/7993/20170404174205/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm" class="extLink">https://wayback.archive-it.org/7993/20170404174205/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm</a> (accessed <span class="NLM_year">2018</span>-08-30).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=New+Molecular%0AEntity+%28NME%29+Drug+and+New+Biologic+Approvals+%282009%E2%80%932015%29.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwayback.archive-it.org%2F7993%2F20170404174205%2Fhttps%3A%2F%2Fwww.fda.gov%2FDrugs%2FDevelopmentApprovalProcess%2FHowDrugsareDevelopedandApproved%2FDrugandBiologicApprovalReports%2FNDAandBLAApprovalReports%2Fucm373420.htm+%28accessed+2018-08-30%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNew%2520Molecular%250AEntity%2520%2528NME%2529%2520Drug%2520and%2520New%2520Biologic%2520Approvals%2520%25282009%25E2%2580%25932015%2529%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span> </span><span class="NLM_article-title">New Molecular
Entity (NME) Drug and New Biologic Approvals 2015–2017</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ndaandblaapprovalreports/ucm373420.htm" class="extLink">https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ndaandblaapprovalreports/ucm373420.htm</a> (accessed <span class="NLM_year">2018</span>-08-30).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=New+Molecular%0AEntity+%28NME%29+Drug+and+New+Biologic+Approvals+2015%E2%80%932017.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdevelopmentapprovalprocess%2Fhowdrugsaredevelopedandapproved%2Fdrugandbiologicapprovalreports%2Fndaandblaapprovalreports%2Fucm373420.htm+%28accessed+2018-08-30%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNew%2520Molecular%250AEntity%2520%2528NME%2529%2520Drug%2520and%2520New%2520Biologic%2520Approvals%25202015%25E2%2580%25932017%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span> </span><span class="NLM_article-title">Novel
Drug Approvals for 2019</span>.  <i>U.S. Food
and Drug Administration</i>. <a href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019" class="extLink">https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019</a> (accessed <span class="NLM_year">2020</span>-02-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novel%0ADrug+Approvals+for+2019.+U.S.+Food%0Aand+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fnew-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products%2Fnovel-drug-approvals-2019+%28accessed+2020-02-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNovel%250ADrug%2520Approvals%2520for%25202019%26jtitle%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">Drug Development and FDA Approval, 1938–2013</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">e39</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1402114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMp1402114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24963591" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=e39&issue=26&author=J.+J.+Darrowauthor=A.+S.+Kesselheim&title=Drug+Development+and+FDA+Approval%2C+1938%E2%80%932013&doi=10.1056%2FNEJMp1402114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1402114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1402114%26sid%3Dliteratum%253Aachs%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DDrug%2520Development%2520and%2520FDA%2520Approval%252C%25201938%25E2%2580%25932013%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D26%26spage%3De39%26doi%3D10.1056%2FNEJMp1402114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="27635552405467616366">[email protected]</a>: FDA-Approved Drugs</span>.  <i>U.S. Food
and Drug Administration</i>. <a href="https://www.accessdata.fda.gov/scripts/cder/daf/" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/</a> (accessed <span class="NLM_year">2018</span>-08-30).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40FDA%3A+FDA-Approved+Drugs.+U.S.+Food%0Aand+Drug+Administration.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2F+%28accessed+2018-08-30%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%2540FDA%253A%2520FDA-Approved%2520Drugs%26jtitle%3DU.S.%2520Food%250Aand%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span> <i>Federal Register.
The Daily Journal of the United States Government</i>. <a href="https://www.federalregister.gov/" class="extLink">https://www.federalregister.gov/</a> (accessed <span class="NLM_year">2020</span>-10-17).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Federal+Register.%0AThe+Daily+Journal+of+the+United+States+Government.+https%3A%2F%2Fwww.federalregister.gov%2F+%28accessed+2020-10-17%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFederal%2520Register.%250AThe%2520Daily%2520Journal%2520of%2520the%2520United%2520States%2520Government%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&issue=2&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0lhcXCE5a3-d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26issue%3D2%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehlings, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestronk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissel, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cwik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanasse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florence, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Deflazacort vs Prednisone and Placebo for Duchenne Muscular Dystrophy</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2123</span>– <span class="NLM_lpage">2131</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000003217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1212%2FWNL.0000000000003217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27566742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyhu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=2123-2131&issue=20&author=R.+C.+Griggsauthor=J.+P.+Millerauthor=C.+R.+Greenbergauthor=D.+L.+Fehlingsauthor=A.+Pestronkauthor=J.+R.+Mendellauthor=R.+T.+Moxleyauthor=W.+Kingauthor=J.+T.+Kisselauthor=V.+Cwikauthor=M.+Vanasseauthor=J.+M.+Florenceauthor=S.+Pandyaauthor=J.+S.+Dubowauthor=J.+M.+Meyer&title=Efficacy+and+Safety+of+Deflazacort+vs+Prednisone+and+Placebo+for+Duchenne+Muscular+Dystrophy&doi=10.1212%2FWNL.0000000000003217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy</span></div><div class="casAuthors">Griggs, Robert C.; Miller, J. Phillip; Greenberg, Cheryl R.; Fehlings, Darcy L.; Pestronk, Alan; Mendell, Jerry R.; Moxley, Richard T., III; King, Wendy; Kissel, John T.; Cwik, Valerie; Vanasse, Michel; Florence, Julaine M.; Pandya, Shree; Dubow, Jordan S.; Meyer, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2123-2131</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To assess safety and efficacy of deflazacort (DFZ) and prednisone (PRED) vs placebo in Duchenne muscular dystrophy (DMD).  Methods: This phase III, double-blind, randomized, placebo-controlled, multicenter study evaluated muscle strength among 196 boys aged 5-15 years with DMD during a 52-wk period.  In phase 1, participants were randomly assigned to receive treatment with DFZ 0.9 mg/kg/d, DFZ 1.2 mg/kg/d, PRED 0.75 mg/kg/d, or placebo for 12 wk.  In phase 2, placebo participants were randomly assigned to 1 of the 3 active treatment groups.  Participants originally assigned to an active treatment continued that treatment for an addnl. 40 wk.  The primary efficacy endpoint was av. change in muscle strength from baseline to week 12 compared with placebo.  The study was completed in 1995.  Results: All treatment groups (DFZ 0.9 mg/kg/d, DFZ 1.2 mg/kg/d, and PRED 0.75 mg/kg/d) demonstrated significant improvement in muscle strength compared with placebo at 12 wk.  Participants taking PRED had significantly more wt. gain than placebo or both doses of DFZ at 12 wk; at 52 wk, participants taking PRED had significantly more wt. gain than both DFZ doses.  The most frequent adverse events in all 3 active treatment arms were Cushingoid appearance, erythema, hirsutism, increased wt., headache, and nasopharyngitis.  Conclusions: After 12 wk of treatment, PRED and both doses of DFZ improved muscle strength compared with placebo.  Deflazacort was assocd. with less wt. gain than PRED.  Classification of evidence: This study provides Class I evidence that for boys with DMD, daily use of either DFZ and PRED is effective in preserving muscle strength over a 12-wk period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIoye0qYEzybVg90H21EOLACvtfcHk0lhcXCE5a3-d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyhu7rO&md5=d58ea71c3c1b165ab4d992bd7b110dc8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000003217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000003217%26sid%3Dliteratum%253Aachs%26aulast%3DGriggs%26aufirst%3DR.%2BC.%26aulast%3DMiller%26aufirst%3DJ.%2BP.%26aulast%3DGreenberg%26aufirst%3DC.%2BR.%26aulast%3DFehlings%26aufirst%3DD.%2BL.%26aulast%3DPestronk%26aufirst%3DA.%26aulast%3DMendell%26aufirst%3DJ.%2BR.%26aulast%3DMoxley%26aufirst%3DR.%2BT.%26aulast%3DKing%26aufirst%3DW.%26aulast%3DKissel%26aufirst%3DJ.%2BT.%26aulast%3DCwik%26aufirst%3DV.%26aulast%3DVanasse%26aufirst%3DM.%26aulast%3DFlorence%26aufirst%3DJ.%2BM.%26aulast%3DPandya%26aufirst%3DS.%26aulast%3DDubow%26aufirst%3DJ.%2BS.%26aulast%3DMeyer%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Deflazacort%2520vs%2520Prednisone%2520and%2520Placebo%2520for%2520Duchenne%2520Muscular%2520Dystrophy%26jtitle%3DNeurology%26date%3D2016%26volume%3D87%26issue%3D20%26spage%3D2123%26epage%3D2131%26doi%3D10.1212%2FWNL.0000000000003217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span> <span> </span><span class="NLM_article-title">Taiwanese Company Wins FDA Approval for HIV Treatment with New Mechanism of Action</span>.  <i>FiercePharma</i>. <a href="https://www.fiercepharma.com/marketing/fda-approves-taimed-s-hiv-treatment-new-mechanism-action" class="extLink">https://www.fiercepharma.com/marketing/fda-approves-taimed-s-hiv-treatment-new-mechanism-action</a> (accessed <span class="NLM_year">2020</span>-04-19).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Liu&title=Taiwanese+Company+Wins+FDA+Approval+for+HIV+Treatment+with+New+Mechanism+of+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DA.%26atitle%3DTaiwanese%2520Company%2520Wins%2520FDA%2520Approval%2520for%2520HIV%2520Treatment%2520with%2520New%2520Mechanism%2520of%2520Action%26jtitle%3DFiercePharma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Win, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinheimer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsolais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span> <span> </span><span class="NLM_article-title">Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1711460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1711460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30110589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKnsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=645-654&issue=7&author=B.+Emuauthor=J.+Fesselauthor=S.+Schraderauthor=P.+Kumarauthor=G.+Richmondauthor=S.+Winauthor=S.+Weinheimerauthor=C.+Marsolaisauthor=S.+Lewis&title=Phase+3+Study+of+Ibalizumab+for+Multidrug-Resistant+HIV-1&doi=10.1056%2FNEJMoa1711460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 study of ibalizumab for multidrug-resistant HIV-1</span></div><div class="casAuthors">Emu, Brinda; Fessel, Jeffrey; Schrader, Shannon; Kumar, Princy; Richmond, Gary; Win, Sandra; Weinheimer, Steven; Marsolais, Christian; Lewis, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">645-654</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ibalizumab, a humanized IgG4 monoclonal antibody, blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4.  In this single-group, open-label, phase 3 study, we enrolled 40 adults with multidrug-resistant (MDR) HIV-1 infection in whom multiple antiretroviral therapies had failed.  All the patients had a viral load of more than 1000 copies of HIV-1 RNA per mL.  After a 7-day control period in which patients continued to receive their current therapy, a loading dose of 2000 mg of ibalizumab was infused; the viral load was quantified 7 days later.  Through week 25 of the study, patients received 800 mg of ibalizumab every 14 days, combined with an individually optimized background regimen including at least one fully active agent.  The primary end point was the proportion of patients with a decrease in viral load of at least 0.5 log10 copies per mL from baseline (day 7) to day 14.  A total of 31 patients completed the study.  The mean baseline viral load was 4.5 log10 copies per mL, and the mean CD4 count was 150 per μL.  Of the 40 patients in the intention-to-treat population, 33 (83%) had a decrease in viral load of at least 0.5 log10 copies per mL from baseline (P<0.001 for the comparison with the control period).  The mean viral-load decrease was 1.1 log10 copies per mL.  During the control period, 1 patient, who received the optimized background regimen prematurely, had a decrease in viral load of 0.5 log10 copies per mL.  At week 25, patients who had received ibalizumab plus an optimized background regimen had a mean decrease of 1.6 log10 copies per mL from baseline; 43% of the patients had a viral load of less than 50 copies per mL, and 50% had a viral load of less than 200 copies per mL.  Among 10 patients who had virol. failure or rebound, in vitro testing identified 9 who had a lower degree of susceptibility to ibalizumab than at baseline.  The most common adverse event was diarrhea (in 20% of patients).  Four patients died from causes related to underlying illnesses; 1 had a serious adverse event (the immune reconstitution inflammatory syndrome) that was deemed to be related to ibalizumab therapy.  In patients with MDR HIV-1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25-wk study.  Evidence of the emergence of diminished ibalizumab susceptibility was obsd. in vitro in patients who had virol. failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZxHWkfJ1Za7Vg90H21EOLACvtfcHk0limH9TEynRVGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKnsrnF&md5=0a2bb3fbe6a637b371c1cd3c9c56ba89</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1711460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1711460%26sid%3Dliteratum%253Aachs%26aulast%3DEmu%26aufirst%3DB.%26aulast%3DFessel%26aufirst%3DJ.%26aulast%3DSchrader%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DWin%26aufirst%3DS.%26aulast%3DWeinheimer%26aufirst%3DS.%26aulast%3DMarsolais%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DS.%26atitle%3DPhase%25203%2520Study%2520of%2520Ibalizumab%2520for%2520Multidrug-Resistant%2520HIV-1%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D7%26spage%3D645%26epage%3D654%26doi%3D10.1056%2FNEJMoa1711460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Ibalizumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0907-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0907-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29675744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVeit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=781-785&issue=7&author=A.+Markham&title=Ibalizumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0907-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ibalizumab: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">781-785</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">TaiMed Biologics is developing ibalizumab (Trogarzo, ibalizumab-uiyk)-a humanised IgG4 monoclonal antibody-as a treatment for HIV-1 infection.  Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunol. function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS.  This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5TKBF_1RnbVg90H21EOLACvtfcHk0limH9TEynRVGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVeit7o%253D&md5=7c66da702b532c85c7afaf6651ee0eb1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0907-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0907-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DIbalizumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D7%26spage%3D781%26epage%3D785%26doi%3D10.1007%2Fs40265-018-0907-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joffe, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easley, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrfeld, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slagle, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, J.</span></span> <span> </span><span class="NLM_article-title">FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1513686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMp1513686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26649985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC28vovVemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=101-104&issue=2&author=H.+V.+Joffeauthor=C.+Changauthor=C.+Sewellauthor=O.+Easleyauthor=C.+Nguyenauthor=S.+Dunnauthor=K.+Lehrfeldauthor=L.+Leeauthor=M.-J.+Kimauthor=A.+F.+Slagleauthor=J.+Beitz&title=FDA+Approval+of+Flibanserin%2D%2DTreating+Hypoactive+Sexual+Desire+Disorder&doi=10.1056%2FNEJMp1513686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder</span></div><div class="casAuthors">Joffe Hylton V; Chang Christina; Sewell Catherine; Easley Olivia; Nguyen Christine; Dunn Somya; Lehrfeld Kimberly; Lee LaiMing; Kim Myong-Jin; Slagle Ashley F; Beitz Julie</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXFy-UI4Wl4uQ4Pl9hzjQhfW6udTcc2eZ5-XepezZik7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vovVemtA%253D%253D&md5=b51c17fa51b2786a0b76c2733a4eb77f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1513686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1513686%26sid%3Dliteratum%253Aachs%26aulast%3DJoffe%26aufirst%3DH.%2BV.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DSewell%26aufirst%3DC.%26aulast%3DEasley%26aufirst%3DO.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DDunn%26aufirst%3DS.%26aulast%3DLehrfeld%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DM.-J.%26aulast%3DSlagle%26aufirst%3DA.%2BF.%26aulast%3DBeitz%26aufirst%3DJ.%26atitle%3DFDA%2520Approval%2520of%2520Flibanserin--Treating%2520Hypoactive%2520Sexual%2520Desire%2520Disorder%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26issue%3D2%26spage%3D101%26epage%3D104%26doi%3D10.1056%2FNEJMp1513686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitin, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCerbo, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasagna, L.</span></span> <span> </span><span class="NLM_article-title">The New Drug Approvals of 1987, 1988, and 1989: Trends in Drug Development</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1991.tb03694.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fj.1552-4604.1991.tb03694.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=2010558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADyaK3M7osFKgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1991&pages=116-122&issue=2&author=K.+I.+Kaitinauthor=P.+A.+DiCerboauthor=L.+Lasagna&title=The+New+Drug+Approvals+of+1987%2C+1988%2C+and+1989%3A+Trends+in+Drug+Development&doi=10.1002%2Fj.1552-4604.1991.tb03694.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The new drug approvals of 1987, 1988, and 1989: trends in drug development</span></div><div class="casAuthors">Kaitin K I; DiCerbo P A; Lasagna L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-22</span>
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">The new drug approvals of 1987, 1988, and 1989 were analyzed to determine whether there are any emerging trends in the US drug development and review processes.  Sixty-four new drugs were approved by the FDA during this period, of which 55 met the Center for the Study of Drug Development's definition of a new chemical entity (NEC).  For the 55 NCEs, the mean length of the investigational new drug application (IND) phase (IND filing to NDA submission) was 5.2 years, the new drug application (NDA) phase (NDA submission to approval) was 2.9 years, and the total phase (IND filing to NDA approval) was 8.1 years.  Nine of the 55 NCEs were classified by the FDA as 1A (important therapeutic gain), 15 were classified as 1B (modest gain), 29 were classified as 1C (little or no gain), and 2 were classified as 1AA (drugs to treat AIDS and AIDS-related conditions); 10 drugs were granted orphan status.  The mean NDA phase for 1A drugs was 2.4 years; 1B drugs, 2.9 years; 1C drugs, 3.1 years; 1AA drugs, 1.4 years; and orphan drugs, 2.5 years.  Forty-four of the 55 NCEs (80%) were available in foreign markets before US approval was given, with a mean of 6.5 years of prior marketing.  These data are consistent with figures for previous years and suggest little change in the rate of new drug development and review in the United States.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG1LiGXyjMdrGbPKh4T9eAfW6udTcc2eZ5-XepezZik7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7osFKgtA%253D%253D&md5=0de45cc35ca4dfce576056a5e543c670</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1991.tb03694.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1991.tb03694.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaitin%26aufirst%3DK.%2BI.%26aulast%3DDiCerbo%26aufirst%3DP.%2BA.%26aulast%3DLasagna%26aufirst%3DL.%26atitle%3DThe%2520New%2520Drug%2520Approvals%2520of%25201987%252C%25201988%252C%2520and%25201989%253A%2520Trends%2520in%2520Drug%2520Development%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1991%26volume%3D31%26issue%3D2%26spage%3D116%26epage%3D122%26doi%3D10.1002%2Fj.1552-4604.1991.tb03694.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitin, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manocchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasagna, L.</span></span> <span> </span><span class="NLM_article-title">The New Drug Approvals of 1990, 1991, and 1992: Trends in Drug Development</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1002/j.1552-4604.1994.tb03975.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fj.1552-4604.1994.tb03975.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=8163711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADyaK2c3hs1Gluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1994&pages=120-127&issue=2&author=K.+I.+Kaitinauthor=M.+Manocchiaauthor=M.+Seibringauthor=L.+Lasagna&title=The+New+Drug+Approvals+of+1990%2C+1991%2C+and+1992%3A+Trends+in+Drug+Development&doi=10.1002%2Fj.1552-4604.1994.tb03975.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The new drug approvals of 1990, 1991, and 1992: trends in drug development</span></div><div class="casAuthors">Kaitin K I; Manocchia M; Seibring M; Lasagna L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-7</span>
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">Efforts to speed the development and review of new drugs have increased sharply in recent years.  This report, which is the third in a series on trends in drug development, examines the new drug approvals of 1990, 1991, and 1992.  During the 3-year study period, the Food and Drug Administration (FDA) approved 79 new drugs, 74 of which met the Center for the Study of Drug Development's definition of a new chemical entity (NCE).  Of the 74 NCEs, 36 (49%) were considered by the FDA to represent notable therapeutic gains and were selected for "priority" review (i.e., drugs rated 1P, 1A, 1AA, and 1B), and 38 (51%) were considered to represent little or no gain and received "standard" reviews (i.e., drugs rated 1S and 1C).  Investigational new drug application (IND) filing and new drug application (NDA) submission dates on all 74 drugs were obtained from responses to our manufacturer surveys as well as from FDA and public sources.  The mean length of the clinical phase (IND filing to NDA submission) was 6.1 years and that of the review phase (NDA submission to approval) was 2.6 years.  Of the 74 NCEs, 43 (58%) were available in foreign markets at least 1 year before U.S. approval, with a mean of 5.6 years of foreign marketing.  In general, 1990 to 1992 figures are similar to those in the last half of the 1980s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQasH_KqiAkCLJzI8owOhpDfW6udTcc2eZJVGjtbaVDZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3hs1Gluw%253D%253D&md5=394edc4368c601e36ddc37fd88215fc7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1994.tb03975.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1994.tb03975.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaitin%26aufirst%3DK.%2BI.%26aulast%3DManocchia%26aufirst%3DM.%26aulast%3DSeibring%26aufirst%3DM.%26aulast%3DLasagna%26aufirst%3DL.%26atitle%3DThe%2520New%2520Drug%2520Approvals%2520of%25201990%252C%25201991%252C%2520and%25201992%253A%2520Trends%2520in%2520Drug%2520Development%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1994%26volume%3D34%26issue%3D2%26spage%3D120%26epage%3D127%26doi%3D10.1002%2Fj.1552-4604.1994.tb03975.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keyhani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener-West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, N.</span></span> <span> </span><span class="NLM_article-title">Are Development Times for Pharmaceuticals Increasing or Decreasing?</span>. <i>Health Aff. Proj. Hope</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1377/hlthaff.25.2.461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1377%2Fhlthaff.25.2.461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=16522587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BD287jsFWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=461-468&issue=2&author=S.+Keyhaniauthor=M.+Diener-Westauthor=N.+Powe&title=Are+Development+Times+for+Pharmaceuticals+Increasing+or+Decreasing%3F&doi=10.1377%2Fhlthaff.25.2.461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Are development times for pharmaceuticals increasing or decreasing?</span></div><div class="casAuthors">Keyhani Salomeh; Diener-West Marie; Powe Neil</div><div class="citationInfo"><span class="NLM_cas:title">Health affairs (Project Hope)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">461-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This study examines trends in drug development times.  Longer clinical trial times have been described as one factor leading to higher drug prices.  Previous reports on development times have been based on proprietary data.  We examined trends in development times for 168 drugs with data collected from publicly available sources.  The median clinical trial and regulatory review periods for drugs approved between 1992 and 2002 were 5.1 and 1.2 years, respectively.  Clinical trial periods have not increased during this time frame, and regulatory review periods have decreased.  Therefore, it is unlikely that longer clinical trial times are contributing to rising prescription drug prices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb6nwqk7-fKqe0F5ixvZgXfW6udTcc2eZJVGjtbaVDZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287jsFWjtQ%253D%253D&md5=c74b7687a7762a2b32ca41e4e43c3882</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1377%2Fhlthaff.25.2.461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1377%252Fhlthaff.25.2.461%26sid%3Dliteratum%253Aachs%26aulast%3DKeyhani%26aufirst%3DS.%26aulast%3DDiener-West%26aufirst%3DM.%26aulast%3DPowe%26aufirst%3DN.%26atitle%3DAre%2520Development%2520Times%2520for%2520Pharmaceuticals%2520Increasing%2520or%2520Decreasing%253F%26jtitle%3DHealth%2520Aff.%2520Proj.%2520Hope%26date%3D2006%26volume%3D25%26issue%3D2%26spage%3D461%26epage%3D468%26doi%3D10.1377%2Fhlthaff.25.2.461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitin, K. I.</span></span> <span> </span><span class="NLM_article-title">The Prescription Drug User Fee Act of 1992 and the New Drug Development Process</span>. <i>Am. J. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1097/00045391-199705000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1097%2F00045391-199705000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10423607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FptFajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=167-172&issue=5&author=K.+I.+Kaitin&title=The+Prescription+Drug+User+Fee+Act+of+1992+and+the+New+Drug+Development+Process&doi=10.1097%2F00045391-199705000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The prescription Drug User Fee Act of 1992 and the new drug development process</span></div><div class="casAuthors">Kaitin K I</div><div class="citationInfo"><span class="NLM_cas:title">American journal of therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">167-72</span>
        ISSN:<span class="NLM_cas:issn">1075-2765</span>.
    </div><div class="casAbstract">The Prescription Drug User Fee Act of 1992 (PDUFA) authorizes the US Food and Drug Administration (FDA) to levy user fees on manufacturers who submit applications to the agency.  Revenues are dedicated to the achievement of a set of specific performance goals, documented by the FDA Commissioner and referenced in the Act.  The FDA currently credits PDUFA with the agency's success in reducing new drug review times and eliminating the formidable new drug application (NDA) backlog.  To provide an independent assessment of PDUFA's impact on the new drug development process, the Tufts Center for the Study of Drug Development established an annual user fee survey of over 50 major pharmaceutical and biotechnology firms with operations in the United States.  As of December 31, 1996, survey data have been collected for fiscal years 1994, 1995, and 1996.  Data from a cohort of user fee drugs approved in 1993-1996 were compared with data from all non-user fee drugs approved in 1990-1992.  Whereas the mean approval phase (NDA submission to approval) for the user fee drugs was considerably shorter than that for the non-user fee drugs (14.5 versus 31.0 months, respectively), the mean clinical phase (investigational new drug application filing to NDA submission) was somewhat longer (88.0 versus 81.1 months, respectively).  As a result, the total time from the start of clinical testing to drug approval (total phase) was only marginally shorter for the user fee drugs (102.0 versus 112.1 months, respectively).  These results highlight the need for efforts to reduce lengthy drug development times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_oT-CMiv0s-2mnZh2OgS0fW6udTcc2eZJVGjtbaVDZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FptFajtA%253D%253D&md5=eefdb3ef2a276d86d93921752bd77994</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2F00045391-199705000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00045391-199705000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DKaitin%26aufirst%3DK.%2BI.%26atitle%3DThe%2520Prescription%2520Drug%2520User%2520Fee%2520Act%2520of%25201992%2520and%2520the%2520New%2520Drug%2520Development%2520Process%26jtitle%3DAm.%2520J.%2520Ther.%26date%3D1997%26volume%3D4%26issue%3D5%26spage%3D167%26epage%3D172%26doi%3D10.1097%2F00045391-199705000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span> <span> </span><span class="NLM_article-title">Trends in Utilization of FDA Expedited Drug Development and Approval Programs, 1987–2014: Cohort Study</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">h4633</span>, <span class="refDoi"> DOI: 10.1136/bmj.h4633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1136%2Fbmj.h4633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26400751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWgtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2015&pages=h4633&author=A.+S.+Kesselheimauthor=B.+Wangauthor=J.+M.+Franklinauthor=J.+J.+Darrow&title=Trends+in+Utilization+of+FDA+Expedited+Drug+Development+and+Approval+Programs%2C+1987%E2%80%932014%3A+Cohort+Study&doi=10.1136%2Fbmj.h4633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study</span></div><div class="casAuthors">Kesselheim, Aaron S.; Wang, Bo; Franklin, Jessica M.; Darrow, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">BMJ [British Medical Journal]</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">h4633/1-h4633/7</span>CODEN:
                <span class="NLM_cas:coden">BMJBFE</span>;
        ISSN:<span class="NLM_cas:issn">1756-1833</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective To evaluate the use of special expedited development and review pathways at the US Food and Drug Administration over the past two decades.  Design Cohort study.  Setting FDA approved novel therapeutics between 1987 and 2014.  Population Publicly available sources provided each drug's year of approval, their innovativeness (first in class vs. not first in class), World Health Organization Anat. Therapeutic Classification, and which (if any) of the FDA's four primary expedited development and review programs or designations were assocd. with each drug: orphan drug, fast track, accelerated approval, and priority review.  Main outcome measures Logistic regression models evaluated trends in the proportion of drugs assocd. with each of the four expedited development and review programs.  To evaluate the no. of programs assocd. with each approved drug over time, Poisson models were employed, with the no. of programs as the dependent variable and a linear term for year of approval.  The difference in trends was compared between drugs that were first in class and those that were not.  Results The FDA approved 774 drugs during the study period, with one third representing first in class agents.  Priority review (43%) was the most prevalent of the four programs, with accelerated approval (9%) the least common.  There was a significant increase of 2.6% per yr in the no. of expedited review and approval programs granted to each newly approved agent (incidence rate ratio 1.026, 95% confidence interval 1.017 to 1.035, P<0.001), and a 2.4% increase in the proportion of drugs assocd. with at least one such program (odds ratio 1.024, 95% confidence interval 1.006 to 1.043, P = 0.009).  Driving this trend was an increase in the proportion of approved, non-first in class drugs assocd. with at least one program for drugs (P = 0.03 for interaction).  Conclusions In the past two decades, drugs newly approved by the FDA have been assocd. with an increasing no. of expedited development or review programs.  Though expedited programs should be strictly limited to drugs providing noticeable clin. advances, this trend is being driven by drugs that are not first in class and thus potentially less innovative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopP9YYTUZJibVg90H21EOLACvtfcHk0ljNpnc3uU5X7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWgtrvE&md5=bd55b182d49474122a46bb75b0a7f108</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1136%2Fbmj.h4633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.h4633%26sid%3Dliteratum%253Aachs%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFranklin%26aufirst%3DJ.%2BM.%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26atitle%3DTrends%2520in%2520Utilization%2520of%2520FDA%2520Expedited%2520Drug%2520Development%2520and%2520Approval%2520Programs%252C%25201987%25E2%2580%25932014%253A%2520Cohort%2520Study%26jtitle%3DBMJ.%26date%3D2015%26volume%3D351%26spage%3Dh4633%26doi%3D10.1136%2Fbmj.h4633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chary, K. V.</span></span> <span> </span><span class="NLM_article-title">Expedited Drug Review Process: Fast, but Flawed</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.184768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.4103%2F0976-500X.184768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27440949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ivF2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=57-61&issue=2&author=K.+V.+Chary&title=Expedited+Drug+Review+Process%3A+Fast%2C+but+Flawed&doi=10.4103%2F0976-500X.184768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Expedited drug review process: Fast, but flawed</span></div><div class="casAuthors">Chary Krishnan Vengadaraga</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">57-61</span>
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXY9sT2o6-sZw7prLlxLOzfW6udTcc2eZxEcwUYaW697ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ivF2gtw%253D%253D&md5=479c219b489e4a4289a71e7f5cc5d489</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.184768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.184768%26sid%3Dliteratum%253Aachs%26aulast%3DChary%26aufirst%3DK.%2BV.%26atitle%3DExpedited%2520Drug%2520Review%2520Process%253A%2520Fast%252C%2520but%2520Flawed%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2016%26volume%3D7%26issue%3D2%26spage%3D57%26epage%3D61%26doi%3D10.4103%2F0976-500X.184768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012–2016</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>318</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1001/jama.2017.14896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1001%2Fjama.2017.14896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29209711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1M3otl2ntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2017&pages=2137-2138&issue=21&author=T.+J.+Hwangauthor=J.+J.+Darrowauthor=A.+S.+Kesselheim&title=The+FDA%E2%80%99s+Expedited+Programs+and+Clinical+Development+Times+for+Novel+Therapeutics%2C+2012%E2%80%932016&doi=10.1001%2Fjama.2017.14896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016</span></div><div class="casAuthors">Hwang Thomas J; Darrow Jonathan J; Kesselheim Aaron S</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2137-2138</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVkldKbp5_JP6BottYdIAWfW6udTcc2eYSQtcOrT1d_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3otl2ntQ%253D%253D&md5=05a9b738737abf7f9c245695aba18fb7</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1001%2Fjama.2017.14896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2017.14896%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DT.%2BJ.%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DThe%2520FDA%25E2%2580%2599s%2520Expedited%2520Programs%2520and%2520Clinical%2520Development%2520Times%2520for%2520Novel%2520Therapeutics%252C%25202012%25E2%2580%25932016%26jtitle%3DJAMA%26date%3D2017%26volume%3D318%26issue%3D21%26spage%3D2137%26epage%3D2138%26doi%3D10.1001%2Fjama.2017.14896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span> </span><span class="NLM_article-title">NDA and BLA Approval Times</span>.  <i>U.S. Food and
Drug Administration</i>. <a href="https://www.fda.gov/drugs/nda-and-bla-approvals/nda-and-bla-approval-times" class="extLink">https://www.fda.gov/drugs/nda-and-bla-approvals/nda-and-bla-approval-times</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NDA+and+BLA+Approval+Times.+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fnda-and-bla-approvals%2Fnda-and-bla-approval-times+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNDA%2520and%2520BLA%2520Approval%2520Times%26jtitle%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, C.</span></span> <span> </span><span class="NLM_article-title">Trial Watch: Clinical Trial Cycle Times Continue to Increase despite Industry Efforts</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2017.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28184041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisV2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=157&issue=3&author=L.+Martinauthor=M.+Hutchensauthor=C.+Hawkins&title=Trial+Watch%3A+Clinical+Trial+Cycle+Times+Continue+to+Increase+despite+Industry+Efforts&doi=10.1038%2Fnrd.2017.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Trial watch Clinical trial cycle times continue to increase despite industry efforts</span></div><div class="casAuthors">Martin, Linda; Hutchens, Melissa; Hawkins, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3cSq3i47XYLVg90H21EOLACvtfcHk0liNqLOcnKHl0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisV2qsro%253D&md5=c4b737bf882e134bf8af47da4058e9d6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.21%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DL.%26aulast%3DHutchens%26aufirst%3DM.%26aulast%3DHawkins%26aufirst%3DC.%26atitle%3DTrial%2520Watch%253A%2520Clinical%2520Trial%2520Cycle%2520Times%2520Continue%2520to%2520Increase%2520despite%2520Industry%2520Efforts%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D3%26spage%3D157%26doi%3D10.1038%2Fnrd.2017.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span> <i>2015 Novel Drugs Summary</i>. <a href="https://www.fda.gov/media/95661/download" class="extLink">https://www.fda.gov/media/95661/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2015+Novel+Drugs+Summary.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F95661%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2015%2520Novel%2520Drugs%2520Summary%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furberg, C. D.</span></span> <span> </span><span class="NLM_article-title">Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration: The Class of 2008</span>. <i>JAMA Int. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>174</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1001/jamainternmed.2013.11813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1001%2Fjamainternmed.2013.11813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24166236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2c7gsVWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2014&pages=90-95&issue=1&author=T.+J.+Mooreauthor=C.+D.+Furberg&title=Development+Times%2C+Clinical+Testing%2C+Postmarket+Follow-up%2C+and+Safety+Risks+for+the+New+Drugs+Approved+by+the+US+Food+and+Drug+Administration%3A+The+Class+of+2008&doi=10.1001%2Fjamainternmed.2013.11813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008</span></div><div class="casAuthors">Moore Thomas J; Furberg Curt D</div><div class="citationInfo"><span class="NLM_cas:title">JAMA internal medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  The US Food and Drug Administration (FDA) has advanced multiple proposals to promote biomedical innovation by making new drugs available more quickly but with shorter, smaller, and more selective clinical trials and less rigorous end points.  OBJECTIVE:  To inform the debate about appropriate standards, we studied the development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the FDA in 2008, when most provisions of current law, regulation, and policies were in effect.  DESIGN:  Descriptive study of the drugs classified as new molecular entities using preapproval FDA evaluation documents, agency drug information databases, prescribing information, and other primary data sources.  MAIN OUTCOMES AND MEASURES:  Comparison of drugs that received standard review and those deemed sufficiently innovative to receive expedited review with regard to clinical development and FDA review time, the size and duration of efficacy trials, safety issues, and postmarket follow-up.  RESULTS:  In 2008, the FDA approved 20 therapeutic drugs, 8 with expedited review and 12 with standard review.  The expedited drugs took a median of 5.1 years (range, 1.6-10.6 years) of clinical development to obtain marketing approval compared with 7.5 years (range, 4.7-19.4 years) for the standard review drugs (P = .05).  The expedited drugs were tested for efficacy in a median of 104 patients receiving the active drug (range, 23-599), compared with a median of 580 patients (range, 75-1207) for standard review drugs (P = .003).  Nonclinical testing showed that 6 therapeutic drugs were animal carcinogens, 5 were in vitro mutagens, and 14 were animal teratogens.  Other safety concerns resulted in 5 Boxed Warnings; 8 drugs required risk management plans.  The FDA required 85 postmarket commitments.  By 2013, 5 drugs acquired a new or expanded Boxed Warning; 26 of 85 (31%) of the postmarketing study commitments had been fulfilled, and 8 (9%) had been submitted for agency review.  CONCLUSIONS AND RELEVANCE:  For new drugs approved by the FDA in 2008, those that received expedited review were approved more rapidly than those that received standard review.  However, considerably fewer patients were studied prior to approval, and many safety questions remained unanswered.  By 2013, many postmarketing studies had not been completed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkudPyAJDRTLmQt-ICR3qNfW6udTcc2eZ18bzmt19fyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7gsVWhuw%253D%253D&md5=b48bfd358d6ac1e236b56c767ab4119d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2013.11813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2013.11813%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DT.%2BJ.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DDevelopment%2520Times%252C%2520Clinical%2520Testing%252C%2520Postmarket%2520Follow-up%252C%2520and%2520Safety%2520Risks%2520for%2520the%2520New%2520Drugs%2520Approved%2520by%2520the%2520US%2520Food%2520and%2520Drug%2520Administration%253A%2520The%2520Class%2520of%25202008%26jtitle%3DJAMA%2520Int.%2520Med.%26date%3D2014%26volume%3D174%26issue%3D1%26spage%3D90%26epage%3D95%26doi%3D10.1001%2Fjamainternmed.2013.11813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span> <i>New Drug Therapy Approvals 2019</i>. <a href="https://www.fda.gov/media/134493/download" class="extLink">https://www.fda.gov/media/134493/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Drug+Therapy+Approvals+2019.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F134493%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Drug%2520Therapy%2520Approvals%25202019%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span> <i>New Drug Therapy
Approvals 2018</i>. <a href="https://www.fda.gov/media/120357/download" class="extLink">https://www.fda.gov/media/120357/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Drug+Therapy%0AApprovals+2018.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F120357%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Drug%2520Therapy%250AApprovals%25202018%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avorn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">FDA Approval and Regulation of Pharmaceuticals, 1983–2018</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>323</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1001/jama.2019.20288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1001%2Fjama.2019.20288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31935033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MbpvVGntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2020&pages=164-176&issue=2&author=J.+J.+Darrowauthor=J.+Avornauthor=A.+S.+Kesselheim&title=FDA+Approval+and+Regulation+of+Pharmaceuticals%2C+1983%E2%80%932018&doi=10.1001%2Fjama.2019.20288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval and Regulation of Pharmaceuticals, 1983-2018</span></div><div class="casAuthors">Darrow Jonathan J; Avorn Jerry; Kesselheim Aaron S</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-176</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  US law requires testing of new drugs before approval to ensure that they provide a well-defined benefit that is commensurate with their risks.  A major challenge for the US Food and Drug Administration (FDA) is to achieve an appropriate balance between rigorous testing and the need for timely approval of drugs that have benefits that outweigh their risks.  Objective:  To describe the evolution of laws and standards affecting drug testing, the use of new approval programs and standards, expansions of the role and authority of the FDA, and changes in the number of drugs approved from the 1980s to 2018.  Evidence:  Sources of evidence included principal federal laws and FDA regulations (1962-2018) and FDA databases of approved new drugs (1984-2018), generic drugs (1970-2018), biologics (1984-2018), and vaccines (1998-2018); special development and approval programs (Orphan drug [1984-2018], Fast-Track [1988-2018], Priority Review and its predecessors [1984-2018], Accelerated Approval [1992-2018], and Breakthrough Therapy [2012-2018]); expanded access (2010-2017) and Risk Evaluation and Mitigation Strategies (2008-2018); and user fees paid to the FDA by industry (1993-2018).  Findings:  From 1983 to 2018, legislation and regulatory initiatives have substantially changed drug approval at the FDA.  The mean annual number of new drug approvals, including biologics, was 34 from 1990-1999, 25 from 2000-2009, and 41 from 2010-2018.  New biologic product approvals increased from a median of 2.5 from 1990-1999, to 5 from 2000-2013, to 12 from 2014-2018.  The median annual number of generic drugs approved was 136 from 1970 to the enactment of the Hatch-Waxman Act in 1984; 284 from 1985 to the enactment of the Generic Drug User Fee Act in 2012; and 588 from 2013-2018.  Prescription drug user fee funding expanded from new drugs and biologics in 1992 to generic and biosimilar drugs in 2012.  The amount of Prescription Drug User Fee Act fees collected from industry increased from an annual mean of $66 million in 1993-1997 to $820 million in 2013-2017, and in 2018, user fees accounted for approximately 80% of the salaries of review personnel responsible for the approval of new drugs.  The proportion of drugs approved with an Orphan Drug Act designation increased from 18% (55/304) in 1984-1995, to 22% (82/379) in 1996-2007, to 41% (154/380) in 2008-2018.  Use of Accelerated Approval, Fast-Track, and Priority Review for new drugs has increased over time, with 81% (48/59) of new drugs benefiting from at least 1 such expedited program in 2018.  The proportion of new approvals supported by at least 2 pivotal trials decreased from 80.6% in 1995-1997 to 52.8% in 2015-2017, based on 124 and 106 approvals, respectively, while the median number of patients studied did not change significantly (774 vs 816).  FDA drug review times declined from more than 3 years in 1983 to less than 1 year in 2017, but total time from the authorization of clinical testing to approval has remained at approximately 8 years over that period.  Conclusions and Relevance:  Over the last 4 decades, the approval and regulation processes for pharmaceutical agents have evolved and increased in complexity as special programs have been added and as the use of surrogate measures has been encouraged.  The FDA funding needed to implement and manage these programs has been addressed by expanding industry-paid user fees.  The FDA has increasingly accepted less data and more surrogate measures, and has shortened its review times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQALVBvmUct2mHOrQ6qeX-mfW6udTcc2eZ18bzmt19fyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbpvVGntQ%253D%253D&md5=5b1fd18963395a89e3865d4ebb430b16</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1001%2Fjama.2019.20288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2019.20288%26sid%3Dliteratum%253Aachs%26aulast%3DDarrow%26aufirst%3DJ.%2BJ.%26aulast%3DAvorn%26aufirst%3DJ.%26aulast%3DKesselheim%26aufirst%3DA.%2BS.%26atitle%3DFDA%2520Approval%2520and%2520Regulation%2520of%2520Pharmaceuticals%252C%25201983%25E2%2580%25932018%26jtitle%3DJAMA%26date%3D2020%26volume%3D323%26issue%3D2%26spage%3D164%26epage%3D176%26doi%3D10.1001%2Fjama.2019.20288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span> <i>FY 2011 Innovative Drug Approvals</i>. <a href="https://wayback.archive-it.org/7993/20170723162306/https:/www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf" class="extLink">https://wayback.archive-it.org/7993/20170723162306/https:/www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FY+2011+Innovative+Drug+Approvals.+https%3A%2F%2Fwayback.archive-it.org%2F7993%2F20170723162306%2Fhttps%3A%2Fwww.fda.gov%2Fdownloads%2FAboutFDA%2FReportsManualsForms%2FReports%2FUCM278358.pdf+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFY%25202011%2520Innovative%2520Drug%2520Approvals%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span> <i>FY 2012 Innovative
Drug Approvals</i>. <a href="https://www.fdanews.com/ext/resources/files/archives/1/12/12-7-12-approvals.pdf" class="extLink">https://www.fdanews.com/ext/resources/files/archives/1/12/12-7-12-approvals.pdf</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FY+2012+Innovative%0ADrug+Approvals.+https%3A%2F%2Fwww.fdanews.com%2Fext%2Fresources%2Ffiles%2Farchives%2F1%2F12%2F12-7-12-approvals.pdf+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFY%25202012%2520Innovative%250ADrug%2520Approvals%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span> <i>Approved Drugs
2013</i>. <a href="https://www.fda.gov/media/87579/download" class="extLink">https://www.fda.gov/media/87579/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Approved+Drugs%0A2013.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F87579%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DApproved%2520Drugs%250A2013%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span> <i>2014 FDA New Drug Approvals</i>. <a href="https://cellculturedish.com/2014-fda-new-drug-approvals-11-biologics-receive-approval/" class="extLink">https://cellculturedish.com/2014-fda-new-drug-approvals-11-biologics-receive-approval/</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2014+FDA+New+Drug+Approvals.+https%3A%2F%2Fcellculturedish.com%2F2014-fda-new-drug-approvals-11-biologics-receive-approval%2F+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2014%2520FDA%2520New%2520Drug%2520Approvals%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span> <i>2016 Novel Drugs
Summary</i>. <a href="https://www.fda.gov/media/102618/download" class="extLink">https://www.fda.gov/media/102618/download</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+2016+Novel+Drugs%0ASummary.+https%3A%2F%2Fwww.fda.gov%2Fmedia%2F102618%2Fdownload+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3D2016%2520Novel%2520Drugs%250ASummary%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span> <i>New Drug Therapy Approvals
2017</i>. <a href="https://www.fda.gov/files/about%20fda/published/2017-New-Drug-Therapy-Approvals-Report.pdf" class="extLink">https://www.fda.gov/files/about%20fda/published/2017-New-Drug-Therapy-Approvals-Report.pdf</a> (accessed <span class="NLM_year">2020</span>-04-06).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Drug+Therapy+Approvals%0A2017.+https%3A%2F%2Fwww.fda.gov%2Ffiles%2Fabout%2520fda%2Fpublished%2F2017-New-Drug-Therapy-Approvals-Report.pdf+%28accessed+2020-04-06%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Drug%2520Therapy%2520Approvals%250A2017%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamrén, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matcham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Impact of a Five-Dimensional Framework on R&D Productivity at AstraZeneca</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2017.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29348681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=167-181&issue=3&author=P.+Morganauthor=D.+G.+Brownauthor=S.+Lennardauthor=M.+J.+Andertonauthor=J.+C.+Barrettauthor=U.+Erikssonauthor=M.+Fidockauthor=B.+Hamr%C3%A9nauthor=A.+Johnsonauthor=R.+E.+Marchauthor=J.+Matchamauthor=J.+Mettetalauthor=D.+J.+Nichollsauthor=S.+Platzauthor=S.+Reesauthor=M.+A.+Snowdenauthor=M.+N.+Pangalos&title=Impact+of+a+Five-Dimensional+Framework+on+R%26D+Productivity+at+AstraZeneca&doi=10.1038%2Fnrd.2017.244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of a five-dimensional framework on R&D productivity at AstraZeneca</span></div><div class="casAuthors">Morgan, Paul; Brown, Dean G.; Lennard, Simon; Anderton, Mark J.; Barrett, J. Carl; Eriksson, Ulf; Fidock, Mark; Hamren, Bengt; Johnson, Anthony; March, Ruth E.; Matcham, James; Mettetal, Jerome; Nicholls, David J.; Platz, Stefan; Rees, Steve; Snowden, Michael A.; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry avs. in 2005-2010.  A cornerstone of the revised strategy was to focus decision-making on five tech. determinants (the right target, right tissue, right safety, right patient and right com. potential).  In this article, we describe the progress made using this '5R framework' in the hope that our experience could be useful to other companies tackling R&D productivity issues.  We focus on the evolution of our approach to target validation, hit and lead optimization, pharmacokinetic/pharmacodynamic modeling and drug safety testing, which have helped improve the quality of candidate drug nomination, as well as the development of the right culture, where 'truth seeking' is encouraged by more rigorous and quant. decision-making.  We also discuss where the approach has failed and the lessons learned.  Overall, the continued evolution and application of the 5R framework are beginning to have an impact, with success rates from candidate drug nomination to phase III completion improving from 4% in 2005-2010 to 19% in 2012-2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdx6OlRZpzrVg90H21EOLACvtfcHk0liIFKWdi6HWaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D&md5=06906e0bc59dc715941998660a514ffe</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.244%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DLennard%26aufirst%3DS.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DEriksson%26aufirst%3DU.%26aulast%3DFidock%26aufirst%3DM.%26aulast%3DHamr%25C3%25A9n%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DMarch%26aufirst%3DR.%2BE.%26aulast%3DMatcham%26aufirst%3DJ.%26aulast%3DMettetal%26aufirst%3DJ.%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DPlatz%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DSnowden%26aufirst%3DM.%2BA.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DImpact%2520of%2520a%2520Five-Dimensional%2520Framework%2520on%2520R%2526D%2520Productivity%2520at%2520AstraZeneca%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26issue%3D3%26spage%3D167%26epage%3D181%26doi%3D10.1038%2Fnrd.2017.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">Development of Immuno-Oncology Drugs - From CTLA4 to PD1 to the Next Generations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2015.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26965203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=235-247&issue=4&author=A.+Hoos&title=Development+of+Immuno-Oncology+Drugs+-+From+CTLA4+to+PD1+to+the+Next+Generations&doi=10.1038%2Fnrd.2015.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations</span></div><div class="casAuthors">Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-247</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance.  This success is based on progress in both preclin. and clin. science, including the development of new methods of investigation.  Immuno-oncol. has become a sub-specialty within oncol. owing to its unique science and its potential for substantial and long-term clin. benefit.  Immunotherapy agents do not directly attack the tumor but instead mobilize the immune system - this can be achieved through various approaches that utilize adaptive or innate immunity.  Therefore, immuno-oncol. drug development encompasses a broad range of agents, including antibodies, peptides, proteins, small mols., adjuvants, cytokines, oncolytic viruses, bi-specific mols. and cellular therapies.  This Perspective summarizes the recent history of cancer immunotherapy, including the factors that led to its success, provides an overview of novel drug-development considerations, summarizes three generations of immunotherapies that have been developed since 2011 and, thus, illustrates the breadth of opportunities these new generations of immunotherapies represent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8GBkFRW-5VLVg90H21EOLACvtfcHk0ljSUGjVkH2rEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D&md5=547a5ef71cf6e494ea3abeb8b2c2e463</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.35%26sid%3Dliteratum%253Aachs%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520Immuno-Oncology%2520Drugs%2520-%2520From%2520CTLA4%2520to%2520PD1%2520to%2520the%2520Next%2520Generations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D4%26spage%3D235%26epage%3D247%26doi%3D10.1038%2Fnrd.2015.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1973</span>– <span class="NLM_lpage">1981</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0314-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-014-0314-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25331768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1973-1981&issue=16&author=R.+M.+Poole&title=Pembrolizumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0314-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1973-1981</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Pembrolizumab [Keytruda (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer.  Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic malignant melanoma in the US, for use in patients with disease progression after prior treatment with ipilimumab and, for BRAF V600 mutation-pos. patients, a BRAF inhibitor.  It is the first anti-PD-1 therapy to receive regulatory approval in the US, and is currently under regulatory review in the EU.  This article summarizes the milestones in the development of pembrolizumab leading to this first approval for the treatment of malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzneRbqZCmrVg90H21EOLACvtfcHk0ljSUGjVkH2rEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVequrrK&md5=a7642d2b422ab8e58a7e49c7ba6cf1f8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0314-5%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DPembrolizumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D16%26spage%3D1973%26epage%3D1981%26doi%3D10.1007%2Fs40265-014-0314-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span> <span> </span><span class="NLM_article-title">Clinical Blockade of PD1 and LAG3--Potential Mechanisms of Action</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/nri3790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnri3790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25534622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKltb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=45-56&issue=1&author=L.+T.+Nguyenauthor=P.+S.+Ohashi&title=Clinical+Blockade+of+PD1+and+LAG3%2D%2DPotential+Mechanisms+of+Action&doi=10.1038%2Fnri3790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical blockade of PD1 and LAG3 - potential mechanisms of action</span></div><div class="casAuthors">Nguyen, Linh T.; Ohashi, Pamela S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-56</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysfunctional T cells can render the immune system unable to eliminate infections and cancer.  Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clin. trials.  In this Review, we discuss the potential mechanisms of action of the clin. agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3).  We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphrWsF__zKXLVg90H21EOLACvtfcHk0lggspgbHGpgpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKltb7I&md5=3802eef86152af75b7a7729b7c9a9050</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnri3790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3790%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BT.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26atitle%3DClinical%2520Blockade%2520of%2520PD1%2520and%2520LAG3--Potential%2520Mechanisms%2520of%2520Action%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2015%26volume%3D15%26issue%3D1%26spage%3D45%26epage%3D56%26doi%3D10.1038%2Fnri3790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span> <i>Pembrolizumab Label</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf</a> (accessed <span class="NLM_year">2020</span>-04-07).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pembrolizumab+Label.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2014%2F125514lbl.pdf+%28accessed+2020-04-07%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPembrolizumab%2520Label%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flower, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">7035</span>),  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&issue=7035&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+Killing+of+BRCA2-Deficient+Tumours+with+Inhibitors+of+Poly%28ADP-Ribose%29+Polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lggspgbHGpgpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520Killing%2520of%2520BRCA2-Deficient%2520Tumours%2520with%2520Inhibitors%2520of%2520Poly%2528ADP-Ribose%2529%2520Polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26issue%3D7035%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J.</span></span> <span> </span><span class="NLM_article-title">Laying a Trap to Kill Cancer Cells: PARP Inhibitors and Their Mechanisms of Action</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">362</span>),  <span class="NLM_fpage">362ps17</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaf9246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscitranslmed.aaf9246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27797957" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=362ps17&issue=362&author=Y.+Pommierauthor=M.+J.+O%E2%80%99Connorauthor=J.+de+Bono&title=Laying+a+Trap+to+Kill+Cancer+Cells%3A+PARP+Inhibitors+and+Their+Mechanisms+of+Action&doi=10.1126%2Fscitranslmed.aaf9246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaf9246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaf9246%26sid%3Dliteratum%253Aachs%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%26atitle%3DLaying%2520a%2520Trap%2520to%2520Kill%2520Cancer%2520Cells%253A%2520PARP%2520Inhibitors%2520and%2520Their%2520Mechanisms%2520of%2520Action%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D362%26spage%3D362ps17%26doi%3D10.1126%2Fscitranslmed.aaf9246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorsell, A.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekblad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trésaugues, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüler, H.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for Potency and Promiscuity in Poly(ADP-Ribose) Polymerase (PARP) and Tankyrase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1271</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2hu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1262-1271&issue=4&author=A.-G.+Thorsellauthor=T.+Ekbladauthor=T.+Karlbergauthor=M.+L%C3%B6wauthor=A.+F.+Pintoauthor=L.+Tr%C3%A9sauguesauthor=M.+Mocheauthor=M.+S.+Cohenauthor=H.+Sch%C3%BCler&title=Structural+Basis+for+Potency+and+Promiscuity+in+Poly%28ADP-Ribose%29+Polymerase+%28PARP%29+and+Tankyrase+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors</span></div><div class="casAuthors">Thorsell, Ann-Gerd; Ekblad, Torun; Karlberg, Tobias; Loew, Mirjam; Pinto, Ana Filipa; Tresaugues, Lionel; Moche, Martin; Cohen, Michael S.; Schuler, Herwig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1262-1271</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective inhibitors could help unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clin. benefits in cancer therapy.  The authors profiled ten clin. PARP inhibitors and commonly used research tools for their inhibition of multiple PARP enzymes.  The authors also detd. crystal structures of these compds. bound to PARP1 or PARP2.  Veliparib and Niraparib are selective inhibitors of PARP1 and PARP2; Olaparib, Rucaparib and Talazoparib are more potent inhibitors of PARP1, but are less selective.  PJ34 and UPF1069 are broad PARP inhibitors; PJ34 inserts a flexible moiety into hydrophobic subpockets in various ADP-ribosyltransferases.  XAV939 is a promiscuous tankyrase inhibitor, and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ6102 are tankyrase selective.  The authors' biochem. and structural anal. of PARP inhibitor potencies establishes a mol. basis for either selectivity or promiscuity and provides a benchmark for exptl. design in assessment of PARP inhibitor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQSmV0dV9abrVg90H21EOLACvtfcHk0lgNa-GNDiADRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2hu77E&md5=fce2c08efcf47cbc24929b62df782a39</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00990%26sid%3Dliteratum%253Aachs%26aulast%3DThorsell%26aufirst%3DA.-G.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DL%25C3%25B6w%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DA.%2BF.%26aulast%3DTr%25C3%25A9saugues%26aufirst%3DL.%26aulast%3DMoche%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26atitle%3DStructural%2520Basis%2520for%2520Potency%2520and%2520Promiscuity%2520in%2520Poly%2528ADP-Ribose%2529%2520Polymerase%2520%2528PARP%2529%2520and%2520Tankyrase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1262%26epage%3D1271%26doi%3D10.1021%2Facs.jmedchem.6b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span> </span><span class="NLM_article-title">Advances in Leukemia Research</span>.  <i>NIH National
Cancer Institute</i>. <a href="https://www.cancer.gov/types/leukemia/research" class="extLink">https://www.cancer.gov/types/leukemia/research</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Advances+in+Leukemia+Research.+NIH+National%0ACancer+Institute.+https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fleukemia%2Fresearch+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%2520in%2520Leukemia%2520Research%26jtitle%3DNIH%2520National%250ACancer%2520Institute%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalamegham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essioux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. A.</span></span> <span> </span><span class="NLM_article-title">Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1111/cts.12455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fcts.12455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28121072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ptFSntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=84-92&issue=2&author=H.+Scheerensauthor=A.+Malongauthor=K.+Bassettauthor=Z.+Boydauthor=V.+Guptaauthor=J.+Harrisauthor=C.+Mesickauthor=S.+Simnettauthor=H.+Stevensauthor=H.+Gilbertauthor=P.+Risserauthor=R.+Kalameghamauthor=J.+Jordanauthor=J.+Engelauthor=S.+Chenauthor=L.+Essiouxauthor=J.+A.+Williams&title=Current+Status+of+Companion+and+Complementary+Diagnostics%3A+Strategic+Considerations+for+Development+and+Launch&doi=10.1111%2Fcts.12455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch</span></div><div class="casAuthors">Scheerens H; Malong A; Bassett K; Boyd Z; Gupta V; Harris J; Mesick C; Simnett S; Gilbert H; Risser P; Kalamegham R; Williams J A; Stevens H; Jordan J; Engel J; Chen S; Essioux L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">84-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">US Food and Drug Administration (FDA)-approved diagnostic assays play an increasingly common role in managing patients to prolong lifespan while also enhancing quality of life.  Diagnostic assays can be essential for the safe and effective use of therapeutics (companion diagnostic), or may inform on improving the benefit/risk ratio without restricting drug access (complementary diagnostic).  This tutorial reviews strategic considerations for drug and assay development resulting in FDA-approved companion or complementary diagnostic status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtZkkpGtP-CyjiVMCqkKxVfW6udTcc2eZRSBqf4kwZXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ptFSntA%253D%253D&md5=c1cff2deadbb709b04458ccea9081a21</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fcts.12455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12455%26sid%3Dliteratum%253Aachs%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DMalong%26aufirst%3DA.%26aulast%3DBassett%26aufirst%3DK.%26aulast%3DBoyd%26aufirst%3DZ.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DMesick%26aufirst%3DC.%26aulast%3DSimnett%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DH.%26aulast%3DGilbert%26aufirst%3DH.%26aulast%3DRisser%26aufirst%3DP.%26aulast%3DKalamegham%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DEssioux%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26atitle%3DCurrent%2520Status%2520of%2520Companion%2520and%2520Complementary%2520Diagnostics%253A%2520Strategic%2520Considerations%2520for%2520Development%2520and%2520Launch%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26issue%3D2%26spage%3D84%26epage%3D92%26doi%3D10.1111%2Fcts.12455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span> </span><span class="NLM_article-title">List of Cleared or Approved Companion Diagnostic
Devices (In Vitro
and Imaging Tools)</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools" class="extLink">https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools</a> (accessed <span class="NLM_year">2020</span>-10-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=List+of+Cleared+or+Approved+Companion+Diagnostic%0ADevices+%28In+Vitro%0Aand+Imaging+Tools%29.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Fvitro-diagnostics%2Flist-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools+%28accessed+2020-10-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DList%2520of%2520Cleared%2520or%2520Approved%2520Companion%2520Diagnostic%250ADevices%2520%2528In%2520Vitro%250Aand%2520Imaging%2520Tools%2529%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewlett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettischer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruebsamen-Schaeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischka, P.</span></span> <span> </span><span class="NLM_article-title">The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">10884</span>– <span class="NLM_lpage">10893</span>, <span class="refDoi"> DOI: 10.1128/JVI.05265-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1128%2FJVI.05265-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=21752907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=10884-10893&issue=20&author=T.+Goldnerauthor=G.+Hewlettauthor=N.+Ettischerauthor=H.+Ruebsamen-Schaeffauthor=H.+Zimmermannauthor=P.+Lischka&title=The+Novel+Anticytomegalovirus+Compound+AIC246+%28Letermovir%29+Inhibits+Human+Cytomegalovirus+Replication+through+a+Specific+Antiviral+Mechanism+That+Involves+the+Viral+Terminase&doi=10.1128%2FJVI.05265-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase</span></div><div class="casAuthors">Goldner, Thomas; Hewlett, Guy; Ettischer, Nicole; Ruebsamen-Schaeff, Helga; Zimmermann, Holger; Lschka, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10884-10893</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) remains the leading viral cause of birth defects and life-threatening disease in transplant recipients.  All approved antiviral drugs target the viral DNA polymerase and are assocd. with severe toxicity issues and the emergence of drug resistance.  Attempts to discover improved anti-HCMV drugs led to the identification of the small-mol.-wt. compd. AIC246 (Letermovir).  AIC246 exhibits outstanding anti-HCMV activity in vitro and in vivo and currently is undergoing a clin. phase IIb trial.  The initial mode-of-action studies suggested that the drug acts late in the HCMV replication cycle via a mechanism distinct from that of polymerase inhibitors.  Here, we extend our mode-of-action analyses and report that AIC246 blocks viral replication without inhibiting the synthesis of progeny HCMV DNA or viral proteins.  The genotyping of mutant viruses that escaped AIC246 inhibition uncovered distinct point mutations in the UL56 subunit of the viral terminase complex.  Marker transfer analyses confirmed that these mutations were sufficient to mediate AIC246 resistance.  The mapping of drug resistance to open reading frame UL56 suggests that viral DNA processing and/or packaging is targeted by AIC246.  In line with this, we demonstrate that AIC246 affects the formation of proper unit-length genomes from viral DNA concatemers and interferes with virion maturation.  However, since AIC246-resistant viruses do not exhibit cross-resistance to previously published terminase inhibitors, our data suggest that AIC246 interferes with HCMV DNA cleavage/packaging via a mol. mechanism that is distinct from that of other compd. classes known to target the viral terminase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswkV2gibRBbVg90H21EOLACvtfcHk0lj9Jg3-_Psf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2nsbzI&md5=63602456ebfb1cf9c2509d26d260487d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FJVI.05265-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.05265-11%26sid%3Dliteratum%253Aachs%26aulast%3DGoldner%26aufirst%3DT.%26aulast%3DHewlett%26aufirst%3DG.%26aulast%3DEttischer%26aufirst%3DN.%26aulast%3DRuebsamen-Schaeff%26aufirst%3DH.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DLischka%26aufirst%3DP.%26atitle%3DThe%2520Novel%2520Anticytomegalovirus%2520Compound%2520AIC246%2520%2528Letermovir%2529%2520Inhibits%2520Human%2520Cytomegalovirus%2520Replication%2520through%2520a%2520Specific%2520Antiviral%2520Mechanism%2520That%2520Involves%2520the%2520Viral%2520Terminase%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26issue%3D20%26spage%3D10884%26epage%3D10893%26doi%3D10.1128%2FJVI.05265-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Helou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razonable, R. R.</span></span> <span> </span><span class="NLM_article-title">Letermovir for the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients: An Evidence-Based Review</span>. <i>Infect. Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.2147/IDR.S180908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.2147%2FIDR.S180908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31239725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Oqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=1481-1491&author=G.+El%0AHelouauthor=R.+R.+Razonable&title=Letermovir+for+the+Prevention+of+Cytomegalovirus+Infection+and+Disease+in+Transplant+Recipients%3A+An+Evidence-Based+Review&doi=10.2147%2FIDR.S180908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review</span></div><div class="casAuthors">El Helou, Guy; Razonable, Raymund R.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Drug Resistance</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1481-1491</span>CODEN:
                <span class="NLM_cas:coden">IDRNAV</span>;
        ISSN:<span class="NLM_cas:issn">1178-6973</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is assocd. with increased morbidity and mortality.  Antiviral drugs are the mainstay for the prevention of CMVinfection and disease, most commonly with valganciclovir.  However, valganciclovir use is often assocd. with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to emergence of antiviral resistance.  Foscarnet and cidofovir, however, are assocd. with nephrotoxicity.  Letermovir, a novel CMV viral terminase inhibitor drug, was recently approved for CMV prophylaxis in allogeneic HSCT recipients.  It has a favorable pharmacokinetic and tolerability profile.  The aim of this paper is to review the evidence supporting the use of letermovir in allogeneic HSCT recipients, and how the drug impacts our contemporary clin. practice.  In addn., we discuss the ongoing clin. trial of letermovir for the prevention of CMVin SOT recipients.  The use of letermovir for treatment of CMVinfection and disease is not yet approved.  However, because of a unique mechanism of activity, we provide our perspective on the potential role of letermovir in the treatment of ganciclovir-resistant CMV infection and disease.  Furthermore, drug-resistant CMV has emerged during use of letermovir for prophylaxis and treatment.  Caution is advised on its use in order to preserve its therapeutic lifespan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3AHrH5Zh9QbVg90H21EOLACvtfcHk0lhpkhTU5mFJgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Oqtbo%253D&md5=b0a0962a19e5bca04251b7cb43cf477f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2147%2FIDR.S180908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIDR.S180908%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BHelou%26aufirst%3DG.%26aulast%3DRazonable%26aufirst%3DR.%2BR.%26atitle%3DLetermovir%2520for%2520the%2520Prevention%2520of%2520Cytomegalovirus%2520Infection%2520and%2520Disease%2520in%2520Transplant%2520Recipients%253A%2520An%2520Evidence-Based%2520Review%26jtitle%3DInfect.%2520Drug%2520Resist.%26date%3D2019%26volume%3D12%26spage%3D1481%26epage%3D1491%26doi%3D10.2147%2FIDR.S180908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howe, A. Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Boceprevir: A Novel, First-Generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2013.002XX</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.14218%2FJCTH.2013.002XX" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26357603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC283htl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=22-32&issue=1&author=A.+Y.+M.+Howeauthor=S.+Venkatraman&title=The+Discovery+and+Development+of+Boceprevir%3A+A+Novel%2C+First-Generation+Inhibitor+of+the+Hepatitis+C+Virus+NS3%2F4A+Serine+Protease&doi=10.14218%2FJCTH.2013.002XX"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease</span></div><div class="casAuthors">Howe Anita Y M; Venkatraman Srikanth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-32</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">An estimated 2-3% of the world's population is infected with hepatitis C virus (HCV), making it a major global health problem.  Consequently, over the past 15 years, there has been a concerted effort to understand the pathophysiology of HCV infection and the molecular virology of replication, and to utilize this knowledge for the development of more effective treatments.  The virally encoded non-structural serine protease (NS3) is required to process the HCV polyprotein and release the individual proteins that form the viral RNA replication machinery.  Given its critical role in the replication of HCV, the NS3 protease has been recognized as a potential drug target for the development of selective HCV therapies.  In this review, we describe the key scientific discoveries that led to the approval of boceprevir, a first-generation, selective, small molecule inhibitor of the NS3 protease.  We highlight the early studies that reported the crystal structure of the NS3 protease, its role in the processing of the HCV polyprotein, and the structural requirements critical for substrate cleavage.  We also consider the novel attributes of the NS3 protease-binding pocket that challenged development of small molecule inhibitors, and the studies that ultimately yielded milligram quantities of this enzyme in a soluble, tractable form suitable for inhibitor screening programs.  Finally, we describe the discovery of boceprevir, from the early chemistry studies, through the development of high-throughput assays, to the phase III clinical development program that ultimately provided the basis for approval of this drug.  This latest phase in the development of boceprevir represents the culmination of a major global effort to understand the pathophysiology of HCV and develop small molecule inhibitors for the NS3 protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKJ8jZszU7eqNc3HjJRoFAfW6udTcc2eZj1CJQQNG5iLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htl2lsg%253D%253D&md5=ec18c56586ad6b5c7fb5ccf47daaee68</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2013.002XX&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2013.002XX%26sid%3Dliteratum%253Aachs%26aulast%3DHowe%26aufirst%3DA.%2BY.%2BM.%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Boceprevir%253A%2520A%2520Novel%252C%2520First-Generation%2520Inhibitor%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%252F4A%2520Serine%2520Protease%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2013%26volume%3D1%26issue%3D1%26spage%3D22%26epage%3D32%26doi%3D10.14218%2FJCTH.2013.002XX" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0179-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-014-0179-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24442794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=273-282&issue=2&author=G.+M.+Keatingauthor=A.+Vaidya&title=Sofosbuvir%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0179-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir: First Global Approval</span></div><div class="casAuthors">Keating, Gillian M.; Vaidya, Asha</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">273-282</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Sofosbuvir (Solvadi®), a nucleotide analog hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component of a combination antiviral regimen.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of sofosbuvir for the treatment of chronic hepatitis C. This article summarizes the milestones in the development of sofosbuvir leading to this first approval for chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpmuxvtmlMbVg90H21EOLACvtfcHk0lhpkhTU5mFJgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyjs7c%253D&md5=9a4835e0b3733e0a91e3dab36a24115c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0179-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0179-7%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DVaidya%26aufirst%3DA.%26atitle%3DSofosbuvir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D2%26spage%3D273%26epage%3D282%26doi%3D10.1007%2Fs40265-014-0179-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinestrosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuluvath, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symonds, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquinelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span> <span> </span><span class="NLM_article-title">AI444040 Study Group. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1306218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24428467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=211-221&issue=3&author=M.+S.+Sulkowskiauthor=D.+F.+Gardinerauthor=M.+Rodriguez-Torresauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=I.+Jacobsonauthor=E.+Lawitzauthor=A.+S.+Lokauthor=F.+Hinestrosaauthor=P.+J.+Thuluvathauthor=H.+Schwartzauthor=D.+R.+Nelsonauthor=G.+T.+Eversonauthor=T.+Eleyauthor=M.+Wind-Rotoloauthor=S.-P.+Huangauthor=M.+Gaoauthor=D.+Hernandezauthor=F.+McPheeauthor=D.+Shermanauthor=R.+Hindesauthor=W.+Symondsauthor=C.+Pasquinelliauthor=D.+M.+Grasela&title=AI444040+Study+Group.+Daclatasvir+plus+Sofosbuvir+for+Previously+Treated+or+Untreated+Chronic+HCV+Infection&doi=10.1056%2FNEJMoa1306218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span></div><div class="casAuthors">Sulkowski, Mark S.; Gardiner, David F.; Rodriguez-Torres, Maribel; Reddy, K. Rajender; Hassanein, Tarek; Jacobson, Ira; Lawitz, Eric; Lok, Anna S.; Hinestrosa, Federico; Thuluvath, Paul J.; Schwartz, Howard; Nelson, David R.; Everson, Gregory T.; Eley, Timothy; Wind-Rotolo, Megan; Huang, Shu-Pang; Gao, Min; Hernandez, Dennis; McPhee, Fiona; Sherman, Diane; Hindes, Robert; Symonds, William; Pasquinelli, Claudio; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.  We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analog HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.  METHODS In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without ribavirin, for 24 wk.  The study was expanded to include 123 addnl. patients with genotype 1 infection who were randomly assigned to daclatasvir plus sofosbuvir, with or without ribavirin, for 12 wk (82 previously untreated patients) or 24 wk (41 patients who had previous virol. failure with telaprevir or boceprevir plus peginterferon alfa ribavirin).  The primary end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) at week 12 after the end of therapy.  RESULTS Overall, 211 patients received treatment.  Among patients with genotype 1 infection, 98% of 126 previously untreated patients and 98% of 41 patients who did not have a sustained virol. response with HCV protease inhibitors had a sustained virol. response at week 12 after the end of therapy.  A total of 92% of 26 patients with genotype 2 infection and 89% of 18 patients with genotype 3 infection had a sustained virol. response at week 12.  High rates of sustained virol. response at week 12 were obsd. among patients with HCV subtypes 1a and 1b (98% and 100%, resp.) and those with CC and non-CC IL28B genotypes (93% and 98%, resp.), as well as among patients who received ribavirin and those who did not (94% and 98%, resp.).  The most common adverse events were fatigue, headache, and nausea.  CONCLUSIONS Once-daily oral daclatasvir plus sofosbuvir was assocd. with high rates of sustained virol. response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMiCkoKS-KUrVg90H21EOLACvtfcHk0liFFYIVpGs_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D&md5=bc9eff52401d2f1e00505d30fcffd2c5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306218%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DAI444040%2520Study%2520Group.%2520Daclatasvir%2520plus%2520Sofosbuvir%2520for%2520Previously%2520Treated%2520or%2520Untreated%2520Chronic%2520HCV%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D3%26spage%3D211%26epage%3D221%26doi%3D10.1056%2FNEJMoa1306218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0381-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-015-0381-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25837989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlCksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=675-685&issue=6&author=G.+M.+Keating&title=Ledipasvir%2FSofosbuvir%3A+A+Review+of+Its+Use+in+Chronic+Hepatitis+C&doi=10.1007%2Fs40265-015-0381-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C</span></div><div class="casAuthors">Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">675-685</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The single-tablet regimen of the hepatitis C virus (HCV) NS5A inhibitor ledipasvir and the HCV NS5B polymerase inhibitor sofosbuvir (ledipasvir/sofosbuvir; Harvoni) was recently approved in the US and the EU.  The phase III ION trials included treatment-naive (ION-1 and -3) or treatment-experienced (ION-2) patients with chronic HCV genotype 1 infection (≈20 % of patients in ION-1 and -2 had cirrhosis, whereas no patient in ION-3 had cirrhosis).  A sustained virol. response 12 wk' post-treatment (SVR12) was seen in 99 % of treatment-naive patients receiving ledipasvir/sofosbuvir for 12 wk in ION-1, with no addnl. benefit conferred by the addn. of ribavirin or extending the treatment duration to 24 wk.  Moreover, in ION-3, an 8-wk regimen achieved an SVR12 rate of 94 % overall and 97 % in the subgroup of patients with a baseline HCV RNA level of <6 million IU/mL.  SVR12 rates of 94 and 99 % were seen in treatment-experienced patients who received ledipasvir/sofosbuvir for 12 and 24 wk in ION-2.  Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 infection, in HCV and HIV co-infection and, in combination with ribavirin, in patients with chronic HCV genotype 1 or 4 infection who have decompensated cirrhosis or are liver transplant recipients and in chronic HCV genotype 3 infection.  Oral ledipasvir/sofosbuvir was generally well tolerated.  In conclusion, ledipasvir/sofosbuvir is an important new single-tablet regimen that represents a significant advance in the treatment of chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqagM_RFKmFKLVg90H21EOLACvtfcHk0lht2JB9tFRgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlCksL8%253D&md5=137b610d65162620fccfeb3783469fb2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0381-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0381-2%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DLedipasvir%252FSofosbuvir%253A%2520A%2520Review%2520of%2520Its%2520Use%2520in%2520Chronic%2520Hepatitis%2520C%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26issue%3D6%26spage%3D675%26epage%3D685%26doi%3D10.1007%2Fs40265-015-0381-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curescu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledinghen, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habersetzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolakopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papatheodoridis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakalos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauss, S.</span></span> <span> </span><span class="NLM_article-title">PegBase Group Investigators. Efficacy and Safety Profile of Boceprevir- or Telaprevir-Based Triple Therapy or Dual Peginterferon Alfa-2a or Alfa-2b plus Ribavirin Therapy in Chronic Hepatitis C: The Real-World PegBase Observational Study</span>. <i>Ann. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.20524/aog.2017.0136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.20524%2Faog.2017.0136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28469364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1crjsl2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=327-343&issue=3&author=A.+Mangiaauthor=G.+R.+Fosterauthor=C.+P.+Bergauthor=M.+Curescuauthor=V.+D.+Ledinghenauthor=F.+Habersetzerauthor=S.+Manolakopoulosauthor=E.+Negriauthor=G.+Papatheodoridisauthor=S.+Ahlersauthor=M.+Castilloauthor=G.+Bakalosauthor=S.+Mauss&title=PegBase+Group+Investigators.+Efficacy+and+Safety+Profile+of+Boceprevir-+or+Telaprevir-Based+Triple+Therapy+or+Dual+Peginterferon+Alfa-2a+or+Alfa-2b+plus+Ribavirin+Therapy+in+Chronic+Hepatitis+C%3A+The+Real-World+PegBase+Observational+Study&doi=10.20524%2Faog.2017.0136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study</span></div><div class="casAuthors">Mangia Alessandra; Foster Graham R; Berg Christoph P; Curescu Manuela; Ledinghen Victor De; Habersetzer Francois; Manolakopoulos Spilios; Negri Elisa; Papatheodoridis George; Ahlers Silke; Castillo Marco; Bakalos Georgios; Mauss Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Annals of gastroenterology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-343</span>
        ISSN:<span class="NLM_cas:issn">1108-7471</span>.
    </div><div class="casAbstract">BACKGROUND:  The aim of the study was to determine the efficacy and safety of triple therapy with a first-generation protease inhibitor (PI; boceprevir, telaprevir) plus peginterferon alfa-2a or -2b plus ribavirin, and dual therapy (peginterferon alfa-2a or -2b plus ribavirin) in patients with chronic hepatitis C (CHC) in routine clinical practice.  METHODS:  PegBase was an international, prospective, observational study in which 4441 patients with CHC were enrolled in 27 countries.  This analysis focuses on results in 4100 treatment-naive and previously treated patients treated with PI-based triple therapy or dual therapy, according to the discretion of the investigator and local standards of practice.  The primary efficacy outcome was sustained virological response after 12-week follow up (SVR12).  RESULTS:  SVR12 rates in treatment-naive genotype (G) 1 patients were 56.6% and 62.9% for recipients of boceprevir plus peginterferon alfa-2a/ribavirin and boceprevir plus peginterferon alfa-2b/ribavirin, respectively, and 65.3% and 58.6% for recipients of telaprevir plus peginterferon alfa-2a/ribavirin and telaprevir plus peginterferon alfa-2b/ribavirin, respectively.  In previously treated patients assigned to these four regimens, SVR12 rates were 43.6%, 48.3%, 60.3% and 56.1%, respectively.  Among treatment-naive patients assigned to peginterferon alfa-2a/ribavirin and peginterferon alfa-2b/ribavirin, respectively, SVR12 rates were 49.2% and 41.9% in G1 patients, 75.7% and 83.3% in G2 patients, 65.9% and 65.9% in G3 patients, and 49.7%, and 51.1% in G4 patients.  The safety and tolerability of dual and triple therapy were consistent with previous reports.  CONCLUSION:  The efficacy and safety of first-generation PI-based triple-therapy and dual-therapy regimens in this real-world cohort were broadly comparable to those of previous studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcf_k-H9XLw9bHMBt0mMIXfW6udTcc2eadyZsX2MMB87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjsl2rsQ%253D%253D&md5=cb6149b78a8550f2e3b9384865129d79</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.20524%2Faog.2017.0136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.20524%252Faog.2017.0136%26sid%3Dliteratum%253Aachs%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBerg%26aufirst%3DC.%2BP.%26aulast%3DCurescu%26aufirst%3DM.%26aulast%3DLedinghen%26aufirst%3DV.%2BD.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DManolakopoulos%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DE.%26aulast%3DPapatheodoridis%26aufirst%3DG.%26aulast%3DAhlers%26aufirst%3DS.%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DBakalos%26aufirst%3DG.%26aulast%3DMauss%26aufirst%3DS.%26atitle%3DPegBase%2520Group%2520Investigators.%2520Efficacy%2520and%2520Safety%2520Profile%2520of%2520Boceprevir-%2520or%2520Telaprevir-Based%2520Triple%2520Therapy%2520or%2520Dual%2520Peginterferon%2520Alfa-2a%2520or%2520Alfa-2b%2520plus%2520Ribavirin%2520Therapy%2520in%2520Chronic%2520Hepatitis%2520C%253A%2520The%2520Real-World%2520PegBase%2520Observational%2520Study%26jtitle%3DAnn.%2520Gastroenterol.%26date%3D2017%26volume%3D30%26issue%3D3%26spage%3D327%26epage%3D343%26doi%3D10.20524%2Faog.2017.0136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zipfel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zablocki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, J. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Pan-Genotypic Hepatitis C Virus NS3/4A Protease Inhibitor Voxilaprevir (GS-9857): A Component of Vosevi</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2428</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.bmcl.2019.03.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31133531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKqu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2428-2436&issue=16&author=J.+G.+Taylorauthor=S.+Zipfelauthor=K.+Rameyauthor=R.+Vivianauthor=A.+Schrierauthor=K.+K.+Karkiauthor=A.+Katanaauthor=D.+Katoauthor=T.+Kobayashiauthor=R.+Martinezauthor=M.+Sangiauthor=D.+Siegelauthor=C.+V.+Tranauthor=Z.-Y.+Yangauthor=J.+Zablockiauthor=C.+Y.+Yangauthor=Y.+Wangauthor=K.+Wangauthor=K.+Chanauthor=O.+Barauskasauthor=G.+Chengauthor=D.+Jinauthor=B.+E.+Schultzauthor=T.+Applebyauthor=A.+G.+Villase%C3%B1orauthor=J.+O.+Link&title=Discovery+of+the+Pan-Genotypic+Hepatitis+C+Virus+NS3%2F4A+Protease+Inhibitor+Voxilaprevir+%28GS-9857%29%3A+A+Component+of+Vosevi&doi=10.1016%2Fj.bmcl.2019.03.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi</span></div><div class="casAuthors">Taylor, James G.; Zipfel, Sheila; Ramey, Kyla; Vivian, Randy; Schrier, Adam; Karki, Kapil K.; Katana, Ashley; Kato, Darryl; Kobayashi, Tetsuya; Martinez, Ruben; Sangi, Michael; Siegel, Dustin; Tran, Chinh V.; Yang, Zheng-Yu; Zablocki, Jeff; Yang, Cheng Y.; Wang, Yujin; Wang, Kelly; Chan, Katie; Barauskas, Ona; Cheng, Guofeng; Jin, Debi; Schultz, Brian E.; Appleby, Todd; Villasenor, Armando G.; Link, John O.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2428-2436</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Treatment of hepatitis C virus (HCV) infection has been historically challenging due the high viral genetic complexity wherein there are eight distinct genotypes and at least 86 viral subtypes.  While HCV NS3/4A protease inhibitors are an established treatment option for genotype 1 infection, limited coverage of genotypes 2 and/or 3 combined with serum alanine transaminase (ALT) elevations for some compds. has limited the broad utility of this therapeutic class.  Our discovery efforts were focused on identifying an NS3/4A protease inhibitor with pan-genotypic antiviral activity, improved coverage of resistance assocd. substitutions, and a decreased risk of hepatotoxicity.  Towards this goal, distinct interactions with the conserved catalytic triad of the NS3/4A protease were identified that improved genotype 3 antiviral activity.  We further discovered that protein adduct formation strongly correlated with clin. ALT elevation for this therapeutic class.  Improving metabolic stability and decreasing protein adduct formation through structural modifications ultimately resulted in voxilaprevir.  Voxilaprevir, in combination with sofosbuvir and velpatasvir, has demonstrated pan-genotypic antiviral clin. activity.  Furthermore, hepatotoxicity was not obsd. in Phase 3 clin. trials with voxilaprevir, consistent with our design strategy.  Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) is now an approved pan-genotypic treatment option for the most difficult-to-cure individuals who have previously failed direct acting antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeOT2WnMaWbVg90H21EOLACvtfcHk0lglFOxEoT4QoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKqu77P&md5=19fb49e30634e8e95d17009cbc81a1a6</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DZipfel%26aufirst%3DS.%26aulast%3DRamey%26aufirst%3DK.%26aulast%3DVivian%26aufirst%3DR.%26aulast%3DSchrier%26aufirst%3DA.%26aulast%3DKarki%26aufirst%3DK.%2BK.%26aulast%3DKatana%26aufirst%3DA.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DSangi%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DC.%2BV.%26aulast%3DYang%26aufirst%3DZ.-Y.%26aulast%3DZablocki%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DK.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DD.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DLink%26aufirst%3DJ.%2BO.%26atitle%3DDiscovery%2520of%2520the%2520Pan-Genotypic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4A%2520Protease%2520Inhibitor%2520Voxilaprevir%2520%2528GS-9857%2529%253A%2520A%2520Component%2520of%2520Vosevi%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2428%26epage%3D2436%26doi%3D10.1016%2Fj.bmcl.2019.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenstein, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harney, C.</span></span> <span> </span><span class="NLM_article-title">The Evolution of the Regulatory Framework for Antibacterial Agents</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1323</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1111/nyas.12441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fnyas.12441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=24797794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2cjgtVWntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1323&publication_year=2014&pages=11-21&author=J.+H.+Rexauthor=M.+Goldbergerauthor=B.+I.+Eisensteinauthor=C.+Harney&title=The+Evolution+of+the+Regulatory+Framework+for+Antibacterial+Agents&doi=10.1111%2Fnyas.12441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of the regulatory framework for antibacterial agents</span></div><div class="casAuthors">Rex John H; Goldberger Mark; Eisenstein Barry I; Harney Carrie</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1323</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The rising tide of antibacterial resistance and the lack of a diverse, vibrant pipeline of novel antibacterial agents is a global crisis that impairs our ability to treat life-threatening infections.  The recent introduction of a tiered approach to the regulatory framework in this area offers one path to resolving some of the challenges.  By drawing heavily on the predictive power of the related sciences of pharmacokinetics and pharmacodynamics, smaller, focused clinical trial programs have become possible for agents that might not otherwise have been possible to progress.  There are limitations to these pathways, and they are not easy to implement, but making reliable noninferiority-based approaches available is critical to reinvigorating the global antibiotic pipeline.  With the recognition of these ideas by key regulatory authorities in recent guidance, the next challenges in this area will focus on interpretive breakpoints, the extent of data in the prescribing information, ensuring that multiple agents can be progressed, and the challenge of the antibiotic business model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRITYa0NchRHCEJCPKhJPuqfW6udTcc2eanOMPGXj_3GLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjgtVWntw%253D%253D&md5=44b33008c61d157f599e76b3260c1e52</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12441%26sid%3Dliteratum%253Aachs%26aulast%3DRex%26aufirst%3DJ.%2BH.%26aulast%3DGoldberger%26aufirst%3DM.%26aulast%3DEisenstein%26aufirst%3DB.%2BI.%26aulast%3DHarney%26aufirst%3DC.%26atitle%3DThe%2520Evolution%2520of%2520the%2520Regulatory%2520Framework%2520for%2520Antibacterial%2520Agents%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1323%26spage%3D11%26epage%3D21%26doi%3D10.1111%2Fnyas.12441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manchester, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span> <span> </span><span class="NLM_article-title">ESKAPEing the Labyrinth of Antibacterial Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1038/nrd4572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd4572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26139286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyks77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=529-542&issue=8&author=R.+Tommasiauthor=D.+G.+Brownauthor=G.+K.+Walkupauthor=J.+I.+Manchesterauthor=A.+A.+Miller&title=ESKAPEing+the+Labyrinth+of+Antibacterial+Discovery&doi=10.1038%2Fnrd4572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">ESKAPEing the labyrinth of antibacterial discovery</span></div><div class="casAuthors">Tommasi, Ruben; Brown, Dean G.; Walkup, Grant K.; Manchester, John I.; Miller, Alita A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">529-542</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antimicrobial drug resistance is a growing threat to global public health.  Multidrug resistance among the 'ESKAPE' organisms - encompassing Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. - is of particular concern because they are responsible for many serious infections in hospitals.  Although some promising agents are in the pipeline, there is an urgent need for new antibiotic scaffolds.  However, antibacterial researchers have struggled to identify new small mols. with meaningful cellular activity, esp. those effective against multidrug-resistant Gram-neg. pathogens.  This difficulty ultimately stems from an incomplete understanding of efflux systems and compd. permeation through bacterial membranes.  This Opinion article describes findings from target-based and phenotypic screening efforts carried out at AstraZeneca over the past decade, discusses some of the subsequent chem. challenges and concludes with a description of new approaches comprising a combination of computational modeling and advanced biol. tools which may pave the way towards the discovery of new antibacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolJg6HXnn7BLVg90H21EOLACvtfcHk0ljW7CHxAa4j2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyks77M&md5=0d3159250e27926ab280c305ea5fb9ef</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnrd4572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4572%26sid%3Dliteratum%253Aachs%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DWalkup%26aufirst%3DG.%2BK.%26aulast%3DManchester%26aufirst%3DJ.%2BI.%26aulast%3DMiller%26aufirst%3DA.%2BA.%26atitle%3DESKAPEing%2520the%2520Labyrinth%2520of%2520Antibacterial%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D8%26spage%3D529%26epage%3D542%26doi%3D10.1038%2Fnrd4572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span> </span><span class="NLM_article-title">GAIN act: H.R.2182 - Generating Antibiotic
Incentives Now Act of
2011 112th Congress (2011–2012)</span>.  <i>Congress.gov</i>. <a href="https://www.congress.gov/bill/112th-congress/house-bill/2182" class="extLink">https://www.congress.gov/bill/112th-congress/house-bill/2182</a> (accessed <span class="NLM_year">2020</span>-04-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GAIN+act%3A+H.R.2182+-+Generating+Antibiotic%0AIncentives+Now+Act+of%0A2011+112th+Congress+%282011%E2%80%932012%29.+Congress.gov.+https%3A%2F%2Fwww.congress.gov%2Fbill%2F112th-congress%2Fhouse-bill%2F2182+%28accessed+2020-04-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGAIN%2520act%253A%2520H.R.2182%2520-%2520Generating%2520Antibiotic%250AIncentives%2520Now%2520Act%2520of%250A2011%2520112th%2520Congress%2520%25282011%25E2%2580%25932012%2529%26jtitle%3DCongress.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0966-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0966-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30128699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGjt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1259-1270&issue=12&author=S.+Dhillon&title=Meropenem%2FVaborbactam%3A+A+Review+in+Complicated+Urinary+Tract+Infections&doi=10.1007%2Fs40265-018-0966-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1259-1270</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials.  I.v. meropenem/vaborbactam (Vabomere) is the first carbapenem/β-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis.  Vaborbactam is a potent inhibitor of class A serine carbapenemases, which, when combined with the antibacterial meropenem, restores the activity of meropenem against β-lactamase producing Enterobacteriaceae, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.  In the phase 3, noninferiority TANGO I trial in patients with cUTIs, i.v. meropenem/vaborbactam was noninferior to i.v. piperacillin/tazobactam for overall success (composite of clin. cure and microbial eradication; FDA primary endpoint) and microbial eradication (EMA primary endpoint).  Meropenem/vaborbactam was generally well tolerated, with a tolerability profile generally similar to that of piperacillin/tazobactam.  TANGO I did not assess the efficacy of meropenem/vaborbactam for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae and meropenem/vaborbactam is currently not indicated for these patients.  Available evidence indicates that meropenem/vaborbactam is a useful treatment option for patients with cUTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfbl_iY8DrWrVg90H21EOLACvtfcHk0ljW7CHxAa4j2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGjt7vE&md5=61025d2c50c93af20f96fc70cbf60a32</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0966-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0966-7%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DMeropenem%252FVaborbactam%253A%2520A%2520Review%2520in%2520Complicated%2520Urinary%2520Tract%2520Infections%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D12%26spage%3D1259%26epage%3D1270%26doi%3D10.1007%2Fs40265-018-0966-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0902-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0902-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29671219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFCmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=675-692&issue=6&author=M.+Shirley&title=Ceftazidime-Avibactam%3A+A+Review+in+the+Treatment+of+Serious+Gram-Negative+Bacterial+Infections&doi=10.1007%2Fs40265-018-0902-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">675-692</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ceftazidime-avibactam (Zavicefta) is an i.v. administered combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam.  In the EU, ceftazidime-avibactam is approved for the treatment of adults with complicated urinary tract infections (cUTIs) [including pyelonephritis], complicated intra-abdominal infections (cIAIs), hospital-acquired pneumonia (HAP) [including ventilator-assocd. pneumonia (VAP)], and other infections caused by aerobic Gram-neg. organisms in patients with limited treatment options.  This article discusses the in vitro activity and pharmacol. properties of ceftazidime-avibactam, and reviews data on the agent's clin. efficacy and tolerability relating to use in these indications, with a focus on the EU label.  Ceftazidime-avibactam has excellent in vitro activity against many important Gram-neg. pathogens, including many extended-spectrum β-lactamase-, AmpC-, Klebsiella pneumoniae carbapenemase- and OXA-48-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa isolates; it is not active against metallo-β-lactamase-producing strains.  The clin. efficacy of ceftazidime-avibactam in the treatment of cUTI, cIAI and HAP (including VAP) in adults was demonstrated in pivotal phase III non-inferiority trials with carbapenem comparators.  Ceftazidime-avibactam treatment was assocd. with high response rates at the test-of-cure visit in patients with infections caused by ceftazidime-susceptible and -nonsusceptible Gram-neg. pathogens.  Ceftazidime-avibactam was generally well tolerated, with a safety and tolerability profile consistent with that of ceftazidime alone and that was generally typical of the injectable cephalosporins.  Thus, ceftazidime-avibactam represents a valuable new treatment option for these serious and difficult-to-treat infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkrfnUfU_goLVg90H21EOLACvtfcHk0liMntbzE9DAtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFCmtLc%253D&md5=f29a308a645b8cf7ec0089d07a1932a4</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0902-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0902-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DCeftazidime-Avibactam%253A%2520A%2520Review%2520in%2520the%2520Treatment%2520of%2520Serious%2520Gram-Negative%2520Bacterial%2520Infections%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D6%26spage%3D675%26epage%3D692%26doi%3D10.1007%2Fs40265-018-0902-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span> </span><span class="NLM_article-title">First Antibiotic with New Mechanisms of Action Approved
in Almost
20 Years</span>.  <i>BioSpace</i>. <a href="https://www.biospace.com/article/fda-approves-nabriva-s-xenleta-for-bacterial-pneumonia/" class="extLink">https://www.biospace.com/article/fda-approves-nabriva-s-xenleta-for-bacterial-pneumonia/</a> (accessed <span class="NLM_year">2020</span>-07-05).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=First+Antibiotic+with+New+Mechanisms+of+Action+Approved%0Ain+Almost%0A20+Years.+BioSpace.+https%3A%2F%2Fwww.biospace.com%2Farticle%2Ffda-approves-nabriva-s-xenleta-for-bacterial-pneumonia%2F+%28accessed+2020-07-05%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFirst%2520Antibiotic%2520with%2520New%2520Mechanisms%2520of%2520Action%2520Approved%250Ain%2520Almost%250A20%2520Years%26jtitle%3DBioSpace%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&issue=16&author=S.+J.+Keam&title=Pretomanid%3A+First+Approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eYfiNL9h-GvILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D16%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maheu-Giroux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. A.</span></span> <span> </span><span class="NLM_article-title">Moxidectin for Deworming: From Trials to Implementation</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30270-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1473-3099%2818%2930270-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29858152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1MbivFSgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=817-819&issue=8&author=M.+Maheu-Girouxauthor=S.+A.+Joseph&title=Moxidectin+for+Deworming%3A+From+Trials+to+Implementation&doi=10.1016%2FS1473-3099%2818%2930270-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Moxidectin for deworming: from trials to implementation</span></div><div class="casAuthors">Maheu-Giroux Mathieu; Joseph Serene A</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">817-819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzbFcp8DttpMjl5L8hwNX0fW6udTcc2eaXAe2J2l8vv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbivFSgtA%253D%253D&md5=a7134981ab65a1ba013df050d00754da</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930270-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930270-6%26sid%3Dliteratum%253Aachs%26aulast%3DMaheu-Giroux%26aufirst%3DM.%26aulast%3DJoseph%26aufirst%3DS.%2BA.%26atitle%3DMoxidectin%2520for%2520Deworming%253A%2520From%2520Trials%2520to%2520Implementation%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26issue%3D8%26spage%3D817%26epage%3D819%26doi%3D10.1016%2FS1473-3099%2818%2930270-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, J. E.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1517</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0979-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0979-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30229442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCjurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1517-1523&issue=14&author=J.+E.+Frampton&title=Tafenoquine%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0979-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine: First Global Approval</span></div><div class="casAuthors">Frampton, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1517-1523</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Tafenoquine (Krintafel, Arakoda), an orally-active 8-aminoquinoline anti-malarial drug, is a long-acting analog of primaquine with activity against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include Plasmodium vivax (P. vivax) and Plasmodium falciparum.  It has been developed by GlaxoSmithKline (formerly SmithKline Beecham) for the radical cure of P. vivax malaria and by 60 Degrees Pharmaceuticals for the prophylaxis of malaria.  The exact mechanism(s) of action underlying the anti-Plasmodium activity of tafenoquine are unknown, although it may exert its effect by inhibiting haematin polymn. and, addnl., by inducing mitochondrial dysfunction leading to the apoptotic-like death of the organism.  In July 2018, tafenoquine was approved in the USA for the radical cure of P. vivax malaria in patients aged ≥ 16 years who are receiving appropriate antimalarial therapy for acute P. vivax malaria.  Subsequently, in August 2018, tafenoquine was approved in the USA for the prophylaxis of malaria in patients aged ≥ 18 years.  This article primarily summarizes the milestones in the development of tafenoquine leading to its first global approval for the radical cure of P. vivax malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrplYl7bXI8L7Vg90H21EOLACvtfcHk0lhB3xqvBgbFhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCjurvM&md5=4e8b6afc2abcb893eb7c428aebe0f152</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0979-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0979-2%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26atitle%3DTafenoquine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D14%26spage%3D1517%26epage%3D1523%26doi%3D10.1007%2Fs40265-018-0979-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novaes, R. D.</span></span> <span> </span><span class="NLM_article-title">An Evaluation of Benznidazole as a Chagas Disease Therapeutic</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1807</span>, <span class="refDoi"> DOI: 10.1080/14656566.2019.1650915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1080%2F14656566.2019.1650915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31456439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1OhsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1797-1807&issue=15&author=I.+S.+Caldasauthor=E.+G.+Santosauthor=R.+D.+Novaes&title=An+Evaluation+of+Benznidazole+as+a+Chagas+Disease+Therapeutic&doi=10.1080%2F14656566.2019.1650915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of benznidazole as a Chagas disease therapeutic</span></div><div class="casAuthors">Caldas, Ivo S.; Santos, Elda G.; Novaes, Romulo D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1797-1807</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: As benznidazole is the first-line treatment for patients with Chagas disease, rational chemotherapy strategies are required based on the crit. anal. of the evidence on the relevance and applicability of this drug at different disease stages.: The authors discuss the current understanding of benznidazole-based chemotherapy for Chagas disease, focusing specifically on epidemiol., pharmacokinetics, mechanism of action, clin. recommendations, cure criteria, and therapeutic efficacy in different phases of the disease.: Benznidazole shows high bioavailability after oral administration.  Benznidazole at 5-8 mg/kg/day and 5-10 mg/kg/day for 30-60 days are consistent clin. recommendations for children and adults, resp.  A high correlation between neg. parasitol., serol., and polymerase chain reaction (PCR) assays in long-term post-therapeutic follow-up has been consistently used to evaluate therapeutic efficacy.  These methods support the evidence that the success of benznidazole-based chemotherapy is closely correlated with the phase of infection in which the treatment is administered.  The greater therapeutic efficacy is obtained in acute infections, gradually worsening as the infection becomes chronic.  When therapeutic failure is confirmed by any diagnostic assay, benznidazole treatment does not always ensure better long-term prognosis, and Chagas cardiomyopathy may develop as well as in untreated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4X8uwosJCYLVg90H21EOLACvtfcHk0lhB3xqvBgbFhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1OhsLzK&md5=9e811af7be3789c0a2f2318e04991fb6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1080%2F14656566.2019.1650915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2019.1650915%26sid%3Dliteratum%253Aachs%26aulast%3DCaldas%26aufirst%3DI.%2BS.%26aulast%3DSantos%26aufirst%3DE.%2BG.%26aulast%3DNovaes%26aufirst%3DR.%2BD.%26atitle%3DAn%2520Evaluation%2520of%2520Benznidazole%2520as%2520a%2520Chagas%2520Disease%2520Therapeutic%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26issue%3D15%26spage%3D1797%26epage%3D1807%26doi%3D10.1080%2F14656566.2019.1650915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span> </span><span class="NLM_article-title">FDA Approves
New Drug for Treatment-Resistant Forms of Tuberculosis
That Affects the Lungs</span>.  <i>U.S. Food and Drug
Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs</a> (accessed <span class="NLM_year">2020</span>-10-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves%0ANew+Drug+for+Treatment-Resistant+Forms+of+Tuberculosis%0AThat+Affects+the+Lungs.+U.S.+Food+and+Drug%0AAdministration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs+%28accessed+2020-10-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%250ANew%2520Drug%2520for%2520Treatment-Resistant%2520Forms%2520of%2520Tuberculosis%250AThat%2520Affects%2520the%2520Lungs%26jtitle%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span> </span><span class="NLM_article-title">US FDA
Approves Krintafel (Tafenoquine) for the Radical Cure of <i>P.
vivax</i> malaria</span>.  <i>Medicines for
Malaria Venture</i>. <a href="https://www.mmv.org/newsroom/press-releases/us-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malaria" class="extLink">https://www.mmv.org/newsroom/press-releases/us-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malaria</a> (accessed <span class="NLM_year">2020</span>-10-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+FDA%0AApproves+Krintafel+%28Tafenoquine%29+for+the+Radical+Cure+of+P.%0Avivax+malaria.+Medicines+for%0AMalaria+Venture.+https%3A%2F%2Fwww.mmv.org%2Fnewsroom%2Fpress-releases%2Fus-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malaria+%28accessed+2020-10-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DUS%2520FDA%250AApproves%2520Krintafel%2520%2528Tafenoquine%2529%2520for%2520the%2520Radical%2520Cure%2520of%2520P.%250Avivax%2520malaria%26jtitle%3DMedicines%2520for%250AMalaria%2520Venture%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rujescu, D.</span></span> <span> </span><span class="NLM_article-title">The Current Development of CNS Drug Research</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1687</span>– <span class="NLM_lpage">1693</span>, <span class="refDoi"> DOI: 10.1017/S1461145713000345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1017%2FS1461145713000345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=23651558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC3snhsFGjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=1687-1693&issue=7&author=G.+Wegenerauthor=D.+Rujescu&title=The+Current+Development+of+CNS+Drug+Research&doi=10.1017%2FS1461145713000345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The current development of CNS drug research</span></div><div class="casAuthors">Wegener Gregers; Rujescu Dan</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1687-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the past few years, several high profiled pharmaceutical companies have decided to shut down major research activities within the central nervous system (CNS) area.  For example, in December 2011 Novartis announced that the company is closing its neuroscience facility in Basel, Switzerland, where Novartis is headquartered (Abbott, 2011).  It follows similar moves by GlaxoSmithKline and AstraZeneca, both based in the UK, which in 2010 announced the closure of major parts of their neuroscience research divisions globally (Jack, Financial Times, 4 February 2010).  Also companies primarily based in the USA, Pfizer and Merck, as well as the French company Sanofi, have pulled back on research into brain disorders.  This development is still proceeding, as e.g.  AstraZeneca closed their CNS/pain centres (Fiercebiotech, press release, 2 February 2012).  Several of the companies have launched smaller new initiatives based on studies of genetics and biomarkers, but as mental disorders such as unipolar depression impose the largest disease burden worldwide, e.g. 6.2% disability-adjusted life year of total (WHO, 2008), and current treatments do not work particularly well for many patients, this has obviously raised a number of concerns related to how the future developments should be carried out, and whether the genetic approach may be sufficient.  In June 2012, the International College of Neuropsychopharmacology (http://www.cinp.org) hosted an international workshop in order to discuss and consider the consequences and implications of the withdrawal of these research activities.  This paper presents the problem background together with a summary of the viewpoints of the invited speakers and recommendations for future intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEM4WnxGgp54JKJbLTgsvCfW6udTcc2ebbF8tzi0wM4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snhsFGjsw%253D%253D&md5=4e666ce86adcc0563589563a520a401f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1017%2FS1461145713000345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145713000345%26sid%3Dliteratum%253Aachs%26aulast%3DWegener%26aufirst%3DG.%26aulast%3DRujescu%26aufirst%3DD.%26atitle%3DThe%2520Current%2520Development%2520of%2520CNS%2520Drug%2520Research%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2013%26volume%3D16%26issue%3D7%26spage%3D1687%26epage%3D1693%26doi%3D10.1017%2FS1461145713000345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, J. D.</span></span> <span> </span><span class="NLM_article-title">Edaravone: A New Drug Approved for ALS</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">725</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.cell.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29100067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyhurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=725&issue=4&author=J.+D.+Rothstein&title=Edaravone%3A+A+New+Drug+Approved+for+ALS&doi=10.1016%2Fj.cell.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Edaravone: A new drug approved for ALS</span></div><div class="casAuthors">Rothstein, Jeffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">725</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal.  The history of ALS drug discovery is fraught with many stops and starts.  It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3cmo73s5DoLVg90H21EOLACvtfcHk0liU8GZOpOXIag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyhurvP&md5=70a3840ab2e174873dbfe2a73334cd28</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DRothstein%26aufirst%3DJ.%2BD.%26atitle%3DEdaravone%253A%2520A%2520New%2520Drug%2520Approved%2520for%2520ALS%26jtitle%3DCell%26date%3D2017%26volume%3D171%26issue%3D4%26spage%3D725%26doi%3D10.1016%2Fj.cell.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Writing
Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group</span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Edaravone
in Well Defined Patients with Amyotrophic Lateral Sclerosis: A Randomised,
Double-Blind, Placebo-Controlled Trial</span>. <i>Lancet
Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(17)30115-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1474-4422%2817%2930115-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28522181" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=505-512&issue=7&author=Writing%0AGroup+on+behalf+of+the+Edaravone+%28MCI-186%29+ALS+19+Study+Group&title=Safety+and+Efficacy+of+Edaravone%0Ain+Well+Defined+Patients+with+Amyotrophic+Lateral+Sclerosis%3A+A+Randomised%2C%0ADouble-Blind%2C+Placebo-Controlled+Trial&doi=10.1016%2FS1474-4422%2817%2930115-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2817%2930115-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252817%252930115-1%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Edaravone%250Ain%2520Well%2520Defined%2520Patients%2520with%2520Amyotrophic%2520Lateral%2520Sclerosis%253A%2520A%2520Randomised%252C%250ADouble-Blind%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%250ANeurol.%26date%3D2017%26volume%3D16%26issue%3D7%26spage%3D505%26epage%3D512%26doi%3D10.1016%2FS1474-4422%2817%2930115-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finkel, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiriboga, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servais, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topaloglu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulinius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanzman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheuens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farwell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, D. C.</span></span> <span> </span><span class="NLM_article-title">ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1702752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1702752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29091570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFChtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1723-1732&issue=18&author=R.+S.+Finkelauthor=E.+Mercuriauthor=B.+T.+Darrasauthor=A.+M.+Connollyauthor=N.+L.+Kuntzauthor=J.+Kirschnerauthor=C.+A.+Chiribogaauthor=K.+Saitoauthor=L.+Servaisauthor=E.+Tizzanoauthor=H.+Topalogluauthor=M.+Tuliniusauthor=J.+Montesauthor=A.+M.+Glanzmanauthor=K.+Bishopauthor=Z.+J.+Zhongauthor=S.+Gheuensauthor=C.+F.+Bennettauthor=E.+Schneiderauthor=W.+Farwellauthor=D.+C.+De+Vivo&title=ENDEAR+Study+Group.+Nusinersen+versus+Sham+Control+in+Infantile-Onset+Spinal+Muscular+Atrophy&doi=10.1056%2FNEJMoa1702752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Nusinersen versus sham control in infantile-onset spinal muscular atrophy</span></div><div class="casAuthors">Finkel, R. S.; Mercuri, E.; Darras, B. T.; Connolly, A. M.; Kuntz, N. L.; Kirschner, J.; Chiriboga, C. A.; Saito, K.; Servais, L.; Tizzano, E.; Topaloglu, H.; Tulinius, M.; Montes, J.; Glanzman, A. M.; Bishop, K.; Zhong, Z. J.; Gheuens, S.; Bennett, C. F.; Schneider, E.; Farwell, W.; De Vivo, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1723-1732</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein.  Nusinersen is an antisense oligonucleotide drug that modifies pre-mRNA splicing of the SMN2 gene and thus promotes increased prodn. of full-length SMN protein. methods We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy.  The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurol. Examn.) and event-free survival (time to death or the use of permanent assisted ventilation).  Secondary end points included overall survival and subgroup analyses of event-free survival according to disease duration at screening.  Only the first primary end point was tested in a prespecified interim anal.  To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final anal. results In the interim anal., a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41%] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial.  In the final anal., a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P = 0.005).  The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P = 0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen.  The incidence and severity of adverse events were similar in the two groups. conclusions Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group.  Early treatment may be necessary to maximize the benefit of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGybyEEOo-zrVg90H21EOLACvtfcHk0lgzfTHSA99usQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFChtbfF&md5=552d3c84f644aee68c96d39c1b5eb280</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1702752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1702752%26sid%3Dliteratum%253Aachs%26aulast%3DFinkel%26aufirst%3DR.%2BS.%26aulast%3DMercuri%26aufirst%3DE.%26aulast%3DDarras%26aufirst%3DB.%2BT.%26aulast%3DConnolly%26aufirst%3DA.%2BM.%26aulast%3DKuntz%26aufirst%3DN.%2BL.%26aulast%3DKirschner%26aufirst%3DJ.%26aulast%3DChiriboga%26aufirst%3DC.%2BA.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DServais%26aufirst%3DL.%26aulast%3DTizzano%26aufirst%3DE.%26aulast%3DTopaloglu%26aufirst%3DH.%26aulast%3DTulinius%26aufirst%3DM.%26aulast%3DMontes%26aufirst%3DJ.%26aulast%3DGlanzman%26aufirst%3DA.%2BM.%26aulast%3DBishop%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DZ.%2BJ.%26aulast%3DGheuens%26aufirst%3DS.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DSchneider%26aufirst%3DE.%26aulast%3DFarwell%26aufirst%3DW.%26aulast%3DDe%2BVivo%26aufirst%3DD.%2BC.%26atitle%3DENDEAR%2520Study%2520Group.%2520Nusinersen%2520versus%2520Sham%2520Control%2520in%2520Infantile-Onset%2520Spinal%2520Muscular%2520Atrophy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D18%26spage%3D1723%26epage%3D1732%26doi%3D10.1056%2FNEJMoa1702752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissel, J. T.</span></span> <span> </span><span class="NLM_article-title">Spinal Muscular Atrophy</span>. <i>Neurol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1016/j.ncl.2015.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.ncl.2015.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26515624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC28zntVGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=831-846&issue=4&author=S.+J.+Kolbauthor=J.+T.+Kissel&title=Spinal+Muscular+Atrophy&doi=10.1016%2Fj.ncl.2015.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal Muscular Atrophy</span></div><div class="casAuthors">Kolb Stephen J; Kissel John T</div><div class="citationInfo"><span class="NLM_cas:title">Neurologic clinics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">831-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal muscular atrophy is an autosomal-recessive disorder characterized by degeneration of motor neurons in the spinal cord and caused by mutations in the survival motor neuron 1 gene, SMN1.  The severity of SMA is variable.  The SMN2 gene produces a fraction of the SMN messenger RNA (mRNA) transcript produced by the SMN1 gene.  There is an inverse correlation between SMN2 gene copy number and clinical severity.  Clinical management focuses on multidisciplinary care.  Preclinical models of SMA have led to an explosion of SMA clinical trials that hold great promise of effective therapy in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ21r5CsgpXTkcLvDNbOD4DfW6udTcc2eakO33BeiDas7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zntVGmsA%253D%253D&md5=9f3a2143e5c0bb515d4850a63edeed58</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2015.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2015.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DS.%2BJ.%26aulast%3DKissel%26aufirst%3DJ.%2BT.%26atitle%3DSpinal%2520Muscular%2520Atrophy%26jtitle%3DNeurol.%2520Clin.%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D831%26epage%3D846%26doi%3D10.1016%2Fj.ncl.2015.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span> <i>Spinraza Information Sheet</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Spinraza+Information+Sheet.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2016%2F209531lbl.pdf+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DSpinraza%2520Information%2520Sheet%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Galcanezumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1769</span>– <span class="NLM_lpage">1775</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1002-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-1002-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30378008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVChsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1769-1775&issue=16&author=Y.+N.+Lamb&title=Galcanezumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1002-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Galcanezumab: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1769-1775</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Galcanezumab-gnlm (Emgality; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand.  A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis.  In Sept. 2018, the US FDA approved galcanezumab as a once-monthly s.c. injection for the preventive treatment of migraine in adults.  In the same month, the EMA issued a pos. opinion for galcanezumab for the prophylaxis of migraine in adults who have at least 4 migraine days per mo.  Galcanezumab is also undergoing phase III evaluation for the preventive treatment of cluster headache in North America and Europe.  This article summarizes the milestones in the development of galcanezumab leading to its first approval for the preventive treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL2marTaXqkrVg90H21EOLACvtfcHk0lgpERwn9HkhQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVChsr3F&md5=3fa40419d417fed604f0c050d674edea</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1002-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1002-7%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DGalcanezumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D16%26spage%3D1769%26epage%3D1775%26doi%3D10.1007%2Fs40265-018-1002-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Erenumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0944-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0944-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29968151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ygur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1157-1161&issue=11&author=A.+Markham&title=Erenumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0944-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Erenumab: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1157-1161</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Amgen and Novartis are developing erenumab (AIMOVIG, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine.  CGRP is a vasodilatory neuropeptide implicated in the pathophysiol. of migraine and treatment with erenumab was assocd. with significant redns. in migraine frequency in phase II and III clin. trials.  Based on these pos. results erenumab was recently approved in the US for the preventive treatment of migraine in adults and has received a pos. opinion in the EU for the prophylaxis of migraines in adults who have at least 4 migraine days per mo.  This article summarizes the milestones in the development of erenumab leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouU__bWPgx77Vg90H21EOLACvtfcHk0lgpERwn9HkhQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ygur7P&md5=d4334e9510d167c037bb1e08dbc49d19</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0944-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0944-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DErenumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D11%26spage%3D1157%26epage%3D1161%26doi%3D10.1007%2Fs40265-018-0944-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Fremanezumab: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1829</span>– <span class="NLM_lpage">1834</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1004-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-1004-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30406901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnvVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1829-1834&issue=17&author=S.+M.+Hoy&title=Fremanezumab%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1004-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Fremanezumab: First Global Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1829-1834</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY®] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine).  Its use has been associated with significant reductions in migraine frequency, the requirement for acute headache medication use and headache-related disability compared with placebo in multinational, phase III studies, and in September 2018 fremanezumab was approved by the US FDA for the preventive treatment of migraine in adults.  A regulatory assessment for fremanezumab as a preventive treatment of migraine in adults is underway in the EU.  Fremanezumab is also undergoing phase III development for the preventive treatment of cluster headache (although a phase III chronic cluster headache study has been suspended due to the results of a prespecified futility analysis) and phase II development for the preventive treatment of post-traumatic headache disorder.  This article summarizes the milestones in the development of fremanezumab leading to this first approval in the USA for the preventive treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA3j7grvNR8O2mnZh2OgS0fW6udTcc2eYIaSeaLTpN27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnvVOqsg%253D%253D&md5=ec04ab0132663db66059da430afc9b77</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1004-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1004-5%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DFremanezumab%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D17%26spage%3D1829%26epage%3D1834%26doi%3D10.1007%2Fs40265-018-1004-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searles, J. W.</span></span> <span> </span><span class="NLM_article-title">The Market for Migraine Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1038/d41573-018-00014-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fd41573-018-00014-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=333-334&author=A.+M.+Sparrowauthor=J.+W.+Searles&title=The+Market+for+Migraine+Drugs&doi=10.1038%2Fd41573-018-00014-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fd41573-018-00014-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-018-00014-3%26sid%3Dliteratum%253Aachs%26aulast%3DSparrow%26aufirst%3DA.%2BM.%26aulast%3DSearles%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520Market%2520for%2520Migraine%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D333%26epage%3D334%26doi%3D10.1038%2Fd41573-018-00014-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-020-01264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32020557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=323-328&issue=3&author=L.+J.+Scott&title=Ubrogepant%3A+First+Approval&doi=10.1007%2Fs40265-020-01264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ubrogepant (Ubrelvy®) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine.  In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults.  This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFMvLc4ARHEmzfW6udTcc2eYIaSeaLTpN27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D&md5=dee277e0c6d6835ea105dbb4024f8a92</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01264-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DUbrogepant%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D3%26spage%3D323%26epage%3D328%26doi%3D10.1007%2Fs40265-020-01264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Lasmiditan: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1996</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01225-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-019-01225-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31749059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1989-1996&issue=18&author=Y.+N.+Lamb&title=Lasmiditan%3A+First+Approval&doi=10.1007%2Fs40265-019-01225-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Lasmiditan: First Approval</span></div><div class="casAuthors">Lamb Yvette N</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1989-1996</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lasmiditan (REYVOW®; Eli Lilly and Company) is an orally available serotonin (5-HT)1F receptor agonist.  In October 2019, the US FDA approved lasmiditan 50 mg and 100 mg tablets for the acute treatment of migraine with or without aura in adults.  Approval was based on positive results from two pivotal phase III trials, in which lasmiditan significantly improved the proportions of patients achieving freedom from headache pain and freedom from the most bothersome symptom (photophobia, phonophobia or nausea), relative to placebo, when used to treat a migraine with moderate to severe pain.  Lasmiditan is not for use in the preventive treatment of migraine.  This article summarizes the milestones in the development of lasmiditan leading to its first approval for the acute treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrg8vE0Fvv8VvAgqb2vdc5fW6udTcc2ebqnqM4ATa7bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D&md5=54ba4498e8b1a3f567f0e56b56e04322</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01225-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01225-7%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DLasmiditan%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D18%26spage%3D1989%26epage%3D1996%26doi%3D10.1007%2Fs40265-019-01225-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span> </span><span class="NLM_article-title">How the Orphan Drug Act Opened the Door
for Rare Disease Research</span>.  <i>Rare Genomics Institute</i>. <a href="https://www.raregenomics.org/blog/2019/1/8/how-the-orphan-drug-act-opened-the-door-for-rare-disease-research" class="extLink">https://www.raregenomics.org/blog/2019/1/8/how-the-orphan-drug-act-opened-the-door-for-rare-disease-research</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=How+the+Orphan+Drug+Act+Opened+the+Door%0Afor+Rare+Disease+Research.+Rare+Genomics+Institute.+https%3A%2F%2Fwww.raregenomics.org%2Fblog%2F2019%2F1%2F8%2Fhow-the-orphan-drug-act-opened-the-door-for-rare-disease-research+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHow%2520the%2520Orphan%2520Drug%2520Act%2520Opened%2520the%2520Door%250Afor%2520Rare%2520Disease%2520Research%26jtitle%3DRare%2520Genomics%2520Institute%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germain, D. P.</span></span> <span> </span><span class="NLM_article-title">Fabry Disease</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.1186/1750-1172-5-30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2F1750-1172-5-30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=21092187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FmsVShtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=30&author=D.+P.+Germain&title=Fabry+Disease&doi=10.1186%2F1750-1172-5-30"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Fabry disease</span></div><div class="casAuthors">Germain Dominique P</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A activity.  FD is pan-ethnic and the reported annual incidence of 1 in 100,000 may underestimate the true prevalence of the disease.  Classically affected hemizygous males, with no residual α-galactosidase A activity may display all the characteristic neurological (pain), cutaneous (angiokeratoma), renal (proteinuria, kidney failure), cardiovascular (cardiomyopathy, arrhythmia), cochleo-vestibular and cerebrovascular (transient ischemic attacks, strokes) signs of the disease while heterozygous females have symptoms ranging from very mild to severe.  Deficient activity of lysosomal α-galactosidase A results in progressive accumulation of globotriaosylceramide within lysosomes, believed to trigger a cascade of cellular events.  Demonstration of marked α-galactosidase A deficiency is the definitive method for the diagnosis of hemizygous males.  Enzyme analysis may occasionnally help to detect heterozygotes but is often inconclusive due to random X-chromosomal inactivation so that molecular testing (genotyping) of females is mandatory.  In childhood, other possible causes of pain such as rheumatoid arthritis and 'growing pains' must be ruled out.  In adulthood, multiple sclerosis is sometimes considered.  Prenatal diagnosis, available by determination of enzyme activity or DNA testing in chorionic villi or cultured amniotic cells is, for ethical reasons, only considered in male fetuses.  Pre-implantation diagnosis is possible.  The existence of atypical variants and the availability of a specific therapy singularly complicate genetic counseling.  A disease-specific therapeutic option - enzyme replacement therapy using recombinant human α-galactosidase A - has been recently introduced and its long term outcome is currently still being investigated.  Conventional management consists of pain relief with analgesic drugs, nephroprotection (angiotensin converting enzyme inhibitors and angiotensin receptors blockers) and antiarrhythmic agents, whereas dialysis or renal transplantation are available for patients experiencing end-stage renal failure.  With age, progressive damage to vital organ systems develops and at some point, organs may start to fail in functioning.  End-stage renal disease and life-threatening cardiovascular or cerebrovascular complications limit life-expectancy of untreated males and females with reductions of 20 and 10 years, respectively, as compared to the general population.  While there is increasing evidence that long-term enzyme therapy can halt disease progression, the importance of adjunctive therapies should be emphasized and the possibility of developing an oral therapy drives research forward into active site specific chaperones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGSVbCPou-cuWhZTslLrfffW6udTcc2ebqnqM4ATa7bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FmsVShtg%253D%253D&md5=9501521191fc72a2325936b5f29c5f8e</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1186%2F1750-1172-5-30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1172-5-30%26sid%3Dliteratum%253Aachs%26aulast%3DGermain%26aufirst%3DD.%2BP.%26atitle%3DFabry%2520Disease%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2010%26volume%3D5%26spage%3D30%26doi%3D10.1186%2F1750-1172-5-30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span> </span><span class="NLM_article-title">How Many
People Have Fabry Disease?</span> <i>National
Fabry Disease Foundation</i>.  <a href="https://www.fabrydisease.org/index.php/about-fabry-disease/how-many-people-have-fabry-disease" class="extLink">https://www.fabrydisease.org/index.php/about-fabry-disease/how-many-people-have-fabry-disease</a> (accessed <span class="NLM_year">2020</span>-04-04).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=How+Many%0APeople+Have+Fabry+Disease%3F+National%0AFabry+Disease+Foundation.+https%3A%2F%2Fwww.fabrydisease.org%2Findex.php%2Fabout-fabry-disease%2Fhow-many-people-have-fabry-disease+%28accessed+2020-04-04%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DHow%2520Many%250APeople%2520Have%2520Fabry%2520Disease%253F%26jtitle%3DNational%250AFabry%2520Disease%2520Foundation%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bichet, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giugliani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliciani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezgu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amartino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldt-Rasmussen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedd, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf El Din, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lourenco, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banikazemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasouki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finegold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goker-Alpan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuffaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovanovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludington, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viereck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skuban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span> <span> </span><span class="NLM_article-title">Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1510198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1510198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27509102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=545-555&issue=6&author=D.+P.+Germainauthor=D.+A.+Hughesauthor=K.+Nichollsauthor=D.+G.+Bichetauthor=R.+Giuglianiauthor=W.+R.+Wilcoxauthor=C.+Felicianiauthor=S.+P.+Shankarauthor=F.+Ezguauthor=H.+Amartinoauthor=D.+Bratkovicauthor=U.+Feldt-Rasmussenauthor=K.+Neddauthor=U.+Sharaf+El+Dinauthor=C.+M.+Lourencoauthor=M.+Banikazemiauthor=J.+Charrowauthor=M.+Dasoukiauthor=D.+Finegoldauthor=P.+Giraldoauthor=O.+Goker-Alpanauthor=N.+Longoauthor=C.+R.+Scottauthor=R.+Torraauthor=A.+Tuffahaauthor=A.+Jovanovicauthor=S.+Waldekauthor=S.+Packmanauthor=E.+Ludingtonauthor=C.+Viereckauthor=J.+Kirkauthor=J.+Yuauthor=E.+R.+Benjaminauthor=F.+Johnsonauthor=D.+J.+Lockhartauthor=N.+Skubanauthor=J.+Castelliauthor=J.+Barthauthor=C.+Barlowauthor=R.+Schiffmann&title=Treatment+of+Fabry%E2%80%99s+Disease+with+the+Pharmacologic+Chaperone+Migalastat&doi=10.1056%2FNEJMoa1510198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of fabry's disease with the pharmacologic chaperone migalastat</span></div><div class="casAuthors">Germain, D. P.; Hughes, D. A.; Nicholls, K.; Bichet, D. G.; Giugliani, R.; Wilcox, W. R.; Feliciani, C.; Shankar, S. P.; Ezgu, F.; Amartino, H.; Bratkovic, D.; Feldt-Rasmussen, U.; Nedd, K.; El Din, U. Sharaf; Lourenco, C. M.; Banikazemi, M.; Charrow, J.; Dasouki, M.; Finegold, D.; Giraldo, P.; Goker-Alpan, O.; Longo, N.; Scott, C. R.; Torra, R.; Tuffaha, A.; Jovanovic, A.; Waldek, S.; Packman, S.; Ludington, E.; Viereck, C.; Kirk, J.; Yu, J.; Benjamin, E. R.; Johnson, F.; Lockhart, D. J.; Skuban, N.; Castelli, J.; Barth, J.; Barlow, C.; Schiffmann, R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs.  Migalastat, an oral pharmacol. chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes.  METHODS: The initial assay of mutant α-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 mo of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 mo (stage 2) plus an addnl. year, had certain limitations.  Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant α-galactosidase forms suitable for targeting by migalastat.  The primary end point was the percentage of patients who had a response (≥50% redn. in the no. of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 mo.  We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes.  RESULTS: The primary end-point anal., involving patients with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41%) who received migalastat and 9 of 32 patients (28%) who received placebo had a response at 6 mo (P = 0.30).  Among patients with suitable mutant α-galactosidase who received migalastat for up to 24 mo, the annualized changes from baseline in the estd. glomerular filtration rate (GFR) and measured GFR were -0.30±0.66 and -1.51±1.33 mL per min per 1.73 m2 of body-surface area, resp.  The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95% confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95% CI, -38.2 to 1.0).  The severity of diarrhea, reflux, and indigestion decreased.  CONCLUSIONS: Among all randomly assigned patients (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 mo did not differ significantly between the migalastat group and the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryg3_Q8v07YrVg90H21EOLACvtfcHk0lgsOHtSwZ9Y_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks77E&md5=451941d2d3b712d1bb5085e681368f6c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1510198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1510198%26sid%3Dliteratum%253Aachs%26aulast%3DGermain%26aufirst%3DD.%2BP.%26aulast%3DHughes%26aufirst%3DD.%2BA.%26aulast%3DNicholls%26aufirst%3DK.%26aulast%3DBichet%26aufirst%3DD.%2BG.%26aulast%3DGiugliani%26aufirst%3DR.%26aulast%3DWilcox%26aufirst%3DW.%2BR.%26aulast%3DFeliciani%26aufirst%3DC.%26aulast%3DShankar%26aufirst%3DS.%2BP.%26aulast%3DEzgu%26aufirst%3DF.%26aulast%3DAmartino%26aufirst%3DH.%26aulast%3DBratkovic%26aufirst%3DD.%26aulast%3DFeldt-Rasmussen%26aufirst%3DU.%26aulast%3DNedd%26aufirst%3DK.%26aulast%3DSharaf%2BEl%2BDin%26aufirst%3DU.%26aulast%3DLourenco%26aufirst%3DC.%2BM.%26aulast%3DBanikazemi%26aufirst%3DM.%26aulast%3DCharrow%26aufirst%3DJ.%26aulast%3DDasouki%26aufirst%3DM.%26aulast%3DFinegold%26aufirst%3DD.%26aulast%3DGiraldo%26aufirst%3DP.%26aulast%3DGoker-Alpan%26aufirst%3DO.%26aulast%3DLongo%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DC.%2BR.%26aulast%3DTorra%26aufirst%3DR.%26aulast%3DTuffaha%26aufirst%3DA.%26aulast%3DJovanovic%26aufirst%3DA.%26aulast%3DWaldek%26aufirst%3DS.%26aulast%3DPackman%26aufirst%3DS.%26aulast%3DLudington%26aufirst%3DE.%26aulast%3DViereck%26aufirst%3DC.%26aulast%3DKirk%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DJohnson%26aufirst%3DF.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSkuban%26aufirst%3DN.%26aulast%3DCastelli%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DBarlow%26aufirst%3DC.%26aulast%3DSchiffmann%26aufirst%3DR.%26atitle%3DTreatment%2520of%2520Fabry%25E2%2580%2599s%2520Disease%2520with%2520the%2520Pharmacologic%2520Chaperone%2520Migalastat%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D6%26spage%3D545%26epage%3D555%26doi%3D10.1056%2FNEJMoa1510198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imel, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Högler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linglart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padidela, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t Hoff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrinar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portale, A. A.</span></span> <span> </span><span class="NLM_article-title">Burosumab Therapy in Children with X-Linked Hypophosphatemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">1987</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1714641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1714641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29791829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGmt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1987-1998&issue=21&author=T.+O.+Carpenterauthor=M.+P.+Whyteauthor=E.+A.+Imelauthor=A.+M.+Bootauthor=W.+H%C3%B6glerauthor=A.+Linglartauthor=R.+Padidelaauthor=W.+Van%E2%80%99t+Hoffauthor=M.+Maoauthor=C.-Y.+Chenauthor=A.+Skrinarauthor=E.+Kakkisauthor=J.+San+Martinauthor=A.+A.+Portale&title=Burosumab+Therapy+in+Children+with+X-Linked+Hypophosphatemia&doi=10.1056%2FNEJMoa1714641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Burosumab therapy in children with x-linked hypophosphatemia</span></div><div class="casAuthors">Carpenter, Thomas O.; Whyte, Michael P.; Imel, Erik A.; Boot, Annemieke M.; Hogler, Wolfgang; Linglart, Agnes; Padidela, Raja; van't Hoff, William; Mao, Meng; Chen, Chao-Yin; Skrinar, Alison; Kakkis, Emil; Martin, Javier San; Portale, Anthony A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1987-1998</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity).  In addn., the Radiog. Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64.  Addnl. end points were changes in pharmacodynamic markers, linear growth, phys. ability, and patient-reported outcomes and the incidence of adverse events. results The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-wk dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-wk dosing (P<0.001 for both comparisons); these improvements persisted at week 64.  The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per dL [1.0 to 2.0 mmol per L]) by week 6.  Stable serum phosphorus levels were maintained through week 64 with every-2-wk dosing.  Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per dL (0.32 mmol per L).  The mean dose of burosumab at week 40 was 0.98 mg per kg of body wt. with every-2-wk dosing and 1.50 mg per kg with every-4-wk dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqgwdwHG6u1LVg90H21EOLACvtfcHk0lhrwU6msUO7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGmt7bK&md5=0c600953279acdfd503ac8a3ea86a390</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1714641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1714641%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DT.%2BO.%26aulast%3DWhyte%26aufirst%3DM.%2BP.%26aulast%3DImel%26aufirst%3DE.%2BA.%26aulast%3DBoot%26aufirst%3DA.%2BM.%26aulast%3DH%25C3%25B6gler%26aufirst%3DW.%26aulast%3DLinglart%26aufirst%3DA.%26aulast%3DPadidela%26aufirst%3DR.%26aulast%3DVan%25E2%2580%2599t%2BHoff%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.-Y.%26aulast%3DSkrinar%26aufirst%3DA.%26aulast%3DKakkis%26aufirst%3DE.%26aulast%3DSan%2BMartin%26aufirst%3DJ.%26aulast%3DPortale%26aufirst%3DA.%2BA.%26atitle%3DBurosumab%2520Therapy%2520in%2520Children%2520with%2520X-Linked%2520Hypophosphatemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D21%26spage%3D1987%26epage%3D1998%26doi%3D10.1056%2FNEJMoa1714641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, T. O.</span></span> <span> </span><span class="NLM_article-title">New Perspectives on the Biology and Treatment of X-Linked Hypophosphatemic Rickets</span>. <i>Pediatr. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/S0031-3955(05)70485-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS0031-3955%2805%2970485-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=9130929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADyaK2s3nslGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1997&pages=443-466&issue=2&author=T.+O.+Carpenter&title=New+Perspectives+on+the+Biology+and+Treatment+of+X-Linked+Hypophosphatemic+Rickets&doi=10.1016%2FS0031-3955%2805%2970485-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives on the biology and treatment of X-linked hypophosphatemic rickets</span></div><div class="casAuthors">Carpenter T O</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric clinics of North America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">443-66</span>
        ISSN:<span class="NLM_cas:issn">0031-3955</span>.
    </div><div class="casAbstract">This article updates the practicing pediatrician's knowledge of the hypophophatemic disorders that may occur in children.  The classic X-linked disorder is emphasized.  Details of clinical manifestations, the wide spectrum of disease severity, and complications of the disorder in adults are reviewed.  Recent research, new genetic findings, and speculations regarding pathophysiology are discussed.  A strategy for approaching medical treatment of X-linked hypophosphatemic rickets is provided, together with complications of treatment and treatment after cessation of growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTTSBc9Wfxur0AGQpJZWpJfW6udTcc2eaigFHXdNC55rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3nslGntw%253D%253D&md5=feb0dfedd9ba8f566abfdcd1627e474d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0031-3955%2805%2970485-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0031-3955%252805%252970485-5%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DT.%2BO.%26atitle%3DNew%2520Perspectives%2520on%2520the%2520Biology%2520and%2520Treatment%2520of%2520X-Linked%2520Hypophosphatemic%2520Rickets%26jtitle%3DPediatr.%2520Clin.%2520North%2520Am.%26date%3D1997%26volume%3D44%26issue%3D2%26spage%3D443%26epage%3D466%26doi%3D10.1016%2FS0031-3955%2805%2970485-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span> </span><span class="NLM_article-title">Paroxysmal Nocturnal Hemoglobinuria</span>.  <i>National
Organization for Rare Diseases</i>. <a href="https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/" class="extLink">https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Paroxysmal+Nocturnal+Hemoglobinuria.+National%0AOrganization+for+Rare+Diseases.+https%3A%2F%2Frarediseases.org%2Frare-diseases%2Fparoxysmal-nocturnal-hemoglobinuria%2F+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DParoxysmal%2520Nocturnal%2520Hemoglobinuria%26jtitle%3DNational%250AOrganization%2520for%2520Rare%2520Diseases%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicre
de Fontbrune, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong Lee Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gualandro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Füreder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptushkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottinghaus, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguzzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrezenmeier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span> <span> </span><span class="NLM_article-title">Ravulizumab (ALXN1210) vs Eculizumab in Adult Patients with PNH Naive to Complement Inhibitors: The 301 Study</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1182/blood-2018-09-876136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1182%2Fblood-2018-09-876136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30510080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFart78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2019&pages=530-539&issue=6&author=J.+W.+Leeauthor=F.+Sicre%0Ade+Fontbruneauthor=L.+Wong+Lee+Leeauthor=V.+Pessoaauthor=S.+Gualandroauthor=W.+F%C3%BCrederauthor=V.+Ptushkinauthor=S.+T.+Rottinghausauthor=L.+Vollesauthor=L.+Shafnerauthor=R.+Aguzziauthor=R.+Pradhanauthor=H.+Schrezenmeierauthor=A.+Hill&title=Ravulizumab+%28ALXN1210%29+vs+Eculizumab+in+Adult+Patients+with+PNH+Naive+to+Complement+Inhibitors%3A+The+301+Study&doi=10.1182%2Fblood-2018-09-876136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study</span></div><div class="casAuthors">Lee, Jong Wook; Sicre de Fontbrune, Flore; Lee, Lily Wong Lee; Pessoa, Viviani; Gualandro, Sandra; Fureder, Wolfgang; Ptushkin, Vadim; Rottinghaus, Scott T.; Volles, Lori; Shafner, Lori; Aguzzi, Rasha; Pradhan, Rajendra; Schrezenmeier, Hubert; Hill, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">530-539</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition.  This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor-naive adults with paroxysmal nocturnal hemoglobinuria (PNH).  Patients with lactate dehydrogenase (LDH)≥ 1.5 times the upper limit of normal and at least 1 PNH symptom were randomized 1:1 to receive ravulizumab or eculizumab for 183 days (N = 246).  Coprimary efficacy end points were proportion of patients remaining transfusion-free and LDH normalization.  Secondary end points were percent change from baseline in LDH, change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, proportion of patients with breakthrough hemolysis, stabilized Hb, and change in serum free C5.  Ravulizumab was noninferior to eculizumab for both coprimary and all key secondary end points (Pinf less than .0001): transfusion avoidance (73.6% vs 66.1%; difference of 6.8% [95% confidence interval (CI), -4.66, 18.14]), LDH normalization (53.6% vs 49.4%; odds ratio, 1.19 [0.80, 1.77]), percent redn. in LDH (-76.8% vs -76.0%; difference [95% CI], -0.83% [-5.21, 3.56]), change in FACIT-Fatigue score (7.07 vs 6.40; difference [95% CI], 0.67 [-1.21, 2.55]), breakthrough hemolysis (4.0% vs 10.7%; difference [95% CI], -6.7% [-14.21, 0.18]), and stabilized Hb (68.0% vs 64.5%; difference [95% CI], 2.9 [-8.80, 14.64]).  The safety and tolerability of ravulizumab and eculizumab were similar; no meningococcal infections occurred.  In conclusion, ravulizumab given every 8 wk achieved noninferiority compared with eculizumab given every 2 wk for all efficacy end points, with a similar safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOeGCVtTx-ObVg90H21EOLACvtfcHk0lhZ4ctFey9XaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFart78%253D&md5=356dc8a9951fcb54b215c2c88b4ab87c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1182%2Fblood-2018-09-876136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2018-09-876136%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DSicre%2Bde%2BFontbrune%26aufirst%3DF.%26aulast%3DWong%2BLee%2BLee%26aufirst%3DL.%26aulast%3DPessoa%26aufirst%3DV.%26aulast%3DGualandro%26aufirst%3DS.%26aulast%3DF%25C3%25BCreder%26aufirst%3DW.%26aulast%3DPtushkin%26aufirst%3DV.%26aulast%3DRottinghaus%26aufirst%3DS.%2BT.%26aulast%3DVolles%26aufirst%3DL.%26aulast%3DShafner%26aufirst%3DL.%26aulast%3DAguzzi%26aufirst%3DR.%26aulast%3DPradhan%26aufirst%3DR.%26aulast%3DSchrezenmeier%26aufirst%3DH.%26aulast%3DHill%26aufirst%3DA.%26atitle%3DRavulizumab%2520%2528ALXN1210%2529%2520vs%2520Eculizumab%2520in%2520Adult%2520Patients%2520with%2520PNH%2520Naive%2520to%2520Complement%2520Inhibitors%253A%2520The%2520301%2520Study%26jtitle%3DBlood%26date%3D2019%26volume%3D133%26issue%3D6%26spage%3D530%26epage%3D539%26doi%3D10.1182%2Fblood-2018-09-876136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condren, M.</span></span> <span> </span><span class="NLM_article-title">Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy</span>. <i>J. Pediatr. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.5863/1551-6776-25.3.192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.5863%2F1551-6776-25.3.192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32265602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38zislKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=192-197&issue=3&author=K.+Ridleyauthor=M.+Condren&title=Elexacaftor-Tezacaftor-Ivacaftor%3A+The+First+Triple-Combination+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulating+Therapy&doi=10.5863%2F1551-6776-25.3.192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy</span></div><div class="casAuthors">Ridley Kaden; Condren Michelle</div><div class="citationInfo"><span class="NLM_cas:title">The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">192-197</span>
        ISSN:<span class="NLM_cas:issn">1551-6776</span>.
    </div><div class="casAbstract">Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel.  Its labeled indication for use is for persons 12 years of age and older with at least 1 F508del mutation for the CFTR gene.  This drug combination provides potential therapy to many patients who had previously been excluded from CFTR modulation therapy due to the nature of their genetic mutations.  The efficacy demonstrated in clinical trials surpasses the currently available therapies related to lung function, quality of life, sweat chloride reduction, and reducing exacerbations.  The most common adverse events seen in clinical trials included rash and headache, and laboratory monitoring is recommended to evaluate liver function.  Continued evaluation of patient data is needed to confirm its long-term safety and efficacy.  Elexacaftor-tezacaftor-ivacaftor is a monumental and encouraging therapy for cystic fibrosis; however, approximately 10% of the CF population are not candidates for this or any other CFTR modulation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDe8STwgEhUhKDYG3bNImrfW6udTcc2ebH5WaSbW9qH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zislKhsQ%253D%253D&md5=af7bf873365bdb46bb54f0b1ff972255</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.5863%2F1551-6776-25.3.192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5863%252F1551-6776-25.3.192%26sid%3Dliteratum%253Aachs%26aulast%3DRidley%26aufirst%3DK.%26aulast%3DCondren%26aufirst%3DM.%26atitle%3DElexacaftor-Tezacaftor-Ivacaftor%253A%2520The%2520First%2520Triple-Combination%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulating%2520Therapy%26jtitle%3DJ.%2520Pediatr.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D25%26issue%3D3%26spage%3D192%26epage%3D197%26doi%3D10.5863%2F1551-6776-25.3.192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span> <i>Application NUMBER: 212273Orig1s000, Risk Assessment
and Risk Mitigation
Review(s)</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000RiskR.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000RiskR.pdf</a> (accessed <span class="NLM_year">2020</span>-04-01).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Application+NUMBER%3A+212273Orig1s000%2C+Risk+Assessment%0Aand+Risk+Mitigation%0AReview%28s%29.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2019%2F212273Orig1s000RiskR.pdf+%28accessed+2020-04-01%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DApplication%2520NUMBER%253A%2520212273Orig1s000%252C%2520Risk%2520Assessment%250Aand%2520Risk%2520Mitigation%250AReview%2528s%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span> </span><span class="NLM_article-title">FDA Approves
New Breakthrough Therapy for Cystic Fibrosis</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves%0ANew+Breakthrough+Therapy+for+Cystic+Fibrosis.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-breakthrough-therapy-cystic-fibrosis+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%250ANew%2520Breakthrough%2520Therapy%2520for%2520Cystic%2520Fibrosis%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekoroski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zepeda, M. L.</span></span> <span> </span><span class="NLM_article-title">Recombinant Human Hyaluronidase PH20 (RHuPH20) Facilitates Subcutaneous Infusions of Large Volumes of Immunoglobulin in a Swine Model</span>. <i>Drug Delivery Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1007/s13346-012-0065-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs13346-012-0065-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25787031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Omtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=254-264&issue=4&author=D.+W.+Kangauthor=L.+Jadinauthor=T.+Nekoroskiauthor=F.+H.+Drakeauthor=M.+L.+Zepeda&title=Recombinant+Human+Hyaluronidase+PH20+%28RHuPH20%29+Facilitates+Subcutaneous+Infusions+of+Large+Volumes+of+Immunoglobulin+in+a+Swine+Model&doi=10.1007%2Fs13346-012-0065-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model</span></div><div class="casAuthors">Kang, David W.; Jadin, Laurence; Nekoroski, Tara; Drake, Fred H.; Zepeda, Monica L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery and Translational Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">254-264</span>CODEN:
                <span class="NLM_cas:coden">DDTRCY</span>;
        ISSN:<span class="NLM_cas:issn">2190-3948</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Many patients with primary immunodeficiency disease (PIDD) require lifelong Ig (Ig) replacement therapy.  Home-based s.c. (SC) infusion provides advantages to patients with PIDD compared to hospital-based i.v. infusion.  One limitation of current practice with SCIg infusion is the need for small-vol. infusions at multiple injection sites on a frequent basis.  A method was developed for large-vol. SC infusion that uses preinfusion of recombinant human hyaluronidase (rHuPH20) to facilitate fluid dispersion.  Miniature swine was used as a preclin. model to assess the effects of rHuPH20-facilitated infusions, of a single monthly dose, on fluid dispersion, infusion-related pressure, swelling, induration, and tissue damage.  Preinfusion of vehicle (control) or rHuPH20 (75 U/g Ig) was performed simultaneously on contralateral abdominal sites on each animal, followed by infusion of 300 mL 10 % Ig (30 g) at each site.  Compared to control infusions, rHuPH20 significantly reduced infusion pressure and induration (p < 0.05) and accelerated postinfusion Ig dispersion.  Histol. evaluation of infusion site tissue showed moderate to severe swelling for the control.  Swelling after rHuPH20-facilitated infusion was mild on day 1 and had completely resolved shortly thereafter.  Laser Doppler imaging of control infusion sites revealed local cutaneous hypoperfusion during Ig infusion, which was reduced almost 7-fold (p < 0.05) with the use of rHuPH20.  These results demonstrate that rHuPH20-facilitated Ig infusion is assocd. with improved dispersion of Ig, resulting in reduced tissue pressure, induration, and reduced risk of tissue damage from mech. trauma or local ischemia, thus enabling SC administration of large vols. of Ig at a single site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp937Ld1IXemLVg90H21EOLACvtfcHk0li732iWD45wyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Omtb3N&md5=545baf8bf2b547f8dcb0eaffa6d870c4</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1007%2Fs13346-012-0065-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13346-012-0065-3%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%2BW.%26aulast%3DJadin%26aufirst%3DL.%26aulast%3DNekoroski%26aufirst%3DT.%26aulast%3DDrake%26aufirst%3DF.%2BH.%26aulast%3DZepeda%26aufirst%3DM.%2BL.%26atitle%3DRecombinant%2520Human%2520Hyaluronidase%2520PH20%2520%2528RHuPH20%2529%2520Facilitates%2520Subcutaneous%2520Infusions%2520of%2520Large%2520Volumes%2520of%2520Immunoglobulin%2520in%2520a%2520Swine%2520Model%26jtitle%3DDrug%2520Delivery%2520Transl.%2520Res.%26date%3D2012%26volume%3D2%26issue%3D4%26spage%3D254%26epage%3D264%26doi%3D10.1007%2Fs13346-012-0065-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppal, P.</span></span> <span> </span><span class="NLM_article-title">Trifluridine/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer</span>. <i>P T</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27162472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC28botFSgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=314-325&issue=5&author=T.+Kishauthor=P.+Uppal&title=Trifluridine%2FTipiracil+%28Lonsurf%29+for+the+Treatment+of+Metastatic+Colorectal+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluridine/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer</span></div><div class="casAuthors">Kish Troy; Uppal Priyasha</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">314-25</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0cDLBzgdho5QHPYJuLg8TfW6udTcc2eYiiIc9WVlGP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28botFSgtg%253D%253D&md5=d7790ae85861a512980553044df99f4d</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKish%26aufirst%3DT.%26aulast%3DUppal%26aufirst%3DP.%26atitle%3DTrifluridine%252FTipiracil%2520%2528Lonsurf%2529%2520for%2520the%2520Treatment%2520of%2520Metastatic%2520Colorectal%2520Cancer%26jtitle%3DP%2520T%26date%3D2016%26volume%3D41%26issue%3D5%26spage%3D314%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, L.</span>; <span class="NLM_string-name">Kesselheim, A. S.</span></span> <span> </span><span class="NLM_article-title">The Role of Black Box Warnings In Safe Prescribing Practices</span>.  <i>Health Affairs</i>. <a href="https://www.healthaffairs.org/do/10.1377/hblog20140820.040875/full/" class="extLink">https://www.healthaffairs.org/do/10.1377/hblog20140820.040875/full/</a> (accessed <span class="NLM_year">2020</span>-08-03).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Maggs&author=A.+S.+Kesselheim&title=The+Role+of+Black+Box+Warnings+In+Safe+Prescribing+Practices"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520Black%2520Box%2520Warnings%2520In%2520Safe%2520Prescribing%2520Practices%26jtitle%3DHealth%2520Affairs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanne, J. H.</span></span> <span> </span><span class="NLM_article-title">FDA Adds “Black Box” Warning Label to Fluoroquinolone Antibiotics</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">a816</span>, <span class="refDoi"> DOI: 10.1136/bmj.a816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1136%2Fbmj.a816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=18632714" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2008&pages=a816&author=J.+H.+Tanne&title=FDA+Adds+%E2%80%9CBlack+Box%E2%80%9D+Warning+Label+to+Fluoroquinolone+Antibiotics&doi=10.1136%2Fbmj.a816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1136%2Fbmj.a816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.a816%26sid%3Dliteratum%253Aachs%26aulast%3DTanne%26aufirst%3DJ.%2BH.%26atitle%3DFDA%2520Adds%2520%25E2%2580%259CBlack%2520Box%25E2%2580%259D%2520Warning%2520Label%2520to%2520Fluoroquinolone%2520Antibiotics%26jtitle%3DBMJ.%26date%3D2008%26volume%3D337%26spage%3Da816%26doi%3D10.1136%2Fbmj.a816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baddley, J. W.</span></span> <span> </span><span class="NLM_article-title">Opportunistic Infections in Biological Therapy, Risk and Prevention</span>. <i>Rheum. Dis. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.rdc.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.rdc.2016.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27890172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2017&pages=27-41&issue=1&author=P.+A.+Bryantauthor=J.+W.+Baddley&title=Opportunistic+Infections+in+Biological+Therapy%2C+Risk+and+Prevention&doi=10.1016%2Fj.rdc.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunistic Infections in Biological Therapy, Risk and Prevention</span></div><div class="casAuthors">Bryant Paul A; Baddley John W</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatic diseases clinics of North America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients being treated with biological therapies are at increased risk for serious infections, including opportunistic infections.  Although more is known about opportunistic infection risk with older biologics, such as antitumor necrosis factor drugs, there is less knowledge of opportunistic infection risk with newer biological therapies.  The incidence of certain opportunistic infections (tuberculosis, herpes zoster, pneumocystosis) has been rigorously evaluated in large observational studies.  However, data are more limited for other infections (histoplasmosis, nontuberculous mycobacteria).  Infectious morbidity and mortality may be preventable with screening and prophylaxis in select populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmopmDE8yyttts4TFFB11gfW6udTcc2ebsys8rDc5Hx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgslWgug%253D%253D&md5=d0ad7a4ffd74e475b85027591800f1bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.rdc.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rdc.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DP.%2BA.%26aulast%3DBaddley%26aufirst%3DJ.%2BW.%26atitle%3DOpportunistic%2520Infections%2520in%2520Biological%2520Therapy%252C%2520Risk%2520and%2520Prevention%26jtitle%3DRheum.%2520Dis.%2520Clin.%2520North%2520Am.%26date%3D2017%26volume%3D43%26issue%3D1%26spage%3D27%26epage%3D41%26doi%3D10.1016%2Fj.rdc.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvana, E. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salata, R. A.</span></span> <span> </span><span class="NLM_article-title">Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1128/CMR.00040-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1128%2FCMR.00040-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=19366915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVSqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=274-290&issue=2&author=E.+M.+T.+Salvanaauthor=R.+A.+Salata&title=Infectious+Complications+Associated+with+Monoclonal+Antibodies+and+Related+Small+Molecules&doi=10.1128%2FCMR.00040-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Infectious complications associated with monoclonal antibodies and related small molecules</span></div><div class="casAuthors">Salvana, Edsel Maurice T.; Salata, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-290</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Biologics are increasingly becoming part of routine disease management.  As more agents are developed, the challenge of keeping track of indications and side effects is growing.  While biologics represent a milestone in targeted and specific therapy, they are not without drawbacks, and the judicious use of these "magic bullets" is essential if their full potential is to be realized.  Infectious complications in particular are not an uncommon side effect of therapy, whether as a direct consequence of the agent or because of the underlying disease process.  With this in mind, we have reviewed and summarized the risks of infection and the infectious disease-related complications for all FDA-approved monoclonal antibodies and some related small mols., and we discuss the probable mechanisms involved in immunosuppression as well as recommendations for prophylaxis and treatment of specific disease entities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn07Dvbh3x3LVg90H21EOLACvtfcHk0ljdWeeLOHix6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVSqt7Y%253D&md5=9d253f89e22dadca0381572722158190</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1128%2FCMR.00040-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00040-08%26sid%3Dliteratum%253Aachs%26aulast%3DSalvana%26aufirst%3DE.%2BM.%2BT.%26aulast%3DSalata%26aufirst%3DR.%2BA.%26atitle%3DInfectious%2520Complications%2520Associated%2520with%2520Monoclonal%2520Antibodies%2520and%2520Related%2520Small%2520Molecules%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2009%26volume%3D22%26issue%3D2%26spage%3D274%26epage%3D290%26doi%3D10.1128%2FCMR.00040-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular Property Design: Does Everyone Get It?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=722-725&issue=7&author=P.+D.+Leesonauthor=R.+J.+Young&title=Molecular+Property+Design%3A+Does+Everyone+Get+It%3F&doi=10.1021%2Facsmedchemlett.5b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0liHYUzbau5SzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Property%2520Design%253A%2520Does%2520Everyone%2520Get%2520It%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D7%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0liHYUzbau5SzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobritzsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2312</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2312-2327&issue=6&author=B.+C.+Doakauthor=J.+Zhengauthor=D.+Dobritzschauthor=J.+Kihlberg&title=How+Beyond+Rule+of+5+Drugs+and+Clinical+Candidates+Bind+to+Their+Targets&doi=10.1021%2Facs.jmedchem.5b01286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span></div><div class="casAuthors">Doak, Bradley C.; Zheng, Jie; Dobritzsch, Doreen; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve discovery of drugs for difficult targets, the opportunities of chem. space beyond the rule of 5 (bRo5) were examd. by retrospective anal. of a comprehensive set of structures for complexes between drugs and clin. candidates and their targets.  The anal. illustrates the potential of compds. far beyond rule of 5 space to modulate novel and difficult target classes that have large, flat, and groove-shaped binding sites.  However, ligand efficiencies are significantly reduced for flat- and groove-shape binding sites, suggesting that adjustments of how to use such metrics are required.  Ligands bRo5 appear to benefit from an appropriate balance between rigidity and flexibility to bind with sufficient affinity to their targets, with macrocycles and nonmacrocycles being found to have similar flexibility.  However, macrocycles were more disk- and spherelike, which may contribute to their superior binding to flat sites, while rigidification of nonmacrocycles lead to rodlike ligands that bind well to groove-shaped binding sites.  These insights should contribute to altering perceptions of what targets are considered "druggable" and provide support for drug design in beyond rule of 5 space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZD-h9VodiPLVg90H21EOLACvtfcHk0liHYUzbau5SzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F&md5=a417b605d1a3ffbc7ee84706401f01f4</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01286%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DDobritzsch%26aufirst%3DD.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DHow%2520Beyond%2520Rule%2520of%25205%2520Drugs%2520and%2520Clinical%2520Candidates%2520Bind%2520to%2520Their%2520Targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2312%26epage%3D2327%26doi%3D10.1021%2Facs.jmedchem.5b01286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&issue=4&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lhwoovtTcymGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tinworth, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">10091</span>– <span class="NLM_lpage">10108</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01596</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01596" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslShtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10091-10108&issue=18&author=C.+P.+Tinworthauthor=R.+J.+Young&title=Facts%2C+Patterns%2C+and+Principles+in+Drug+Discovery%3A+Appraising+the+Rule+of+5+with+Measured+Physicochemical+Data&doi=10.1021%2Facs.jmedchem.9b01596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data</span></div><div class="casAuthors">Tinworth, Christopher P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10091-10108</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The rule of 5 was designed to est. the likelihood of poor absorption or permeation, noting the impact of poor soly.  This Perspective explores the impact of various physicochem. descriptors and contemporary lipophilicity measurements on permeability and soly., showing that the distribution coeff. log D7.4 (rather than log P) is the most impactful parameter.  Mol. wt., almost invariably the defining characteristic of "beyond the rule of 5" compds., has little impact on soly. when log D7.4 measurements and aromaticity are considered.  Predicting permeation is more complex, given passive and carrier transport mechanisms; however, notable patterns of behavior are apparent, giving insight even "beyond the rule of 5".  Recommended best practices should involve using the facts (measurements) and the patterns they reveal to establish informative principles rather than fastidious rules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBT9kzvTWdTbVg90H21EOLACvtfcHk0lhwoovtTcymGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslShtb4%253D&md5=c93bbcd944dcb41c0d38d2a3881b8593</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01596%26sid%3Dliteratum%253Aachs%26aulast%3DTinworth%26aufirst%3DC.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DFacts%252C%2520Patterns%252C%2520and%2520Principles%2520in%2520Drug%2520Discovery%253A%2520Appraising%2520the%2520Rule%2520of%25205%2520with%2520Measured%2520Physicochemical%2520Data%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D18%26spage%3D10091%26epage%3D10108%26doi%3D10.1021%2Facs.jmedchem.9b01596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6421</span>– <span class="NLM_lpage">6467</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00180</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00180" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6421-6467&issue=15&author=R.+J.+Youngauthor=P.+D.+Leeson&title=Mapping+the+Efficiency+and+Physicochemical+Trajectories+of+Successful+Optimizations&doi=10.1021%2Facs.jmedchem.8b00180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations</span></div><div class="casAuthors">Young, Robert J.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6421-6467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The practices and tactics employed in successful optimizations are examd., judged from the trajectories of ligand efficiency and property evolution.  A wide range of targets is analyzed, encompassing a variety of hit finding methods (HTS, fragments, encoded library technol.) and types of mols., including those beyond the rule of five.  The wider employment of efficiency metrics and lipophilicity control is evident in contemporary practice and the impact on quality demonstrable.  What is clear is that while targets are different, successful mols. are almost invariably among the most efficient for their target, even at the extremes.  Trajectory mapping, based on principles rather than rules, is useful in assessing quality and progress in optimizations while benchmarking against competitors and assessing property-dependent risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCQtcLKSk7q7Vg90H21EOLACvtfcHk0lgSr0bZkxtjVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmu7Y%253D&md5=f040ef02d161e070bb5021fde1585e66</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DMapping%2520the%2520Efficiency%2520and%2520Physicochemical%2520Trajectories%2520of%2520Successful%2520Optimizations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467%26doi%3D10.1021%2Facs.jmedchem.8b00180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&issue=21&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Where+Do+Recent+Small+Molecule+Clinical+Development+Candidates+Come+From%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0lgSr0bZkxtjVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DWhere%2520Do%2520Recent%2520Small%2520Molecule%2520Clinical%2520Development%2520Candidates%2520Come%2520From%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserű, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span> <span> </span><span class="NLM_article-title">Why Some Targets Benefit from beyond Rule of Five Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10005</span>– <span class="NLM_lpage">10025</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01732</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01732" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKktr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10005-10025&issue=22&author=M.+Egbertauthor=A.+Whittyauthor=G.+M.+Keser%C5%B1author=S.+Vajda&title=Why+Some+Targets+Benefit+from+beyond+Rule+of+Five+Drugs&doi=10.1021%2Facs.jmedchem.8b01732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Why Some Targets Benefit from beyond Rule of Five Drugs</span></div><div class="casAuthors">Egbert, Megan; Whitty, Adrian; Keseru, Gyorgy M.; Vajda, Sandor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10005-10025</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Beyond rule-of-five (bRo5) compds. are increasingly used in drug discovery.  Here we analyze 37 target proteins that have bRo5 drugs or clin. candidates.  Targets can benefit from bRo5 drugs if they have "complex" hot spot structure with four or more hots spots, including some strong ones.  Complex I targets show pos. correlation between binding affinity and mol. wt.  These targets are conventionally druggable, but reaching addnl. hot spots enables improved pharmaceutical properties.  Complex II targets, mostly protein kinases, also have strong hot spots but show no correlation between affinity and ligand mol. wt., and the primary motivation for creating larger drugs is to increase selectivity.  Each target considered as complex III has some specific reason for requiring bRo5 drugs.  Finally, targets with "simple" hot spot structure, i.e., three or fewer weak hot spots, must use larger compds. that interact with surfaces beyond the hot spot region to achieve acceptable affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZIR5KB1PgHLVg90H21EOLACvtfcHk0livC1c7FdwBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKktr%252FE&md5=cef48829657115db9d8d48e6d54d2398</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01732%26sid%3Dliteratum%253Aachs%26aulast%3DEgbert%26aufirst%3DM.%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DKeser%25C5%25B1%26aufirst%3DG.%2BM.%26aulast%3DVajda%26aufirst%3DS.%26atitle%3DWhy%2520Some%2520Targets%2520Benefit%2520from%2520beyond%2520Rule%2520of%2520Five%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10005%26epage%3D10025%26doi%3D10.1021%2Facs.jmedchem.8b01732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&issue=7&author=D.+A.+DeGoeyauthor=H.-J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+Rule+of+5%3A+Lessons+Learned+from+AbbVie%E2%80%99s+Drugs+and+Compound+Collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0livC1c7FdwBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.-J.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520Rule%2520of%25205%253A%2520Lessons%2520Learned%2520from%2520AbbVie%25E2%2580%2599s%2520Drugs%2520and%2520Compound%2520Collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanotto, D.</span></span> <span> </span><span class="NLM_article-title">FDA-Approved Oligonucleotide Therapies in 2017</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.ymthe.2017.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28366767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1069-1075&issue=5&author=C.+A.+Steinauthor=D.+Castanotto&title=FDA-Approved+Oligonucleotide+Therapies+in+2017&doi=10.1016%2Fj.ymthe.2017.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-Approved Oligonucleotide Therapies in 2017</span></div><div class="casAuthors">Stein, Cy A.; Castanotto, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1075</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oligonucleotides (oligos) have been under clin. development for approx. the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs.  During that lengthy period of time, numerous clin. trials have been performed and thousands of trial participants accrued onto studies.  Of all the mols. evaluated as of Jan. 2017, the regulatory authorities assessed that six provided clear clin. benefit in rigorously controlled trials.  The story of these six is given in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNtVeb7iVOxrVg90H21EOLACvtfcHk0livC1c7FdwBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D&md5=d9f556e813d1070c6af77b34fe051fd2</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DC.%2BA.%26aulast%3DCastanotto%26aufirst%3DD.%26atitle%3DFDA-Approved%2520Oligonucleotide%2520Therapies%2520in%25202017%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26issue%3D5%26spage%3D1069%26epage%3D1075%26doi%3D10.1016%2Fj.ymthe.2017.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddington-Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polydefkis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planté-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannagan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchy, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conceição, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vita, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campistol, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorevic, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwoh, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span> <span> </span><span class="NLM_article-title">Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1716793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29972757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=22-31&issue=1&author=M.+D.+Bensonauthor=M.+Waddington-Cruzauthor=J.+L.+Berkauthor=M.+Polydefkisauthor=P.+J.+Dyckauthor=A.+K.+Wangauthor=V.+Plant%C3%A9-Bordeneuveauthor=F.+A.+Barrosoauthor=G.+Merliniauthor=L.+Obiciauthor=M.+Scheinbergauthor=T.+H.+Brannaganauthor=W.+J.+Litchyauthor=C.+Whelanauthor=B.+M.+Drachmanauthor=D.+Adamsauthor=S.+B.+Heitnerauthor=I.+Concei%C3%A7%C3%A3oauthor=H.+H.+Schmidtauthor=G.+Vitaauthor=J.+M.+Campistolauthor=J.+Gamezauthor=P.+D.+Gorevicauthor=E.+Ganeauthor=A.+M.+Shahauthor=S.+D.+Solomonauthor=B.+P.+Moniaauthor=S.+G.+Hughesauthor=T.+J.+Kwohauthor=B.+W.+McEvoyauthor=S.+W.+Jungauthor=B.+F.+Bakerauthor=E.+J.+Ackermannauthor=M.+A.+Gertzauthor=T.+Coelho&title=Inotersen+Treatment+for+Patients+with+Hereditary+Transthyretin+Amyloidosis&doi=10.1056%2FNEJMoa1716793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Inotersen treatment for patients with hereditary transthyretin amyloidosis</span></div><div class="casAuthors">Benson, M. D.; Waddington-Cruz, M.; Berk, J. L.; Polydefkis, M.; Dyck, P. J.; Wang, A. K.; Plante-Bordeneuve, V.; Barroso, F. A.; Merlini, G.; Obici, L.; Scheinberg, M.; Brannagan, T. H., III; Litchy, W. J.; Whelan, C.; Drachman, B. M.; Adams, D.; Heitner, S. B.; Conceicao, I.; Schmidt, H. H.; Vita, G.; Campistol, J. M.; Gamez, J.; Gorevic, P. D.; Gane, E.; Shah, A. M.; Solomon, S. D.; Monia, B. P.; Hughes, S. G.; Kwoh, T. J.; McEvoy, B. W.; Jung, S. W.; Baker, B. F.; Ackermann, E. J.; Gertz, M. A.; Coelho, T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-31</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin (TTR) that induce transthyretin misfolding and systemic deposition of amyloid.  Progressive amyloid accumulation leads to multiorgan dysfunction and death.  Inotersen, a 2'-O-methoxyethyl-modified antisense oligonucleotide, inhibits hepatic prodn. of transthyretin.  Methods: We conducted an international, randomized, double-blind, placebo-controlled, 15-mo, phase 3 trial of inotersen in adults with stage 1 (patient is ambulatory) or stage 2 (patient is ambulatory with assistance) hereditary transthyretin amyloidosis with polyneuropathy.  Patients were randomly assigned, in a 2:1 ratio, to receive weekly s.c. injections of inotersen (300 mg) or placebo.  The primary end points were the change in the modified Neuropathy Impairment Score + 7 (mNIS + 7; range, -22.3 to 346.3, with higher scores indicating poorer function; minimal clin. meaningful change, 2 points) and the change in the score on the patient-reported Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating poorer quality of life).  A decrease in scores indicated improvement.  Results: A total of 172 patients (112 in the inotersen group and 60 in the placebo group) received at least one dose of a trial regimen, and 139 (81%) completed the intervention period.  Both primary efficacy assessments favored inotersen: the difference in the least-squares mean change from baseline to week 66 between the two groups (inotersen minus placebo) was -19.7 points (95% confidence interval [CI], -26.4 to -13.0; P<0.001) for the mNIS + 7 and -11.7 points (95% CI, -18.3 to -5.1; P<0.001) for the Norfolk QOL-DN score.  These improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.  There were five deaths in the inotersen group and none in the placebo group.  The most frequent serious adverse events in the inotersen group were glomerulonephritis (in 3 patients [3%]) and thrombocytopenia (in 3 patients [3%]), with one death assocd. with one of the cases of grade 4 thrombocytopenia.  Thereafter, all patients received enhanced monitoring.  Conclusions: Inotersen improved the course of neurol. disease and quality of life in patients with hereditary transthyretin amyloidosis.  Thrombocytopenia and glomerulonephritis were managed with enhanced monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBEWIP8nbbdbVg90H21EOLACvtfcHk0liRzEgJYDgWkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zK&md5=f22e3bc79225bb739cff9e32d3630ab4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716793%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DM.%2BD.%26aulast%3DWaddington-Cruz%26aufirst%3DM.%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DPolydefkis%26aufirst%3DM.%26aulast%3DDyck%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DA.%2BK.%26aulast%3DPlant%25C3%25A9-Bordeneuve%26aufirst%3DV.%26aulast%3DBarroso%26aufirst%3DF.%2BA.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DObici%26aufirst%3DL.%26aulast%3DScheinberg%26aufirst%3DM.%26aulast%3DBrannagan%26aufirst%3DT.%2BH.%26aulast%3DLitchy%26aufirst%3DW.%2BJ.%26aulast%3DWhelan%26aufirst%3DC.%26aulast%3DDrachman%26aufirst%3DB.%2BM.%26aulast%3DAdams%26aufirst%3DD.%26aulast%3DHeitner%26aufirst%3DS.%2BB.%26aulast%3DConcei%25C3%25A7%25C3%25A3o%26aufirst%3DI.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DVita%26aufirst%3DG.%26aulast%3DCampistol%26aufirst%3DJ.%2BM.%26aulast%3DGamez%26aufirst%3DJ.%26aulast%3DGorevic%26aufirst%3DP.%2BD.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DShah%26aufirst%3DA.%2BM.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DHughes%26aufirst%3DS.%2BG.%26aulast%3DKwoh%26aufirst%3DT.%2BJ.%26aulast%3DMcEvoy%26aufirst%3DB.%2BW.%26aulast%3DJung%26aufirst%3DS.%2BW.%26aulast%3DBaker%26aufirst%3DB.%2BF.%26aulast%3DAckermann%26aufirst%3DE.%2BJ.%26aulast%3DGertz%26aufirst%3DM.%2BA.%26aulast%3DCoelho%26aufirst%3DT.%26atitle%3DInotersen%2520Treatment%2520for%2520Patients%2520with%2520Hereditary%2520Transthyretin%2520Amyloidosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D1%26spage%3D22%26epage%3D31%26doi%3D10.1056%2FNEJMoa1716793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D. R.</span></span> <span> </span><span class="NLM_article-title">Chemistry, Mechanism and Clinical Status of Antisense Oligonucleotides and Duplex RNAs</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1584</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1093%2Fnar%2Fgkx1239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29240946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1584-1600&issue=4&author=X.+Shenauthor=D.+R.+Corey&title=Chemistry%2C+Mechanism+and+Clinical+Status+of+Antisense+Oligonucleotides+and+Duplex+RNAs&doi=10.1093%2Fnar%2Fgkx1239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs</span></div><div class="casAuthors">Shen, Xiulong; Corey, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1584-1600</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  RNA plays a central role in the expression of all genes.  Because any sequence within RNA can be recognized by complementary base pairing, synthetic oligonucleotides and oligonucleotide mimics offer a general strategy for controlling processes that affect disease.  The two primary antisense approaches for regulating expression through recognition of cellular RNAs are single-stranded antisense oligonucleotides and duplex RNAs.  This review will discuss the chem. modifications and mol. mechanisms that make synthetic nucleic acid drugs possible.  Lessons learned from recent clin. trials will be summarized.  Ongoing clin. trials are likely to decisively test the adequacy of our current generation of antisense nucleic acid technologies and highlight areas where more basic research is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHfDaQwcmtD7Vg90H21EOLACvtfcHk0lhUJSIDSMPE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F&md5=b5bdec984635f12162386b6f8a6f6fe0</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1239%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DCorey%26aufirst%3DD.%2BR.%26atitle%3DChemistry%252C%2520Mechanism%2520and%2520Clinical%2520Status%2520of%2520Antisense%2520Oligonucleotides%2520and%2520Duplex%2520RNAs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D1584%26epage%3D1600%26doi%3D10.1093%2Fnar%2Fgkx1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keefe, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellington, A.</span></span> <span> </span><span class="NLM_article-title">Aptamers as Therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrd3141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd3141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=20592747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotFelsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=537-550&issue=7&author=A.+D.+Keefeauthor=S.+Paiauthor=A.+Ellington&title=Aptamers+as+Therapeutics&doi=10.1038%2Fnrd3141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamers as therapeutics</span></div><div class="casAuthors">Keefe, Anthony D.; Pai, Supriya; Ellington, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">537-550</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with affinities and specificities that are comparable to antibodies.  Aptamers exhibit significant advantages relative to protein therapeutics in terms of size, synthetic accessibility and modification by medicinal chem.  Despite these properties, aptamers have been slow to reach the marketplace, with only one aptamer-based drug receiving approval so far.  A series of aptamers currently in development may change how nucleic acid therapeutics are perceived.  It is likely that in the future, aptamers will increasingly find use in concert with other therapeutic mols. and modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHt9O_VBa_rLVg90H21EOLACvtfcHk0lhUJSIDSMPE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotFelsLY%253D&md5=37135269c7c403087bd0e992d981fd31</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnrd3141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3141%26sid%3Dliteratum%253Aachs%26aulast%3DKeefe%26aufirst%3DA.%2BD.%26aulast%3DPai%26aufirst%3DS.%26aulast%3DEllington%26aufirst%3DA.%26atitle%3DAptamers%2520as%2520Therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D7%26spage%3D537%26epage%3D550%26doi%3D10.1038%2Fnrd3141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, J.</span></span> <span> </span><span class="NLM_article-title">Aptamers as Targeted Therapeutics: Current Potential and Challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2016.199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27807347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOqtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=181-202&issue=3&author=J.+Zhouauthor=J.+Rossi&title=Aptamers+as+Targeted+Therapeutics%3A+Current+Potential+and+Challenges&doi=10.1038%2Fnrd.2016.199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Aptamers as targeted therapeutics: current potential and challenges</span></div><div class="casAuthors">Zhou, Jiehua; Rossi, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-202</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nucleic acid aptamers, often termed 'chem. antibodies', are functionally comparable to traditional antibodies, but offer several advantages, including their relatively small phys. size, flexible structure, quick chem. prodn., versatile chem. modification, high stability and lack of immunogenicity.  In addn., many aptamers are internalized upon binding to cellular receptors, making them useful targeted delivery agents for small interfering RNAs (siRNAs), microRNAs and conventional drugs.  However, several crucial factors have delayed the clin. translation of therapeutic aptamers, such as their inherent physicochem. characteristics and lack of safety data.  This Review discusses these challenges, highlighting recent clin. developments and technol. advances that have revived the impetus for this promising class of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KSEhC4dW0LVg90H21EOLACvtfcHk0lhUJSIDSMPE8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOqtr3I&md5=3d79942589e20829b3e8de582a08d6e1</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.199%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DRossi%26aufirst%3DJ.%26atitle%3DAptamers%2520as%2520Targeted%2520Therapeutics%253A%2520Current%2520Potential%2520and%2520Challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D3%26spage%3D181%26epage%3D202%26doi%3D10.1038%2Fnrd.2016.199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Patisiran: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0983-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-018-0983-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30251172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1625-1631&issue=15&author=S.+M.+Hoy&title=Patisiran%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0983-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1625-1631</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Patisiran (ONPATTRO) is a double-stranded small interfering RNA encapsulated in a lipid nanoparticle for delivery to hepatocytes.  By specifically binding to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type transthyretin (TTR) mRNA, patisiran causes its degrdn. (via RNA interference) and subsequently a redn. in serum TTR protein levels and tissue TTR protein deposits.  Patisiran has been developed by Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and subsequently approved in the EU for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy.  The recommended dosage, administered as a single i.v. infusion over approx. 80 min, is 0.3 mg/kg once every 3 wk for patients weighing < 100 kg and 30 mg once every 3 wk for patients weighing ≥ 100 kg.  This article summarizes the milestones in the development of patisiran leading to these approvals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69gWrTaxHmLVg90H21EOLACvtfcHk0lhhtepJlW60RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI&md5=94abed01abbe7ba7b679224a42338810</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0983-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0983-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DPatisiran%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D15%26spage%3D1625%26epage%3D1631%26doi%3D10.1007%2Fs40265-018-0983-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Golodirsen: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01267-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-020-01267-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32026421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FovFGjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=329-333&issue=3&author=Y.-A.+Heo&title=Golodirsen%3A+First+Approval&doi=10.1007%2Fs40265-020-01267-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Golodirsen: First Approval</span></div><div class="casAuthors">Heo Young-A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-333</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Golodirsen (Vyondys 53(®)), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD).  In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial.  Golodirsen is in phase III clinical development for the treatment of DMD worldwide.  This article summarizes the milestones in the development of golodirsen leading to this first approval for DMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfkeM-ZqSk0wxyojvcjibhfW6udTcc2eYQCk7Wf_jIJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FovFGjuw%253D%253D&md5=8c87286872bea509d97f40bc4cdbc042</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01267-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01267-2%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DGolodirsen%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D3%26spage%3D329%26epage%3D333%26doi%3D10.1007%2Fs40265-020-01267-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Givosiran: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01269-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs40265-020-01269-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32034693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=335-339&issue=3&author=L.+J.+Scott&title=Givosiran%3A+First+Approval&doi=10.1007%2Fs40265-020-01269-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Givosiran: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-339</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Givosiran (Givlaari®) is an aminolevulinate synthase 1 (ALAS1)-directed small interfering RNA (siRNA) covalently linked to a ligand to enable specific delivery of the siRNA to hepatocytes.  This results in downregulation of ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels that are associated with acute porphyria attacks.  Givosiran is being developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP).  In November 2019, givosiran was approved in the USA for the treatment of adults with AHP based on the positive results from the multinational, phase III ENVISION trial.  In the EU, givosiran received a positive opinion in January 2020 for the treatment of AHP in adults and adolescents aged 12 years and older.  This article summarizes the milestones in the development of givosiran leading to this first approval for the treatment of adults with AHP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDp3euVwlvRZw7prLlxLOzfW6udTcc2eb8_bqcPJKM4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FpslOktw%253D%253D&md5=d3d9d673974d3c8f9525c37fae4b7f80</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01269-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01269-0%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DGivosiran%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D3%26spage%3D335%26epage%3D339%26doi%3D10.1007%2Fs40265-020-01269-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denduluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span> <span> </span><span class="NLM_article-title">DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1914510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1914510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31825192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=610-621&issue=7&author=S.+Modiauthor=C.+Sauraauthor=T.+Yamashitaauthor=Y.+H.+Parkauthor=S.-B.+Kimauthor=K.+Tamuraauthor=F.+Andreauthor=H.+Iwataauthor=Y.+Itoauthor=J.+Tsurutaniauthor=J.+Sohnauthor=N.+Denduluriauthor=C.+Perrinauthor=K.+Aogiauthor=E.+Tokunagaauthor=S.-A.+Imauthor=K.+S.+Leeauthor=S.+A.+Hurvitzauthor=J.+Cortesauthor=C.+Leeauthor=S.+Chenauthor=L.+Zhangauthor=J.+Shahidiauthor=A.+Yverauthor=I.+Krop&title=DESTINY-Breast01+Investigators.+Trastuzumab+Deruxtecan+in+Previously+Treated+HER2-Positive+Breast+Cancer&doi=10.1056%2FNEJMoa1914510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span></div><div class="casAuthors">Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.-A.; Lee, K. S.; Hurvitz, S. A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathol. documented HER2-pos. metastatic breast cancer who had received previous treatment with trastuzumab emtansine.  In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose.  Key secondary end points were the disease-control rate, clin.-benefit rate, duration of response and progression-free survival, and safety. results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kg of body wt.).  During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%).  On independent adjudication, the trial drug was assocd. with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-pos. metastatic breast cancer.  In addn. to nausea and myelosuppression, interstitial lung disease was obsd. in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Uc2NDB76h7Vg90H21EOLACvtfcHk0lgcwp3Yl90EEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D&md5=0b142802a47c4f50f0b2cdc82f22ce87</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1914510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1914510%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DS.-B.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DDenduluri%26aufirst%3DN.%26aulast%3DPerrin%26aufirst%3DC.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DDESTINY-Breast01%2520Investigators.%2520Trastuzumab%2520Deruxtecan%2520in%2520Previously%2520Treated%2520HER2-Positive%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26issue%3D7%26spage%3D610%26epage%3D621%26doi%3D10.1056%2FNEJMoa1914510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrétien, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasnovas, R.-O.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review</span>. <i>Target. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/s11523-018-0558-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1007%2Fs11523-018-0558-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29556925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1MnivVyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=287-308&issue=3&author=C.+Rossiauthor=M.-L.+Chr%C3%A9tienauthor=R.-O.+Casasnovas&title=Antibody-Drug+Conjugates+for+the+Treatment+of+Hematological+Malignancies%3A+A+Comprehensive+Review&doi=10.1007%2Fs11523-018-0558-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review</span></div><div class="casAuthors">Rossi Cedric; Rossi Cedric; Chretien Marie-Lorraine; Casasnovas Rene-Olivier; Chretien Marie-Lorraine; Casasnovas Rene-Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are an emerging class of therapeutic agents that bring new opportunities for the treatment of hematological malignancies by meeting unmet medical needs.  These drugs consist of a cytotoxic agent connected by a linker to a human, humanized, or chimeric antibody targeting a surface antigen specifically expressed by tumor cells.  These ADCs are being developed to specifically deliver the cytotoxic agent into tumor cells.  The cytotoxic payload is released from the ADC after internalization and cleavage of the linker, ultimately triggering the death of the cancer cell.  Second- and even third-generation ADCs are currently being developed and have more stable linkers and more potent payloads, which should improve ADC efficacy even further.  In this review, we analyze the results for the main ADCs currently developed and discuss the advantages and drawbacks of this therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqmuXC7xz1NKcY7HFp97qMfW6udTcc2eboGOGzyjWAyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnivVyqtQ%253D%253D&md5=508db14c33f1f4f38f7c688e35d53f83</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1007%2Fs11523-018-0558-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-018-0558-1%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DC.%26aulast%3DChr%25C3%25A9tien%26aufirst%3DM.-L.%26aulast%3DCasasnovas%26aufirst%3DR.-O.%26atitle%3DAntibody-Drug%2520Conjugates%2520for%2520the%2520Treatment%2520of%2520Hematological%2520Malignancies%253A%2520A%2520Comprehensive%2520Review%26jtitle%3DTarget.%2520Oncol.%26date%3D2018%26volume%3D13%26issue%3D3%26spage%3D287%26epage%3D308%26doi%3D10.1007%2Fs11523-018-0558-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1490</span>– <span class="NLM_lpage">1496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=11410481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1490-1496&issue=6&author=P.+F.+Brossauthor=J.+Beitzauthor=G.+Chenauthor=X.+H.+Chenauthor=E.+Duffyauthor=L.+Kiefferauthor=S.+Royauthor=R.+Sridharaauthor=A.+Rahmanauthor=G.+Williamsauthor=R.+Pazdur&title=Approval+Summary%3A+Gemtuzumab+Ozogamicin+in+Relapsed+Acute+Myeloid+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia</span></div><div class="casAuthors">Bross, Peter F.; Beitz, Julie; Chen, Gang; Chen, Xiao Hong; Duffy, Eric; Kieffer, Lydia; Roy, Sandip; Sridhara, Rajeshwari; Rahman, Atiqur; Williams, Grant; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1490-1496</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review with refs.  Gemtuzumab ozogamicin (Mylotarg; Wyeth Labs., Philadelphia, PA) consists of a semisynthetic deriv. of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).  In this study, we review the preclin. and clin. profiles of this immuno-conjugate and the regulatory review that led to marketing approval by the United States Food and Drug Administration.  From the literature and manufacturer's data, we review the activity, tolerability, and pharmacokinetics of gemtuzumab ozogamicin in preclin. and Phase I studies and its activity, efficacy, and side effects in three Phase 2 trials of 142 patients with relapsed AML.  In Phase I studies, the major toxicity was myelosuppression, esp. neutropenia and thrombocytopenia, resulting from the expression of CD33 on myeloid progenitor cells.  The Phase 2 dose was 9 mg/m2 infused i.v. over 4 h, repeated on day 14.  A minority of patients experienced acute infusion-related symptoms, usually transient and occasionally requiring hospitalization.  The complete response (CR) rate with full recovery of hematopoiesis was 16%.  A subset of patients [CRs with incomplete platelet recovery (CRps)] was identified with blast clearance and neutrophil recovery but incomplete platelet recovery.  The duration of responses of CRps appeared to be similar to those of the CRs, although the nos. were small.  The question of the equivalence of these response groups was a central issue in the review of this new drug application (NDA).  After considerable discussion, the Oncol. Drugs Advisory Committee recommended allowing inclusion of CRps resulting in an overall response rate in the Phase 2 studies of 30%.  In the subgroup of patients over 60 yr of age, the overall response rate was 26%.  Response duration was difficult to establish because of the high prevalence of postremission therapies.  Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes.  One patient died of liver failure in the Phase 2 trials.  Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by the United States Food and Drug Administration under the Accelerated Approval regulations.  Gemtuzumab ozogamicin is indicated for the treatment of patients with CD33 pos. AML in first relapse who are 60 yr of age or older and who are not considered candidates for cytotoxic chemotherapy.  The approved dose was 9 mg/m2 i.v. over 4 h and repeated in 14 days.  Completion of the ongoing studies of gemtuzumab ozogamicin in relapsed AML and initiation of randomized clin. trials comparing the effects of gemtuzumab ozogamicin in combination with conventional induction chemotherapy to conventional chemotherapy alone on survival are mandated to confirm clin. benefit under the accelerated approval Subpart H regulations.  Postmarketing reports of fatal anaphylaxis, adult respiratory distress syndrome (ARDS), and hepatotoxicity, esp. venoocclusive disease (VOD) in patients treated with gemtuzumab ozogamicin, with and without assocd. hematopoietic stem cell transplantation (HSCT), have required labeling revisions and the initiation of a registration surveillance program.  Tumor lysis and ARDS have been reported in patients with leukocytes above 30,000/mL treated with gemtuzumab ozogamicin; therefore, the redn. of leukocyte counts to below 30,000/mL is recommended prior to treatment.  Patients should be carefully monitored for acute hypersensitivity, hypoxia, and delayed hepatotoxicity following treatment with gemtuzumab ozogamicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxE3VNYYST67Vg90H21EOLACvtfcHk0lgtE56v1td4iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltV2iu78%253D&md5=8a85e32e3113034e98f05dfbd119110b</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DBeitz%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DDuffy%26aufirst%3DE.%26aulast%3DKieffer%26aufirst%3DL.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520Summary%253A%2520Gemtuzumab%2520Ozogamicin%2520in%2520Relapsed%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26issue%3D6%26spage%3D1490%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span> </span><span class="NLM_article-title">Top Drugs by Sales in 2017: Who Sold the Blockbuster Drugs?</span> <i>PharmaCompass</i>. <a href="https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-in-2017-who-sold-the-blockbuster-drugs" class="extLink">https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-in-2017-who-sold-the-blockbuster-drugs</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Top+Drugs+by+Sales+in+2017%3A+Who+Sold+the+Blockbuster+Drugs%3F+PharmaCompass.+https%3A%2F%2Fwww.pharmacompass.com%2Fradio-compass-blog%2Ftop-drugs-by-sales-in-2017-who-sold-the-blockbuster-drugs+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DTop%2520Drugs%2520by%2520Sales%2520in%25202017%253A%2520Who%2520Sold%2520the%2520Blockbuster%2520Drugs%253F%26jtitle%3DPharmaCompass%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span> </span><span class="NLM_article-title">Top Drugs
and Pharmaceutical Companies of 2018 by Revenues</span>.  <i>PharmaCompass</i>. <a href="https://www.pharmacompass.com/radio-compass-blog/top-drugs-and-pharmaceutical-companies-of-2018-by-revenues" class="extLink">https://www.pharmacompass.com/radio-compass-blog/top-drugs-and-pharmaceutical-companies-of-2018-by-revenues</a> (accessed <span class="NLM_year">2020</span>-04-10).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Top+Drugs%0Aand+Pharmaceutical+Companies+of+2018+by+Revenues.+PharmaCompass.+https%3A%2F%2Fwww.pharmacompass.com%2Fradio-compass-blog%2Ftop-drugs-and-pharmaceutical-companies-of-2018-by-revenues+%28accessed+2020-04-10%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DTop%2520Drugs%250Aand%2520Pharmaceutical%2520Companies%2520of%25202018%2520by%2520Revenues%26jtitle%3DPharmaCompass%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urquhart, L.</span></span> <span> </span><span class="NLM_article-title">Top Product Forecasts for 2019</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">91</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00012-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fd41573-019-00012-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30710137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3cjotFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=91&issue=2&author=L.+Urquhart&title=Top+Product+Forecasts+for+2019&doi=10.1038%2Fd41573-019-00012-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Top product forecasts for 2019</span></div><div class="casAuthors">Urquhart Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9BeM5inOu_8ScOqQTSkOffW6udTcc2eZeB6USm-rZ7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjotFantw%253D%253D&md5=93896dd3e52db4657adf9f9872b08a68</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00012-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00012-z%26sid%3Dliteratum%253Aachs%26aulast%3DUrquhart%26aufirst%3DL.%26atitle%3DTop%2520Product%2520Forecasts%2520for%25202019%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26issue%3D2%26spage%3D91%26doi%3D10.1038%2Fd41573-019-00012-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gammon, K.</span></span> <span> </span><span class="NLM_article-title">Neurodegenerative Disease: Brain Windfall</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span> (<span class="NLM_issue">7526</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1038/nj7526-299a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnj7526-299a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=25396246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC2M3ot12kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=299-300&issue=7526&author=K.+Gammon&title=Neurodegenerative+Disease%3A+Brain+Windfall&doi=10.1038%2Fnj7526-299a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Neurodegenerative disease: brain windfall</span></div><div class="casAuthors">Gammon Katharine</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7526</span>),
    <span class="NLM_cas:pages">299-300</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDfOo1BTaCdG52AMpI4GK2fW6udTcc2eZeB6USm-rZ7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3ot12kuw%253D%253D&md5=1ee40ff6fc8fab21a70d1df7a0b12674</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnj7526-299a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnj7526-299a%26sid%3Dliteratum%253Aachs%26aulast%3DGammon%26aufirst%3DK.%26atitle%3DNeurodegenerative%2520Disease%253A%2520Brain%2520Windfall%26jtitle%3DNature%26date%3D2014%26volume%3D515%26issue%3D7526%26spage%3D299%26epage%3D300%26doi%3D10.1038%2Fnj7526-299a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wobst, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shorter, J.</span></span> <span> </span><span class="NLM_article-title">The Clinical Trial Landscape in Amyotrophic Lateral Sclerosis-Past, Present, and Future</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1352</span>, <span class="refDoi"> DOI: 10.1002/med.21661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fmed.21661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32043626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CrtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=1352&author=H.+J.+Wobstauthor=K.+L.+Mackauthor=D.+G.+Brownauthor=N.+J.+Brandonauthor=J.+Shorter&title=The+Clinical+Trial+Landscape+in+Amyotrophic+Lateral+Sclerosis-Past%2C+Present%2C+and+Future&doi=10.1002%2Fmed.21661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future</span></div><div class="casAuthors">Wobst, Heike J.; Mack, Korrie L.; Brown, Dean G.; Brandon, Nicholas J.; Shorter, James</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1352-1384</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by progressive loss of muscle function.  It is the most common adult-onset form of motor neuron disease, affecting about 16 000 people in the United States alone.  The av. survival is about 3 years.  Only two interventional drugs, the antiglutamatergic small-mol. riluzole and the more recent antioxidant edaravone, have been approved for the treatment of ALS to date.  Therapeutic strategies under investigation in clin. trials cover a range of different modalities and targets, and more than 70 different drugs have been tested in the clinic to date.  Here, we summarize and classify interventional therapeutic strategies based on their mol. targets and phenotypic effects.  We also discuss possible reasons for the failure of clin. trials in ALS and highlight emerging preclin. strategies that could provide a breakthrough in the battle against this relentless disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6iM59ajg057Vg90H21EOLACvtfcHk0ljsdCAIyHGkWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CrtLvJ&md5=4457c1fdc5f5d2257185e22ca507321d</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fmed.21661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21661%26sid%3Dliteratum%253Aachs%26aulast%3DWobst%26aufirst%3DH.%2BJ.%26aulast%3DMack%26aufirst%3DK.%2BL.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBrandon%26aufirst%3DN.%2BJ.%26aulast%3DShorter%26aufirst%3DJ.%26atitle%3DThe%2520Clinical%2520Trial%2520Landscape%2520in%2520Amyotrophic%2520Lateral%2520Sclerosis-Past%252C%2520Present%252C%2520and%2520Future%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D1352%26doi%3D10.1002%2Fmed.21661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span> </span><span class="NLM_article-title">After 190 Tries, Are We Any Closer to a
Cure for Alzheimer’s?</span> <i>Bloomberg Businessweek</i>. <a href="https://www.bloomberg.com/news/articles/2016-06-27/after-190-tries-are-we-any-closer-to-a-cure-for-alzheimer-s" class="extLink">https://www.bloomberg.com/news/articles/2016-06-27/after-190-tries-are-we-any-closer-to-a-cure-for-alzheimer-s</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=After+190+Tries%2C+Are+We+Any+Closer+to+a%0ACure+for+Alzheimer%E2%80%99s%3F+Bloomberg+Businessweek.+https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2016-06-27%2Fafter-190-tries-are-we-any-closer-to-a-cure-for-alzheimer-s+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAfter%2520190%2520Tries%252C%2520Are%2520We%2520Any%2520Closer%2520to%2520a%250ACure%2520for%2520Alzheimer%25E2%2580%2599s%253F%26jtitle%3DBloomberg%2520Businessweek%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sevigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussière, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunstan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Gorman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chollate, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintero-Monzon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scannevin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulskis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandrock, A.</span></span> <span> </span><span class="NLM_article-title">The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span> (<span class="NLM_issue">7618</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/nature19323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnature19323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27582220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCqur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=50-56&issue=7618&author=J.+Sevignyauthor=P.+Chiaoauthor=T.+Bussi%C3%A8reauthor=P.+H.+Weinrebauthor=L.+Williamsauthor=M.+Maierauthor=R.+Dunstanauthor=S.+Sallowayauthor=T.+Chenauthor=Y.+Lingauthor=J.+O%E2%80%99Gormanauthor=F.+Qianauthor=M.+Arastuauthor=M.+Liauthor=S.+Chollateauthor=M.+S.+Brennanauthor=O.+Quintero-Monzonauthor=R.+H.+Scannevinauthor=H.+M.+Arnoldauthor=T.+Engberauthor=K.+Rhodesauthor=J.+Ferreroauthor=Y.+Hangauthor=A.+Mikulskisauthor=J.+Grimmauthor=C.+Hockauthor=R.+M.+Nitschauthor=A.+Sandrock&title=The+Antibody+Aducanumab+Reduces+A%CE%B2+Plaques+in+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fnature19323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The antibody aducanumab reduces Aβ plaques in Alzheimer's disease</span></div><div class="casAuthors">Sevigny, Jeff; Chiao, Ping; Bussiere, Thierry; Weinreb, Paul H.; Williams, Leslie; Maier, Marcel; Dunstan, Robert; Salloway, Stephen; Chen, Tianle; Ling, Yan; O'Gorman, John; Qian, Fang; Arastu, Mahin; Li, Mingwei; Chollate, Sowmya; Brennan, Melanie S.; Quintero-Monzon, Omar; Scannevin, Robert H.; Arnold, H. Moore; Engber, Thomas; Rhodes, Kenneth; Ferrero, James; Hang, Yaming; Mikulskis, Alvydas; Grimm, Jan; Hock, Christoph; Nitsch, Roger M.; Sandrock, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7618</span>),
    <span class="NLM_cas:pages">50-56</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration.  Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful.  Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ.  In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce sol. and insol. Aβ in a dose-dependent manner.  In patients with prodromal or mild AD, one year of monthly i.v. infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner.  This is accompanied by a slowing of clin. decline measured by Clin. Dementia Rating-Sum of Boxes and Mini Mental State Examn. scores.  The main safety and tolerability findings are amyloid-related imaging abnormalities.  These results justify further development of aducanumab for the treatment of AD.  Should the slowing of clin. decline be confirmed in ongoing phase 3 clin. trials, it would provide compelling support for the amyloid hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojFdrufBYOgbVg90H21EOLACvtfcHk0ljQ4LeDPEG1eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCqur%252FJ&md5=62aa713f842093cead6b40cb523417a7</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnature19323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19323%26sid%3Dliteratum%253Aachs%26aulast%3DSevigny%26aufirst%3DJ.%26aulast%3DChiao%26aufirst%3DP.%26aulast%3DBussi%25C3%25A8re%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DP.%2BH.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DMaier%26aufirst%3DM.%26aulast%3DDunstan%26aufirst%3DR.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Gorman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DArastu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DChollate%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BS.%26aulast%3DQuintero-Monzon%26aufirst%3DO.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DArnold%26aufirst%3DH.%2BM.%26aulast%3DEngber%26aufirst%3DT.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DFerrero%26aufirst%3DJ.%26aulast%3DHang%26aufirst%3DY.%26aulast%3DMikulskis%26aufirst%3DA.%26aulast%3DGrimm%26aufirst%3DJ.%26aulast%3DHock%26aufirst%3DC.%26aulast%3DNitsch%26aufirst%3DR.%2BM.%26aulast%3DSandrock%26aufirst%3DA.%26atitle%3DThe%2520Antibody%2520Aducanumab%2520Reduces%2520A%25CE%25B2%2520Plaques%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNature%26date%3D2016%26volume%3D537%26issue%3D7618%26spage%3D50%26epage%3D56%26doi%3D10.1038%2Fnature19323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L.</span></span> <span> </span><span class="NLM_article-title">A Resurrection of Aducanumab for Alzheimer’s Disease</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30480-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1474-4422%2819%2930480-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31978357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=111-112&issue=2&author=L.+Schneider&title=A+Resurrection+of+Aducanumab+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2FS1474-4422%2819%2930480-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A resurrection of aducanumab for Alzheimer's disease</span></div><div class="casAuthors">Schneider Lon</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtdxhWBoi5aDQLBVDQn4bCfW6udTcc2eY2TEIOjsBx7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FktFKrtg%253D%253D&md5=5ce903ac47c76caa5954b1d7feafdb97</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930480-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930480-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%26atitle%3DA%2520Resurrection%2520of%2520Aducanumab%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26issue%3D2%26spage%3D111%26epage%3D112%26doi%3D10.1016%2FS1474-4422%2819%2930480-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Servick, K.</span></span> <span> </span><span class="NLM_article-title">Doubts Persist for Claimed Alzheimer’s Drug</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">6471</span>),  <span class="NLM_fpage">1298</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1126/science.366.6471.1298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscience.366.6471.1298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31831649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=1298-1298&issue=6471&author=K.+Servick&title=Doubts+Persist+for+Claimed+Alzheimer%E2%80%99s+Drug&doi=10.1126%2Fscience.366.6471.1298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Doubts persist for claimed Alzheimer's drug</span></div><div class="casAuthors">Servick, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">6471</span>),
    <span class="NLM_cas:pages">1298</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Last week, Biogen gave its first scientific presentation in defense of its startling claim to have developed the first drug that can change the devastating course of Alzheimer's disease.  At the Clin. Trials on Alzheimer's Disease congress in San Diego, California, Samantha Budd Haeberlein, Biogen's head of clin. development, tried to clarify what had emboldened the Cambridge, Massachusetts-based biotech to say in Oct. it would soon ask the U.S. Food and Drug Administration to approve its antibody drug, aducanumab, even though the company publicly declared the drug a failure back in March.  After examg. more patient data, she explained, investigators found in one trial that the higher of two tested doses led to 22% less cognitive decline after 78 wk than a placebo.  However, the small margins sepg. the treated and placebo groups and the failure of a second trial leave some researchers skeptical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJILt9Omfja7Vg90H21EOLACvtfcHk0lhtetkJItN7vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSnsLbO&md5=21cd0c17fb44dbb076eb950e2a1bd38a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1126%2Fscience.366.6471.1298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.366.6471.1298%26sid%3Dliteratum%253Aachs%26aulast%3DServick%26aufirst%3DK.%26atitle%3DDoubts%2520Persist%2520for%2520Claimed%2520Alzheimer%25E2%2580%2599s%2520Drug%26jtitle%3DScience%26date%3D2019%26volume%3D366%26issue%3D6471%26spage%3D1298%26epage%3D1298%26doi%3D10.1126%2Fscience.366.6471.1298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dearment, A.</span></span> <span> </span><span class="NLM_article-title">Biogen Presents Data on Controversial Alzheimer’s Drug, but Doesn’t Sway Analysts</span>.  <i>MedCity News</i>. <a href="https://medcitynews.com/2019/12/biogen-presents-data-on-controversial-alzheimers-drug-but-doesnt-dampen-analyst-skepticism/" class="extLink">https://medcitynews.com/2019/12/biogen-presents-data-on-controversial-alzheimers-drug-but-doesnt-dampen-analyst-skepticism/</a> (accessed <span class="NLM_year">2020</span>-07-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Dearment&title=Biogen+Presents+Data+on+Controversial+Alzheimer%E2%80%99s+Drug%2C+but+Doesn%E2%80%99t+Sway+Analysts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DDearment%26aufirst%3DA.%26atitle%3DBiogen%2520Presents%2520Data%2520on%2520Controversial%2520Alzheimer%25E2%2580%2599s%2520Drug%252C%2520but%2520Doesn%25E2%2580%2599t%2520Sway%2520Analysts%26jtitle%3DMedCity%2520News%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leavitt, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, S. J.</span></span> <span> </span><span class="NLM_article-title">Antisense Oligonucleotides for Neurodegeneration</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">6485</span>),  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1126/science.aba4624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscience.aba4624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32217715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslymsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&pages=1428-1429&issue=6485&author=B.+R.+Leavittauthor=S.+J.+Tabrizi&title=Antisense+Oligonucleotides+for+Neurodegeneration&doi=10.1126%2Fscience.aba4624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense oligonucleotides for neurodegeneration</span></div><div class="casAuthors">Leavitt, Blair R.; Tabrizi, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6485</span>),
    <span class="NLM_cas:pages">1428-1429</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Antisense oligonucleotides (ASOs) have the potential to reduce, restore, or modify RNA and protein expression.  Thus, they can target disease pathogenesis by altering the expression of mutant proteins ().  The recent regulatory approval of ASOs for the pediatric motor neuron disease spinal muscular atrophy has provided a regulatory pathway for addnl. ASO therapies in other central nervous system (CNS) diseases.  Developments in ASO chem. and advances in CNS delivery methods have enabled ASOs to enter clin. trials to treat Huntington's disease (HD).  There are currently no available treatments that slow or prevent progression of HD, but two ongoing ASO-based clin. programs have shown promising results.  Addnl., clin. trials of ASOs to treat amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease are under way, with more in development for other neurodegenerative diseases.  It is hoped that ASO-based approaches will provide effective diseasemodifying therapies for HD and similar neurodegenerative diseases soon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlOZAc9MJOQ7Vg90H21EOLACvtfcHk0lhcNCOL8aPM8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslymsbs%253D&md5=1b131a781357016dad46d764fff19d05</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1126%2Fscience.aba4624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aba4624%26sid%3Dliteratum%253Aachs%26aulast%3DLeavitt%26aufirst%3DB.%2BR.%26aulast%3DTabrizi%26aufirst%3DS.%2BJ.%26atitle%3DAntisense%2520Oligonucleotides%2520for%2520Neurodegeneration%26jtitle%3DScience%26date%3D2020%26volume%3D367%26issue%3D6485%26spage%3D1428%26epage%3D1429%26doi%3D10.1126%2Fscience.aba4624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span> </span><span class="NLM_article-title">A Study to Evaluate the Safety, Tolerability,
and Pharmacokinetics
of BIIB094 in Adults with Parkinson’s Disease</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT03976349" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03976349</a> (accessed <span class="NLM_year">2020</span>-07-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+to+Evaluate+the+Safety%2C+Tolerability%2C%0Aand+Pharmacokinetics%0Aof+BIIB094+in+Adults+with+Parkinson%E2%80%99s+Disease.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03976349+%28accessed+2020-07-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520to%2520Evaluate%2520the%2520Safety%252C%2520Tolerability%252C%250Aand%2520Pharmacokinetics%250Aof%2520BIIB094%2520in%2520Adults%2520with%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, S. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Antisense Targeting of Huntingtin</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1089/dna.2019.5188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1089%2Fdna.2019.5188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31821021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=154-158&issue=2&author=A.+V.+Smithauthor=S.+J.+Tabrizi&title=Therapeutic+Antisense+Targeting+of+Huntingtin&doi=10.1089%2Fdna.2019.5188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Antisense Targeting of Huntingtin</span></div><div class="casAuthors">Smith, Anne V.; Tabrizi, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-158</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  This brief review summarizes the preclin., translational, and early clin. development of an ASO designed to reduce the prodn. of the disease-causing protein in Huntington's disease, an inherited neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoieL_bom1-3bVg90H21EOLACvtfcHk0lhcNCOL8aPM8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVGns7Y%253D&md5=848089afbe53785607d24a94bbc356b2</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1089%2Fdna.2019.5188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2019.5188%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BV.%26aulast%3DTabrizi%26aufirst%3DS.%2BJ.%26atitle%3DTherapeutic%2520Antisense%2520Targeting%2520of%2520Huntingtin%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2020%26volume%3D39%26issue%3D2%26spage%3D154%26epage%3D158%26doi%3D10.1089%2Fdna.2019.5188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cudkowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atassi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucelli, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludolph, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestronk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salachas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houshyar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCampbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestorov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, T. A.</span></span> <span> </span><span class="NLM_article-title">Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2003715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa2003715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32640130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVeis7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=109-119&issue=2&author=T.+Millerauthor=M.+Cudkowiczauthor=P.+J.+Shawauthor=P.+M.+Andersenauthor=N.+Atassiauthor=R.+C.+Bucelliauthor=A.+Gengeauthor=J.+Glassauthor=S.+Ladhaauthor=A.+L.+Ludolphauthor=N.+J.+Maragakisauthor=C.+J.+McDermottauthor=A.+Pestronkauthor=J.+Ravitsauthor=F.+Salachasauthor=R.+Trudellauthor=P.+Van+Dammeauthor=L.+Zinmanauthor=C.+F.+Bennettauthor=R.+Laneauthor=A.+Sandrockauthor=H.+Runzauthor=D.+Grahamauthor=H.+Houshyarauthor=A.+McCampbellauthor=I.+Nestorovauthor=I.+Changauthor=M.+McNeillauthor=L.+Fanningauthor=S.+Fradetteauthor=T.+A.+Ferguson&title=Phase+1%E2%80%932+Trial+of+Antisense+Oligonucleotide+Tofersen+for+SOD1+ALS&doi=10.1056%2FNEJMoa2003715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS</span></div><div class="casAuthors">Miller, T.; Cudkowicz, M.; Shaw, P. J.; Andersen, P. M.; Atassi, N.; Bucelli, R. C.; Genge, A.; Glass, J.; Ladha, S.; Ludolph, A. L.; Maragakis, N. J.; McDermott, C. J.; Pestronk, A.; Ravits, J.; Salachas, F.; Trudell, R.; Van Damme, P.; Zinman, L.; Bennett, C. F.; Lane, R.; Sandrock, A.; Runz, H.; Graham, D.; Houshyar, H.; McCampbell, A.; Nestorov, I.; Chang, I.; McNeill, M.; Fanning, L.; Fradette, S.; Ferguson, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-119</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tofersen is an antisense oligonucleotide that mediates the degrdn. of superoxide dismutase 1 (SOD1) mRNA to reduce SOD1 protein synthesis.  Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.  We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS due to SOD1 mutations.  In each dose cohort (20, 40, 60, or 100 mg), participants were randomly assigned in a 3:1 ratio to receive five doses of tofersen or placebo, administered intrathecally for 12 wk.  The primary outcomes were safety and pharmacokinetics.  The secondary outcome was the change from baseline in the cerebrospinal fluid (CSF) SOD1 concn. at day 85.  Clin. function and vital capacity were measured.  A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses.  Lumbar puncture-related adverse events were obsd. in most participants.  Elevations in CSF white-cell count and protein were reported as adverse events in 4 and 5 participants, resp., who received tofersen.  Among participants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the placebo group died from respiratory failure on day 52.  The difference at day 85 in the change from baseline in the CSF SOD1 concn. between the tofersen groups and the placebo group was 2 percentage points (95% confidence interval [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16) for the 100-mg dose.  In adults with ALS due to SOD1 mutations, CSF SOD1 concns. decreased at the highest concn. of tofersen administered intrathecally over a period of 12 wk.  CSF pleocytosis occurred in some participants receiving tofersen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlGCCoE7Z6hrVg90H21EOLACvtfcHk0lhhopbZ17AACg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVeis7jE&md5=9bd3795b9300a32f6278efe78d3f5b8f</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2003715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2003715%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCudkowicz%26aufirst%3DM.%26aulast%3DShaw%26aufirst%3DP.%2BJ.%26aulast%3DAndersen%26aufirst%3DP.%2BM.%26aulast%3DAtassi%26aufirst%3DN.%26aulast%3DBucelli%26aufirst%3DR.%2BC.%26aulast%3DGenge%26aufirst%3DA.%26aulast%3DGlass%26aufirst%3DJ.%26aulast%3DLadha%26aufirst%3DS.%26aulast%3DLudolph%26aufirst%3DA.%2BL.%26aulast%3DMaragakis%26aufirst%3DN.%2BJ.%26aulast%3DMcDermott%26aufirst%3DC.%2BJ.%26aulast%3DPestronk%26aufirst%3DA.%26aulast%3DRavits%26aufirst%3DJ.%26aulast%3DSalachas%26aufirst%3DF.%26aulast%3DTrudell%26aufirst%3DR.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DZinman%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DLane%26aufirst%3DR.%26aulast%3DSandrock%26aufirst%3DA.%26aulast%3DRunz%26aufirst%3DH.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DHoushyar%26aufirst%3DH.%26aulast%3DMcCampbell%26aufirst%3DA.%26aulast%3DNestorov%26aufirst%3DI.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DFanning%26aufirst%3DL.%26aulast%3DFradette%26aufirst%3DS.%26aulast%3DFerguson%26aufirst%3DT.%2BA.%26atitle%3DPhase%25201%25E2%2580%25932%2520Trial%2520of%2520Antisense%2520Oligonucleotide%2520Tofersen%2520for%2520SOD1%2520ALS%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26issue%3D2%26spage%3D109%26epage%3D119%26doi%3D10.1056%2FNEJMoa2003715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span> </span><span class="NLM_article-title">Safety, Tolerability, Pharmacokinetics,
and Pharmacodynamics of IONIS-MAPTRx
in Patients with Mild Alzheimer’s Disease</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT03186989" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03186989</a> (accessed <span class="NLM_year">2020</span>-11-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C+Tolerability%2C+Pharmacokinetics%2C%0Aand+Pharmacodynamics+of+IONIS-MAPTRx%0Ain+Patients+with+Mild+Alzheimer%E2%80%99s+Disease.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03186989+%28accessed+2020-11-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSafety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%250Aand%2520Pharmacodynamics%2520of%2520IONIS-MAPTRx%250Ain%2520Patients%2520with%2520Mild%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moufawad El Achkar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douville, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergast, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldkind, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuniholm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belur, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojkovska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsytsykova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustine, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genetti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dies, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodlett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflock, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beggs, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urion, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waisbren, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poduri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biffi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzulli, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodamer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berde, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T. W.</span></span> <span> </span><span class="NLM_article-title">Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1652</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1813279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31597037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1644-1652&issue=17&author=J.+Kimauthor=C.+Huauthor=C.+Moufawad+El+Achkarauthor=L.+E.+Blackauthor=J.+Douvilleauthor=A.+Larsonauthor=M.+K.+Pendergastauthor=S.+F.+Goldkindauthor=E.+A.+Leeauthor=A.+Kuniholmauthor=A.+Soucyauthor=J.+Vazeauthor=N.+R.+Belurauthor=K.+Fredriksenauthor=I.+Stojkovskaauthor=A.+Tsytsykovaauthor=M.+Armantauthor=R.+L.+DiDonatoauthor=J.+Choiauthor=L.+Cornelissenauthor=L.+M.+Pereiraauthor=E.+F.+Augustineauthor=C.+A.+Genettiauthor=K.+Diesauthor=B.+Bartonauthor=L.+Williamsauthor=B.+D.+Goodlettauthor=B.+L.+Rileyauthor=A.+Pasternakauthor=E.+R.+Berryauthor=K.+A.+Pflockauthor=S.+Chuauthor=C.+Reedauthor=K.+Tyndallauthor=P.+B.+Agrawalauthor=A.+H.+Beggsauthor=P.+E.+Grantauthor=D.+K.+Urionauthor=R.+O.+Snyderauthor=S.+E.+Waisbrenauthor=A.+Poduriauthor=P.+J.+Parkauthor=A.+Pattersonauthor=A.+Biffiauthor=J.+R.+Mazzulliauthor=O.+Bodamerauthor=C.+B.+Berdeauthor=T.+W.+Yu&title=Patient-Customized+Oligonucleotide+Therapy+for+a+Rare+Genetic+Disease&doi=10.1056%2FNEJMoa1813279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Patient-customized oligonucleotide therapy for a rare genetic disease</span></div><div class="casAuthors">Kim, J.; Hu, C.; El Achkar, C. Moufawad; Black, L. E.; Douville, J.; Larson, A.; Pendergast, M. K.; Goldkind, S. F.; Lee, E. A.; Kuniholm, A.; Soucy, A.; Vaze, J.; Belur, N. R.; Fredriksen, K.; Stojkovska, I.; Tsytsykova, A.; Armant, M.; DiDonato, R. L.; Choi, J.; Cornelissen, L.; Pereira, L. M.; Augustine, E. F.; Genetti, C. A.; Dies, K.; Barton, B.; Williams, L.; Goodlett, B. D.; Riley, B. L.; Pasternak, A.; Berry, E. R.; Pflock, K. A.; Chu, S.; Reed, C.; Tyndall, K.; Agrawal, P. B.; Beggs, A. H.; Grant, P. E.; Urion, D. K.; Snyder, R. O.; Waisbren, S. E.; Poduri, A.; Park, P. J.; Patterson, A.; Biffi, A.; Mazzulli, J. R.; Bodamer, O.; Berde, C. B.; Yu, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1644-1652</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Genome sequencing is often pivotal in the diagnosis of rare diseases, but many of these conditions lack specific treatments.  We describe how mol. diagnosis of a rare, fatal neurodegenerative condition led to the rational design, testing, and manuf. of milasen, a splice-modulating antisense oligonucleotide drug tailored to a particular patient.  Proof-of-concept expts. in cell lines from the patient served as the basis for launching an "N-of-1" study of milasen within 1 yr after first contact with the patient.  There were no serious adverse events, and treatment was assocd. with objective redn. in seizures (detd. by electroencephalog. and parental reporting).  This study offers a possible template for the rapid development of patient-customized treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEdC1RDufqFLVg90H21EOLACvtfcHk0lisc_VaBZfP_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWkt73I&md5=bb1983cc9dc5932d35346d16e68b974d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813279%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DMoufawad%2BEl%2BAchkar%26aufirst%3DC.%26aulast%3DBlack%26aufirst%3DL.%2BE.%26aulast%3DDouville%26aufirst%3DJ.%26aulast%3DLarson%26aufirst%3DA.%26aulast%3DPendergast%26aufirst%3DM.%2BK.%26aulast%3DGoldkind%26aufirst%3DS.%2BF.%26aulast%3DLee%26aufirst%3DE.%2BA.%26aulast%3DKuniholm%26aufirst%3DA.%26aulast%3DSoucy%26aufirst%3DA.%26aulast%3DVaze%26aufirst%3DJ.%26aulast%3DBelur%26aufirst%3DN.%2BR.%26aulast%3DFredriksen%26aufirst%3DK.%26aulast%3DStojkovska%26aufirst%3DI.%26aulast%3DTsytsykova%26aufirst%3DA.%26aulast%3DArmant%26aufirst%3DM.%26aulast%3DDiDonato%26aufirst%3DR.%2BL.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DCornelissen%26aufirst%3DL.%26aulast%3DPereira%26aufirst%3DL.%2BM.%26aulast%3DAugustine%26aufirst%3DE.%2BF.%26aulast%3DGenetti%26aufirst%3DC.%2BA.%26aulast%3DDies%26aufirst%3DK.%26aulast%3DBarton%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DGoodlett%26aufirst%3DB.%2BD.%26aulast%3DRiley%26aufirst%3DB.%2BL.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DBerry%26aufirst%3DE.%2BR.%26aulast%3DPflock%26aufirst%3DK.%2BA.%26aulast%3DChu%26aufirst%3DS.%26aulast%3DReed%26aufirst%3DC.%26aulast%3DTyndall%26aufirst%3DK.%26aulast%3DAgrawal%26aufirst%3DP.%2BB.%26aulast%3DBeggs%26aufirst%3DA.%2BH.%26aulast%3DGrant%26aufirst%3DP.%2BE.%26aulast%3DUrion%26aufirst%3DD.%2BK.%26aulast%3DSnyder%26aufirst%3DR.%2BO.%26aulast%3DWaisbren%26aufirst%3DS.%2BE.%26aulast%3DPoduri%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DPatterson%26aufirst%3DA.%26aulast%3DBiffi%26aufirst%3DA.%26aulast%3DMazzulli%26aufirst%3DJ.%2BR.%26aulast%3DBodamer%26aufirst%3DO.%26aulast%3DBerde%26aufirst%3DC.%2BB.%26aulast%3DYu%26aufirst%3DT.%2BW.%26atitle%3DPatient-Customized%2520Oligonucleotide%2520Therapy%2520for%2520a%2520Rare%2520Genetic%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D17%26spage%3D1644%26epage%3D1652%26doi%3D10.1056%2FNEJMoa1813279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keshavan, M.</span></span> <span> </span><span class="NLM_article-title">Saving Mila: How a Tailor-Made Therapy, Developed in a Flash, May Have Halted a Young Girl’s Rare Disease</span>.  <i>STAT</i>. <a href="https://www.statnews.com/2018/10/22/a-tailor-made-therapy-may-have-halted-a-rare-disease/" class="extLink">https://www.statnews.com/2018/10/22/a-tailor-made-therapy-may-have-halted-a-rare-disease/</a> (accessed <span class="NLM_year">2020</span>-07-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Keshavan&title=Saving+Mila%3A+How+a+Tailor-Made+Therapy%2C+Developed+in+a+Flash%2C+May+Have+Halted+a+Young+Girl%E2%80%99s+Rare+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DKeshavan%26aufirst%3DM.%26atitle%3DSaving%2520Mila%253A%2520How%2520a%2520Tailor-Made%2520Therapy%252C%2520Developed%2520in%2520a%2520Flash%252C%2520May%2520Have%2520Halted%2520a%2520Young%2520Girl%25E2%2580%2599s%2520Rare%2520Disease%26jtitle%3DSTAT%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booth, B.</span></span> <span> </span><span class="NLM_article-title">Venturing Boldly Into Neuroscience</span>.  <i>Life Sci VC</i>. <a href="https://lifescivc.com/2017/09/venturing-boldly-neuroscience/" class="extLink">https://lifescivc.com/2017/09/venturing-boldly-neuroscience/</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+Booth&title=Venturing+Boldly+Into+Neuroscience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBooth%26aufirst%3DB.%26atitle%3DVenturing%2520Boldly%2520Into%2520Neuroscience%26jtitle%3DLife%2520Sci%2520VC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span> </span><span class="NLM_article-title">CNS drugs
take 20% longer to develop and to approve vs. non-CNS drugs</span>.  <i>Tufts Center for the Study of Drug Development</i>. <a href="https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5b97b8f5575d1f202ba413c3/1536669941287/summary_septoct18.pdf" class="extLink">https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5b97b8f5575d1f202ba413c3/1536669941287/summary_septoct18.pdf</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CNS+drugs%0Atake+20%25+longer+to+develop+and+to+approve+vs.+non-CNS+drugs.+Tufts+Center+for+the+Study+of+Drug+Development.+https%3A%2F%2Fstatic1.squarespace.com%2Fstatic%2F5a9eb0c8e2ccd1158288d8dc%2Ft%2F5b97b8f5575d1f202ba413c3%2F1536669941287%2Fsummary_septoct18.pdf+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCNS%2520drugs%250Atake%252020%2525%2520longer%2520to%2520develop%2520and%2520to%2520approve%2520vs.%2520non-CNS%2520drugs%26jtitle%3DTufts%2520Center%2520for%2520the%2520Study%2520of%2520Drug%2520Development%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratti, E.</span></span> <span> </span><span class="NLM_article-title">Strategies to Address Challenges in Neuroscience Drug Discovery and Development</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyz027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1093%2Fijnp%2Fpyz027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31139821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gvVGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2019&pages=445-448&issue=7&author=P.+O%E2%80%99Donnellauthor=L.+Rosenauthor=R.+Alexanderauthor=V.+Murthyauthor=C.+H.+Daviesauthor=E.+Ratti&title=Strategies+to+Address+Challenges+in+Neuroscience+Drug+Discovery+and+Development&doi=10.1093%2Fijnp%2Fpyz027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to Address Challenges in Neuroscience Drug Discovery and Development</span></div><div class="casAuthors">O'Donnell Patricio; Rosen Laura; Alexander Robert; Murthy Venkatesha; Ratti Emiliangelo; Davies Ceri H</div><div class="citationInfo"><span class="NLM_cas:title">The international journal of neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">445-448</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The paucity of novel drugs for neuropsychiatric indications contrasts with the remarkable recent advances in neuroscience research.  We have identified 5 challenges the field needs to address and recommend potential solutions.  First, we need to drive discovery efforts based on human data.  Second, we need to think more carefully about animal models, embracing them as tools to test pathophysiological alterations.  Third, we need to develop strategies to select more homogenous groups of patients in our clinical trials.  Fourth, we need to develop and validate translational biomarkers, which can be used for pharmacodynamic assessments as well as for patient selection.  Fifth, we need to adopt more reliable and objective measures to capture clinical efficacy.  The tools that will allow these solutions to be implemented may already be in place but not routinely adopted or are still being developed.  Overall, a change in mindset to adopt science- and data-driven paths is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRpfI4sEPq943yKPtYViAGfW6udTcc2eayVtELDLSEX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gvVGgtQ%253D%253D&md5=d86c1f4aac93062adaf7dc17f0f39c7e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyz027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyz027%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DL.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMurthy%26aufirst%3DV.%26aulast%3DDavies%26aufirst%3DC.%2BH.%26aulast%3DRatti%26aufirst%3DE.%26atitle%3DStrategies%2520to%2520Address%2520Challenges%2520in%2520Neuroscience%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2019%26volume%3D22%26issue%3D7%26spage%3D445%26epage%3D448%26doi%3D10.1093%2Fijnp%2Fpyz027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span> </span><span class="NLM_article-title">Opioid Overdose</span>.  <i>Center for Disease Control
and Prevention</i>. <a href="https://www.cdc.gov/drugoverdose/epidemic/index.html" class="extLink">https://www.cdc.gov/drugoverdose/epidemic/index.html</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Opioid+Overdose.+Center+for+Disease+Control%0Aand+Prevention.+https%3A%2F%2Fwww.cdc.gov%2Fdrugoverdose%2Fepidemic%2Findex.html+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DOpioid%2520Overdose%26jtitle%3DCenter%2520for%2520Disease%2520Control%250Aand%2520Prevention%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doughty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, T.</span></span> <span> </span><span class="NLM_article-title">Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1177/1060028019828954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1177%2F1060028019828954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30724094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=746-753&issue=7&author=B.+Doughtyauthor=D.+Morgensonauthor=T.+Brooks&title=Lofexidine%3A+A+Newly+FDA-Approved%2C+Nonopioid+Treatment+for+Opioid+Withdrawal&doi=10.1177%2F1060028019828954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal</span></div><div class="casAuthors">Doughty, Bennett; Morgenson, Daralyn; Brooks, Tracy</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">746-753</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., efficacy, and safety of lofexidine for the treatment of opioid withdrawal secondary to the recent Food and Drug Administration (FDA) approval.  Data Sources: A literature search using PubMed was conducted (inception to Dec. 2018) using the terms lofexidine, opioid, opiate, and withdrawal.  Refs. from retrieved articles and the prescribing information were reviewed for any addnl. material.  Study Selection/Data Extn.: The literature search was limited to human studies published in English that pertained to human pharmacol., pharmacokinetics, pharmacodynamics, dosing, efficacy, and safety regarding opioid withdrawal.  Phase I, II, and III studies of lofexidine for opioid withdrawal were reviewed for inclusion.  Data Synthesis: Lofexidine is newly FDA approved in the United States for the treatment of opioid withdrawal symptoms in adults.  Several randomized controlled trials and a Cochrane review noted the effectiveness of lofexidine vs. placebo for this indication.  The efficacy of lofexidine has also been shown to be comparable to that of other indicated first- and second-line pharmacol. agents.  Relevance to Patient Care and Clin. Practice: This article examines the trials that led to lofexidine's new FDA-approved indication as well as other recent literature published since its last major review, seeking to guide providers in the appropriate use of lofexidine for its new indication.  Conclusions: Lofexidine is an effective and safe agent in treating symptoms related to opioid withdrawal in adults when compared with placebo; although it is more widely accessible than other first-line therapies, its use in practice may be limited by cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohcyqmCUKki7Vg90H21EOLACvtfcHk0lgkAPfYq8h4RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfF&md5=1e7755a13d9a6fee8cbac7e9a41152e0</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1177%2F1060028019828954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019828954%26sid%3Dliteratum%253Aachs%26aulast%3DDoughty%26aufirst%3DB.%26aulast%3DMorgenson%26aufirst%3DD.%26aulast%3DBrooks%26aufirst%3DT.%26atitle%3DLofexidine%253A%2520A%2520Newly%2520FDA-Approved%252C%2520Nonopioid%2520Treatment%2520for%2520Opioid%2520Withdrawal%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2019%26volume%3D53%26issue%3D7%26spage%3D746%26epage%3D753%26doi%3D10.1177%2F1060028019828954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span> </span><span class="NLM_article-title">FDA Approves the First Non-Opioid Treatment
for Management of Opioid
Withdrawal Symptoms in Adults</span>.  <i>U.S. Food and
Drug Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+the+First+Non-Opioid+Treatment%0Afor+Management+of+Opioid%0AWithdrawal+Symptoms+in+Adults.+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults+%28accessed+2020-04-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520the%2520First%2520Non-Opioid%2520Treatment%250Afor%2520Management%2520of%2520Opioid%250AWithdrawal%2520Symptoms%2520in%2520Adults%26jtitle%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span> <i>Reviving the
Pipeline of Live-saving Antibiotics: Exploring Solutions
to Spur Innovation</i>. <a href="https://www.pewtrusts.org/-/media/legacy/uploadedfiles/phg/content_level_pages/issue_briefs/aippipelineproceedings9webpdf.pdf" class="extLink">https://www.pewtrusts.org/-/media/legacy/uploadedfiles/phg/content_level_pages/issue_briefs/aippipelineproceedings9webpdf.pdf</a> (accessed <span class="NLM_year">2020</span>-10-24).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Reviving+the%0APipeline+of+Live-saving+Antibiotics%3A+Exploring+Solutions%0Ato+Spur+Innovation.+https%3A%2F%2Fwww.pewtrusts.org%2F-%2Fmedia%2Flegacy%2Fuploadedfiles%2Fphg%2Fcontent_level_pages%2Fissue_briefs%2Faippipelineproceedings9webpdf.pdf+%28accessed+2020-10-24%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DReviving%2520the%250APipeline%2520of%2520Live-saving%2520Antibiotics%253A%2520Exploring%2520Solutions%250Ato%2520Spur%2520Innovation%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span> </span><span class="NLM_article-title">Rick
Brown</span>.  <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">18</span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">11</span>.<span class="refDoi"> DOI: 10.1038/nrd.2018.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fnrd.2018.237" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Rick%0ABrown.+Nat.+Rev.+Drug+Discovery+2019%2C+18+%281%29%2C+10%E2%80%9311.+10.1038%2Fnrd.2018.237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.237%26sid%3Dliteratum%253Aachs%26atitle%3DRick%250ABrown%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26issue%3D1%26spage%3D10%26epage%3D11%26doi%3D10.1038%2Fnrd.2018.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbarth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulcini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahlmeter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluytmans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmeli, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Outterson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaleri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houchens, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theuretzbacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magrini, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">WHO Pathogens Priority List Working Group. Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30753-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1473-3099%2817%2930753-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29276051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC1MzkvFOgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=318-327&issue=3&author=E.+Tacconelliauthor=E.+Carraraauthor=A.+Savoldiauthor=S.+Harbarthauthor=M.+Mendelsonauthor=D.+L.+Monnetauthor=C.+Pulciniauthor=G.+Kahlmeterauthor=J.+Kluytmansauthor=Y.+Carmeliauthor=M.+Ouelletteauthor=K.+Outtersonauthor=J.+Patelauthor=M.+Cavaleriauthor=E.+M.+Coxauthor=C.+R.+Houchensauthor=M.+L.+Graysonauthor=P.+Hansenauthor=N.+Singhauthor=U.+Theuretzbacherauthor=N.+Magrini&title=WHO+Pathogens+Priority+List+Working+Group.+Discovery%2C+Research%2C+and+Development+of+New+Antibiotics%3A+The+WHO+Priority+List+of+Antibiotic-Resistant+Bacteria+and+Tuberculosis&doi=10.1016%2FS1473-3099%2817%2930753-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</span></div><div class="casAuthors">Tacconelli Evelina; Carrara Elena; Savoldi Alessia; Harbarth Stephan; Mendelson Marc; Monnet Dominique L; Pulcini Celine; Kahlmeter Gunnar; Kluytmans Jan; Carmeli Yehuda; Ouellette Marc; Outterson Kevin; Patel Jean; Cavaleri Marco; Cox Edward M; Houchens Chris R; Grayson M Lindsay; Hansen Paul; Singh Nalini; Theuretzbacher Ursula; Magrini Nicola</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-327</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide.  Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs.  In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs.  METHODS:  We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated.  The final priority ranking of the antibiotic-resistant bacteria was established after a preference-based survey was used to obtain expert weighting of criteria.  FINDINGS:  We selected 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority: mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline.  We stratified the priority list into three tiers (critical, high, and medium priority), using the 33rd percentile of the bacterium's total scores as the cutoff.  Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae.  The highest ranked Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin-resistant Staphylococcus aureus.  Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori, and fluoroquinolone-resistant Campylobacter spp, Neisseria gonorrhoeae, and Salmonella typhi were included in the high-priority tier.  INTERPRETATION:  Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria.  The global strategy should include antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, N gonorrhoeae, and H pylori.  FUNDING:  World Health Organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkARC7DR8uZLGbPKh4T9eAfW6udTcc2eY4bGFg94yvAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzkvFOgsA%253D%253D&md5=14021ec57670b29fec6a88226a6a1fdd</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930753-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930753-3%26sid%3Dliteratum%253Aachs%26aulast%3DTacconelli%26aufirst%3DE.%26aulast%3DCarrara%26aufirst%3DE.%26aulast%3DSavoldi%26aufirst%3DA.%26aulast%3DHarbarth%26aufirst%3DS.%26aulast%3DMendelson%26aufirst%3DM.%26aulast%3DMonnet%26aufirst%3DD.%2BL.%26aulast%3DPulcini%26aufirst%3DC.%26aulast%3DKahlmeter%26aufirst%3DG.%26aulast%3DKluytmans%26aufirst%3DJ.%26aulast%3DCarmeli%26aufirst%3DY.%26aulast%3DOuellette%26aufirst%3DM.%26aulast%3DOutterson%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DCavaleri%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DE.%2BM.%26aulast%3DHouchens%26aufirst%3DC.%2BR.%26aulast%3DGrayson%26aufirst%3DM.%2BL.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DTheuretzbacher%26aufirst%3DU.%26aulast%3DMagrini%26aufirst%3DN.%26atitle%3DWHO%2520Pathogens%2520Priority%2520List%2520Working%2520Group.%2520Discovery%252C%2520Research%252C%2520and%2520Development%2520of%2520New%2520Antibiotics%253A%2520The%2520WHO%2520Priority%2520List%2520of%2520Antibiotic-Resistant%2520Bacteria%2520and%2520Tuberculosis%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26issue%3D3%26spage%3D318%26epage%3D327%26doi%3D10.1016%2FS1473-3099%2817%2930753-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, D. L.</span></span> <span> </span><span class="NLM_article-title">Antibiotics in the Clinical Pipeline in October 2019</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1038/s41429-020-0291-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41429-020-0291-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32152527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2020&pages=329-364&issue=6&author=M.+S.+Butlerauthor=D.+L.+Paterson&title=Antibiotics+in+the+Clinical+Pipeline+in+October+2019&doi=10.1038%2Fs41429-020-0291-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Antibiotics in the clinical pipeline in October 2019</span></div><div class="casAuthors">Butler, Mark S.; Paterson, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">329-364</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR) bacteria, esp. Gram-neg. (G-ve) pathogens, is acknowledged as one of the world's most pressing health issues; however, the discovery and development of new, nontoxic antibacterials is not a straightforward scientific task, which is compounded by a challenging economic model.  This review lists the antibacterials, β-lactamase/β-lactam inhibitor (BLI) combinations, and monoclonal antibodies (mAbs) first launched around the world since 2009 and details the seven new antibiotics and two new β-lactam/BLI combinations launched since 2016.  The development status, mode of action, spectra of activity, lead source, and administration route for the 44 small mol. antibacterials, eight β-lactamase/BLI combinations, and one antibody drug conjugate (ADC) being evaluated in worldwide clin. trials at the end of Oct. 2019 are described.  Compds. discontinued from clin. development since 2016 and new antibacterial pharmacophores are also reviewed.  There has been an increase in the no. of early stage clin. candidates, which has been fueled by antibiotic-focused funding agencies; however, there is still a significant gap in the pipeline for the development of new antibacterials with activity against β-metallolactamases, orally administered with broad spectrum G-ve activity, and new treatments for MDR Acinetobacter and gonorrhea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDTAYv4MlaorVg90H21EOLACvtfcHk0lgclsb2w5X5ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeqsb8%253D&md5=8144b41888383c0bf8af6d6e0d7dc1c4</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1038%2Fs41429-020-0291-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41429-020-0291-8%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DPaterson%26aufirst%3DD.%2BL.%26atitle%3DAntibiotics%2520in%2520the%2520Clinical%2520Pipeline%2520in%2520October%25202019%26jtitle%3DJ.%2520Antibiot.%26date%3D2020%26volume%3D73%26issue%3D6%26spage%3D329%26epage%3D364%26doi%3D10.1038%2Fs41429-020-0291-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Triguero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teufel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonardelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavel, J. A.</span></span> <span> </span><span class="NLM_article-title">A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus Aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e02588</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1128/AAC.02588-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1128%2FAAC.02588-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30910894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1SgsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e02588-18&issue=6&author=M.+Peckauthor=M.+E.+Rothenbergauthor=R.+Dengauthor=N.+Lewin-Kohauthor=G.+Sheauthor=A.+V.+Kamathauthor=M.+Carrasco-Trigueroauthor=O.+Saadauthor=A.+Castroauthor=L.+Teufelauthor=D.+S.+Dickersonauthor=M.+Leonardelliauthor=J.+A.+Tavel&title=A+Phase+1%2C+Randomized%2C+Single-Ascending-Dose+Study+To+Investigate+the+Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+DSTA4637S%2C+an+Anti-Staphylococcus+Aureus+Thiomab+Antibody-Antibiotic+Conjugate%2C+in+Healthy+Volunteers&doi=10.1128%2FAAC.02588-18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti- Staphylococcus aureus Thiomab antibody-antibiotic conjugate, in healthy volunteers</span></div><div class="casAuthors">Peck, Melicent; Rothenberg, Michael E.; Deng, Rong; Lewin-Koh, Nicholas; She, Gaohong; Kamath, Amrita V.; Carrasco-Triguero, Montserrat; Saad, Ola; Castro, Aide; Teufel, Lisa; Dickerson, Daniel S.; Leonardelli, Marisa; Tavel, Jorge A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e02588-18</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Staphylococcus aureus causes serious bacterial infections with high morbidity and mortality, necessitating the discovery of new antibiotics.  DSTA4637S is a novel antibody-antibiotic conjugate designed to target intracellular S. aureus that is not adequately eliminated by current std.-of-care antibiotics.  Phagocytic cells ingest DSTA4637S-bound S. aureus, and intracellular cathepsins cleave the linker, releasing dmDNA31and killing intracellular S. aureus.  This first-in-human, randomized, doubleblind, placebo-controlled, single-ascending-dose phase 1 trial analyzed the safety, pharmacokinetics, and immunogenicity of DSTA4637S in healthy volunteers.  Thirty healthy male and female volunteers, 18-65 years old, subjects were followed for 85 days after dosing.  No subject withdrew from the study, and no serious or severe adverse events.  One moderate infusion-related reaction (150 mg/kg DSTA4637S).  No clin. meaningful or dose-related changes in lab. parameters or vital signs.  Pharmacokinetics of plasma DSTA4637S conjugate and serum DSTA4637S total antibody were dose proportional.  Systemic exposure of unconjugated dmDNA31 was low.  No DSTA4637S-induced anti-drug antibody responses were obsd.  DSTA4637S was generally safe and well tolerated as a single i.v. dose in healthy volunteers.  DSTA4637S has a favorable safety and pharmacokinetic profile that supports future development as a novel therapeutic for S. aureus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdRbuoylerrLVg90H21EOLACvtfcHk0lgEHSMxYYdaAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1SgsrfN&md5=81b5b5182885d6ff7192290ecf16990b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1128%2FAAC.02588-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02588-18%26sid%3Dliteratum%253Aachs%26aulast%3DPeck%26aufirst%3DM.%26aulast%3DRothenberg%26aufirst%3DM.%2BE.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DShe%26aufirst%3DG.%26aulast%3DKamath%26aufirst%3DA.%2BV.%26aulast%3DCarrasco-Triguero%26aufirst%3DM.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DTeufel%26aufirst%3DL.%26aulast%3DDickerson%26aufirst%3DD.%2BS.%26aulast%3DLeonardelli%26aufirst%3DM.%26aulast%3DTavel%26aufirst%3DJ.%2BA.%26atitle%3DA%2520Phase%25201%252C%2520Randomized%252C%2520Single-Ascending-Dose%2520Study%2520To%2520Investigate%2520the%2520Safety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520DSTA4637S%252C%2520an%2520Anti-Staphylococcus%2520Aureus%2520Thiomab%2520Antibody-Antibiotic%2520Conjugate%252C%2520in%2520Healthy%2520Volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26issue%3D6%26spage%3De02588%26epage%3D18%26doi%3D10.1128%2FAAC.02588-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theuretzbacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbarth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacconelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, G. E.</span></span> <span> </span><span class="NLM_article-title">Critical Analysis of Antibacterial Agents in Clinical Development</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/s41579-020-0340-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41579-020-0340-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32152509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXks1Kgur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=286-298&issue=5&author=U.+Theuretzbacherauthor=K.+Bushauthor=S.+Harbarthauthor=M.+Paulauthor=J.+H.+Rexauthor=E.+Tacconelliauthor=G.+E.+Thwaites&title=Critical+Analysis+of+Antibacterial+Agents+in+Clinical+Development&doi=10.1038%2Fs41579-020-0340-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Critical analysis of antibacterial agents in clinical development</span></div><div class="casAuthors">Theuretzbacher, Ursula; Bush, Karen; Harbarth, Stephan; Paul, Mical; Rex, John H.; Tacconelli, Evelina; Thwaites, Guy E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">286-298</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The antibacterial agents currently in clin. development are predominantly derivs. of well-established antibiotic classes and were selected to address the class-specific resistance mechanisms and determinants that were known at the time of their discovery.  Many of these agents aim to target the antibiotic-resistant priority pathogens listed by the WHO, including Gram-neg. bacteria in the crit. priority category, such as carbapenem-resistant Acinetobacter, Pseudomonas and Enterobacterales.  Although some current compds. in the pipeline have exhibited increased susceptibility rates in surveillance studies that depend on geog., pre-existing cross-resistance both within and across antibacterial classes limits the activity of many of the new agents against the most extensively drug-resistant (XDR) and pan-drug-resistant (PDR) Gram-neg. pathogens.  In particular, cross-resistance to unrelated classes may occur by co-selection of resistant strains, thus leading to the rapid emergence and subsequent spread of resistance.  There is a continued need for innovation and new-class antibacterial agents in order to provide effective therapeutic options against infections specifically caused by XDR and PDR Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPNVOvIzBXbVg90H21EOLACvtfcHk0lgEHSMxYYdaAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXks1Kgur0%253D&md5=2fb35747299e6fc8a6bea5e4619968a5</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fs41579-020-0340-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41579-020-0340-0%26sid%3Dliteratum%253Aachs%26aulast%3DTheuretzbacher%26aufirst%3DU.%26aulast%3DBush%26aufirst%3DK.%26aulast%3DHarbarth%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DJ.%2BH.%26aulast%3DTacconelli%26aufirst%3DE.%26aulast%3DThwaites%26aufirst%3DG.%2BE.%26atitle%3DCritical%2520Analysis%2520of%2520Antibacterial%2520Agents%2520in%2520Clinical%2520Development%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2020%26volume%3D18%26issue%3D5%26spage%3D286%26epage%3D298%26doi%3D10.1038%2Fs41579-020-0340-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batteiger, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seña, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzbicki, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span> <span> </span><span class="NLM_article-title">Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1845</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1706988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30403954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1835-1845&issue=19&author=S.+N.+Taylorauthor=J.+Marrazzoauthor=B.+E.+Batteigerauthor=E.+W.+Hookauthor=A.+C.+Se%C3%B1aauthor=J.+Longauthor=M.+R.+Wierzbickiauthor=H.+Kwakauthor=S.+M.+Johnsonauthor=K.+Lawrenceauthor=J.+Mueller&title=Single-Dose+Zoliflodacin+%28ETX0914%29+for+Treatment+of+Urogenital+Gonorrhea&doi=10.1056%2FNEJMoa1706988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea</span></div><div class="casAuthors">Taylor, Stephanie N.; Marrazzo, Jeanne; Batteiger, Byron E.; Hook, Edward W.; Sena, Arlene C.; Long, Jill; Wierzbicki, Michael R.; Kwak, Hannah; Johnson, Shacondra M.; Lawrence, Kenneth; Mueller, John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1835-1845</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this multi-center, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated gonorrhea.  We randomly assigned eligible men and women who had signs or symptoms of uncomplicated urogenital gonorrhea or untreated urogenital gonorrhea or who had had sexual contact in the preceding 14 days with a person who had gonorrhea to receive a single oral dose of zoliflodacin (2 g or 3 g) or a single 500-mg i.m. dose of ceftriaxone in a ratio of approx. 70:70:40.  Among the 141 participants in the micro-ITT population who could be evaluated, microbiol. cure at urogenital sites was documented in 55 of 57 (96%) who received 2 g of zoliflodacin, 54 of 56 (96%) who received 3 g of zoliflodacin, and 28 of 28 (100%) who received ceftriaxone.  Pharyngeal infections were cured in 4 of 8 participants (50%), 9 of 11 participants (82%), and 4 of 4 participants (100%) in the groups that received 2 g of zoliflodacin, 3 g of zoliflodacin, and ceftriaxone, resp.  A total of 84 adverse events were reported: 24 in the group that received 2 g of zoliflodacin, 37 in the group that received 3 g of zoliflodacin, and 23 in the group that received ceftriaxone.  The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin, but this agent was less efficacious in the treatment of pharyngeal infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohoirIrYFf7Vg90H21EOLACvtfcHk0lgrVRtLSUxREA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN&md5=f26717391c8d3764114c8fee2a359b8b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706988%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BN.%26aulast%3DMarrazzo%26aufirst%3DJ.%26aulast%3DBatteiger%26aufirst%3DB.%2BE.%26aulast%3DHook%26aufirst%3DE.%2BW.%26aulast%3DSe%25C3%25B1a%26aufirst%3DA.%2BC.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DWierzbicki%26aufirst%3DM.%2BR.%26aulast%3DKwak%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DJ.%26atitle%3DSingle-Dose%2520Zoliflodacin%2520%2528ETX0914%2529%2520for%2520Treatment%2520of%2520Urogenital%2520Gonorrhea%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26issue%3D19%26spage%3D1835%26epage%3D1845%26doi%3D10.1056%2FNEJMoa1706988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Activity of Artefenomel (OZ439), a Novel Synthetic Antimalarial Endoperoxide, in Patients with Plasmodium Falciparum and Plasmodium Vivax Malaria: An Open-Label Phase 2 Trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)00320-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1473-3099%2815%2900320-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26448141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=61-69&issue=1&author=A.+P.+Phyoauthor=P.+Jittamalaauthor=F.+H.+Nostenauthor=S.+Pukrittayakameeauthor=M.+Imwongauthor=N.+J.+Whiteauthor=S.+Duparcauthor=F.+Macintyreauthor=M.+Bakerauthor=J.+J.+M%C3%B6hrle&title=Antimalarial+Activity+of+Artefenomel+%28OZ439%29%2C+a+Novel+Synthetic+Antimalarial+Endoperoxide%2C+in+Patients+with+Plasmodium+Falciparum+and+Plasmodium+Vivax+Malaria%3A+An+Open-Label+Phase+2+Trial&doi=10.1016%2FS1473-3099%2815%2900320-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial</span></div><div class="casAuthors">Phyo, Aung Pyae; Jittamala, Podjanee; Nosten, Francois H.; Pukrittayakamee, Sasithon; Imwong, Mallika; White, Nicholas J.; Duparc, Stephan; MacIntyre, Fiona; Baker, Mark; Mohrle, Jorg J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared with other antimalarial drugs with the artemisinin pharmacophore.  Artefenomel has been generally well tolerated in volunteers at doses up to 1600 mg and is being developed as a partner drug in an antimalarial combination treatment.  We investigated the efficacy, tolerability, and pharmacokinetics of artefenomel at different doses in patients with Plasmodium falciparum or Plasmodium vivax malaria.  This phase 2a exploratory, open-label trial was done at the Hospital for Tropical Diseases, Bangkok, and the Shoklo Malaria Research Unit in Thailand.  Adult patients with acute, uncomplicated P falciparum or P vivax malaria received artefenomel in a single oral dose (200 mg, 400 mg, 800 mg, or 1200 mg).  The first cohort received 800 mg.  Testing of a new dose of artefenomel in a patient cohort was decided on after safety and efficacy assessment of the preceding cohort.  The primary endpoint was the natural log parasite redn. per 24 h.  Definitive oral treatment was given at 36 h.  This trial is registered with ClinicalTrials.gov, no. NCT01213966.  Between Oct 24, 2010, and May 25, 2012, 82 patients were enrolled (20 in each of the 200 mg, 400 mg, and 800 mg cohorts, and 21 in the 1200 mg cohort).  One patient withdrew consent (before the administration of artefenomel) but there were no further dropouts.  The parasite redn. rates per 24 h ranged from 0·90 to 1·88 for P falciparum, and 2·09 to 2·53 for P vivax.  All doses were equally effective in both P falciparum and P vivax malaria, with median parasite clearance half-lives of 4·1 h (range 1·3-6·7) to 5·6 h (2·0-8·5) for P falciparum and 2·3 h (1·2-3·9) to 3·2 h (0·9-15·0) for P vivax.  Maximum plasma concns., dose-proportional to 800 mg, occurred at 4 h (median).  The estd. elimination half-life was 46-62 h.  No serious drug-related adverse effects were reported; other adverse effects were generally mild and reversible, with the highest no. in the 1200 mg cohort (17 [81%] patients with at least one adverse event).  The most frequently reported adverse effect was an asymptomatic increase in plasma creatine phosphokinase concn. (200 mg, n=5; 400 mg, n=3; 800 mg, n=1; 1200 mg, n=3).  Artefenomel is a new synthetic antimalarial peroxide with a good safety profile that clears parasitemia rapidly in both P falciparum and P vivax malaria.  Its long half-life suggests a possible use in a single-dose treatment in combination with other drugs.  Bill & Melinda Gates Foundation, Wellcome Trust, and UK Department for International Development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_OEYJuv5VVrVg90H21EOLACvtfcHk0lgrVRtLSUxREA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjs7vP&md5=368550e5ec73242c603c8abdc6a66f12</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900320-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900320-5%26sid%3Dliteratum%253Aachs%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DNosten%26aufirst%3DF.%2BH.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DBaker%26aufirst%3DM.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26atitle%3DAntimalarial%2520Activity%2520of%2520Artefenomel%2520%2528OZ439%2529%252C%2520a%2520Novel%2520Synthetic%2520Antimalarial%2520Endoperoxide%252C%2520in%2520Patients%2520with%2520Plasmodium%2520Falciparum%2520and%2520Plasmodium%2520Vivax%2520Malaria%253A%2520An%2520Open-Label%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26issue%3D1%26spage%3D61%26epage%3D69%26doi%3D10.1016%2FS1473-3099%2815%2900320-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uthaisin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanboonkunupakarn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuthasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, F. J.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1602250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=27653565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1152-1160&issue=12&author=N.+J.+Whiteauthor=T.+T.+Duongauthor=C.+Uthaisinauthor=F.+Nostenauthor=A.+P.+Phyoauthor=B.+Hanboonkunupakarnauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chuthasmitauthor=M.+S.+Cheungauthor=Y.+Fengauthor=R.+Liauthor=B.+Magnussonauthor=M.+Sultanauthor=D.+Wieserauthor=X.+Xunauthor=R.+Zhaoauthor=T.+T.+Diaganaauthor=P.+Pertelauthor=F.+J.+Leong&title=Antimalarial+Activity+of+KAF156+in+Falciparum+and+Vivax+Malaria&doi=10.1056%2FNEJMoa1602250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of KAF156 in falciparum and vivax malaria</span></div><div class="casAuthors">White, Nicholas J.; Duong, Tran T.; Uthaisin, Chirapong; Nosten, Francois; Phyo, Aung P.; Hanboonkunupakarn, Borimas; Pukrittayakamee, Sasithon; Jittamala, Podjanee; Chuthasmit, Kittiphum; Cheung, Ming S.; Feng, Yiyan; Li, Ruobing; Magnusson, Baldur; Sultan, Marc; Wieser, Daniela; Xun, Xiaolei; Zhao, Rong; Diagana, Thierry T.; Pertel, Peter; Leong, F. Joel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1152-1160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines), with activity against asexual and sexual blood stages and the preerythrocytic liver stages of malarial parasites.  METHODS: We conducted a phase 2, open-label, two-part study at five centers in Thailand and Vietnam to assess the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 in adults with acute Plasmodium vivax or P. falciparum malaria.  Assessment of parasite clearance rates in cohorts of patients with vivax or falciparum malaria who were treated with multiple doses (400 mg once daily for 3 days) was followed by assessment of the cure rate at 28 days in a sep. cohort of patients with falciparum malaria who received a single dose (800 mg).  RESULTS: Median parasite clearance times were 45 h (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 h (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 h (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.  Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84).  The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 h.  There were no serious adverse events in this small study.  The most common adverse events included sinus bradycardia, thrombocytopenia, hypokalemia, anemia, and hyperbilirubinemia.  Vomiting of grade 2 or higher occurred in 2 patients, 1 of whom discontinued treatment because of repeated vomiting after receiving the single 800-mg dose.  More adverse events were reported in the single-dose cohort, which had longer follow-up, than in the multiple-dose cohorts.  CONCLUSIONS: KAF156 showed antimalarial activity without evident safety concerns in a small no. of adults with uncomplicated P. vivax or P. falciparum malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHzWNldN2RLbVg90H21EOLACvtfcHk0liw2hA2vvrdKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrnN&md5=24d0943da6d583f8c0fe4fe9f380ec99</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602250%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DUthaisin%26aufirst%3DC.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DHanboonkunupakarn%26aufirst%3DB.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChuthasmit%26aufirst%3DK.%26aulast%3DCheung%26aufirst%3DM.%2BS.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DSultan%26aufirst%3DM.%26aulast%3DWieser%26aufirst%3DD.%26aulast%3DXun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DPertel%26aufirst%3DP.%26aulast%3DLeong%26aufirst%3DF.%2BJ.%26atitle%3DAntimalarial%2520Activity%2520of%2520KAF156%2520in%2520Falciparum%2520and%2520Vivax%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D12%26spage%3D1152%26epage%3D1160%26doi%3D10.1056%2FNEJMoa1602250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adoke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiono, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mombo-Ngoma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouyou-Akotet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassat, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issifou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demarest, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duparc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurijssens, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biguenet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibuuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leipoldt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phuc, B. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouedraogo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramharter, M.</span></span> <span> </span><span class="NLM_article-title">OZ-Piperaquine Study Group. A Randomised, Double-Blind Clinical Phase II Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Combination Treatment with Artefenomel and Piperaquine in Adults and Children with Uncomplicated Plasmodium Falciparum Malaria</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">181</span>, <span class="refDoi"> DOI: 10.1186/s12916-017-0940-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2Fs12916-017-0940-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28988541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=181&issue=1&author=F.+Macintyreauthor=Y.+Adokeauthor=A.+B.+Tionoauthor=T.+T.+Duongauthor=G.+Mombo-Ngomaauthor=M.+Bouyou-Akotetauthor=H.+Tintoauthor=Q.+Bassatauthor=S.+Issifouauthor=M.+Adamyauthor=H.+Demarestauthor=S.+Duparcauthor=D.+Leroyauthor=B.+E.+Laurijssensauthor=S.+Biguenetauthor=A.+Kibuukaauthor=A.+K.+Tshefuauthor=M.+Smithauthor=C.+Fosterauthor=I.+Leipoldtauthor=P.+G.+Kremsnerauthor=B.+Q.+Phucauthor=A.+Ouedraogoauthor=M.+Ramharter&title=OZ-Piperaquine+Study+Group.+A+Randomised%2C+Double-Blind+Clinical+Phase+II+Trial+of+the+Efficacy%2C+Safety%2C+Tolerability+and+Pharmacokinetics+of+a+Single+Dose+Combination+Treatment+with+Artefenomel+and+Piperaquine+in+Adults+and+Children+with+Uncomplicated+Plasmodium+Falciparum+Malaria&doi=10.1186%2Fs12916-017-0940-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria</span></div><div class="casAuthors">Macintyre, Fiona; Adoke, Yeka; Tiono, Alfred B.; Duong, Tran Thanh; Mombo-Ngoma, Ghyslain; Bouyou-Akotet, Marielle; Tinto, Halidou; Bassat, Quique; Issifou, Saadou; Adamy, Marc; Demarest, Helen; Duparc, Stephan; Leroy, Didier; Laurijssens, Bart E.; Biguenet, Sophie; Kibuuka, Afizi; Tshefu, Antoinette Kitoto; Smith, Melnick; Foster, Chanelle; Leipoldt, Illse; Kremsner, Peter G.; Phuc, Bui Quang; Ouedraogo, Alphonse; Ramharter, Michael</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181/1-181/19</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The clin. development of a single encounter treatment for uncomplicated malaria has the potential to significantly improve the effectiveness of antimalarials.  Exploratory data suggested that the combination of artefenomel and piperaquine phosphate (PQP) has the potential to achieve satisfactory cure rates as a single dose therapy.  The primary objective of the study was to det. whether a single dose of artefenomel (800 mg) plus PQP in ascending doses is an efficacious treatment for uncomplicated Plasmodium falciparum malaria in the 'target' population of children ≤ 5 years of age in Africa as well as Asian patients of all ages.  Methods: Patients in six African countries and in Vietnam were randomised to treatment with follow-up for 42 - 63 days.  Efficacy, tolerability, safety and pharmacokinetics were assessed.  Addnl. key objectives were to characterize the exposure - response relationship for polymerase chain reaction (PCR)-adjusted adequate clin. and parasitol. response at day 28 post-dose (ACPR28) and to further investigate Kelch13 mutations.  Patients in Africa (n = 355) and Vietnam (n = 82) were included, with 85% of the total population being children < 5 years of age.  Results: ACPR28 in the per protocol population (95% confidence interval) was 70.8% (61.13 - 79.19), 68.4% (59.13 - 76.66) and 78.6% (70.09 - 85.67) for doses of 800 mg artefenomel with 640 mg, 960 mg and 1440 mg of PQP resp.  ACPR28 was lower in Vietnamese than in African patients (66.2%; 54.55 - 76.62 and 74.5%; 68.81 - 79.68) resp.  Within the African population, efficacy was lowest in the youngest age group of ≥ 0.5 to ≤ 2 years, 52.7% (38.80 - 66.35).  Initial parasite clearance was twice as long in Vietnam than in Africa.  Within Vietnam, the frequency of the Kelch13 mutation was 70.1% and was clearly assocd. with parasite clearance half-life (PCt1/2).  The most significant tolerability finding was vomiting (28.8%).  Conclusions: In this first clin. trial evaluating a single encounter antimalarial therapy, none of the treatment arms reached the target efficacy of > 95% PCR-adjusted ACPR at day 28.  Achieving very high efficacy following single dose treatment is challenging, since > 95% of the population must have sufficient concns. to achieve cure across a range of parasite sensitivities and baseline parasitemia levels.  While challenging, the development of tools suitable for deployment as single encounter curative treatments for adults and children in Africa and to support elimination strategies remains a key development goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopmM9eSHRjJbVg90H21EOLACvtfcHk0lgq5lIHtnI01w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgsLvP&md5=2329f0f780c46d2fbf9e648171b9459c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs12916-017-0940-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12916-017-0940-3%26sid%3Dliteratum%253Aachs%26aulast%3DMacintyre%26aufirst%3DF.%26aulast%3DAdoke%26aufirst%3DY.%26aulast%3DTiono%26aufirst%3DA.%2BB.%26aulast%3DDuong%26aufirst%3DT.%2BT.%26aulast%3DMombo-Ngoma%26aufirst%3DG.%26aulast%3DBouyou-Akotet%26aufirst%3DM.%26aulast%3DTinto%26aufirst%3DH.%26aulast%3DBassat%26aufirst%3DQ.%26aulast%3DIssifou%26aufirst%3DS.%26aulast%3DAdamy%26aufirst%3DM.%26aulast%3DDemarest%26aufirst%3DH.%26aulast%3DDuparc%26aufirst%3DS.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DLaurijssens%26aufirst%3DB.%2BE.%26aulast%3DBiguenet%26aufirst%3DS.%26aulast%3DKibuuka%26aufirst%3DA.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DLeipoldt%26aufirst%3DI.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DPhuc%26aufirst%3DB.%2BQ.%26aulast%3DOuedraogo%26aufirst%3DA.%26aulast%3DRamharter%26aufirst%3DM.%26atitle%3DOZ-Piperaquine%2520Study%2520Group.%2520A%2520Randomised%252C%2520Double-Blind%2520Clinical%2520Phase%2520II%2520Trial%2520of%2520the%2520Efficacy%252C%2520Safety%252C%2520Tolerability%2520and%2520Pharmacokinetics%2520of%2520a%2520Single%2520Dose%2520Combination%2520Treatment%2520with%2520Artefenomel%2520and%2520Piperaquine%2520in%2520Adults%2520and%2520Children%2520with%2520Uncomplicated%2520Plasmodium%2520Falciparum%2520Malaria%26jtitle%3DBMC%2520Med.%26date%3D2017%26volume%3D15%26issue%3D1%26spage%3D181%26doi%3D10.1186%2Fs12916-017-0940-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sen Nag, O.</span></span> <span> </span><span class="NLM_article-title">The Deadliest Epidemics of the 21st Century So Far</span>.  <i>WorldAtlas</i>. <a href="https://www.worldatlas.com/articles/the-deadliest-epidemics-of-the-21st-century-till-date.html" class="extLink">https://www.worldatlas.com/articles/the-deadliest-epidemics-of-the-21st-century-till-date.html</a> (accessed <span class="NLM_year">2020</span>-01-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=O.+Sen+Nag&title=The+Deadliest+Epidemics+of+the+21st+Century+So+Far"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSen%2BNag%26aufirst%3DO.%26atitle%3DThe%2520Deadliest%2520Epidemics%2520of%2520the%252021st%2520Century%2520So%2520Far%26jtitle%3DWorldAtlas%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span> <i>Johns Hopkins
Coronavirus Resource Center</i>. <a href="https://coronavirus.jhu.edu" class="extLink">https://coronavirus.jhu.edu</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Johns+Hopkins%0ACoronavirus+Resource+Center.+https%3A%2F%2Fcoronavirus.jhu.edu+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJohns%2520Hopkins%250ACoronavirus%2520Resource%2520Center%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span> </span><span class="NLM_article-title">Coronavirus
Treatment Acceleration Program (CTAP)</span>.  <i>U.S.
Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap" class="extLink">https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Coronavirus%0ATreatment+Acceleration+Program+%28CTAP%29.+U.S.%0AFood+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fcoronavirus-covid-19-drugs%2Fcoronavirus-treatment-acceleration-program-ctap+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCoronavirus%250ATreatment%2520Acceleration%2520Program%2520%2528CTAP%2529%26jtitle%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlIbrahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hijazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkalamouni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaraket, H.</span></span> <span> </span><span class="NLM_article-title">COVID-19 Therapeutic Options Under Investigation</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1196</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.01196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.3389%2Ffphar.2020.01196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32848795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlSitbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1196&author=M.+Kaddouraauthor=M.+AlIbrahimauthor=G.+Hijaziauthor=N.+Soudaniauthor=A.+Audiauthor=H.+Alkalamouniauthor=S.+Haddadauthor=A.+Eidauthor=H.+Zaraket&title=COVID-19+Therapeutic+Options+Under+Investigation&doi=10.3389%2Ffphar.2020.01196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 therapeutic options under investigation</span></div><div class="casAuthors">Kaddoura, Malak; Alibrahim, Malak; Hijazi, Ghina; Soudani, Nadia; Audi, Amani; Alkalamouni, Habib; Haddad, Salame; Eid, Ali; Zaraket, Hassan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1196</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Since its emergence in China in Dec. 2019, COVID-19 has quickly spread around the globe causing a pandemic.  Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future.  Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed.  Preclin. and clin. studies of potential antiviral and immunomodulatory compds. and mols. to identify safe and efficacious therapeutics for COVID-19 are ongoing.  Two compds., remdesivir, and dexamethasone have been so far shown to reduce COVID-19-assocd. death.  Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvKrqvys1A4rVg90H21EOLACvtfcHk0lhuHkE7ZWpqEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlSitbzK&md5=d52c134dc91a76f7c2c7ddb3e196ff49</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.01196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.01196%26sid%3Dliteratum%253Aachs%26aulast%3DKaddoura%26aufirst%3DM.%26aulast%3DAlIbrahim%26aufirst%3DM.%26aulast%3DHijazi%26aufirst%3DG.%26aulast%3DSoudani%26aufirst%3DN.%26aulast%3DAudi%26aufirst%3DA.%26aulast%3DAlkalamouni%26aufirst%3DH.%26aulast%3DHaddad%26aufirst%3DS.%26aulast%3DEid%26aufirst%3DA.%26aulast%3DZaraket%26aufirst%3DH.%26atitle%3DCOVID-19%2520Therapeutic%2520Options%2520Under%2520Investigation%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D1196%26doi%3D10.3389%2Ffphar.2020.01196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouanounou, A.</span></span> <span> </span><span class="NLM_article-title">COVID-19: A Review of the Proposed Pharmacological Treatments</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>886</i></span>,  <span class="NLM_fpage">173451</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2020.173451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.ejphar.2020.173451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32768505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2qt7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=886&publication_year=2020&pages=173451&author=S.+Lamauthor=A.+Lombardiauthor=A.+Ouanounou&title=COVID-19%3A+A+Review+of+the+Proposed+Pharmacological+Treatments&doi=10.1016%2Fj.ejphar.2020.173451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19: A review of the proposed pharmacological treatments</span></div><div class="casAuthors">Lam, Sarah; Lombardi, Andrew; Ouanounou, Aviv</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">886</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173451</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The emerging pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge for healthcare systems globally.  The clin. course of COVID-19 and its ability to rapidly create widespread infection has major implications, warranting vigorous infection prevention and control measures.  As the confirmed no. of cases has surpassed 5.6 million worldwide and continues to grow, the potential severity of the disease and its deadly complications requires urgent development of novel therapeutic agents to both prevent and treat COVID-19.  Although vaccines and specific drug therapies have yet to be discovered, ongoing research and clin. trials are being conducted to investigate the efficacy of repurposed drugs for treating COVID-19.  In the present review, the drug candidates that have been suggested to treat COVID-19 will be discussed.  These include anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, chloroquine, hydroxychloroquine, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other misc. agents.  The mechanisms of action and further pharmacol. properties will be explored, with a particular focus on the evidence-based safety and efficacy of each agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfXWuFsC1wyrVg90H21EOLACvtfcHk0lhuHkE7ZWpqEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2qt7nF&md5=a16e77fe6eb4ce4b01611c7197a8a78d</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2020.173451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2020.173451%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DS.%26aulast%3DLombardi%26aufirst%3DA.%26aulast%3DOuanounou%26aufirst%3DA.%26atitle%3DCOVID-19%253A%2520A%2520Review%2520of%2520the%2520Proposed%2520Pharmacological%2520Treatments%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D886%26spage%3D173451%26doi%3D10.1016%2Fj.ejphar.2020.173451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span> </span><span class="NLM_article-title">Emergency Use Authorization</span>.  <i>U.S. Food and
Drug Administration</i>. <a href="https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs" class="extLink">https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Emergency+Use+Authorization.+U.S.+Food+and%0ADrug+Administration.+https%3A%2F%2Fwww.fda.gov%2Femergency-preparedness-and-response%2Fmcm-legal-regulatory-and-policy-framework%2Femergency-use-authorization%23coviddrugs+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEmergency%2520Use%2520Authorization%26jtitle%3DU.S.%2520Food%2520and%250ADrug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">RECOVERY Collaborative
Group</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emberson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mafham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staplin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustianowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmahi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rege, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faust, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juszczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landray, M. J.</span></span> <span> </span><span class="NLM_article-title">Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">NEJMoa2021436</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2021436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa2021436" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=NEJMoa2021436&author=RECOVERY+Collaborative%0AGroupauthor=P.+Horbyauthor=W.+S.+Limauthor=J.+R.+Embersonauthor=M.+Mafhamauthor=J.+L.+Bellauthor=L.+Linsellauthor=N.+Staplinauthor=C.+Brightlingauthor=A.+Ustianowskiauthor=E.+Elmahiauthor=B.+Prudonauthor=C.+Greenauthor=T.+Feltonauthor=D.+Chadwickauthor=K.+Regeauthor=C.+Feganauthor=L.+C.+Chappellauthor=S.+N.+Faustauthor=T.+Jakiauthor=K.+Jefferyauthor=A.+Montgomeryauthor=K.+Rowanauthor=E.+Juszczakauthor=J.+K.+Baillieauthor=R.+Haynesauthor=M.+J.+Landray&title=Dexamethasone+in+Hospitalized+Patients+with+Covid-19+-+Preliminary+Report&doi=10.1056%2FNEJMoa2021436"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2021436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2021436%26sid%3Dliteratum%253Aachs%26aulast%3D%26aulast%3DHorby%26aufirst%3DP.%26aulast%3DLim%26aufirst%3DW.%2BS.%26aulast%3DEmberson%26aufirst%3DJ.%2BR.%26aulast%3DMafham%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DJ.%2BL.%26aulast%3DLinsell%26aufirst%3DL.%26aulast%3DStaplin%26aufirst%3DN.%26aulast%3DBrightling%26aufirst%3DC.%26aulast%3DUstianowski%26aufirst%3DA.%26aulast%3DElmahi%26aufirst%3DE.%26aulast%3DPrudon%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DFelton%26aufirst%3DT.%26aulast%3DChadwick%26aufirst%3DD.%26aulast%3DRege%26aufirst%3DK.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DChappell%26aufirst%3DL.%2BC.%26aulast%3DFaust%26aufirst%3DS.%2BN.%26aulast%3DJaki%26aufirst%3DT.%26aulast%3DJeffery%26aufirst%3DK.%26aulast%3DMontgomery%26aufirst%3DA.%26aulast%3DRowan%26aufirst%3DK.%26aulast%3DJuszczak%26aufirst%3DE.%26aulast%3DBaillie%26aufirst%3DJ.%2BK.%26aulast%3DHaynes%26aufirst%3DR.%26aulast%3DLandray%26aufirst%3DM.%2BJ.%26atitle%3DDexamethasone%2520in%2520Hospitalized%2520Patients%2520with%2520Covid-19%2520-%2520Preliminary%2520Report%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26spage%3DNEJMoa2021436%26doi%3D10.1056%2FNEJMoa2021436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span> </span><span class="NLM_article-title">FDA Approves First Treatment for COVID-19.
FDA News Release</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19</a> (accessed <span class="NLM_year">2020</span>-10-31).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+First+Treatment+for+COVID-19.%0AFDA+News+Release.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-treatment-covid-19+%28accessed+2020-10-31%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520First%2520Treatment%2520for%2520COVID-19.%250AFDA%2520News%2520Release%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessoku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imajo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, A.</span></span> <span> </span><span class="NLM_article-title">Present and Emerging Pharmacotherapies for Non-Alcoholic Steatohepatitis in Adults</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1543403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1080%2F14656566.2018.1543403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30411635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=69-82&issue=1&author=Y.+Ogawaauthor=M.+Yonedaauthor=T.+Kobayashiauthor=Y.+Hondaauthor=T.+Kessokuauthor=K.+Imajoauthor=S.+Saitoauthor=A.+Nakajima&title=Present+and+Emerging+Pharmacotherapies+for+Non-Alcoholic+Steatohepatitis+in+Adults&doi=10.1080%2F14656566.2018.1543403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults</span></div><div class="casAuthors">Ogawa, Yuji; Yoneda, Masato; Kobayashi, Takashi; Honda, Yasushi; Kessoku, Takaomi; Imajo, Kento; Saito, Satoru; Nakajima, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-82</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Multiple parallel factors are implicated in the pathogenesis and progression of non-alc. fatty liver disease (NAFLD)/non-alc. steatohepatitis (NASH).  Currently recommended therapies for NASH include vitamin E and pioglitazone, besides dietary and lifestyle changes.: This review focuses on the clin. development of several emerging drugs for the treatment of NASH and the impact of these drugs on current treatment stds.: Four drug classes (FXR agonists, CCR2/CCR5 antagonists, ASK1 inhibitors, and PPARα/δ agonists) have moved into phase 3 trials for their investigation as NASH treatments.  Results from phase 2 trials of other therapeutic agents with other pharmacol. actions are also expected.  The importance of combinational therapies with synergistic benefits engaging different targets, is now understood.  Furthermore, studies have detd. that the Mediterranean diet is beneficial for patients with NAFLD, while the traditional Okinawan diet is also considered useful.  In the future, it will be important to establish new biomarkers to assess NAFLD activity, furthermore non-invasive diagnostic methods will promote the development of new drugs for NASH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsG9wiycgi3LVg90H21EOLACvtfcHk0ljoD911zpYNTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOjtbrP&md5=4a21ba29982206798c7bd98c7307ae0b</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1543403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1543403%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DYoneda%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DY.%26aulast%3DKessoku%26aufirst%3DT.%26aulast%3DImajo%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DA.%26atitle%3DPresent%2520and%2520Emerging%2520Pharmacotherapies%2520for%2520Non-Alcoholic%2520Steatohepatitis%2520in%2520Adults%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26issue%3D1%26spage%3D69%26epage%3D82%26doi%3D10.1080%2F14656566.2018.1543403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Attia, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Softic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouzaki, M.</span></span> <span> </span><span class="NLM_article-title">Evolving Role for Pharmacotherapy in NAFLD/NASH</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi"> DOI: 10.1111/cts.12839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fcts.12839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32583961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3MXksV2hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2021&pages=11&author=S.+L.+Attiaauthor=S.+Softicauthor=M.+Mouzaki&title=Evolving+Role+for+Pharmacotherapy+in+NAFLD%2FNASH&doi=10.1111%2Fcts.12839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving Role for Pharmacotherapy in NAFLD/NASH</span></div><div class="casAuthors">Attia, Suzanna L.; Softic, Samir; Mouzaki, Marialena</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma.  There are currently no US Food and Drug Administration (FDA) approved treatments for NAFLD; however, this is a field of active research.  This review summarizes emerging pharmacotherapies for the treatment of adult and pediatric NAFLD.  Investigated pharmacotherapies predominantly target bile acid signaling, insulin resistance, and lipid handling within the liver.  Three drugs have gone on to phase III trials for which results are available.  Of those, obeticholic acid is the single agent that demonstrates promise according to the interim analyses of the REGENERATE trial.  Obeticholic acid showed redn. of fibrosis in adults with nonalcoholic steatohepatitis (NASH) taking 25 mg daily for 18 mo (n = 931, redn. in fibrosis in 25% vs. 12% placebo, P < 0.01).  Ongoing phase III trials include REGENERATE and MAESTRO-NASH, which investigates thyroid hormone receptor-β agonist MGL-3196.  Outcomes of promising phase II trials in adults with NASH are also available and those have investigated agents, including the fibroblast growth factor (FGF)19 analog NGM282, the GLP1 agonist liraglutide, the FGF21 analog Pegbelfermin, the sodium glucose co-transporter 2 inhibitor Empagliflozin, the ketohexokinase inhibitor PF-06835919, the acetyl-CoA carboxylase inhibitor GS-0976, and the chemokine receptor antagonist Cenicriviroc.  Completed and ongoing clin. trials emphasize the need for a more nuanced understanding of the phenotypes of subgroups within NAFLD that may respond to an individualized approach to pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwIV4TUPWqMLVg90H21EOLACvtfcHk0ljvozeH8aqhKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXksV2hsLw%253D&md5=912b1c8438d22b43661271da9314d43c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1111%2Fcts.12839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12839%26sid%3Dliteratum%253Aachs%26aulast%3DAttia%26aufirst%3DS.%2BL.%26aulast%3DSoftic%26aufirst%3DS.%26aulast%3DMouzaki%26aufirst%3DM.%26atitle%3DEvolving%2520Role%2520for%2520Pharmacotherapy%2520in%2520NAFLD%252FNASH%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2021%26volume%3D14%26spage%3D11%26doi%3D10.1111%2Fcts.12839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younossi, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratziu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anstee, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckebaum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapple, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalek, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano-Loza, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boursier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathurin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugianesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olveira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez-Pinto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graupera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gluud, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufour, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shringarpure, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">REGENERATE Study Investigators. Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">10215</span>),  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2196</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)33041-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS0140-6736%2819%2933041-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31813633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlegsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=2184-2196&issue=10215&author=Z.+M.+Younossiauthor=V.+Ratziuauthor=R.+Loombaauthor=M.+Rinellaauthor=Q.+M.+Ansteeauthor=Z.+Goodmanauthor=P.+Bedossaauthor=A.+Geierauthor=S.+Beckebaumauthor=P.+N.+Newsomeauthor=D.+Sheridanauthor=M.+Y.+Sheikhauthor=J.+Trotterauthor=W.+Knappleauthor=E.+Lawitzauthor=M.+F.+Abdelmalekauthor=K.+V.+Kowdleyauthor=A.+J.+Montano-Lozaauthor=J.+Boursierauthor=P.+Mathurinauthor=E.+Bugianesiauthor=G.+Mazzellaauthor=A.+Olveiraauthor=H.+Cortez-Pintoauthor=I.+Grauperaauthor=D.+Orrauthor=L.+L.+Gluudauthor=J.-F.+Dufourauthor=D.+Shapiroauthor=J.+Campagnaauthor=L.+Zaruauthor=L.+MacConellauthor=R.+Shringarpureauthor=S.+Harrisonauthor=A.+J.+Sanyal&title=REGENERATE+Study+Investigators.+Obeticholic+Acid+for+the+Treatment+of+Non-Alcoholic+Steatohepatitis%3A+Interim+Analysis+from+a+Multicentre%2C+Randomised%2C+Placebo-Controlled+Phase+3+Trial&doi=10.1016%2FS0140-6736%2819%2933041-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial</span></div><div class="casAuthors">Younossi, Zobair M.; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M.; Goodman, Zachary; Bedossa, Pierre; Geier, Andreas; Beckebaum, Susanne; Newsome, Philip N.; Sheridan, David; Sheikh, Muhammad Y.; Trotter, James; Knapple, Whitfield; Lawitz, Eric; Abdelmalek, Manal F.; Kowdley, Kris V.; Montano-Loza, Aldo J.; Boursier, Jerome; Mathurin, Philippe; Bugianesi, Elisabetta; Mazzella, Giuseppe; Olveira, Antonio; Cortez-Pinto, Helena; Graupera, Isabel; Orr, David; Gluud, Lise Lotte; Dufour, Jean-Francois; Shapiro, David; Campagna, Jason; Zaru, Luna; MacConell, Leigh; Shringarpure, Reshma; Harrison, Stephen; Sanyal, Arun J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10215</span>),
    <span class="NLM_cas:pages">2184-2196</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Non-alc. steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis.  Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histol. features of NASH.  Here we report results from a planned interim anal. of an ongoing, phase 3 study of obeticholic acid for NASH.  In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alc. fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily.  Patients were excluded if cirrhosis, other chronic liver disease, elevated alc. consumption, or confounding conditions were present.  The primary endpoints for the month-18 interim anal. were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resoln. with no worsening of fibrosis, with the study considered successful if either primary endpoint was met.  Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim anal. cutoff date.  The study also evaluated other histol. and biochem. markers of NASH and fibrosis, and safety.  This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6.  Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary anal. (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group).  The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002).  The NASH resoln. endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]).  In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity.  The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group).  Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH.  The results from this planned interim anal. show clin. significant histol. improvement that is reasonably likely to predict clin. benefit.  This study is ongoing to assess clin. outcomes.Intercept Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWL0KDSXp0urVg90H21EOLACvtfcHk0lhkXbjiOwRqcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlegsLfP&md5=debf7f9209691d856c4e489cd766affd</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2933041-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252933041-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounossi%26aufirst%3DZ.%2BM.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DRinella%26aufirst%3DM.%26aulast%3DAnstee%26aufirst%3DQ.%2BM.%26aulast%3DGoodman%26aufirst%3DZ.%26aulast%3DBedossa%26aufirst%3DP.%26aulast%3DGeier%26aufirst%3DA.%26aulast%3DBeckebaum%26aufirst%3DS.%26aulast%3DNewsome%26aufirst%3DP.%2BN.%26aulast%3DSheridan%26aufirst%3DD.%26aulast%3DSheikh%26aufirst%3DM.%2BY.%26aulast%3DTrotter%26aufirst%3DJ.%26aulast%3DKnapple%26aufirst%3DW.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DAbdelmalek%26aufirst%3DM.%2BF.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DMontano-Loza%26aufirst%3DA.%2BJ.%26aulast%3DBoursier%26aufirst%3DJ.%26aulast%3DMathurin%26aufirst%3DP.%26aulast%3DBugianesi%26aufirst%3DE.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DOlveira%26aufirst%3DA.%26aulast%3DCortez-Pinto%26aufirst%3DH.%26aulast%3DGraupera%26aufirst%3DI.%26aulast%3DOrr%26aufirst%3DD.%26aulast%3DGluud%26aufirst%3DL.%2BL.%26aulast%3DDufour%26aufirst%3DJ.-F.%26aulast%3DShapiro%26aufirst%3DD.%26aulast%3DCampagna%26aufirst%3DJ.%26aulast%3DZaru%26aufirst%3DL.%26aulast%3DMacConell%26aufirst%3DL.%26aulast%3DShringarpure%26aufirst%3DR.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DSanyal%26aufirst%3DA.%2BJ.%26atitle%3DREGENERATE%2520Study%2520Investigators.%2520Obeticholic%2520Acid%2520for%2520the%2520Treatment%2520of%2520Non-Alcoholic%2520Steatohepatitis%253A%2520Interim%2520Analysis%2520from%2520a%2520Multicentre%252C%2520Randomised%252C%2520Placebo-Controlled%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26issue%3D10215%26spage%3D2184%26epage%3D2196%26doi%3D10.1016%2FS0140-6736%2819%2933041-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span> </span><span class="NLM_article-title">Genfit’s
Elafibranor En Route to NASH Graveyard with Phase
3 Flop</span>.  <i>Fierce Biotech</i>. <a href="https://www.fiercebiotech.com/biotech/genfit-s-elafibranor-en-route-to-nash-graveyard-phase-3-flop" class="extLink">https://www.fiercebiotech.com/biotech/genfit-s-elafibranor-en-route-to-nash-graveyard-phase-3-flop</a> (accessed <span class="NLM_year">2020</span>-07-16).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Genfit%E2%80%99s%0AElafibranor+En+Route+to+NASH+Graveyard+with+Phase%0A3+Flop.+Fierce+Biotech.+https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fgenfit-s-elafibranor-en-route-to-nash-graveyard-phase-3-flop+%28accessed+2020-07-16%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGenfit%25E2%2580%2599s%250AElafibranor%2520En%2520Route%2520to%2520NASH%2520Graveyard%2520with%2520Phase%250A3%2520Flop%26jtitle%3DFierce%2520Biotech%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span> </span><span class="NLM_article-title">Gilead’s
Selonsertib Flunks Another NASH Phase 3</span>.  <i>Fierce
Biotech</i>. <a href="https://www.fiercebiotech.com/biotech/gilead-s-selonsertib-flunks-another-nash-phase-3" class="extLink">https://www.fiercebiotech.com/biotech/gilead-s-selonsertib-flunks-another-nash-phase-3</a> (accessed <span class="NLM_year">2020</span>-07-16).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gilead%E2%80%99s%0ASelonsertib+Flunks+Another+NASH+Phase+3.+Fierce%0ABiotech.+https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fgilead-s-selonsertib-flunks-another-nash-phase-3+%28accessed+2020-07-16%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGilead%25E2%2580%2599s%250ASelonsertib%2520Flunks%2520Another%2520NASH%2520Phase%25203%26jtitle%3DFierce%250ABiotech%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span> </span><span class="NLM_article-title">Allergan
| Cenicriviroc</span>.  <i>Fierce Biotech</i>. <a href="https://www.fiercebiotech.com/special-report/allergan-cenicriviroc" class="extLink">https://www.fiercebiotech.com/special-report/allergan-cenicriviroc</a> (accessed <span class="NLM_year">2020</span>-07-16).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allergan%0A%7C+Cenicriviroc.+Fierce+Biotech.+https%3A%2F%2Fwww.fiercebiotech.com%2Fspecial-report%2Fallergan-cenicriviroc+%28accessed+2020-07-16%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAllergan%250A%257C%2520Cenicriviroc%26jtitle%3DFierce%2520Biotech%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span> </span><span class="NLM_article-title">Cardiovascular
Diseases</span>.  <i>World Health Organization</i>. <a href="https://www.who.int/health-topics/cardiovascular-diseases/" class="extLink">https://www.who.int/health-topics/cardiovascular-diseases/</a> (accessed <span class="NLM_year">2020</span>-07-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cardiovascular%0ADiseases.+World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fhealth-topics%2Fcardiovascular-diseases%2F+%28accessed+2020-07-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCardiovascular%250ADiseases%26jtitle%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallend, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijngaard, P. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastelein, J. J. P.</span></span> <span> </span><span class="NLM_article-title">ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1912387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1056%2FNEJMoa1912387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32187462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvV2iurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=1507-1519&issue=16&author=K.+K.+Rayauthor=R.+S.+Wrightauthor=D.+Kallendauthor=W.+Koenigauthor=L.+A.+Leiterauthor=F.+J.+Raalauthor=J.+A.+Bischauthor=T.+Richardsonauthor=M.+Jarosauthor=P.+L.+J.+Wijngaardauthor=J.+J.+P.+Kastelein&title=ORION-10+and+ORION-11+Investigators.+Two+Phase+3+Trials+of+Inclisiran+in+Patients+with+Elevated+LDL+Cholesterol&doi=10.1056%2FNEJMoa1912387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol</span></div><div class="casAuthors">Ray, Kausik K.; Wright, R. Scott; Kallend, David; Koenig, Wolfgang; Leiter, Lawrence A.; Raal, Frederick J.; Bisch, Jenna A.; Richardson, Tara; Jaros, Mark; Wijngaard, Peter L. J.; Kastelein, John J. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1507-1519</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9.  Previous studies suggest that inclisiran might provide sustained redns. in low-d. lipoprotein (LDL) cholesterol levels with infrequent dosing. methods We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equiv. (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the max. tolerated dose.  Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by s.c. injection on day 1, day 90, and every 6 mo thereafter over a period of 540 days.  The coprimary end points in each trial were the placebo-cor. percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. results A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, resp.  Mean (±SD) LDL cholesterol levels at baseline were 104.7 ± 38.3 mg per dL (2.71 ± 0.99 mmol per L) and 105.5 ± 39.1 mg per dL (2.73 ± 1.01 mmol per L), resp.  At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted redns. of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo).  Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. conclusions Redns. in LDL cholesterol levels of approx. 50% were obtained with inclisiran, administered s.c. every 6 mo.  More injection-site adverse events occurred with inclisiran than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod5zBwqvm-aLVg90H21EOLACvtfcHk0linb_9hVO5mTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvV2iurg%253D&md5=0fc3b30b322cf3a1b785abf8057c40cb</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1912387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1912387%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DK.%2BK.%26aulast%3DWright%26aufirst%3DR.%2BS.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DKoenig%26aufirst%3DW.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DRaal%26aufirst%3DF.%2BJ.%26aulast%3DBisch%26aufirst%3DJ.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%26aulast%3DJaros%26aufirst%3DM.%26aulast%3DWijngaard%26aufirst%3DP.%2BL.%2BJ.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%2BP.%26atitle%3DORION-10%2520and%2520ORION-11%2520Investigators.%2520Two%2520Phase%25203%2520Trials%2520of%2520Inclisiran%2520in%2520Patients%2520with%2520Elevated%2520LDL%2520Cholesterol%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26issue%3D16%26spage%3D1507%26epage%3D1519%26doi%3D10.1056%2FNEJMoa1912387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span> <i>Science Global
Oncology Trends 2019</i>; <span class="NLM_publisher-name">IQVIA
Institute for Human Data</span>, 2019. <a href="https://intelligencepharma.files.wordpress.com/2019/05/global-oncology-trends-2019-report.pdf" class="extLink">https://intelligencepharma.files.wordpress.com/2019/05/global-oncology-trends-2019-report.pdf</a> (accessed <span class="NLM_year">2020</span>-04-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Science+Global%0AOncology+Trends+2019%3B+IQVIA%0AInstitute+for+Human+Data%2C+2019.+https%3A%2F%2Fintelligencepharma.files.wordpress.com%2F2019%2F05%2Fglobal-oncology-trends-2019-report.pdf+%28accessed+2020-04-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Global%250AOncology%2520Trends%25202019%26pub%3DIQVIA%250AInstitute%2520for%2520Human%2520Data%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, O.</span></span> <span> </span><span class="NLM_article-title">CD19 as an Attractive Target for Antibody-Based Therapy</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">577</span>, <span class="refDoi"> DOI: 10.4161/mabs.21338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.4161%2Fmabs.21338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=22820352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BC38fhvF2jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=571-577&issue=5&author=O.+Hammer&title=CD19+as+an+Attractive+Target+for+Antibody-Based+Therapy&doi=10.4161%2Fmabs.21338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">CD19 as an attractive target for antibody-based therapy</span></div><div class="casAuthors">Hammer Ohad</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">571-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite progress in the treatment of B cell disorders, novel treatment approaches are still highly needed.  CD19 is a pan-B cell marker that is recognized as a potential immunotherapy target for B cell disorders, including blood-borne malignancies and autoimmune diseases.  Although initial attempts to target CD19 were unsuccessful, a new wave of investigational agents is currently in development.  These agents are based on novel antibody-based technologies and formats that appear to better exploit CD19's therapeutic potential, and some promising clinical study data has already been reported.  This review provides an overview and the rationale for the most advanced CD19-targeting programs in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdTLA0ViNPxD69zv1FsJFMfW6udTcc2eYTuf8AxIg5bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fhvF2jtQ%253D%253D&md5=401d1bde023e96c3d7e8974e57888002</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.4161%2Fmabs.21338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.21338%26sid%3Dliteratum%253Aachs%26aulast%3DHammer%26aufirst%3DO.%26atitle%3DCD19%2520as%2520an%2520Attractive%2520Target%2520for%2520Antibody-Based%2520Therapy%26jtitle%3DmAbs%26date%3D2012%26volume%3D4%26issue%3D5%26spage%3D571%26epage%3D577%26doi%3D10.4161%2Fmabs.21338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span> </span><span class="NLM_article-title">FDA Grants Accelerated Approval to Tafasitamab-cxix for Diffuse large
B-Cell Lymphoma</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma" class="extLink">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma</a> (accessed <span class="NLM_year">2020</span>-08-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Grants+Accelerated+Approval+to+Tafasitamab-cxix+for+Diffuse+large%0AB-Cell+Lymphoma.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Ffda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma+%28accessed+2020-08-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Grants%2520Accelerated%2520Approval%2520to%2520Tafasitamab-cxix%2520for%2520Diffuse%2520large%250AB-Cell%2520Lymphoma%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaplon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, J. M.</span></span> <span> </span><span class="NLM_article-title">Antibodies to Watch in 2020</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1703531</span>, <span class="refDoi"> DOI: 10.1080/19420862.2019.1703531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1080%2F19420862.2019.1703531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31847708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyqs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1703531&issue=1&author=H.+Kaplonauthor=M.+Muralidharanauthor=Z.+Schneiderauthor=J.+M.+Reichert&title=Antibodies+to+Watch+in+2020&doi=10.1080%2F19420862.2019.1703531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Antibodies to watch in 2020</span></div><div class="casAuthors">Kaplon, Helene; Muralidharan, Mrinalini; Schneider, Zita; Reichert, Janice M.</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1703531/1</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  This 2020 installment of the annual 'Antibodies to Watch' series documents the antibody therapeutics approved in 2019 and in regulatory review in the United States or European Union, as well as those in late-stage clin. studies, as of Nov. 2019*.  At this time, a total of 5 novel antibody therapeutics (romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, and crizanlizumab) had been granted a first approval in either the US or EU, and marketing applications for 13 novel antibody therapeutics (eptinezumab, teprotumumab, enfortumab vedotin, isatuximab, [fam-]trastuzumab deruxtecan, inebilizumab, leronlimab, sacituzumab govitecan, satralizumab, narsoplimab, tafasitamab, REGNEB3 and naxituximab) were undergoing review in these regions, which represent the major markets for antibody therapeutics.  Also as of Nov. 2019, 79 novel antibodies were undergoing evaluation in late-stage clin. studies.  Of the 79 antibodies, 39 were undergoing evaluation in late-stage studies for non-cancer indications, with 2 of these (ublituximab, pamrevlumab) also in late-stage studies for cancer indications.  Companies developing 7 (tanezumab, aducanumab, evinacumab, etrolizumab, sutimlimab, anifrolumab, and teplizumab) of the 39 drugs have indicated that they may submit a marketing application in either the US or EU in 2020.  Of the 79 antibodies in late-stage studies, 40 were undergoing evaluation as treatments for cancer, and potentially 9 of these (belantamab mafodotin, oportuzumab monatox, margetuximab, dostarlimab, spartalizumab, 131I-omburtamab, loncastuximab tesirine, balstilimab, and zalifrelimab) may enter regulatory review in late 2019 or in 2020.  Overall, the biopharmaceutical industry's clin. pipeline of antibody therapeutics is robust, and should provide a continuous supply of innovative products for patients in the future. *Note on key updates through Dec. 18, 2019: 1) the US Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev) on Dec. 18, 2019, bringing the ; 2) the European Commission approved romosozumab on Dec. 9, 2019; 3) the European Medicines Agency issued a pos. opinion for brolucizumab; 4) Sesen Bio initiated a rolling biologics license application (BLA) on Dec. 6, 2019; 5) GlaxoSmithKline submitted a BLA for belantamab mafodotin; and 6) the status of the Phase 3 study (NCT04128696) of GSK3359609, a humanized IgG4 anti-ICOS antibody, in patients with head and neck squamous cell carcinoma was updated to recruiting from not yet recruiting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK1XTnR9QLarVg90H21EOLACvtfcHk0licCvCjxRFoAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyqs7vM&md5=39480ff4c59bba9a5a935e6872c46f4e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1080%2F19420862.2019.1703531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2019.1703531%26sid%3Dliteratum%253Aachs%26aulast%3DKaplon%26aufirst%3DH.%26aulast%3DMuralidharan%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DZ.%26aulast%3DReichert%26aufirst%3DJ.%2BM.%26atitle%3DAntibodies%2520to%2520Watch%2520in%25202020%26jtitle%3DmAbs%26date%3D2020%26volume%3D12%26issue%3D1%26spage%3D1703531%26doi%3D10.1080%2F19420862.2019.1703531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span> </span><span class="NLM_article-title">FDA Approves Brexucabtagene Autoleucel
for Relapsed or Refractory
Mantle Cell Lymphoma</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma" class="extLink">https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma</a> (accessed <span class="NLM_year">2020</span>-04-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Brexucabtagene+Autoleucel%0Afor+Relapsed+or+Refractory%0AMantle+Cell+Lymphoma.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Ffda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma+%28accessed+2020-04-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Brexucabtagene%2520Autoleucel%250Afor%2520Relapsed%2520or%2520Refractory%250AMantle%2520Cell%2520Lymphoma%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phiphatwatchara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">The Promising Immune Checkpoint LAG-3: From Tumor Microenvironment to Cancer Immunotherapy</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.18632/genesandcancer.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.18632%2Fgenesandcancer.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30603054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ejsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=176-189&issue=5%E2%80%936&author=L.+Longauthor=X.+Zhangauthor=F.+Chenauthor=Q.+Panauthor=P.+Phiphatwatcharaauthor=Y.+Zengauthor=H.+Chen&title=The+Promising+Immune+Checkpoint+LAG-3%3A+From+Tumor+Microenvironment+to+Cancer+Immunotherapy&doi=10.18632%2Fgenesandcancer.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy</span></div><div class="casAuthors">Long, Long; Zhang, Xue; Chen, Fuchun; Pan, Qi; Phiphatwatchara, Pronnaphat; Zeng, Yuyang; Chen, Honglei</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">176-189</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades.  Targeting immune checkpoints esp. programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) has made a breakthrough in treating advanced malignancies.  However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets.  Strikingly, the inhibitory immune checkpoint lymphocyte activation gene-3 (LAG-3) holds considerable potential.  LAG-3 suppresses T cells activation and cytokines secretion, thereby ensuring immune homeostasis.  It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses.  Targeting LAG-3 immunotherapy is moving forward in active clin. trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 has shown exciting efficacy in fighting PD-1 resistance.  Herein, we shed light on the significance of LAG-3 in the tumor microenvironment, highlight its role to regulate different lymphocytes, interplay with other immune checkpoints esp. PD-1, and emphasize new advances in LAG-3-targeted immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu9ifqDRBr7Vg90H21EOLACvtfcHk0licCvCjxRFoAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ejsrrP&md5=4ed25333c2909d45f2ed673651551893</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.18632%2Fgenesandcancer.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Fgenesandcancer.180%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DPhiphatwatchara%26aufirst%3DP.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DThe%2520Promising%2520Immune%2520Checkpoint%2520LAG-3%253A%2520From%2520Tumor%2520Microenvironment%2520to%2520Cancer%2520Immunotherapy%26jtitle%3DGenes%2520Cancer%26date%3D2018%26volume%3D9%26issue%3D5%25E2%2580%25936%26spage%3D176%26epage%3D189%26doi%3D10.18632%2Fgenesandcancer.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciscano, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignali, D. A. A.</span></span> <span> </span><span class="NLM_article-title">LAG3 (CD223) as a Cancer Immunotherapy Target</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1111/imr.12519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1111%2Fimr.12519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28258692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1elurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2017&pages=80-96&issue=1&author=L.+P.+Andrewsauthor=A.+E.+Marciscanoauthor=C.+G.+Drakeauthor=D.+A.+A.+Vignali&title=LAG3+%28CD223%29+as+a+Cancer+Immunotherapy+Target&doi=10.1111%2Fimr.12519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">LAG3 (CD223) as a cancer immunotherapy target</span></div><div class="casAuthors">Andrews, Lawrence P.; Marciscano, Ariel E.; Drake, Charles G.; Vignali, Dario A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-96</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Despite the impressive impact of CTLA4 and PD1-PDL1-targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond.  Consequently, the focus has shifted to targeting alternative inhibitory receptors (IRs) and suppressive mechanisms within the tumor microenvironment.  Lymphocyte activation gene-3 (LAG3) (CD223) is the third IR to be targeted in the clinic, consequently garnering considerable interest and scrutiny.  LAG3 upregulation is required to control overt activation and prevent the onset of autoimmunity.  However, persistent antigen exposure in the tumor microenvironment results in sustained LAG3 expression, contributing to a state of exhaustion manifest in impaired proliferation and cytokine prodn.  The exact signaling mechanisms downstream of LAG3 and interplay with other IRs remain largely unknown.  However, the striking synergy between LAG3 and PD1 obsd. in multiple settings, coupled with the contrasting intracellular cytoplasmic domain of LAG3 as compared with other IRs, highlights the potential uniqueness of LAG3.  There are now four LAG3-targeted therapies in the clinic with many more in preclin. development, emphasizing the broad interest in this IR.  Given the translational relevance of LAG3 and the heightened interest in the impact of dual LAG3/PD1 targeting in the clinic, the outcome of these trials could serve as a nexus; significantly increasing or dampening enthusiasm for subsequent targets in the cancer immunotherapeutic pipeline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMEKswM_iiVbVg90H21EOLACvtfcHk0ljaq_h8gw3xjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1elurY%253D&md5=3b7c9895ff7c60df5c9f172ddd9b4f27</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1111%2Fimr.12519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimr.12519%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DL.%2BP.%26aulast%3DMarciscano%26aufirst%3DA.%2BE.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DVignali%26aufirst%3DD.%2BA.%2BA.%26atitle%3DLAG3%2520%2528CD223%2529%2520as%2520a%2520Cancer%2520Immunotherapy%2520Target%26jtitle%3DImmunol.%2520Rev.%26date%3D2017%26volume%3D276%26issue%3D1%26spage%3D80%26epage%3D96%26doi%3D10.1111%2Fimr.12519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span> </span><span class="NLM_article-title">Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016
in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy
in the Metastatic Setting</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT03743766" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03743766</a> (accessed <span class="NLM_year">2020</span>-04-13).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nivolumab%2C+BMS-936558+in+Combination+with+Relatlimab%2C+BMS-986016%0Ain+Patients+with+Metastatic+Melanoma+Na%C3%AFve+to+Prior+Immunotherapy%0Ain+the+Metastatic+Setting.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03743766+%28accessed+2020-04-13%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNivolumab%252C%2520BMS-936558%2520in%2520Combination%2520with%2520Relatlimab%252C%2520BMS-986016%250Ain%2520Patients%2520with%2520Metastatic%2520Melanoma%2520Na%25C3%25AFve%2520to%2520Prior%2520Immunotherapy%250Ain%2520the%2520Metastatic%2520Setting%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">328</span>),  <span class="NLM_fpage">328rv4</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad7118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1126%2Fscitranslmed.aad7118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=26936508" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=328rv4&issue=328&author=W.+Zouauthor=J.+D.+Wolchokauthor=L.+Chen&title=PD-L1+%28B7-H1%29+and+PD-1+Pathway+Blockade+for+Cancer+Therapy%3A+Mechanisms%2C+Response+Biomarkers+and+Combinations&doi=10.1126%2Fscitranslmed.aad7118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad7118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad7118%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DPD-L1%2520%2528B7-H1%2529%2520and%2520PD-1%2520Pathway%2520Blockade%2520for%2520Cancer%2520Therapy%253A%2520Mechanisms%252C%2520Response%2520Biomarkers%2520and%2520Combinations%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D328%26spage%3D328rv4%26doi%3D10.1126%2Fscitranslmed.aad7118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span> <span> </span><span class="NLM_article-title">PD-L1 and Emerging Biomarkers in PD-1/PD-L1 Blockade Therapy</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1097/PPO.0000000000000301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1097%2FPPO.0000000000000301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29360727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=41-46&issue=1&author=T.+Cottrellauthor=J.+M.+Taube&title=PD-L1+and+Emerging+Biomarkers+in+PD-1%2FPD-L1+Blockade+Therapy&doi=10.1097%2FPPO.0000000000000301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy</span></div><div class="casAuthors">Cottrell, Tricia R.; Taube, Janis M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-46</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">PD-L1 checkpoint blockade is revolutionizing cancer therapy, and biomarkers capable of predicting which patients are most likely to respond are highly desired.  The detection of PD-L1 protein expression by immunohistochem. can enrich for response to anti-PD-(L)1 blockade in a variety of tumor types, but is not abs.  Limitations of current com. PD-L1 immunohistochem. (IHC) assays and improvements anticipated in next-generation PD-L1 testing are reviewed.  Assessment of tumor-infiltrating lymphocytes in conjunction with PD-L1 testing could improve specificity by distinguishing adaptive (interferon γ driven and cytotoxic T-lymphocyte assocd.) from constitutive (non-immune mediated) expression.  The presence of a high tumor mutational burden also enriches for response to therapy, and early data indicate that this may provide additive predictive value beyond PD-L1 IHC alone.  As candidate biomarkers continue to emerge, the pathologist's assessment of the tumor microenvironment on hematoxylin-eosin stain combined with PD-L1 IHC remains a rapid and robust way to evaluate the tumor-immune dynamic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsTIilwNojorVg90H21EOLACvtfcHk0ljaq_h8gw3xjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrk%253D&md5=15c61479a78a8dcc4f010551dfc9c38c</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000301%26sid%3Dliteratum%253Aachs%26aulast%3DCottrell%26aufirst%3DT.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26atitle%3DPD-L1%2520and%2520Emerging%2520Biomarkers%2520in%2520PD-1%252FPD-L1%2520Blockade%2520Therapy%26jtitle%3DCancer%2520J.%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D41%26epage%3D46%26doi%3D10.1097%2FPPO.0000000000000301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.3389%2Ffimmu.2020.00339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32226426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=339&author=Y.+Jiangauthor=X.+Zhaoauthor=J.+Fuauthor=H.+Wang&title=Progress+and+Challenges+in+Precise+Treatment+of+Tumors+With+PD-1%2FPD-L1+Blockade&doi=10.3389%2Ffimmu.2020.00339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Progress and challenges in precisetreatment of tumors withPD-1/PD-L1 blockade</span></div><div class="casAuthors">Jiang, Youhai; Zhao, Xiaofang; Fu, Jing; Wang, Hongyang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their antitumor ability and have shown significant efficacy in treating various cancers.  However, because of tumor heterogeneity and many other uncover reasons, the objective response rate for programmed death 1 and programmed death-ligand 1 (PD-1/PD-L1) blockade is only 20 to 30%; its response rate in solid tumors is relatively low, and different degrees of side effects have occurred.  There are still many unknown factors affecting the therapeutic effectiveness of PD-1/PD-L1 blockade.  Addnl., screening the responding tumor patients accurately and improving the response rate and efficacy are huge challenges for tumor precise treatment.  Here, we attempt to summarize the recent progress in response prediction and combined application of PD-1/PD-L1 blockade and briefly discuss the methods and evaluations combined with PD-1/PD-L1 blockade to improve the implementation of precision immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHpj67N22cXLVg90H21EOLACvtfcHk0liGkX4AuIP1Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7%252FF&md5=bf7f484e6ccb566221b04eb20ed9dae4</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00339%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DProgress%2520and%2520Challenges%2520in%2520Precise%2520Treatment%2520of%2520Tumors%2520With%2520PD-1%252FPD-L1%2520Blockade%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D339%26doi%3D10.3389%2Ffimmu.2020.00339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span> <span> </span><span class="NLM_article-title">Biomarkers for Predicting Efficacy of PD-1/PD-L1 Inhibitors</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">129</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0864-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2Fs12943-018-0864-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=30139382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslSmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=129&issue=1&author=M.+Yiauthor=D.+Jiaoauthor=H.+Xuauthor=Q.+Liuauthor=W.+Zhaoauthor=X.+Hanauthor=K.+Wu&title=Biomarkers+for+Predicting+Efficacy+of+PD-1%2FPD-L1+Inhibitors&doi=10.1186%2Fs12943-018-0864-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers for predicting efficacy of pd-1/ pd-l1 inhibitors</span></div><div class="casAuthors">Yi, Ming; Jiao, Dechao; Xu, Hanxiao; Liu, Qian; Zhao, Weiheng; Han, Xinwei; Wu, Kongming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129/1-129/14</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a neg. modulatory signaling pathway for activation of T cell.  It is acknowledged that PD-1/PD-L1 axis plays a crucial role in the progression of tumor by altering status of immune surveillance.  As one of the most promising immune therapy strategies, PD-1/ PD-L1 inhibitor is a breakthrough for the therapy of some refractory tumors.  However, response rate of PD-1/PD-L1 inhibitors in overall patients is unsatisfactory, which limits the application in clin. practice.  Therefore, biomarkers which could effectively predict the efficacy of PD-1/PD-L1 inhibitors are crucial for patient selection.  Biomarkers reflecting tumor immune microenvironment and tumor cell intrinsic features, such as PD-L1 expression, d. of tumor infiltrating lymphocyte (TIL), tumor mutational burden, and mismatch-repair (MMR) deficiency, have been noticed to assoc. with treatment effect of anti-PD-1/anti-PD-L1 therapy.  Furthermore, gut microbiota, circulating biomarkers, and patient previous history have been found as valuable predictors as well.  Therefore establishing a comprehensive assessment framework involving multiple biomarkers would be meaningful to interrogate tumor immune landscape and select sensitive patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCaje2gngEbVg90H21EOLACvtfcHk0liGkX4AuIP1Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslSmtrw%253D&md5=62be2968466cad48add2aeb07bda7e2c</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0864-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0864-3%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26atitle%3DBiomarkers%2520for%2520Predicting%2520Efficacy%2520of%2520PD-1%252FPD-L1%2520Inhibitors%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D129%26doi%3D10.1186%2Fs12943-018-0864-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Carrigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA Repair in Cancer: Beyond PARP Inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1158%2F2159-8290.CD-16-0860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=28003236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsF2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=20-37&issue=1&author=J.+S.+Brownauthor=B.+O%E2%80%99Carriganauthor=S.+P.+Jacksonauthor=T.+A.+Yap&title=Targeting+DNA+Repair+in+Cancer%3A+Beyond+PARP+Inhibitors&doi=10.1158%2F2159-8290.CD-16-0860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA Repair in Cancer: Beyond PARP Inhibitors</span></div><div class="casAuthors">Brown, Jessica S.; O'Carrigan, Brent; Jackson, Stephen P.; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-37</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Germline aberrations in crit. DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair.  The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers.  Herein, we detail how cellular DDR processes engage various proteins that sense DNA damage, initiate signaling pathways to promote cell-cycle checkpoint activation, trigger apoptosis, and coordinate DNA repair.  We focus on novel therapeutic strategies targeting promising DDR targets and discuss challenges of patient selection and the development of rational drug combinations.  Significance: Various inhibitors of DDR components are in preclin. and clin. development.  A thorough understanding of DDR pathway complexities must now be combined with strategies and lessons learned from the successful registration of PARP inhibitors in order to fully exploit the potential of DDR inhibitors and to ensure their long-term clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKRh_Xp_7H7Vg90H21EOLACvtfcHk0lgn9YsI9SYulQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsF2mtA%253D%253D&md5=ce622565880cf0186abc9af39a5e82c4</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0860%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BS.%26aulast%3DO%25E2%2580%2599Carrigan%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DTargeting%2520DNA%2520Repair%2520in%2520Cancer%253A%2520Beyond%2520PARP%2520Inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D20%26epage%3D37%26doi%3D10.1158%2F2159-8290.CD-16-0860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lecona, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Capetillo, O.</span></span> <span> </span><span class="NLM_article-title">Targeting ATR in Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">586</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0034-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41568-018-0034-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29899559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFelsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=586-595&issue=9&author=E.+Leconaauthor=O.+Fernandez-Capetillo&title=Targeting+ATR+in+Cancer&doi=10.1038%2Fs41568-018-0034-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ATR in cancer</span></div><div class="casAuthors">Lecona, Emilio; Fernandez-Capetillo, Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">586-595</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The chem. treatment of cancer started with the realization that DNA damaging agents such as mustard gas present notable antitumoral properties.  Consequently, early drug development focused on genotoxic chems., some of which are still widely used in the clinic.  However, the efficacy of such therapies is often limited by the side effects of these drugs on healthy cells.  A refinement to this approach is to use compds. that can exploit the presence of DNA damage in cancer cells.  Given that replication stress (RS) is a major source of genomic instability in cancer, targeting the RS-response kinase ataxia telangiectasia and Rad3-related protein (ATR) has emerged as a promising alternative.  With ATR inhibitors now entering clin. trials, we here revisit the biol. behind this strategy and discuss potential biomarkers that could be used for a better selection of patients who respond to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvSqZUpGo6e7Vg90H21EOLACvtfcHk0lgn9YsI9SYulQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFelsrbN&md5=502575a5e0cc75d42968bed402611c1d</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0034-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0034-3%26sid%3Dliteratum%253Aachs%26aulast%3DLecona%26aufirst%3DE.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26atitle%3DTargeting%2520ATR%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26issue%3D9%26spage%3D586%26epage%3D595%26doi%3D10.1038%2Fs41568-018-0034-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahner Hendrickson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumer, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duska, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispens, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olawaiye, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroilhet, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilder, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Färkkilä, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span> <span> </span><span class="NLM_article-title">Berzosertib plus Gemcitabine versus Gemcitabine Alone in Platinum-Resistant High-Grade Serous Ovarian Cancer: A Multicentre, Open-Label, Randomised, Phase 2 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">968</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(20)30180-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2FS1470-2045%2820%2930180-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32553118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Skt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=957-968&issue=7&author=P.+A.+Konstantinopoulosauthor=S.-C.+Chengauthor=A.+E.+Wahner+Hendricksonauthor=R.+T.+Pensonauthor=S.+T.+Schumerauthor=L.+A.+Doyleauthor=E.+K.+Leeauthor=E.+C.+Kohnauthor=L.+R.+Duskaauthor=M.+A.+Crispensauthor=A.+B.+Olawaiyeauthor=I.+S.+Winerauthor=L.+M.+Barroilhetauthor=S.+Fuauthor=M.+T.+McHaleauthor=R.+J.+Schilderauthor=A.+F%C3%A4rkkil%C3%A4author=D.+Chowdhuryauthor=J.+Curtisauthor=R.+S.+Quinnauthor=B.+Bowesauthor=A.+D.+D%E2%80%99Andreaauthor=G.+I.+Shapiroauthor=U.+A.+Matulonis&title=Berzosertib+plus+Gemcitabine+versus+Gemcitabine+Alone+in+Platinum-Resistant+High-Grade+Serous+Ovarian+Cancer%3A+A+Multicentre%2C+Open-Label%2C+Randomised%2C+Phase+2+Trial&doi=10.1016%2FS1470-2045%2820%2930180-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial</span></div><div class="casAuthors">Konstantinopoulos, Panagiotis A.; Cheng, Su-Chun; Wahner Hendrickson, Andrea E.; Penson, Richard T.; Schumer, Susan T.; Doyle, L. Austin; Lee, Elizabeth K.; Kohn, Elise C.; Duska, Linda R.; Crispens, Marta A.; Olawaiye, Alexander B.; Winer, Ira S.; Barroilhet, Lisa M.; Fu, Siqing; McHale, Michael T.; Schilder, Russell J.; Farkkila, Anniina; Chowdhury, Dipanjan; Curtis, Jennifer; Quinn, Roxanne S.; Bowes, Brittany; D'Andrea, Alan D.; Shapiro, Geoffrey I.; Matulonis, Ursula A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">957-968</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S phase entry (due to CCNE1 amplification, RB1 loss, or CDKN2A mRNA downregulation), alterations of homologous recombination repair genes, and expression of oncogenic drivers (through MYC amplification and other mechanisms).  We hypothesised that the combination of the selective ATR inhibitor, berzosertib, and gemcitabine could show acceptable toxicity and superior efficacy to gemcitabine alone in high-grade serous ovarian cancer.  In this multicentre, open-label, randomised, phase 2 study, 11 different centers in the US Exptl. Therapeutics Clin. Trials Network enrolled women (aged ≥18 years) with recurrent, platinum-resistant high-grade serous ovarian cancer (detd. histol.) and Eastern Cooperative Oncol. Group performance status of 0 or 1, who had unlimited previous lines of cytotoxic therapy in the platinum-sensitive setting but no more than one line of cytotoxic therapy in the platinum-resistant setting.  Eligible patients were randomly assigned (1:1) to receive i.v. gemcitabine (1000 mg/m2) on day 1 and day 8, or gemcitabine plus i.v. berzosertib (210 mg/m2) on day 2 and day 9 of a 21-day cycle until disease progression or intolerable toxicity.  Randomisation was done centrally using the Theradex Interactive Web Response System, stratified by platinum-free interval, and with a permuted block size of six.  Following central randomisation, patients and investigators were not masked to treatment assignment.  The primary endpoint was investigator-assessed progression-free survival, and analyses included all patients who received at least one dose of the study drugs.  The study is registered with ClinicalTrials.gov, NCT02595892, and is active but closed to enrolment.  Between Feb 14, 2017, and Sept 7, 2018, 88 patients were assessed for eligibility, of whom 70 were randomly assigned to treatment with gemcitabine alone (36 patients) or gemcitabine plus berzosertib (34 patients).  At the data cutoff date (Feb 21, 2020), the median follow-up was 53·2 wk (25·6-81·8) in the gemcitabine plus berzosertib group and 43·0 wk (IQR 23·2-69·1) in the gemcitabine alone group.  Median progression-free survival was 22·9 wk (17·9-72·0) for gemcitabine plus berzosertib and 14·7 wk (90% CI 9·7-36·7) for gemcitabine alone (hazard ratio 0·57, 90% CI 0·33-0·98; one-sided log-rank test p=0·044).  The most common treatment-related grade 3 or 4 adverse events were decreased neutrophil count (14 [39%] of 36 patients in the gemcitabine alone group vs 16 [47%] of 34 patients in the gemcitabine plus berzosertib group) and decreased platelet count (two [6%] vs eight [24%]).  Serious adverse events were obsd. in ten (28%) patients in the gemcitabine alone group and nine (26%) patients in the gemcitabine plus berzosertib group.  There was one treatment-related death in the gemcitabine alone group due to sepsis and one treatment-related death in the gemcitabine plus berzosertib group due to pneumonitis.  To our knowledge, this is the first randomised study of an ATR inhibitor in any tumor type.  This study shows a benefit of adding berzosertib to gemcitabine in platinum-resistant high-grade serous ovarian cancer.  This combination warrants further investigation in this setting.US National Cancer Institute.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI8--FOraDYbVg90H21EOLACvtfcHk0lj2C_M7rVeQaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Skt73O&md5=afc762e5a18335c80840251765f08556</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2820%2930180-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252820%252930180-7%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DCheng%26aufirst%3DS.-C.%26aulast%3DWahner%2BHendrickson%26aufirst%3DA.%2BE.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DSchumer%26aufirst%3DS.%2BT.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DDuska%26aufirst%3DL.%2BR.%26aulast%3DCrispens%26aufirst%3DM.%2BA.%26aulast%3DOlawaiye%26aufirst%3DA.%2BB.%26aulast%3DWiner%26aufirst%3DI.%2BS.%26aulast%3DBarroilhet%26aufirst%3DL.%2BM.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DM.%2BT.%26aulast%3DSchilder%26aufirst%3DR.%2BJ.%26aulast%3DF%25C3%25A4rkkil%25C3%25A4%26aufirst%3DA.%26aulast%3DChowdhury%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DR.%2BS.%26aulast%3DBowes%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26atitle%3DBerzosertib%2520plus%2520Gemcitabine%2520versus%2520Gemcitabine%2520Alone%2520in%2520Platinum-Resistant%2520High-Grade%2520Serous%2520Ovarian%2520Cancer%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%252C%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26issue%3D7%26spage%3D957%26epage%3D968%26doi%3D10.1016%2FS1470-2045%2820%2930180-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Ataxia Telangiectasia and Rad3-Related Inhibitors and Cancer Therapy: Where We Stand</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/s13045-019-0733-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1186%2Fs13045-019-0733-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31018854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FovVSntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=43&issue=1&author=L.+Meiauthor=J.+Zhangauthor=K.+Heauthor=J.+Zhang&title=Ataxia+Telangiectasia+and+Rad3-Related+Inhibitors+and+Cancer+Therapy%3A+Where+We+Stand&doi=10.1186%2Fs13045-019-0733-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand</span></div><div class="casAuthors">Mei Lin; Zhang Junran; He Kai; Zhang Jingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase 1 (CHK1) pathway plays an essential role in suppressing replication stress from DNA damage and oncogene activation.  MAIN BODY:  Preclinical studies have shown that cancer cells with defective DNA repair mechanisms or cell cycle checkpoints may be particularly sensitive to ATR inhibitors.  Preclinical and clinical data from early-phase trials on three ATR inhibitors (M6620, AZD6738, and BAY1895344), either as monotherapy or in combination, were reviewed.  CONCLUSION:  Data from ATR inhibitor-based combinational trials might lead to future expansion of this therapy to homologous recombination repair pathway-proficient cancers and potentially serve as a rescue therapy for patients who have progressed through poly ADP-ribose polymerase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1hnSigdvKH_xQvRxYU81tfW6udTcc2ebGI-Zdx_T5brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FovVSntw%253D%253D&md5=375804d5e67e7aa87c2d8509ab12b513</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1186%2Fs13045-019-0733-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-019-0733-6%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DAtaxia%2520Telangiectasia%2520and%2520Rad3-Related%2520Inhibitors%2520and%2520Cancer%2520Therapy%253A%2520Where%2520We%2520Stand%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D12%26issue%3D1%26spage%3D43%26doi%3D10.1186%2Fs13045-019-0733-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span> </span><span class="NLM_article-title">Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent
Protein
Kinase, in Combination With Radiotherapy</span>.  <i>ClinicalTrials.gov</i>. <a href="https://clinicaltrials.gov/ct2/show/NCT02516813" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02516813</a> (accessed <span class="NLM_year">2020</span>-08-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+1+Trial+of+MSC2490484A%2C+an+Inhibitor+of+a+DNA-dependent%0AProtein%0AKinase%2C+in+Combination+With+Radiotherapy.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02516813+%28accessed+2020-08-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%25201%2520Trial%2520of%2520MSC2490484A%252C%2520an%2520Inhibitor%2520of%2520a%2520DNA-dependent%250AProtein%250AKinase%252C%2520in%2520Combination%2520With%2520Radiotherapy%26jtitle%3DClinicalTrials.gov%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fok, J. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos-Montoya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Chantada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnhoven, P. W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrington, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmokar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikkilä, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span> <span> </span><span class="NLM_article-title">AZD7648 Is a Potent and Selective DNA-PK Inhibitor That Enhances Radiation, Chemotherapy and Olaparib Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5065</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-12836-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fs41467-019-12836-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31699977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5065&issue=1&author=J.+H.+L.+Fokauthor=A.+Ramos-Montoyaauthor=M.+Vazquez-Chantadaauthor=P.+W.+G.+Wijnhovenauthor=V.+Folliaauthor=N.+Jamesauthor=P.+M.+Farringtonauthor=A.+Karmokarauthor=S.+E.+Willisauthor=J.+Cairnsauthor=J.+Nikkil%C3%A4author=D.+Beattieauthor=G.+M.+Lamontauthor=M.+R.+V.+Finlayauthor=J.+Wilsonauthor=A.+Smithauthor=L.+O.+O%E2%80%99Connorauthor=S.+Lingauthor=S.+E.+Fawellauthor=M.+J.+O%E2%80%99Connorauthor=S.+J.+Hollingsworthauthor=E.+Deanauthor=F.+W.+Goldbergauthor=B.+R.+Daviesauthor=E.+B.+Cadogan&title=AZD7648+Is+a+Potent+and+Selective+DNA-PK+Inhibitor+That+Enhances+Radiation%2C+Chemotherapy+and+Olaparib+Activity&doi=10.1038%2Fs41467-019-12836-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity</span></div><div class="casAuthors">Fok Jacqueline H L; Ramos-Montoya Antonio; Wijnhoven Paul W G; Follia Valeria; James Neil; Farrington Paul M; Karmokar Ankur; Nikkila Jenni; Fawell Stephen E; O'Connor Mark J; Davies Barry R; Cadogan Elaine B; Vazquez-Chantada Mercedes; Ling Stephanie; Willis Sophie E; O'Connor Lenka Oplustil; Cairns Jonathan; Beattie David; Lamont Gillian M; Finlay M Raymond V; Goldberg Frederick W; Wilson Joanne; Smith Aaron; Hollingsworth Simon J; Dean Emma</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5065</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">DNA-dependent protein kinase (DNA-PK) is a critical player in the DNA damage response (DDR) and instrumental in the non-homologous end-joining pathway (NHEJ) used to detect and repair DNA double-strand breaks (DSBs).  We demonstrate that the potent and highly selective DNA-PK inhibitor, AZD7648, is an efficient sensitizer of radiation- and doxorubicin-induced DNA damage, with combinations in xenograft and patient-derived xenograft (PDX) models inducing sustained regressions.  Using ATM-deficient cells, we demonstrate that AZD7648, in combination with the PARP inhibitor olaparib, increases genomic instability, resulting in cell growth inhibition and apoptosis.  AZD7648 enhanced olaparib efficacy across a range of doses and schedules in xenograft and PDX models, enabling sustained tumour regression and providing a clear rationale for its clinical investigation.  Through its differentiated mechanism of action as an NHEJ inhibitor, AZD7648 complements the current armamentarium of DDR-targeted agents and has potential in combination with these agents to achieve deeper responses to current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQf_5P1MX4JaXtlzo9xastyfW6udTcc2eaUQj3Y2lLcvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmsVOltA%253D%253D&md5=b41d0e83963ad440f12b93fbdeed861e</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-12836-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-12836-9%26sid%3Dliteratum%253Aachs%26aulast%3DFok%26aufirst%3DJ.%2BH.%2BL.%26aulast%3DRamos-Montoya%26aufirst%3DA.%26aulast%3DVazquez-Chantada%26aufirst%3DM.%26aulast%3DWijnhoven%26aufirst%3DP.%2BW.%2BG.%26aulast%3DFollia%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DN.%26aulast%3DFarrington%26aufirst%3DP.%2BM.%26aulast%3DKarmokar%26aufirst%3DA.%26aulast%3DWillis%26aufirst%3DS.%2BE.%26aulast%3DCairns%26aufirst%3DJ.%26aulast%3DNikkil%25C3%25A4%26aufirst%3DJ.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DLamont%26aufirst%3DG.%2BM.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DL.%2BO.%26aulast%3DLing%26aufirst%3DS.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DHollingsworth%26aufirst%3DS.%2BJ.%26aulast%3DDean%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DF.%2BW.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26atitle%3DAZD7648%2520Is%2520a%2520Potent%2520and%2520Selective%2520DNA-PK%2520Inhibitor%2520That%2520Enhances%2520Radiation%252C%2520Chemotherapy%2520and%2520Olaparib%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D5065%26doi%3D10.1038%2Fs41467-019-12836-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span> <span> </span><span class="NLM_article-title">ATM in DNA Repair in Cancer</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">107391</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.pharmthera.2019.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31299316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtl2isrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2019&pages=107391&author=M.+H.+Jinauthor=D.-Y.+Oh&title=ATM+in+DNA+Repair+in+Cancer&doi=10.1016%2Fj.pharmthera.2019.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">ATM in DNA repair in cancer</span></div><div class="casAuthors">Jin, Mei Hua; Oh, Do-Youn</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107391</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Alterations in DNA damage response (DDR) pathways are hallmarks of cancer.  Incorrect repair of DNA lesions often leads to genomic instability.  Ataxia telangiectasia mutated (ATM), a core component of the DNA repair system, is activated to enhance the homologous recombination (HR) repair pathway upon DNA double-strand breaks.  Although ATM signaling has been widely studied in different types of cancer, its research is still lacking compared with other DDR-involved mols. such as PARP and ATR.  There is still a vast research opportunity for the development of ATM inhibitors as anticancer agents.  Here, we focus on the recent findings of ATM signaling in DNA repair of cancer.  Previous studies have identified several partners of ATM, some of which promote ATM signaling, while others have the opposite effect.  ATM inhibitors, including KU-55933, KU-60019, KU-59403, CP-466722, AZ31, AZ32, AZD0156, and AZD1390, have been evaluated for their antitumor effects.  It has been revealed that ATM inhibition increases a cancer cell's sensitivity to radiotherapy.  Moreover, the combination with PARP or ATR inhibitors has synergistic lethality in some cancers.  Of note, among these ATM inhibitors, AZD0156 and AZD1390 achieve potent and highly selective ATM kinase inhibition and have an excellent ability to penetrate the blood-brain barrier.  Currently, AZD0156 and AZD1390 are under investigation in phase I clin. trials.  Taken together, targeting ATM may be a promising strategy for cancer treatment.  Hence, further development of ATM inhibitors is urgently needed in cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxD2jj0D2fArVg90H21EOLACvtfcHk0lhNpLcON5Ws1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtl2isrrJ&md5=1ab2f96461142d9913d5859c309e853e</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DM.%2BH.%26aulast%3DOh%26aufirst%3DD.-Y.%26atitle%3DATM%2520in%2520DNA%2520Repair%2520in%2520Cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D203%26spage%3D107391%26doi%3D10.1016%2Fj.pharmthera.2019.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witztum, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. F.</span></span> <span> </span><span class="NLM_article-title">RNA-Targeted Therapeutics</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.cmet.2018.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=29617640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=714-739&issue=4&author=S.+T.+Crookeauthor=J.+L.+Witztumauthor=C.+F.+Bennettauthor=B.+F.+Baker&title=RNA-Targeted+Therapeutics&doi=10.1016%2Fj.cmet.2018.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Targeted Therapeutics</span></div><div class="casAuthors">Crooke, Stanley T.; Witztum, Joseph L.; Bennett, C. Frank; Baker, Brenda F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">714-739</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">RNA-targeted therapies represent a platform for drug discovery involving chem. modified oligonucleotides, a wide range of cellular RNAs, and a novel target-binding motif, Watson-Crick base pairing.  Numerous hurdles considered by many to be impassable have been overcome.  Today, four RNA-targeted therapies are approved for com. use for indications as diverse as Spinal Muscular Atrophy (SMA) and redn. of low-d. lipoprotein cholesterol (LDL-C) and by routes of administration including s.c., intravitreal, and intrathecal delivery.  The technol. is efficient and supports approaching "undruggable" targets.  Three addnl. agents are progressing through registration, and more are in clin. development, representing several chem. and structural classes.  Moreover, progress in understanding the mol. mechanisms by which these drugs work has led to steadily better clin. performance and a wide range of mechanisms that may be exploited for therapeutic purposes.  Here we summarize the progress, future challenges, and opportunities for this drug discovery platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYy4nInax5iLVg90H21EOLACvtfcHk0lhU5eP6T2R9vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqsLc%253D&md5=81de41b2b10fcab31787b830932d5b64</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26aulast%3DWitztum%26aufirst%3DJ.%2BL.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26aulast%3DBaker%26aufirst%3DB.%2BF.%26atitle%3DRNA-Targeted%2520Therapeutics%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26issue%3D4%26spage%3D714%26epage%3D739%26doi%3D10.1016%2Fj.cmet.2018.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span> </span><span class="NLM_article-title">FDA Approves Emicizumab-kxwh for Prevention
and Reduction of Bleeding
in Patients with Hemophilia A with Factor VIII Inhibitors</span>.  <i>U.S. Food and Drug Administration</i>. <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Emicizumab-kxwh+for+Prevention%0Aand+Reduction+of+Bleeding%0Ain+Patients+with+Hemophilia+A+with+Factor+VIII+Inhibitors.+U.S.+Food+and+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii+%28accessed+2020-08-08%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Emicizumab-kxwh%2520for%2520Prevention%250Aand%2520Reduction%2520of%2520Bleeding%250Ain%2520Patients%2520with%2520Hemophilia%2520A%2520with%2520Factor%2520VIII%2520Inhibitors%26jtitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, J. M.</span></span> <span> </span><span class="NLM_article-title">Bispecific Antibodies Come to the Fore</span>.  <i>Antibody Society</i>. <a href="https://www.antibodysociety.org/tag/bispecific/" class="extLink">https://www.antibodysociety.org/tag/bispecific/</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+M.+Reichert&title=Bispecific+Antibodies+Come+to+the+Fore"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DReichert%26aufirst%3DJ.%2BM.%26atitle%3DBispecific%2520Antibodies%2520Come%2520to%2520the%2520Fore%26jtitle%3DAntibody%2520Society%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suurs, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lub-de Hooge, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de
Groot, D. J. A.</span></span> <span> </span><span class="NLM_article-title">A Review of Bispecific Antibodies and Antibody Constructs in Oncology and Clinical Challenges</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1016%2Fj.pharmthera.2019.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=31028837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVynsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2019&pages=103-119&author=F.+V.+Suursauthor=M.+N.+Lub-de+Hoogeauthor=E.+G.+E.+de+Vriesauthor=D.+J.+A.+de%0AGroot&title=A+Review+of+Bispecific+Antibodies+and+Antibody+Constructs+in+Oncology+and+Clinical+Challenges&doi=10.1016%2Fj.pharmthera.2019.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">A review of bispecific antibodies and antibody constructs in oncology and clinical challenges</span></div><div class="casAuthors">Suurs, Frans V.; Lub-de Hooge, Marjolijn N.; de Vries, Elisabeth G. E.; de Groot, Derk Jan A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-119</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to can target cancer.  For use in oncol., one bsAb has been approved and 57 bsAbs are in clin. trials, none of which has reached phase 3.  These bsAbs show great variability in design and mechanism of action.  The various designs are often linked to the mechanisms of actions.  The majority of bsAbs engage immune cells to destroy tumor cells.  However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways.  This review provides insight into the choice of construct for bsAbs, summarizes the clin. development of bsAbs in oncol. and identifies subsequent challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBPP04rWjOQLVg90H21EOLACvtfcHk0lhU5eP6T2R9vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVynsbvM&md5=bc858d195fb3c7b202f3e91c15c1f427</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DSuurs%26aufirst%3DF.%2BV.%26aulast%3DLub-de%2BHooge%26aufirst%3DM.%2BN.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26aulast%3Dde%2BGroot%26aufirst%3DD.%2BJ.%2BA.%26atitle%3DA%2520Review%2520of%2520Bispecific%2520Antibodies%2520and%2520Antibody%2520Constructs%2520in%2520Oncology%2520and%2520Clinical%2520Challenges%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D201%26spage%3D103%26epage%3D119%26doi%3D10.1016%2Fj.pharmthera.2019.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luh, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheib, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juenemann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span> <span> </span><span class="NLM_article-title">Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist’s Perspective</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">15448</span>, <span class="refDoi"> DOI: 10.1002/anie.202004310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1002%2Fanie.202004310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyisL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=15448&author=L.+M.+Luhauthor=U.+Scheibauthor=K.+Juenemannauthor=L.+Wortmannauthor=M.+Brandsauthor=P.+M.+Cromm&title=Prey+for+the+Proteasome%3A+Targeted+Protein+Degradation-A+Medicinal+Chemist%E2%80%99s+Perspective&doi=10.1002%2Fanie.202004310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective</span></div><div class="casAuthors">Luh, Laura M.; Scheib, Ulrike; Juenemann, Katrin; Wortmann, Lars; Brands, Michael; Cromm, Philipp M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">15448-15466</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Targeted protein degrdn. (TPD), the ability to control a proteins fate by triggering its degrdn. in a highly selective and effective manner, has created tremendous excitement in chem. biol. and drug discovery within the past decades.  The TPD field is spearheaded by small mol. induced protein degrdn. with mol. glues and proteolysis targeting chimeras (PROTACs) paving the way to expand the druggable space and to create a new paradigm in drug discovery.  However, besides the therapeutic angle of TPD a plethora of novel techniques to modulate and control protein levels have been developed.  This enables chem. biologists to better understand protein function and to discover and verify new therapeutic targets.  This Review gives a comprehensive overview of chem. biol. techniques inducing TPD.  It explains the strengths and weaknesses of these methods in the context of drug discovery and discusses their future potential from a medicinal chemist's perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWPsv2tjJdobVg90H21EOLACvtfcHk0ljwtccSpNoQng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyisL7M&md5=e7585296878017cd5394a5345b07e047</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1002%2Fanie.202004310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202004310%26sid%3Dliteratum%253Aachs%26aulast%3DLuh%26aufirst%3DL.%2BM.%26aulast%3DScheib%26aufirst%3DU.%26aulast%3DJuenemann%26aufirst%3DK.%26aulast%3DWortmann%26aufirst%3DL.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DCromm%26aufirst%3DP.%2BM.%26atitle%3DPrey%2520for%2520the%2520Proteasome%253A%2520Targeted%2520Protein%2520Degradation-A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D15448%26doi%3D10.1002%2Fanie.202004310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span> <i>PharmiWeb</i>. <a href="https://www.pharmiweb.com/press-release/2020-03-10/with-over-usd-35-billion-in-capital-investment-and-numerous-high-value-licensing-deals-the-target" class="extLink">https://www.pharmiweb.com/press-release/2020-03-10/with-over-usd-35-billion-in-capital-investment-and-numerous-high-value-licensing-deals-the-target</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PharmiWeb.+https%3A%2F%2Fwww.pharmiweb.com%2Fpress-release%2F2020-03-10%2Fwith-over-usd-35-billion-in-capital-investment-and-numerous-high-value-licensing-deals-the-target+%28accessed+2020-08-08%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmiWeb%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mullard, A.</span></span> <span> </span><span class="NLM_article-title">Targeted Degraders Clear First Safety Hurdles</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">435</span>, <span class="refDoi"> DOI: 10.1038/d41573-020-00109-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1038%2Fd41573-020-00109-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlShtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=435&author=A.+Mullard&title=Targeted+Degraders+Clear+First+Safety+Hurdles&doi=10.1038%2Fd41573-020-00109-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted degraders clear first safety hurdles</span></div><div class="casAuthors">Mullard, Asher</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">435</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nHwwDZKMr7Vg90H21EOLACvtfcHk0ljwtccSpNoQng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlShtbrM&md5=122b44714339e8b38fc418c2f8732706</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1038%2Fd41573-020-00109-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-020-00109-w%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DTargeted%2520Degraders%2520Clear%2520First%2520Safety%2520Hurdles%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2020%26volume%3D19%26spage%3D435%26doi%3D10.1038%2Fd41573-020-00109-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirakawa, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnakumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timlin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carney, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. S.</span></span> <span> </span><span class="NLM_article-title">Gene Editing and CRISPR in the Clinic: Current and Future Perspectives</span>. <i>Biosci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">BSR20200127</span>, <span class="refDoi"> DOI: 10.1042/BSR20200127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=10.1042%2FBSR20200127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;key=32207531" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=BSR20200127&issue=4&author=M.+P.+Hirakawaauthor=R.+Krishnakumarauthor=J.+A.+Timlinauthor=J.+P.+Carneyauthor=K.+S.+Butler&title=Gene+Editing+and+CRISPR+in+the+Clinic%3A+Current+and+Future+Perspectives&doi=10.1042%2FBSR20200127"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1042%2FBSR20200127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20200127%26sid%3Dliteratum%253Aachs%26aulast%3DHirakawa%26aufirst%3DM.%2BP.%26aulast%3DKrishnakumar%26aufirst%3DR.%26aulast%3DTimlin%26aufirst%3DJ.%2BA.%26aulast%3DCarney%26aufirst%3DJ.%2BP.%26aulast%3DButler%26aufirst%3DK.%2BS.%26atitle%3DGene%2520Editing%2520and%2520CRISPR%2520in%2520the%2520Clinic%253A%2520Current%2520and%2520Future%2520Perspectives%26jtitle%3DBiosci.%2520Rep.%26date%3D2020%26volume%3D40%26issue%3D4%26spage%3DBSR20200127%26doi%3D10.1042%2FBSR20200127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span> </span><span class="NLM_article-title">Allergan and Editas Medicine Initiate the
Brilliance Phase 1/2 Clinical
Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10</span>.  <i>GlobeNewsWire</i>. <a href="https://www.globenewswire.com/news-release/2019/07/25/1888031/0/en/Allergan-and-Editas-Medicine-Initiate-the-Brilliance-Phase-1-2-Clinical-Trial-of-AGN-151587-EDIT-101-for-the-Treatment-of-LCA10.html" class="extLink">https://www.globenewswire.com/news-release/2019/07/25/1888031/0/en/Allergan-and-Editas-Medicine-Initiate-the-Brilliance-Phase-1-2-Clinical-Trial-of-AGN-151587-EDIT-101-for-the-Treatment-of-LCA10.html</a> (accessed <span class="NLM_year">2020</span>-08-08).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allergan+and+Editas+Medicine+Initiate+the%0ABrilliance+Phase+1%2F2+Clinical%0ATrial+of+AGN-151587+%28EDIT-101%29+for+the+Treatment+of+LCA10.+GlobeNewsWire.+https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2019%2F07%2F25%2F1888031%2F0%2Fen%2FAllergan-and-Editas-Medicine-Initiate-the-Brilliance-Phase-1-2-Clinical-Trial-of-AGN-151587-EDIT-101-for-the-Treatment-of-LCA10.html+%28accessed+2020-08-08%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAllergan%2520and%2520Editas%2520Medicine%2520Initiate%2520the%250ABrilliance%2520Phase%25201%252F2%2520Clinical%250ATrial%2520of%2520AGN-151587%2520%2528EDIT-101%2529%2520for%2520the%2520Treatment%2520of%2520LCA10%26jtitle%3DGlobeNewsWire%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munos, B. H.</span></span> <span> </span><span class="NLM_article-title">2018 New Drugs Approvals: An All-Time Record, And A Watershed</span>.  <i>Forbes</i>. <a href="https://www.forbes.com/sites/bernardmunos/2019/01/14/2018-new-drugs-approvals-an-all-time-record-and-a-watershed/amp" class="extLink">https://www.forbes.com/sites/bernardmunos/2019/01/14/2018-new-drugs-approvals-an-all-time-record-and-a-watershed/amp</a> (accessed <span class="NLM_year">2020</span>-04-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+H.+Munos&title=2018+New+Drugs+Approvals%3A+An+All-Time+Record%2C+And+A+Watershed"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DMunos%26aufirst%3DB.%2BH.%26atitle%3D2018%2520New%2520Drugs%2520Approvals%253A%2520An%2520All-Time%2520Record%252C%2520And%2520A%2520Watershed%26jtitle%3DForbes%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i35"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01516">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21425"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01516?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01516</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Complete list of 2010–2019 FDA Approved NME, BLA and biosimilars categorized by year, class, FIC, target, indication, orphan designation, and route of administration (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf">jm0c01516_si_001.pdf (802.73 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01516&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01516%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01516" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d3e38ec13c94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
